- Split View
-
Views
-
Cite
Cite
Quinn T. Ostrom, Haley Gittleman, Peter M. de Blank, Jonathan L. Finlay, James G. Gurney, Roberta McKean-Cowdin, Duncan S. Stearns, Johannes E. Wolff, Max Liu, Yingli Wolinsky, Carol Kruchko, Jill S. Barnholtz-Sloan, American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012, Neuro-Oncology, Volume 18, Issue suppl_1, January 2016, Pages i1–i50, https://doi.org/10.1093/neuonc/nov297
- Share Icon Share
Introduction
Brain and central nervous system (CNS) tumors found in adolescents and young adults (AYA) are a distinct group of tumors that pose challenges not only to treatment but also to reporting. Overall, cancer that occurs in this age group is biologically distinct from those that occur in both younger and older age groups1,2 posing significant challenges for clinicians. The most commonly diagnosed histologies in AYA vary from those in both children age (0-14 years), and older adults (40+ years).3,4 Prognosis and expected survival also varies between younger and older adults, with those who are diagnosed with brain and CNS tumors at younger ages having significantly longer survival. Despite this survival advantage, recent analyses have reported that while cancer survival has been improving overall, AYA have not experienced these same increases in survival and in some cases may have worse survival than those cancers diagnosed in persons over age 40 years.5 This report provides an in depth analyses of the epidemiology of brain and CNS tumors in adolescents and young adults in the United States (US), and is the first report to provide histology-specific statistics in this population for both malignant and non-malignant brain and other CNS tumors.
In 2006, the National Institutes of Health, the National Cancer Institute (NCI) and the LiveStrong Young Adult Alliance conducted a Progress Review Group to investigate AYA Oncology entitled Research and care imperatives for adolescents and young adults with cancer: A Report of the Adolescent and Young Adult Oncology Progress Review Group. This group established the standard age range for the AYA group as 15-39 years. This is the age range used by the Surveillance Epidemiology and End Results (SEER) program of the NCI, as well as in the 2015 CBTRUS Statistical Report.3,6 Brain tumors and other CNS tumors are less common in AYA than in older adults, but they have a higher incidence than brain tumors in children (age 0-14 years).3 Non-malignant tumors are significantly more common in AYA than children (Average annual age adjusted incidence in age 15-39 years: 6.17 per 100,000; age 0-14 years: 0.79 per 100,000), while malignant tumors are slightly more common in those age 0-14 years (Average annual age adjusted incidence in 15-39 years old: 3.26 per 100,000; 0-14 years old: 3.73 per 100,000). While a rare cancer overall, brain and CNS tumors are among the most common cancers occurring in this age group (4.4% of all cancers in those age 15-39 years as compared to 32.4% in children age 0-14 years, and 2.2% of cancers in adults age 40+ years).3,4,7 Malignant brain and CNS tumors are the 11th most common cancer and the 3rd most common cause of cancer death7,8 in the AYA population. Incidence rates of brain tumors overall as well as specific histologies vary significantly by age. It is, therefore, important to provide an accurate statistical assessment of brain and other CNS tumors in the adolescent and young adult population to better understand their impact on the US population and to serve as a reference for afflicted individuals, for researchers investigating new therapies and for clinicians treating patients.
Background
CBTRUS is a population-based site-specific registry in the US that works in partnership with a public cancer surveillance organization, the CDC's National Program of Central Registries (NPCR), and from which data are directly received under a special agreement. This agreement permits transfer of data through the NPCR Cancer Surveillance System (NPCR-CSS) Submission Specifications mechanism. CBTRUS researchers combine the NPCR data with data from the NCI SEER program9 which was established for national cancer surveillance in the early 1970s. All data from NPCR and SEER originate from tumor registrars who adhere to the Uniform Data Standards (UDS) for malignant and non-malignant brain and CNS tumors as directed by the North American Association of Central Cancer Registries (NAACCR) (http://www.naaccr.org) and report these data to the central cancer registry in their state. Along with the UDS, there are quality control checks and a system for rating each central cancer registry to further insure that these data are reported as accurately and completely as possible. As a surveillance partner, CBTRUS can, therefore, report high quality data on brain and CNS tumors with histological specificity useful to the communities it serves. Its database represents the largest aggregation of population-based data on the incidence of primary brain and CNS tumors in the US. Aggregate information on all cancers from all central cancer registries in the United States, including primary brain and CNS, is available in United States Cancer Statistics.7,10
Technical Notes
Data Collection
CBTRUS contains incidence data from 51 independent central cancer registries (46 NPCR and 5 SEER registries), including 50 state cancer registries and the District of Columbia, representing ∼99.9% of the US population for the time period examined in this report (for 1 of 51 registries, data were available only from 2008-2010).3 Please see The CBTRUS Statistical Report: Primary and Central Nervous System Tumors Diagnosed in the US in 2008-2012 for additional information about the way that these data are obtained and processed.3
Incidence is a measure of newly diagnosed cases of a disease in a population. Crude incidence rates are calculated by dividing total number of new cases, by the overall population for the same time period. Age-adjusted incidence rates are calculated by generating crude rates by age group, and then summing these together based on a standard age distribution which adjusts for the effect of age distribution variation between different populations. Age-adjusted incidence rates per 100,000 for the entire US for selected other cancers were obtained from the US Cancer Statistics (USCS),7 produced by the CDC and the NCI, via CDC Wide-ranging Online Data for Epidemiologic Research (WONDER), for the purpose of comparison with brain and CNS tumor incidence rates. This database includes both NPCR and SEER data and represents nearly 100% of the US population.
Survival information derived from active patient follow-up is not available in the data that CBTRUS receives from NPCR registries, so SEER data are used to generate these Tables. Survival data for malignant brain and CNS tumors were obtained from 18 SEER registries for the years 1995 to 2012. This dataset spanning 17 years currently provides population-based information for approximately 28% of the US population as of the US 2010 Census,11,12 and is a subset of the CBTRUS combined NPCR and SEER data used for the incidence calculations in this report.
Mortality data used in this report are from the National Center for Health Statistics and include deaths where primary brain or CNS tumor was listed as cause of death on the death certificate for all 50 states and the District of Columbia. Population data for each geographic region were obtained from the SEER program website13 for the purpose of rate calculations.
Data Reporting – Definitions
It should be noted that other surveillance organizations and researchers may report brain tumors differently from CBTRUS. CBTRUS uses the site definition agreed upon in the Consensus Conference on brain tumor definition and includes lymphoma and other hematopoietic histologies (9590–9989), and olfactory tumors of the nasal cavity [C30.0 (9522–9523)].13,14 The definition of brain and CNS tumors used by SEER, NPCR, and NAACCR in their published incidence and mortality statistics is based on the Consensus Conference and, like CBTRUS, includes tumors located in the following sites with their International Classification of Disease, Oncology 3rd edition (ICD-O-3)15 site codes in parentheses: brain (C70.0–9), meninges (C71.0–9), and other central nervous system tumors (C72.0–9), but, unlike CBTRUS, excludes lymphoma and leukemia histologies (ICD-O-3 histology codes 9590–9989) from all brain and CNS sites (Table 1 provides information on included site codes). Leukemias and lymphomas of the brain and CNS are rare, and account for ∼1% of all brain and CNS tumors from 2008-2012. This difference in reporting does not significantly affect rates.
Adolescent and Young Adult Report Major Site Grouping . | Site . | ICD-O-3a Site Code . |
---|---|---|
Supratentorial | Cerebrum | C71.0 |
Frontal lobe of brain | C71.1 | |
Temporal lobe of brain | C71.2 | |
Parietal lobe of brain | C71.3 | |
Occipital lobe of brain | C71.4 | |
Ventricle, NOS | Ventricle | C71.5 |
Cerebellum | Cerebellum | C71.6 |
Brain Stem | Brain stem | C71.7 |
Other Brain | Other brain | C71.8-C71.9 |
Overlapping lesion of brain | C71.8 | |
Brain, NOS | C71.9 | |
Other Nervous System | Spinal cord and cauda equine | C72.0-C72.1 |
Spinal cord | C72.0 | |
Cauda equina | C72.1 | |
Cranial nerves | C72.2-C72.5 | |
Olfactory nerve | C72.2 | |
Optic nerve | C72.3 | |
Acoustic nerve | C72.4 | |
Cranial nerve, NOS | C72.5 | |
Other nervous system | C72.8-C72.9 | |
Overlapping lesion of brain and central nervous system | C72.8 | |
Nervous system, NOS | C72.9 | |
Meninges (cerebral & spinal) | C70.0-C70.9 | |
Cerebral meninges | C70.0 | |
Spinal meninges | C70.1 | |
Meninges, NOS | C70.9 | |
Pituitary and craniopharyngeal duct | C75.1-C75.2 | |
Pituitary gland | C75.1 | |
Craniopharyngeal duct | C75.2 | |
Pineal Gland | C75.3 | |
Olfactory tumors of the nasal cavityb | C30.0 |
Adolescent and Young Adult Report Major Site Grouping . | Site . | ICD-O-3a Site Code . |
---|---|---|
Supratentorial | Cerebrum | C71.0 |
Frontal lobe of brain | C71.1 | |
Temporal lobe of brain | C71.2 | |
Parietal lobe of brain | C71.3 | |
Occipital lobe of brain | C71.4 | |
Ventricle, NOS | Ventricle | C71.5 |
Cerebellum | Cerebellum | C71.6 |
Brain Stem | Brain stem | C71.7 |
Other Brain | Other brain | C71.8-C71.9 |
Overlapping lesion of brain | C71.8 | |
Brain, NOS | C71.9 | |
Other Nervous System | Spinal cord and cauda equine | C72.0-C72.1 |
Spinal cord | C72.0 | |
Cauda equina | C72.1 | |
Cranial nerves | C72.2-C72.5 | |
Olfactory nerve | C72.2 | |
Optic nerve | C72.3 | |
Acoustic nerve | C72.4 | |
Cranial nerve, NOS | C72.5 | |
Other nervous system | C72.8-C72.9 | |
Overlapping lesion of brain and central nervous system | C72.8 | |
Nervous system, NOS | C72.9 | |
Meninges (cerebral & spinal) | C70.0-C70.9 | |
Cerebral meninges | C70.0 | |
Spinal meninges | C70.1 | |
Meninges, NOS | C70.9 | |
Pituitary and craniopharyngeal duct | C75.1-C75.2 | |
Pituitary gland | C75.1 | |
Craniopharyngeal duct | C75.2 | |
Pineal Gland | C75.3 | |
Olfactory tumors of the nasal cavityb | C30.0 |
aInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
bICD-O-3 histology codes 9522-9523 only.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Adolescent and Young Adult Report Major Site Grouping . | Site . | ICD-O-3a Site Code . |
---|---|---|
Supratentorial | Cerebrum | C71.0 |
Frontal lobe of brain | C71.1 | |
Temporal lobe of brain | C71.2 | |
Parietal lobe of brain | C71.3 | |
Occipital lobe of brain | C71.4 | |
Ventricle, NOS | Ventricle | C71.5 |
Cerebellum | Cerebellum | C71.6 |
Brain Stem | Brain stem | C71.7 |
Other Brain | Other brain | C71.8-C71.9 |
Overlapping lesion of brain | C71.8 | |
Brain, NOS | C71.9 | |
Other Nervous System | Spinal cord and cauda equine | C72.0-C72.1 |
Spinal cord | C72.0 | |
Cauda equina | C72.1 | |
Cranial nerves | C72.2-C72.5 | |
Olfactory nerve | C72.2 | |
Optic nerve | C72.3 | |
Acoustic nerve | C72.4 | |
Cranial nerve, NOS | C72.5 | |
Other nervous system | C72.8-C72.9 | |
Overlapping lesion of brain and central nervous system | C72.8 | |
Nervous system, NOS | C72.9 | |
Meninges (cerebral & spinal) | C70.0-C70.9 | |
Cerebral meninges | C70.0 | |
Spinal meninges | C70.1 | |
Meninges, NOS | C70.9 | |
Pituitary and craniopharyngeal duct | C75.1-C75.2 | |
Pituitary gland | C75.1 | |
Craniopharyngeal duct | C75.2 | |
Pineal Gland | C75.3 | |
Olfactory tumors of the nasal cavityb | C30.0 |
Adolescent and Young Adult Report Major Site Grouping . | Site . | ICD-O-3a Site Code . |
---|---|---|
Supratentorial | Cerebrum | C71.0 |
Frontal lobe of brain | C71.1 | |
Temporal lobe of brain | C71.2 | |
Parietal lobe of brain | C71.3 | |
Occipital lobe of brain | C71.4 | |
Ventricle, NOS | Ventricle | C71.5 |
Cerebellum | Cerebellum | C71.6 |
Brain Stem | Brain stem | C71.7 |
Other Brain | Other brain | C71.8-C71.9 |
Overlapping lesion of brain | C71.8 | |
Brain, NOS | C71.9 | |
Other Nervous System | Spinal cord and cauda equine | C72.0-C72.1 |
Spinal cord | C72.0 | |
Cauda equina | C72.1 | |
Cranial nerves | C72.2-C72.5 | |
Olfactory nerve | C72.2 | |
Optic nerve | C72.3 | |
Acoustic nerve | C72.4 | |
Cranial nerve, NOS | C72.5 | |
Other nervous system | C72.8-C72.9 | |
Overlapping lesion of brain and central nervous system | C72.8 | |
Nervous system, NOS | C72.9 | |
Meninges (cerebral & spinal) | C70.0-C70.9 | |
Cerebral meninges | C70.0 | |
Spinal meninges | C70.1 | |
Meninges, NOS | C70.9 | |
Pituitary and craniopharyngeal duct | C75.1-C75.2 | |
Pituitary gland | C75.1 | |
Craniopharyngeal duct | C75.2 | |
Pineal Gland | C75.3 | |
Olfactory tumors of the nasal cavityb | C30.0 |
aInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
bICD-O-3 histology codes 9522-9523 only.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Gliomas are tumors that arise from glial (supportive tissue in the brain) or precursor cells and include astrocytoma, glioblastoma, oligodendroglioma, ependymoma, mixed glioma, malignant glioma, not otherwise specified (NOS), and a few rare histologies. Because there is no standard definition for gliomas, CBTRUS defines glioma as ICD-O-3 histology codes 9380-9384 and 9391-9460 as starred in Tables 2a, 2b and 2c. Additional information on glioma histology categorization is provided in Table 2d. Additionally, CBTRUS reports data on all brain and CNS tumors irrespective of behavior, whereas many reporting organizations may only publish rates for malignant brain and CNS tumors (tumors with an ICD-O-3 behavior code of /3). This policy presents a problem for reporting pilocytic astrocytoma. Pilocytic astrocytoma was assigned an ICD-O-315 behavior code of uncertain/1 in 2007 WHO Classification of Tumours of the Central Nervous System.16,35 Prior to this classification change, these tumors were historically classified as a malignant tumor,17 and as a results have been defined as a malignant tumor for the purposes of US cancer registration reporting practices. In keeping with these practices CBTRUS categorizes these tumors as malignant tumors in this report and its other statistical reports.
Histology . | ICD-O-3a Histology Codeb . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421, 9425c |
Diffuse astrocytoma* | 9400, 9410, 9411, 9420 |
Anaplastic astrocytoma* | 9401 |
Unique astrocytoma variants* | 9381, 9384, 9424 |
Glioblastoma* | 9440, 9441, 9442/3d |
Oligodendroglioma* | 9450 |
Anaplastic oligodendroglioma* | 9451, 9460 |
Oligoastrocytic tumors* | 9382 |
Ependymal tumors* | 9383, 9391, 9392, 9393, 9394 |
Glioma malignant, NOS* | 9380, 9431c, 9432c |
Choroid plexus tumors | 9390 |
Other neuroepithelial tumors* | 9363, 9423, 9430, 9444 |
Neuronal and mixed neuronal-glial tumors* | 8680, 8681, 8690, 8693, 9412, 9413, 9442/1e, 9492 (excluding site C75.1), 9493, 9505, 9506, 9522, 9523, 9509c |
Tumors of the pineal region | 9360, 9361, 9362, 9395c |
Embryonal tumors | 8963, 9364, 9470, 9471, 9472, 9473, 9474, 9480, 9490, 9500, 9501, 9502, 9508 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540, 9541, 9550, 9560, 9561, 9570, 9571 |
Other tumors of cranial and spinal nerves | 9562 |
Tumors of Meninges | |
Meningioma | 9530, 9531, 9532, 9533, 9534, 9537, 9538, 9539 |
Mesenchymal tumors | 8324, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8810, 8815, 8824, 8830, 8831, 8835, 8836, 8850, 8851, 8852, 8853, 8854, 8857, 8861, 8870 , 8880, 8890, 8897, 8900, 8901, 8902, 8910, 8912, 8920, 8921, 8935, 8990, 9040, 9136, 9150, 9170, 9180, 9210, 9241, 9260, 9373 |
Primary melanocytic lesions | 8720, 8728, 8770, 8771 |
Other neoplasms related to the meninges | 9161, 9220, 9231, 9240, 9243, 9370, 9371, 9372, 9535 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590, 9591, 9596, 9650, 9651, 9652, 9653, 9654, 9655, 9659, 9661, 9662, 9663, 9664, 9665, 9667, 9670, 9671, 9673, 9675, 9680, 9684, 9687, 9690, 9691, 9695, 9698, 9699, 9701, 9702, 9705, 9714, 9719, 9728, 9729 |
Other hemopoietic neoplasms | 9727, 9731, 9733, 9734, 9740, 9741, 9750, 9751, 9752, 9753, 9754, 9755, 9756, 9757, 9758, 9760, 9766, 9823, 9826, 9827, 9832, 9837, 9860, 9861, 9866, 9930, 9970 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020, 8440, 9060, 9061, 9064, 9065, 9070, 9071, 9072, 9080, 9081, 9082, 9083, 9084, 9085, 9100, 9101 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272, 8280, 8281, 8290, 8300, 8310, 8323, 9492 (Site C75.1 only), 9582 |
Craniopharyngioma | 9350, 9351, 9352 |
Unclassified Tumors | |
Hemangioma | 9120, 9121, 9122, 9123, 9125, 9130, 9131, 9133, 9140 |
Neoplasm, unspecified | 8000, 8001, 8002, 8003, 8004, 8005, 8010, 8021 |
All other | 8320, 8452, 8710, 8711, 8713, 8811, 8840, 8896, 8980, 9173, 9503, 9580 |
Histology . | ICD-O-3a Histology Codeb . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421, 9425c |
Diffuse astrocytoma* | 9400, 9410, 9411, 9420 |
Anaplastic astrocytoma* | 9401 |
Unique astrocytoma variants* | 9381, 9384, 9424 |
Glioblastoma* | 9440, 9441, 9442/3d |
Oligodendroglioma* | 9450 |
Anaplastic oligodendroglioma* | 9451, 9460 |
Oligoastrocytic tumors* | 9382 |
Ependymal tumors* | 9383, 9391, 9392, 9393, 9394 |
Glioma malignant, NOS* | 9380, 9431c, 9432c |
Choroid plexus tumors | 9390 |
Other neuroepithelial tumors* | 9363, 9423, 9430, 9444 |
Neuronal and mixed neuronal-glial tumors* | 8680, 8681, 8690, 8693, 9412, 9413, 9442/1e, 9492 (excluding site C75.1), 9493, 9505, 9506, 9522, 9523, 9509c |
Tumors of the pineal region | 9360, 9361, 9362, 9395c |
Embryonal tumors | 8963, 9364, 9470, 9471, 9472, 9473, 9474, 9480, 9490, 9500, 9501, 9502, 9508 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540, 9541, 9550, 9560, 9561, 9570, 9571 |
Other tumors of cranial and spinal nerves | 9562 |
Tumors of Meninges | |
Meningioma | 9530, 9531, 9532, 9533, 9534, 9537, 9538, 9539 |
Mesenchymal tumors | 8324, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8810, 8815, 8824, 8830, 8831, 8835, 8836, 8850, 8851, 8852, 8853, 8854, 8857, 8861, 8870 , 8880, 8890, 8897, 8900, 8901, 8902, 8910, 8912, 8920, 8921, 8935, 8990, 9040, 9136, 9150, 9170, 9180, 9210, 9241, 9260, 9373 |
Primary melanocytic lesions | 8720, 8728, 8770, 8771 |
Other neoplasms related to the meninges | 9161, 9220, 9231, 9240, 9243, 9370, 9371, 9372, 9535 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590, 9591, 9596, 9650, 9651, 9652, 9653, 9654, 9655, 9659, 9661, 9662, 9663, 9664, 9665, 9667, 9670, 9671, 9673, 9675, 9680, 9684, 9687, 9690, 9691, 9695, 9698, 9699, 9701, 9702, 9705, 9714, 9719, 9728, 9729 |
Other hemopoietic neoplasms | 9727, 9731, 9733, 9734, 9740, 9741, 9750, 9751, 9752, 9753, 9754, 9755, 9756, 9757, 9758, 9760, 9766, 9823, 9826, 9827, 9832, 9837, 9860, 9861, 9866, 9930, 9970 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020, 8440, 9060, 9061, 9064, 9065, 9070, 9071, 9072, 9080, 9081, 9082, 9083, 9084, 9085, 9100, 9101 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272, 8280, 8281, 8290, 8300, 8310, 8323, 9492 (Site C75.1 only), 9582 |
Craniopharyngioma | 9350, 9351, 9352 |
Unclassified Tumors | |
Hemangioma | 9120, 9121, 9122, 9123, 9125, 9130, 9131, 9133, 9140 |
Neoplasm, unspecified | 8000, 8001, 8002, 8003, 8004, 8005, 8010, 8021 |
All other | 8320, 8452, 8710, 8711, 8713, 8811, 8840, 8896, 8980, 9173, 9503, 9580 |
aInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
bSee the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.
cHistology not currently used to US cancer registration, will be included starting with diagnosis year 2015. See NAACCR website: http://www.naaccr.org/LinkClick.aspx?fileticket=4Hx-2XJJqFo%3d&tabid=161&mid=523.
dMorphology 9442/3 only.
eMorphology 9442/1 only.
*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Histology . | ICD-O-3a Histology Codeb . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421, 9425c |
Diffuse astrocytoma* | 9400, 9410, 9411, 9420 |
Anaplastic astrocytoma* | 9401 |
Unique astrocytoma variants* | 9381, 9384, 9424 |
Glioblastoma* | 9440, 9441, 9442/3d |
Oligodendroglioma* | 9450 |
Anaplastic oligodendroglioma* | 9451, 9460 |
Oligoastrocytic tumors* | 9382 |
Ependymal tumors* | 9383, 9391, 9392, 9393, 9394 |
Glioma malignant, NOS* | 9380, 9431c, 9432c |
Choroid plexus tumors | 9390 |
Other neuroepithelial tumors* | 9363, 9423, 9430, 9444 |
Neuronal and mixed neuronal-glial tumors* | 8680, 8681, 8690, 8693, 9412, 9413, 9442/1e, 9492 (excluding site C75.1), 9493, 9505, 9506, 9522, 9523, 9509c |
Tumors of the pineal region | 9360, 9361, 9362, 9395c |
Embryonal tumors | 8963, 9364, 9470, 9471, 9472, 9473, 9474, 9480, 9490, 9500, 9501, 9502, 9508 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540, 9541, 9550, 9560, 9561, 9570, 9571 |
Other tumors of cranial and spinal nerves | 9562 |
Tumors of Meninges | |
Meningioma | 9530, 9531, 9532, 9533, 9534, 9537, 9538, 9539 |
Mesenchymal tumors | 8324, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8810, 8815, 8824, 8830, 8831, 8835, 8836, 8850, 8851, 8852, 8853, 8854, 8857, 8861, 8870 , 8880, 8890, 8897, 8900, 8901, 8902, 8910, 8912, 8920, 8921, 8935, 8990, 9040, 9136, 9150, 9170, 9180, 9210, 9241, 9260, 9373 |
Primary melanocytic lesions | 8720, 8728, 8770, 8771 |
Other neoplasms related to the meninges | 9161, 9220, 9231, 9240, 9243, 9370, 9371, 9372, 9535 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590, 9591, 9596, 9650, 9651, 9652, 9653, 9654, 9655, 9659, 9661, 9662, 9663, 9664, 9665, 9667, 9670, 9671, 9673, 9675, 9680, 9684, 9687, 9690, 9691, 9695, 9698, 9699, 9701, 9702, 9705, 9714, 9719, 9728, 9729 |
Other hemopoietic neoplasms | 9727, 9731, 9733, 9734, 9740, 9741, 9750, 9751, 9752, 9753, 9754, 9755, 9756, 9757, 9758, 9760, 9766, 9823, 9826, 9827, 9832, 9837, 9860, 9861, 9866, 9930, 9970 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020, 8440, 9060, 9061, 9064, 9065, 9070, 9071, 9072, 9080, 9081, 9082, 9083, 9084, 9085, 9100, 9101 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272, 8280, 8281, 8290, 8300, 8310, 8323, 9492 (Site C75.1 only), 9582 |
Craniopharyngioma | 9350, 9351, 9352 |
Unclassified Tumors | |
Hemangioma | 9120, 9121, 9122, 9123, 9125, 9130, 9131, 9133, 9140 |
Neoplasm, unspecified | 8000, 8001, 8002, 8003, 8004, 8005, 8010, 8021 |
All other | 8320, 8452, 8710, 8711, 8713, 8811, 8840, 8896, 8980, 9173, 9503, 9580 |
Histology . | ICD-O-3a Histology Codeb . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421, 9425c |
Diffuse astrocytoma* | 9400, 9410, 9411, 9420 |
Anaplastic astrocytoma* | 9401 |
Unique astrocytoma variants* | 9381, 9384, 9424 |
Glioblastoma* | 9440, 9441, 9442/3d |
Oligodendroglioma* | 9450 |
Anaplastic oligodendroglioma* | 9451, 9460 |
Oligoastrocytic tumors* | 9382 |
Ependymal tumors* | 9383, 9391, 9392, 9393, 9394 |
Glioma malignant, NOS* | 9380, 9431c, 9432c |
Choroid plexus tumors | 9390 |
Other neuroepithelial tumors* | 9363, 9423, 9430, 9444 |
Neuronal and mixed neuronal-glial tumors* | 8680, 8681, 8690, 8693, 9412, 9413, 9442/1e, 9492 (excluding site C75.1), 9493, 9505, 9506, 9522, 9523, 9509c |
Tumors of the pineal region | 9360, 9361, 9362, 9395c |
Embryonal tumors | 8963, 9364, 9470, 9471, 9472, 9473, 9474, 9480, 9490, 9500, 9501, 9502, 9508 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540, 9541, 9550, 9560, 9561, 9570, 9571 |
Other tumors of cranial and spinal nerves | 9562 |
Tumors of Meninges | |
Meningioma | 9530, 9531, 9532, 9533, 9534, 9537, 9538, 9539 |
Mesenchymal tumors | 8324, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8810, 8815, 8824, 8830, 8831, 8835, 8836, 8850, 8851, 8852, 8853, 8854, 8857, 8861, 8870 , 8880, 8890, 8897, 8900, 8901, 8902, 8910, 8912, 8920, 8921, 8935, 8990, 9040, 9136, 9150, 9170, 9180, 9210, 9241, 9260, 9373 |
Primary melanocytic lesions | 8720, 8728, 8770, 8771 |
Other neoplasms related to the meninges | 9161, 9220, 9231, 9240, 9243, 9370, 9371, 9372, 9535 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590, 9591, 9596, 9650, 9651, 9652, 9653, 9654, 9655, 9659, 9661, 9662, 9663, 9664, 9665, 9667, 9670, 9671, 9673, 9675, 9680, 9684, 9687, 9690, 9691, 9695, 9698, 9699, 9701, 9702, 9705, 9714, 9719, 9728, 9729 |
Other hemopoietic neoplasms | 9727, 9731, 9733, 9734, 9740, 9741, 9750, 9751, 9752, 9753, 9754, 9755, 9756, 9757, 9758, 9760, 9766, 9823, 9826, 9827, 9832, 9837, 9860, 9861, 9866, 9930, 9970 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020, 8440, 9060, 9061, 9064, 9065, 9070, 9071, 9072, 9080, 9081, 9082, 9083, 9084, 9085, 9100, 9101 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272, 8280, 8281, 8290, 8300, 8310, 8323, 9492 (Site C75.1 only), 9582 |
Craniopharyngioma | 9350, 9351, 9352 |
Unclassified Tumors | |
Hemangioma | 9120, 9121, 9122, 9123, 9125, 9130, 9131, 9133, 9140 |
Neoplasm, unspecified | 8000, 8001, 8002, 8003, 8004, 8005, 8010, 8021 |
All other | 8320, 8452, 8710, 8711, 8713, 8811, 8840, 8896, 8980, 9173, 9503, 9580 |
aInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
bSee the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.
cHistology not currently used to US cancer registration, will be included starting with diagnosis year 2015. See NAACCR website: http://www.naaccr.org/LinkClick.aspx?fileticket=4Hx-2XJJqFo%3d&tabid=161&mid=523.
dMorphology 9442/3 only.
eMorphology 9442/1 only.
*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421/1 [Included with malignant tumors], 9425/3d |
Diffuse astrocytoma* | 9400/3, 9410/3, 9411/3, 9420/3 |
Anaplastic astrocytoma* | 9401/3 |
Unique astrocytoma variants* | 9381/3, 9424/3 |
Glioblastoma* | 9440/3, 9441/3, 9442/3 |
Oligodendroglioma* | 9450/3 |
Anaplastic oligodendroglioma* | 9451/3, 9460/3 |
Oligoastrocytic tumors* | 9382/3 |
Ependymal tumors* | 9391/3, 9392/3d, 9393/3d |
Glioma malignant, NOS* | 9380/3 |
Choroid plexus tumors | 9390/3 |
Other neuroepithelial tumors* | 9423/3, 9430/3 |
Neuronal and mixed neuronal-glial tumors* | 8680/3, 8693/3, 9505/3, 9522/3, 9523/3 |
Tumors of the pineal region | 9362/3, 9395/3d |
Embryonal tumors | 8963/3, 9364/3, 9470/3, 9471/3, 9472/3,9473/3, 9474/3, 9480/3, 9490/3, 9500/3, 9501/3, 9502/3, 9508/3 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/3, 9560/3, 9561/3, 9571/3 |
Tumors of Meninges | |
Meningioma | 9530/3, 9538/3, 9539/3 |
Mesenchymal tumors | 8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3, 850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3, 8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3 |
Primary melanocytic lesions | 8720/3, 8728/3, 8770/3, 8771/3 |
Other neoplasms related to the meninges | 9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3, 9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3, 9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3, 9705/3, 9714/3, 9719/3, 9728/3, 9729/3 |
Other hemopoietic neoplasms | 9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3, 9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3 |
Unclassified Tumors | |
Hemangioma | 9120/3, 9130/3, 9133/3, 9140/3 |
Neoplasm, unspecified | 8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3 |
All other | 8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3 |
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421/1 [Included with malignant tumors], 9425/3d |
Diffuse astrocytoma* | 9400/3, 9410/3, 9411/3, 9420/3 |
Anaplastic astrocytoma* | 9401/3 |
Unique astrocytoma variants* | 9381/3, 9424/3 |
Glioblastoma* | 9440/3, 9441/3, 9442/3 |
Oligodendroglioma* | 9450/3 |
Anaplastic oligodendroglioma* | 9451/3, 9460/3 |
Oligoastrocytic tumors* | 9382/3 |
Ependymal tumors* | 9391/3, 9392/3d, 9393/3d |
Glioma malignant, NOS* | 9380/3 |
Choroid plexus tumors | 9390/3 |
Other neuroepithelial tumors* | 9423/3, 9430/3 |
Neuronal and mixed neuronal-glial tumors* | 8680/3, 8693/3, 9505/3, 9522/3, 9523/3 |
Tumors of the pineal region | 9362/3, 9395/3d |
Embryonal tumors | 8963/3, 9364/3, 9470/3, 9471/3, 9472/3,9473/3, 9474/3, 9480/3, 9490/3, 9500/3, 9501/3, 9502/3, 9508/3 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/3, 9560/3, 9561/3, 9571/3 |
Tumors of Meninges | |
Meningioma | 9530/3, 9538/3, 9539/3 |
Mesenchymal tumors | 8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3, 850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3, 8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3 |
Primary melanocytic lesions | 8720/3, 8728/3, 8770/3, 8771/3 |
Other neoplasms related to the meninges | 9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3, 9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3, 9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3, 9705/3, 9714/3, 9719/3, 9728/3, 9729/3 |
Other hemopoietic neoplasms | 9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3, 9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3 |
Unclassified Tumors | |
Hemangioma | 9120/3, 9130/3, 9133/3, 9140/3 |
Neoplasm, unspecified | 8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3 |
All other | 8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3 |
aIncludes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definitions.
bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
cSee the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.
dHistology not currently used to US cancer registration, will be included starting with diagnosis year 2015. See NAACCR website: http://www.naaccr.org/LinkClick.aspx?fileticket=4Hx-2XJJqFo%3d&tabid=161&mid=523.
*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421/1 [Included with malignant tumors], 9425/3d |
Diffuse astrocytoma* | 9400/3, 9410/3, 9411/3, 9420/3 |
Anaplastic astrocytoma* | 9401/3 |
Unique astrocytoma variants* | 9381/3, 9424/3 |
Glioblastoma* | 9440/3, 9441/3, 9442/3 |
Oligodendroglioma* | 9450/3 |
Anaplastic oligodendroglioma* | 9451/3, 9460/3 |
Oligoastrocytic tumors* | 9382/3 |
Ependymal tumors* | 9391/3, 9392/3d, 9393/3d |
Glioma malignant, NOS* | 9380/3 |
Choroid plexus tumors | 9390/3 |
Other neuroepithelial tumors* | 9423/3, 9430/3 |
Neuronal and mixed neuronal-glial tumors* | 8680/3, 8693/3, 9505/3, 9522/3, 9523/3 |
Tumors of the pineal region | 9362/3, 9395/3d |
Embryonal tumors | 8963/3, 9364/3, 9470/3, 9471/3, 9472/3,9473/3, 9474/3, 9480/3, 9490/3, 9500/3, 9501/3, 9502/3, 9508/3 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/3, 9560/3, 9561/3, 9571/3 |
Tumors of Meninges | |
Meningioma | 9530/3, 9538/3, 9539/3 |
Mesenchymal tumors | 8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3, 850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3, 8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3 |
Primary melanocytic lesions | 8720/3, 8728/3, 8770/3, 8771/3 |
Other neoplasms related to the meninges | 9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3, 9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3, 9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3, 9705/3, 9714/3, 9719/3, 9728/3, 9729/3 |
Other hemopoietic neoplasms | 9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3, 9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3 |
Unclassified Tumors | |
Hemangioma | 9120/3, 9130/3, 9133/3, 9140/3 |
Neoplasm, unspecified | 8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3 |
All other | 8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3 |
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Pilocytic astrocytoma* | 9421/1 [Included with malignant tumors], 9425/3d |
Diffuse astrocytoma* | 9400/3, 9410/3, 9411/3, 9420/3 |
Anaplastic astrocytoma* | 9401/3 |
Unique astrocytoma variants* | 9381/3, 9424/3 |
Glioblastoma* | 9440/3, 9441/3, 9442/3 |
Oligodendroglioma* | 9450/3 |
Anaplastic oligodendroglioma* | 9451/3, 9460/3 |
Oligoastrocytic tumors* | 9382/3 |
Ependymal tumors* | 9391/3, 9392/3d, 9393/3d |
Glioma malignant, NOS* | 9380/3 |
Choroid plexus tumors | 9390/3 |
Other neuroepithelial tumors* | 9423/3, 9430/3 |
Neuronal and mixed neuronal-glial tumors* | 8680/3, 8693/3, 9505/3, 9522/3, 9523/3 |
Tumors of the pineal region | 9362/3, 9395/3d |
Embryonal tumors | 8963/3, 9364/3, 9470/3, 9471/3, 9472/3,9473/3, 9474/3, 9480/3, 9490/3, 9500/3, 9501/3, 9502/3, 9508/3 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/3, 9560/3, 9561/3, 9571/3 |
Tumors of Meninges | |
Meningioma | 9530/3, 9538/3, 9539/3 |
Mesenchymal tumors | 8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3, 850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3, 8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3 |
Primary melanocytic lesions | 8720/3, 8728/3, 8770/3, 8771/3 |
Other neoplasms related to the meninges | 9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3 |
Lymphomas and Hemopoietic Neoplasms | |
Lymphoma | 9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3, 9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3, 9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3, 9705/3, 9714/3, 9719/3, 9728/3, 9729/3 |
Other hemopoietic neoplasms | 9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3, 9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3 |
Unclassified Tumors | |
Hemangioma | 9120/3, 9130/3, 9133/3, 9140/3 |
Neoplasm, unspecified | 8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3 |
All other | 8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3 |
aIncludes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definitions.
bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
cSee the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.
dHistology not currently used to US cancer registration, will be included starting with diagnosis year 2015. See NAACCR website: http://www.naaccr.org/LinkClick.aspx?fileticket=4Hx-2XJJqFo%3d&tabid=161&mid=523.
*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Unique astrocytoma variants* | 9384/1 |
Ependymal tumors* | 9383/1, 9394/1 |
Choroid plexus | 9390/0,1 |
Other neuroepithelial tumors | 9363/0, 9444/1 |
Neuronal and mixed neuronal- glial tumors* | 8680/0,1, 8681/1, 8690/1, 8693/1, 9412/1, 9413/0, 9442/1, 9492/0 (excluding site C75.1), 9493/0, 9505/1, 9506/1, 9509/1d |
Tumors of the pineal region | 9360/1, 9361/1 |
Embryonal tumors | 9490/0 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/0,1, 9541/0, 9550/0, 9560/0,1, 9570/0, 9571/0 |
Other tumors of cranial and spinal nerves | 9562/0 |
Tumors of Meninges | |
Meningioma | 9530/0,1, 9531/0, 9532/0, 9533/0, 9534/0, 9537/0, 9538/1, 9539/1 |
Mesenchymal tumors | 8324/0, 8800/0, 8810/0, 8815/0, 8824/0,1, 8830/0,1, 8831/0, 8835/1, 8836/1, 8850/0,1, 8851/0, 8852/0, 8854/0, 8857/0, 8861/0, 8870/0, 8880/0, 8890/0,1, 8897/1, 8900/0, 8920/1, 8935/0,1, 8990/0,1, 9040/0, 9136/1, 9150/0,1, 9170/0, 9180/0, 9210/0, 9241/0, 9373/0 |
Primary melanocytic lesions | 8728/0,1, 8770/0, 8771/0 |
Other neoplasms related to the meninges | 9161/1, 9220/0,1, 9535/0 |
Lymphomas and Hemopoietic Neoplasms | |
Other hemopoietic neoplasms | 9740/1, 9751/1, 9752/1, 9753/1, 9766/1, 9970/1 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8440/0, 9080/0,1, 9084/0 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040/0,1, 8140/0,1, 8146/0, 8260/0, 8270/0, 8271/0, 8272/0, 8280/0, 8281/0, 8290/0, 8300/0, 8310/0, 8323/0, 9492/0 (site C75.1 only), 9582/0 |
Craniopharyngioma | 9350/1, 9351/1, 9352/1 |
Unclassified Tumors | |
Hemangioma | 9120/0, 9121/0, 9122/0, 9123/0, 9125/0, 9130/0,1, 9131/0, 9133/1 |
Neoplasm, unspecified | 8000/0,1, 8001/0,1, 8005/0, 8010/0 |
All other | 8452/1, 8711/0, 8713/0, 8811/0, 8840/0, 9173/0, 9580/0 |
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Unique astrocytoma variants* | 9384/1 |
Ependymal tumors* | 9383/1, 9394/1 |
Choroid plexus | 9390/0,1 |
Other neuroepithelial tumors | 9363/0, 9444/1 |
Neuronal and mixed neuronal- glial tumors* | 8680/0,1, 8681/1, 8690/1, 8693/1, 9412/1, 9413/0, 9442/1, 9492/0 (excluding site C75.1), 9493/0, 9505/1, 9506/1, 9509/1d |
Tumors of the pineal region | 9360/1, 9361/1 |
Embryonal tumors | 9490/0 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/0,1, 9541/0, 9550/0, 9560/0,1, 9570/0, 9571/0 |
Other tumors of cranial and spinal nerves | 9562/0 |
Tumors of Meninges | |
Meningioma | 9530/0,1, 9531/0, 9532/0, 9533/0, 9534/0, 9537/0, 9538/1, 9539/1 |
Mesenchymal tumors | 8324/0, 8800/0, 8810/0, 8815/0, 8824/0,1, 8830/0,1, 8831/0, 8835/1, 8836/1, 8850/0,1, 8851/0, 8852/0, 8854/0, 8857/0, 8861/0, 8870/0, 8880/0, 8890/0,1, 8897/1, 8900/0, 8920/1, 8935/0,1, 8990/0,1, 9040/0, 9136/1, 9150/0,1, 9170/0, 9180/0, 9210/0, 9241/0, 9373/0 |
Primary melanocytic lesions | 8728/0,1, 8770/0, 8771/0 |
Other neoplasms related to the meninges | 9161/1, 9220/0,1, 9535/0 |
Lymphomas and Hemopoietic Neoplasms | |
Other hemopoietic neoplasms | 9740/1, 9751/1, 9752/1, 9753/1, 9766/1, 9970/1 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8440/0, 9080/0,1, 9084/0 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040/0,1, 8140/0,1, 8146/0, 8260/0, 8270/0, 8271/0, 8272/0, 8280/0, 8281/0, 8290/0, 8300/0, 8310/0, 8323/0, 9492/0 (site C75.1 only), 9582/0 |
Craniopharyngioma | 9350/1, 9351/1, 9352/1 |
Unclassified Tumors | |
Hemangioma | 9120/0, 9121/0, 9122/0, 9123/0, 9125/0, 9130/0,1, 9131/0, 9133/1 |
Neoplasm, unspecified | 8000/0,1, 8001/0,1, 8005/0, 8010/0 |
All other | 8452/1, 8711/0, 8713/0, 8811/0, 8840/0, 9173/0, 9580/0 |
aIncludes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on brain tumor definition.
bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
cSee the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.
dHistology not currently used to US cancer registration, will be included starting with diagnosis year 2015. See NAACCR website: http://www.naaccr.org/LinkClick.aspx?fileticket=4Hx-2XJJqFo%3d&tabid=161&mid=523.
*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Unique astrocytoma variants* | 9384/1 |
Ependymal tumors* | 9383/1, 9394/1 |
Choroid plexus | 9390/0,1 |
Other neuroepithelial tumors | 9363/0, 9444/1 |
Neuronal and mixed neuronal- glial tumors* | 8680/0,1, 8681/1, 8690/1, 8693/1, 9412/1, 9413/0, 9442/1, 9492/0 (excluding site C75.1), 9493/0, 9505/1, 9506/1, 9509/1d |
Tumors of the pineal region | 9360/1, 9361/1 |
Embryonal tumors | 9490/0 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/0,1, 9541/0, 9550/0, 9560/0,1, 9570/0, 9571/0 |
Other tumors of cranial and spinal nerves | 9562/0 |
Tumors of Meninges | |
Meningioma | 9530/0,1, 9531/0, 9532/0, 9533/0, 9534/0, 9537/0, 9538/1, 9539/1 |
Mesenchymal tumors | 8324/0, 8800/0, 8810/0, 8815/0, 8824/0,1, 8830/0,1, 8831/0, 8835/1, 8836/1, 8850/0,1, 8851/0, 8852/0, 8854/0, 8857/0, 8861/0, 8870/0, 8880/0, 8890/0,1, 8897/1, 8900/0, 8920/1, 8935/0,1, 8990/0,1, 9040/0, 9136/1, 9150/0,1, 9170/0, 9180/0, 9210/0, 9241/0, 9373/0 |
Primary melanocytic lesions | 8728/0,1, 8770/0, 8771/0 |
Other neoplasms related to the meninges | 9161/1, 9220/0,1, 9535/0 |
Lymphomas and Hemopoietic Neoplasms | |
Other hemopoietic neoplasms | 9740/1, 9751/1, 9752/1, 9753/1, 9766/1, 9970/1 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8440/0, 9080/0,1, 9084/0 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040/0,1, 8140/0,1, 8146/0, 8260/0, 8270/0, 8271/0, 8272/0, 8280/0, 8281/0, 8290/0, 8300/0, 8310/0, 8323/0, 9492/0 (site C75.1 only), 9582/0 |
Craniopharyngioma | 9350/1, 9351/1, 9352/1 |
Unclassified Tumors | |
Hemangioma | 9120/0, 9121/0, 9122/0, 9123/0, 9125/0, 9130/0,1, 9131/0, 9133/1 |
Neoplasm, unspecified | 8000/0,1, 8001/0,1, 8005/0, 8010/0 |
All other | 8452/1, 8711/0, 8713/0, 8811/0, 8840/0, 9173/0, 9580/0 |
Histology . | ICD-O-3b Histology Codec . |
---|---|
Tumors of Neuroepithelial Tissue | |
Unique astrocytoma variants* | 9384/1 |
Ependymal tumors* | 9383/1, 9394/1 |
Choroid plexus | 9390/0,1 |
Other neuroepithelial tumors | 9363/0, 9444/1 |
Neuronal and mixed neuronal- glial tumors* | 8680/0,1, 8681/1, 8690/1, 8693/1, 9412/1, 9413/0, 9442/1, 9492/0 (excluding site C75.1), 9493/0, 9505/1, 9506/1, 9509/1d |
Tumors of the pineal region | 9360/1, 9361/1 |
Embryonal tumors | 9490/0 |
Tumors of Cranial and Spinal Nerves | |
Nerve sheath tumors | 9540/0,1, 9541/0, 9550/0, 9560/0,1, 9570/0, 9571/0 |
Other tumors of cranial and spinal nerves | 9562/0 |
Tumors of Meninges | |
Meningioma | 9530/0,1, 9531/0, 9532/0, 9533/0, 9534/0, 9537/0, 9538/1, 9539/1 |
Mesenchymal tumors | 8324/0, 8800/0, 8810/0, 8815/0, 8824/0,1, 8830/0,1, 8831/0, 8835/1, 8836/1, 8850/0,1, 8851/0, 8852/0, 8854/0, 8857/0, 8861/0, 8870/0, 8880/0, 8890/0,1, 8897/1, 8900/0, 8920/1, 8935/0,1, 8990/0,1, 9040/0, 9136/1, 9150/0,1, 9170/0, 9180/0, 9210/0, 9241/0, 9373/0 |
Primary melanocytic lesions | 8728/0,1, 8770/0, 8771/0 |
Other neoplasms related to the meninges | 9161/1, 9220/0,1, 9535/0 |
Lymphomas and Hemopoietic Neoplasms | |
Other hemopoietic neoplasms | 9740/1, 9751/1, 9752/1, 9753/1, 9766/1, 9970/1 |
Germ Cell Tumors and Cysts | |
Germ cell tumors, cysts and heterotopias | 8440/0, 9080/0,1, 9084/0 |
Tumors of Sellar Region | |
Tumors of the pituitary | 8040/0,1, 8140/0,1, 8146/0, 8260/0, 8270/0, 8271/0, 8272/0, 8280/0, 8281/0, 8290/0, 8300/0, 8310/0, 8323/0, 9492/0 (site C75.1 only), 9582/0 |
Craniopharyngioma | 9350/1, 9351/1, 9352/1 |
Unclassified Tumors | |
Hemangioma | 9120/0, 9121/0, 9122/0, 9123/0, 9125/0, 9130/0,1, 9131/0, 9133/1 |
Neoplasm, unspecified | 8000/0,1, 8001/0,1, 8005/0, 8010/0 |
All other | 8452/1, 8711/0, 8713/0, 8811/0, 8840/0, 9173/0, 9580/0 |
aIncludes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on brain tumor definition.
bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
cSee the CBTRUS website for additional information about the specific histology codes included in each group: http://www.cbtrus.org.
dHistology not currently used to US cancer registration, will be included starting with diagnosis year 2015. See NAACCR website: http://www.naaccr.org/LinkClick.aspx?fileticket=4Hx-2XJJqFo%3d&tabid=161&mid=523.
*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Adolescent and Young Adult Report Major Histology Groupings . | CBTRUS Histology Groupings . | ICD-O-3b Morphology Code . | Histology Name . | Sub-histologies . |
---|---|---|---|---|
Astrocytomas | Pilocytic astrocytoma | 9421/1 | Pilocytic astrocytoma | Piloid astrocytoma; Juvenile astrocytoma; Spongioblastoma, NOS |
9425/3 | Pilomyxoid astrocytoma | |||
Diffuse astrocytoma | 9400/3 | Astrocytoma, NOS | Astroglioma; Astrocytic glioma; Diffuse astrocytoma; Astrocytoma, low grade; Cystic astrocytoma; Diffuse astrocytoma, low grade | |
9410/3 | Protoplasmic astrocytoma | |||
9411/3 | Gemistocytic astrocytoma | Gemistocytoma | ||
9420/3 | Fibrillary astrocytoma | Fibrous astrocytoma | ||
Anaplastic astrocytoma | 9401/3 | Astrocytoma, anaplastic | ||
Unique astrocytoma variants | 9381/3 | Gliomatosis cerebri | ||
9384/1 | Subependymal giant cell astrocytoma | |||
9424/3 | Pleomorphic xanthoastrocytoma | |||
Glioblastoma | 9440/3 | Glioblastoma | Glioblastoma multiforme; Spongioblastoma multiforme | |
9441/3 | Giant cell glioblastoma | Monstrocellular sarcoma | ||
9442/3 | Gliosarcoma | Glioblastoma with sarcomatous component | ||
Oligodendrogliomas | Oligodendroglioma | 9450/3 | Oligodendroglioma, NOS | |
Anaplastic oligodendroglioma | 9451/3 | Oligodendroglioma, anaplastic | ||
9460/3 | Oligodendroblastoma | |||
Oligoastrocytoma | Oligoastrocytic tumors | 9382/3 | Mixed glioma | Oligoastrocytoma; Anaplastic oligoastrocytoma |
Ependymal tumors | Ependymal tumors | 9383/1 | Subependymoma | Subependymal glioma; Subependymal astrocytoma, NOS; Mixed subependymoma-ependymoma |
9391/3 | Ependymoma, NOS | Epithelial ependymoma; Cellular ependymoma; Clear cell ependymoma; Tanycytic ependymoma | ||
9392/3 | Ependymoma, anaplastic | Ependymoblastoma | ||
9393/3 | Papillary ependymoma | |||
9394/1 | Myxopapillary ependymoma | |||
Glioma malignant, NOS | Glioma malignant, NOS | 9380/3 | Glioma, malignant | Glioma, NOS (except nasal glioma, not neoplastic) |
Other neuroepithelial tumors | Other neuroepithelial tumors | 9423/3 | Polar spongioblastoma | Spongioblastoma polare; Primitive polar spongioblastoma |
9430/3 | Astroblastoma | |||
9444/1 | Chordoid glioma | Chordoid glioma of third ventricle | ||
Neuronal and mixed neuronal-glial tumors | Neuronal and mixed neuronal-glial tumors | 9412/1 | Desmoplastic infantile astrocytoma | Desmoplastic infantile ganglioglioma |
9413/0 | Dysembryoplastic neuroepithelial tumor | |||
9442/1 | Gliofibroma |
Adolescent and Young Adult Report Major Histology Groupings . | CBTRUS Histology Groupings . | ICD-O-3b Morphology Code . | Histology Name . | Sub-histologies . |
---|---|---|---|---|
Astrocytomas | Pilocytic astrocytoma | 9421/1 | Pilocytic astrocytoma | Piloid astrocytoma; Juvenile astrocytoma; Spongioblastoma, NOS |
9425/3 | Pilomyxoid astrocytoma | |||
Diffuse astrocytoma | 9400/3 | Astrocytoma, NOS | Astroglioma; Astrocytic glioma; Diffuse astrocytoma; Astrocytoma, low grade; Cystic astrocytoma; Diffuse astrocytoma, low grade | |
9410/3 | Protoplasmic astrocytoma | |||
9411/3 | Gemistocytic astrocytoma | Gemistocytoma | ||
9420/3 | Fibrillary astrocytoma | Fibrous astrocytoma | ||
Anaplastic astrocytoma | 9401/3 | Astrocytoma, anaplastic | ||
Unique astrocytoma variants | 9381/3 | Gliomatosis cerebri | ||
9384/1 | Subependymal giant cell astrocytoma | |||
9424/3 | Pleomorphic xanthoastrocytoma | |||
Glioblastoma | 9440/3 | Glioblastoma | Glioblastoma multiforme; Spongioblastoma multiforme | |
9441/3 | Giant cell glioblastoma | Monstrocellular sarcoma | ||
9442/3 | Gliosarcoma | Glioblastoma with sarcomatous component | ||
Oligodendrogliomas | Oligodendroglioma | 9450/3 | Oligodendroglioma, NOS | |
Anaplastic oligodendroglioma | 9451/3 | Oligodendroglioma, anaplastic | ||
9460/3 | Oligodendroblastoma | |||
Oligoastrocytoma | Oligoastrocytic tumors | 9382/3 | Mixed glioma | Oligoastrocytoma; Anaplastic oligoastrocytoma |
Ependymal tumors | Ependymal tumors | 9383/1 | Subependymoma | Subependymal glioma; Subependymal astrocytoma, NOS; Mixed subependymoma-ependymoma |
9391/3 | Ependymoma, NOS | Epithelial ependymoma; Cellular ependymoma; Clear cell ependymoma; Tanycytic ependymoma | ||
9392/3 | Ependymoma, anaplastic | Ependymoblastoma | ||
9393/3 | Papillary ependymoma | |||
9394/1 | Myxopapillary ependymoma | |||
Glioma malignant, NOS | Glioma malignant, NOS | 9380/3 | Glioma, malignant | Glioma, NOS (except nasal glioma, not neoplastic) |
Other neuroepithelial tumors | Other neuroepithelial tumors | 9423/3 | Polar spongioblastoma | Spongioblastoma polare; Primitive polar spongioblastoma |
9430/3 | Astroblastoma | |||
9444/1 | Chordoid glioma | Chordoid glioma of third ventricle | ||
Neuronal and mixed neuronal-glial tumors | Neuronal and mixed neuronal-glial tumors | 9412/1 | Desmoplastic infantile astrocytoma | Desmoplastic infantile ganglioglioma |
9413/0 | Dysembryoplastic neuroepithelial tumor | |||
9442/1 | Gliofibroma |
aICD-O-3 histology codes: 9380-9384, 9391-9460.
bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Adolescent and Young Adult Report Major Histology Groupings . | CBTRUS Histology Groupings . | ICD-O-3b Morphology Code . | Histology Name . | Sub-histologies . |
---|---|---|---|---|
Astrocytomas | Pilocytic astrocytoma | 9421/1 | Pilocytic astrocytoma | Piloid astrocytoma; Juvenile astrocytoma; Spongioblastoma, NOS |
9425/3 | Pilomyxoid astrocytoma | |||
Diffuse astrocytoma | 9400/3 | Astrocytoma, NOS | Astroglioma; Astrocytic glioma; Diffuse astrocytoma; Astrocytoma, low grade; Cystic astrocytoma; Diffuse astrocytoma, low grade | |
9410/3 | Protoplasmic astrocytoma | |||
9411/3 | Gemistocytic astrocytoma | Gemistocytoma | ||
9420/3 | Fibrillary astrocytoma | Fibrous astrocytoma | ||
Anaplastic astrocytoma | 9401/3 | Astrocytoma, anaplastic | ||
Unique astrocytoma variants | 9381/3 | Gliomatosis cerebri | ||
9384/1 | Subependymal giant cell astrocytoma | |||
9424/3 | Pleomorphic xanthoastrocytoma | |||
Glioblastoma | 9440/3 | Glioblastoma | Glioblastoma multiforme; Spongioblastoma multiforme | |
9441/3 | Giant cell glioblastoma | Monstrocellular sarcoma | ||
9442/3 | Gliosarcoma | Glioblastoma with sarcomatous component | ||
Oligodendrogliomas | Oligodendroglioma | 9450/3 | Oligodendroglioma, NOS | |
Anaplastic oligodendroglioma | 9451/3 | Oligodendroglioma, anaplastic | ||
9460/3 | Oligodendroblastoma | |||
Oligoastrocytoma | Oligoastrocytic tumors | 9382/3 | Mixed glioma | Oligoastrocytoma; Anaplastic oligoastrocytoma |
Ependymal tumors | Ependymal tumors | 9383/1 | Subependymoma | Subependymal glioma; Subependymal astrocytoma, NOS; Mixed subependymoma-ependymoma |
9391/3 | Ependymoma, NOS | Epithelial ependymoma; Cellular ependymoma; Clear cell ependymoma; Tanycytic ependymoma | ||
9392/3 | Ependymoma, anaplastic | Ependymoblastoma | ||
9393/3 | Papillary ependymoma | |||
9394/1 | Myxopapillary ependymoma | |||
Glioma malignant, NOS | Glioma malignant, NOS | 9380/3 | Glioma, malignant | Glioma, NOS (except nasal glioma, not neoplastic) |
Other neuroepithelial tumors | Other neuroepithelial tumors | 9423/3 | Polar spongioblastoma | Spongioblastoma polare; Primitive polar spongioblastoma |
9430/3 | Astroblastoma | |||
9444/1 | Chordoid glioma | Chordoid glioma of third ventricle | ||
Neuronal and mixed neuronal-glial tumors | Neuronal and mixed neuronal-glial tumors | 9412/1 | Desmoplastic infantile astrocytoma | Desmoplastic infantile ganglioglioma |
9413/0 | Dysembryoplastic neuroepithelial tumor | |||
9442/1 | Gliofibroma |
Adolescent and Young Adult Report Major Histology Groupings . | CBTRUS Histology Groupings . | ICD-O-3b Morphology Code . | Histology Name . | Sub-histologies . |
---|---|---|---|---|
Astrocytomas | Pilocytic astrocytoma | 9421/1 | Pilocytic astrocytoma | Piloid astrocytoma; Juvenile astrocytoma; Spongioblastoma, NOS |
9425/3 | Pilomyxoid astrocytoma | |||
Diffuse astrocytoma | 9400/3 | Astrocytoma, NOS | Astroglioma; Astrocytic glioma; Diffuse astrocytoma; Astrocytoma, low grade; Cystic astrocytoma; Diffuse astrocytoma, low grade | |
9410/3 | Protoplasmic astrocytoma | |||
9411/3 | Gemistocytic astrocytoma | Gemistocytoma | ||
9420/3 | Fibrillary astrocytoma | Fibrous astrocytoma | ||
Anaplastic astrocytoma | 9401/3 | Astrocytoma, anaplastic | ||
Unique astrocytoma variants | 9381/3 | Gliomatosis cerebri | ||
9384/1 | Subependymal giant cell astrocytoma | |||
9424/3 | Pleomorphic xanthoastrocytoma | |||
Glioblastoma | 9440/3 | Glioblastoma | Glioblastoma multiforme; Spongioblastoma multiforme | |
9441/3 | Giant cell glioblastoma | Monstrocellular sarcoma | ||
9442/3 | Gliosarcoma | Glioblastoma with sarcomatous component | ||
Oligodendrogliomas | Oligodendroglioma | 9450/3 | Oligodendroglioma, NOS | |
Anaplastic oligodendroglioma | 9451/3 | Oligodendroglioma, anaplastic | ||
9460/3 | Oligodendroblastoma | |||
Oligoastrocytoma | Oligoastrocytic tumors | 9382/3 | Mixed glioma | Oligoastrocytoma; Anaplastic oligoastrocytoma |
Ependymal tumors | Ependymal tumors | 9383/1 | Subependymoma | Subependymal glioma; Subependymal astrocytoma, NOS; Mixed subependymoma-ependymoma |
9391/3 | Ependymoma, NOS | Epithelial ependymoma; Cellular ependymoma; Clear cell ependymoma; Tanycytic ependymoma | ||
9392/3 | Ependymoma, anaplastic | Ependymoblastoma | ||
9393/3 | Papillary ependymoma | |||
9394/1 | Myxopapillary ependymoma | |||
Glioma malignant, NOS | Glioma malignant, NOS | 9380/3 | Glioma, malignant | Glioma, NOS (except nasal glioma, not neoplastic) |
Other neuroepithelial tumors | Other neuroepithelial tumors | 9423/3 | Polar spongioblastoma | Spongioblastoma polare; Primitive polar spongioblastoma |
9430/3 | Astroblastoma | |||
9444/1 | Chordoid glioma | Chordoid glioma of third ventricle | ||
Neuronal and mixed neuronal-glial tumors | Neuronal and mixed neuronal-glial tumors | 9412/1 | Desmoplastic infantile astrocytoma | Desmoplastic infantile ganglioglioma |
9413/0 | Dysembryoplastic neuroepithelial tumor | |||
9442/1 | Gliofibroma |
aICD-O-3 histology codes: 9380-9384, 9391-9460.
bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.
Caution should be used in comparing incidence rates between statistical reports from different reporting agencies or previous CBTRUS statistical reports due to differences in case definition, data collection, rate calculations, and/or reporting delays.
Methods
Counts, means, rates, ratios, proportions, and other relevant statistics were calculated using R 3.1.2 statistical software18 and/or SEER*Stat 8.2.1.19 Figures were created in R 3.1.218 using rgeos,20 rgdal,21 maptools,22 ggplot2,23 plotrix,24 and SEER2R.25 Statistics are suppressed when counts are fewer than 16 within a cell. However, the data in the suppressed cells are included in the counts and rates for the totals except when data from only one cell are suppressed within a category to prevent identification of the number in the suppressed cell. Note that reported percentages may not add up to 100% due to rounding.
Population data for each geographic region were obtained from the SEER program website13 for the purpose of rate calculations.
Age-adjusted incidence rates and 95% confidence intervals26 were estimated for malignant and non-malignant tumors and for selected histology groupings by gender, race, Hispanic ethnicity, and age groups. Age-adjustment was based on one-year age groupings and standardized to the 2000 US standard population. Combined populations for the regions included in this report are shown in Appendix A and Appendix B.
CBTRUS presents statistics on specific brain and CNS tumor patterns in age groups 15-19, 20-24, 25-29, 30-34 and 35-39 years. Race categories in this report are all races, White, Black, American Indian/Alaskan Native (AIAN), and Asian/Pacific Islander (API). Other race, unspecified, and unknown race are included in statistics that are not race-specific. Hispanic ethnicity was defined using the NAACCR Hispanic Identification Algorithm, version 2, data element, which utilizes a combination of cancer registry data fields (Spanish/Hispanic Origin data element, birthplace, race, and surnames) to directly and indirectly classify cases as Hispanic or Non-Hispanic.27 The NAACCR regional scheme (http://faststats.naaccr.org/usregions.php) was used for statistics reported by region of the US.
Estimation of Expected Numbers of Brain and CNS Tumors in 2015 and 2016
Estimated numbers of expected malignant and non-malignant brain and CNS tumors in adolescents and young adults (age 15-39 years) were calculated for 2015 and 2016. To project 2015 and 2016 counts of newly diagnosed brain and CNS tumors, age-adjusted annual brain tumor incidence rates were generated for 2000-2012 for malignant tumors and 2006-2012 for non-malignant tumors. These were generated by state, age, and histologic type. Joinpoint 4.2.028 was used to fit regression models to these incidence rates,29 which were used to predict numbers of cases in future years using the parameter from the selected models. The models allowed for a maximum of two joinpoints (one for non-malignant tumors), a minimum of three observations from a joinpoint to either end of the data, and a minimum of three observations between joinpoints.30 Permutation procedures included in Joinpoint were used to select the best fitting model.
Estimation of Mortality Rates
Age-adjusted mortality rates for deaths resulting in adolescents and young adults (age 15-39 years) from all malignant brain and CNS tumors were calculated using the mortality data available in the CDC WONDER Online Database provided by National Center for Health Statistics (NCHS).8 The SEER cause of death recode31 was used to categorize all mortality data used in this report. In addition to total age-adjusted rate for the US, age-adjusted rates are presented by gender and region of the US.
Estimation of Lifetime Risk of Developing or Dying from a Malignant Brain and CNS Tumor
Probability of developing or dying from a malignant brain and CNS tumor was estimated for the years 2009 to 2011 using the SEER 18 incidence data,32 and total US mortality data using DevCan.33
Estimation of Survival Rates
Survival analyses were conducted using multiple-year cohorts which include all persons diagnosed during the time period specified for the survival calculation.34 Second or later primary tumors, cases diagnosed at autopsy, cases in which race or sex is coded as other or unknown, and cases known to be alive but for whom follow-up time could not be calculated were excluded from the SEER survival data analyses. SEER*Stat 8.2.1 statistical software was used to estimate one-, two-, three-, four-, five-, and ten-year relative survival rates for primary malignant brain tumor cases diagnosed between 1995-2012 in eighteen SEER areas.19,32 This software utilizes life-table (actuarial) methods to compute survival estimates and accounts for current follow-up. Survival was estimated for brain (C71.0-C71.9), meninges (C70.0-C70.9), spinal cord, cranial nerves, and other parts of the central nervous system (C72.0-C72.9), pituitary and pineal glands (C75.1-C75.3), and olfactory tumors of the nasal cavity [C30.0 (9522-9523)]. Survival was not calculated for non-malignant tumors as collection of these cases has only been mandated since 2004, and, therefore, not enough time has elapsed to accurately calculate relative survival.
Five-year conditional survival estimates were calculated for brain tumor cases diagnosed between 1995-2012 in eighteen SEER areas using SEER*Stat 8.2.1 statistical software.19,32 Conditional survival is an estimate of the probability that a patient will survive for a specific time period given that they have already survived a certain number of years. For example, 5-year conditional survival for an adolescent (age 15-19 years) who has lived two years since their diagnosis with pilocytic astrocytoma is 98.5%, which means that 98.5% of adolescents who have already survived two years will eventually survive five years.
Results
Cancer is a significant source of morbidity and mortality for adolescents and young adults (age 15-39 years) in the US. Death due to cancer is the fourth most common cause of death overall in this age group (8.78 deaths per 100,000 persons annually) with only accidents (32.95 deaths per 100,000), suicide (12.77 deaths per 100,000), and homicide (10.06 per 100,000) causing more deaths annually in this population between 2008 and 2012. Among all deaths due to cancer by histology, brain and CNS tumors are the 3rd most common cause of cancer death. Approximately 1.5% of persons will be diagnosed with cancer between the ages of 15 and 39 years, and approximately 0.07% will develop a primary malignant brain tumor.33 Approximately 10,600 brain and CNS tumors are diagnosed in AYA per year, and they are the cause of approximately 450 deaths annually in this age group.
Comparison to Other Common AYA Cancers
Average annual age-adjusted and crude incidence rates for the five most common cancers in adolescents and young adults (age 15-39 years) are shown in Figure 1A-F. Due to the comparatively low mortality rate that many common cancers have, these may not be the same cancers included for mortality comparison.
Primary brain and CNS tumors are the third most common cancer in those age 15-39 years (10.43 per 100,000 population), with only breast (21.22 per 100,000 population) and thyroid cancer (10.84 per 100,000 population) occurring more frequently.
Primary brain and CNS tumors are the most commonly occurring type of cancer in those age 15-19 years (6.19 per 100,000 population), followed by testes (3.61 per 100,000 male population), Hodgkin lymphoma (3.23 per 100,000 population), leukemia (2.92 per 100,000), and thyroid (2.58 per 100,000 population).
Brain and CNS tumors are the second most commonly occurring cancer in those age 20-24 years (7.12 per 100,000), with only cancer of the testes occurring more frequently (9.43 per 100,000 males).
Brain and CNS tumors are the third most commonly occurring cancer in those age 25-29 years (9.93 per 100,000 population), preceded by cancer of the testes (14.01 per 100,000 male population) and thyroid (10.23 per 100,000 population).
Brain and CNS tumors are the fourth most commonly occurring cancer in those age 30-34 years (12.65 per 100,000 population), preceded by cancer of the breast (27.14 per 100,000 female population), thyroid (15.52 per 100,000 population), and testes (13.84 per 100,000 male population).
Brain and CNS tumors are the third most commonly occurring cancer in those age 35-39 years (15.54 per 100,000 population), preceded by cancer of the breast (60.91 per 100,000 population), and thyroid (18.87 per 100,000 population).
Average annual age-adjusted and crude mortality rates overall and by 5-year age groups for the five most common causes of cancer death in adolescents and young adults are showed in Figure 2A-F. Due to the high mortality caused by cancers with lower incidence, these cancers may be different than those displayed in incidence comparisons. Age ranges for mortality figures reflect age at death, as compared to incidence rates that reflect age at diagnosis. Time period between diagnosis and death can vary substantially by tumor type and by individual.
Primary brain and CNS tumors are the third most common cause of cancer death in those age 15-39 years (1.09 per 100,000 population), with only breast cancer (1.78 per 100,000 female population) and colorectal cancer (1.19 per 100,000 population population) causing a higher rate of deaths.
Primary brain and CNS tumors are the second most common cause of cancer death in persons age 15-19 years (0.49 per 100,000 population in age 15-19 years, 0.56 per 100,000 in age 20-24 years, and 0.77 per 100,000 population in age 25-29 years), with only leukemia causing more deaths (0.79 per 100,000 in age 15-19 years, 0.97 per 100,000 population in age 20-24 years, and 1.03 per 100,000 population in age 25-29 years).
Primary brain and CNS tumors are the third most common cause of cancer death in persons age 30-39 years (1.11 per 100,000 population in age 30-34 years, and 1.62 per 100,000 population in age 35-39 years). In those age 30-34 years, the more common causes of cancer death are leukemia (1.14 per 100,000 population) and breast cancer (1.36 per 100,000 population), while in those age 35-39 years the more common causes are due to colorectal cancer (2.21 per 100,000 population) and breast cancer (3.36 per 100,000 population).
Overall Incidence by Age Group and Year of Diagnosis
Between 2008 and 2012, 53,083 primary brain and CNS tumors were diagnosed in adolescents and young adults (age 15-39 years) in the US, for a total annual age-adjusted incidence of 10.43 per 100,000 population (Table 3). Average annual age-adjusted incidence rates of primary brain and CNS tumors and total tumors occurring in the five year period covered in this report are shown in Figure 3 and Table 3.
Incidence of primary brain and CNS tumors increases with increasing age in those age 15-39 years.
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 3.44 | (3.39-3.49) | 2.83 | (2.73-2.93) | 2.75 | (2.65-2.85) | 3.49 | (3.38-3.61) | 3.91 | (3.79-4.04) | 4.14 | (4.01-4.26) |
Pilocytic astrocytoma | 1,519 | 304 | 0.28 | (0.27-0.30) | 0.60 | (0.55-0.65) | 0.31 | (0.28-0.35) | 0.21 | (0.18-0.24) | 0.18 | (0.16-0.21) | 0.13 | (0.11-0.15) |
Diffuse astrocytoma | 2,413 | 483 | 0.47 | (0.45-0.49) | 0.27 | (0.24-0.31) | 0.35 | (0.32-0.39) | 0.52 | (0.47-0.56) | 0.61 | (0.56-0.66) | 0.58 | (0.53-0.63) |
Anaplastic astrocytoma | 1,398 | 280 | 0.27 | (0.26-0.29) | 0.10 | (0.08-0.12) | 0.19 | (0.16-0.21) | 0.33 | (0.29-0.36) | 0.36 | (0.32-0.40) | 0.39 | (0.35-0.43) |
Unique astrocytoma variants | 381 | 76 | 0.07 | (0.06-0.08) | 0.11 | (0.09-0.13) | 0.10 | (0.09-0.13) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.06) | 0.04 | (0.02-0.05) |
Glioblastoma | 2,393 | 479 | 0.48 | (0.46-0.50) | 0.19 | (0.17-0.22) | 0.28 | (0.25-0.31) | 0.43 | (0.39-0.47) | 0.56 | (0.51-0.61) | 0.88 | (0.82-0.94) |
Oligodendroglioma | 1,488 | 298 | 0.29 | (0.28-0.31) | 0.09 | (0.07-0.11) | 0.16 | (0.14-0.19) | 0.32 | (0.28-0.35) | 0.43 | (0.39-0.47) | 0.45 | (0.41-0.49) |
Anaplastic oligodendroglioma | 420 | 84 | 0.08 | (0.08-0.09) | 0.02 | (0.01-0.02) | 0.04 | (0.03-0.05) | 0.09 | (0.07-0.11) | 0.12 | (0.10-0.14) | 0.15 | (0.13-0.17) |
Oligoastrocytic tumors | 1,333 | 267 | 0.26 | (0.25-0.28) | 0.06 | (0.05-0.08) | 0.16 | (0.13-0.18) | 0.36 | (0.32-0.39) | 0.38 | (0.34-0.42) | 0.35 | (0.31-0.39) |
Ependymal tumors | 1,888 | 378 | 0.37 | (0.35-0.38) | 0.25 | (0.22-0.28) | 0.28 | (0.25-0.32) | 0.38 | (0.34-0.42) | 0.45 | (0.41-0.50) | 0.46 | (0.42-0.51) |
Glioma malignant, NOS | 1,384 | 277 | 0.26 | (0.25-0.28) | 0.32 | (0.29-0.36) | 0.24 | (0.21-0.27) | 0.25 | (0.22-0.28) | 0.26 | (0.23-0.30) | 0.25 | (0.22-0.29) |
Choroid plexus tumors | 183 | 37 | 0.03 | (0.03-0.04) | 0.05 | (0.04-0.06) | 0.02 | (0.01-0.03) | 0.04 | (0.03-0.05) | 0.04 | (0.03-0.05) | 0.03 | (0.02-0.05) |
Other neuroepithelial tumors | 30 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 0.33 | (0.32-0.35) | 0.48 | (0.44-0.53) | 0.37 | (0.33-0.41) | 0.30 | (0.27-0.34) | 0.28 | (0.25-0.32) | 0.25 | (0.22-0.28) |
Tumors of the pineal region | 258 | 52 | 0.05 | (0.04-0.06) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.05 | (0.04-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.07) |
Embryonal tumors | 915 | 183 | 0.17 | (0.16-0.18) | 0.24 | (0.21-0.27) | 0.19 | (0.17-0.22) | 0.18 | (0.15-0.20) | 0.14 | (0.12-0.16) | 0.12 | (0.10-0.14) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 0.91 | (0.88-0.94) | 0.36 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.54-1.69) |
Nerve sheath tumors | 4,545 | 909 | 0.91 | (0.88-0.93) | 0.35 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.53-1.69) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 1.98 | (1.95-2.02) | 0.45 | (0.41-0.49) | 0.76 | (0.71-0.81) | 1.43 | (1.36-1.50) | 2.65 | (2.55-2.76) | 4.25 | (4.12-4.38) |
Meningioma | 8,440 | 1,688 | 1.74 | (1.70-1.77) | 0.30 | (0.27-0.34) | 0.57 | (0.53-0.62) | 1.20 | (1.14-1.27) | 2.34 | (2.24-2.43) | 3.90 | (3.78-4.03) |
Mesenchymal tumors | 336 | 67 | 0.07 | (0.06-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.11) | 0.10 | (0.08-0.12) |
Primary melanocytic lesions | 22 | – | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 0.18 | (0.17-0.19) | 0.10 | (0.08-0.12) | 0.14 | (0.12-0.16) | 0.18 | (0.15-0.21) | 0.22 | (0.20-0.26) | 0.24 | (0.21-0.27) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 0.12 | (0.11-0.13) | 0.04 | (0.03-0.05) | 0.07 | (0.06-0.09) | 0.10 | (0.08-0.12) | 0.16 | (0.14-0.19) | 0.24 | (0.21-0.27) |
Lymphoma | 576 | 115 | 0.12 | (0.11-0.13) | 0.02 | (0.02-0.04) | 0.07 | (0.05-0.08) | 0.09 | (0.07-0.11) | 0.15 | (0.13-0.18) | 0.23 | (0.20-0.26) |
Other hematopoietic neoplasms | 43 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Tumors of Sellar Region | 16,559 | 3,312 | 3.23 | (3.18-3.28) | 1.79 | (1.71-1.87) | 2.44 | (2.35-2.54) | 3.36 | (3.25-3.47) | 4.00 | (3.88-4.13) | 4.43 | (4.30-4.56) |
Tumors of the pituitary | 15,892 | 3,178 | 3.10 | (3.05-3.15) | 1.66 | (1.58-1.73) | 2.32 | (2.24-2.42) | 3.25 | (3.14-3.36) | 3.87 | (3.75-3.99) | 4.27 | (4.15-4.40) |
Craniopharyngioma | 667 | 133 | 0.13 | (0.12-0.14) | 0.13 | (0.11-0.15) | 0.12 | (0.10-0.14) | 0.11 | (0.09-0.13) | 0.13 | (0.11-0.16) | 0.15 | (0.13-0.18) |
Unclassified Tumors | 3,217 | 643 | 0.63 | (0.60-0.65) | 0.46 | (0.42-0.50) | 0.46 | (0.42-0.50) | 0.63 | (0.58-0.68) | 0.72 | (0.67-0.77) | 0.83 | (0.77-0.89) |
Hemangioma | 1,538 | 308 | 0.30 | (0.29-0.32) | 0.20 | (0.17-0.23) | 0.23 | (0.20-0.26) | 0.31 | (0.27-0.34) | 0.34 | (0.31-0.38) | 0.41 | (0.37-0.46) |
Neoplasm, unspecified | 1,667 | 333 | 0.32 | (0.31-0.34) | 0.26 | (0.23-0.29) | 0.23 | (0.20-0.26) | 0.32 | (0.29-0.36) | 0.37 | (0.33-0.41) | 0.42 | (0.38-0.46) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 10.43 | (10.34-10.52) | 6.19 | (6.04-6.34) | 7.12 | (6.97-7.28) | 9.93 | (9.73-10.12) | 12.65 | (12.43-12.88) | 15.54 | (15.3-15.79) |
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 3.44 | (3.39-3.49) | 2.83 | (2.73-2.93) | 2.75 | (2.65-2.85) | 3.49 | (3.38-3.61) | 3.91 | (3.79-4.04) | 4.14 | (4.01-4.26) |
Pilocytic astrocytoma | 1,519 | 304 | 0.28 | (0.27-0.30) | 0.60 | (0.55-0.65) | 0.31 | (0.28-0.35) | 0.21 | (0.18-0.24) | 0.18 | (0.16-0.21) | 0.13 | (0.11-0.15) |
Diffuse astrocytoma | 2,413 | 483 | 0.47 | (0.45-0.49) | 0.27 | (0.24-0.31) | 0.35 | (0.32-0.39) | 0.52 | (0.47-0.56) | 0.61 | (0.56-0.66) | 0.58 | (0.53-0.63) |
Anaplastic astrocytoma | 1,398 | 280 | 0.27 | (0.26-0.29) | 0.10 | (0.08-0.12) | 0.19 | (0.16-0.21) | 0.33 | (0.29-0.36) | 0.36 | (0.32-0.40) | 0.39 | (0.35-0.43) |
Unique astrocytoma variants | 381 | 76 | 0.07 | (0.06-0.08) | 0.11 | (0.09-0.13) | 0.10 | (0.09-0.13) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.06) | 0.04 | (0.02-0.05) |
Glioblastoma | 2,393 | 479 | 0.48 | (0.46-0.50) | 0.19 | (0.17-0.22) | 0.28 | (0.25-0.31) | 0.43 | (0.39-0.47) | 0.56 | (0.51-0.61) | 0.88 | (0.82-0.94) |
Oligodendroglioma | 1,488 | 298 | 0.29 | (0.28-0.31) | 0.09 | (0.07-0.11) | 0.16 | (0.14-0.19) | 0.32 | (0.28-0.35) | 0.43 | (0.39-0.47) | 0.45 | (0.41-0.49) |
Anaplastic oligodendroglioma | 420 | 84 | 0.08 | (0.08-0.09) | 0.02 | (0.01-0.02) | 0.04 | (0.03-0.05) | 0.09 | (0.07-0.11) | 0.12 | (0.10-0.14) | 0.15 | (0.13-0.17) |
Oligoastrocytic tumors | 1,333 | 267 | 0.26 | (0.25-0.28) | 0.06 | (0.05-0.08) | 0.16 | (0.13-0.18) | 0.36 | (0.32-0.39) | 0.38 | (0.34-0.42) | 0.35 | (0.31-0.39) |
Ependymal tumors | 1,888 | 378 | 0.37 | (0.35-0.38) | 0.25 | (0.22-0.28) | 0.28 | (0.25-0.32) | 0.38 | (0.34-0.42) | 0.45 | (0.41-0.50) | 0.46 | (0.42-0.51) |
Glioma malignant, NOS | 1,384 | 277 | 0.26 | (0.25-0.28) | 0.32 | (0.29-0.36) | 0.24 | (0.21-0.27) | 0.25 | (0.22-0.28) | 0.26 | (0.23-0.30) | 0.25 | (0.22-0.29) |
Choroid plexus tumors | 183 | 37 | 0.03 | (0.03-0.04) | 0.05 | (0.04-0.06) | 0.02 | (0.01-0.03) | 0.04 | (0.03-0.05) | 0.04 | (0.03-0.05) | 0.03 | (0.02-0.05) |
Other neuroepithelial tumors | 30 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 0.33 | (0.32-0.35) | 0.48 | (0.44-0.53) | 0.37 | (0.33-0.41) | 0.30 | (0.27-0.34) | 0.28 | (0.25-0.32) | 0.25 | (0.22-0.28) |
Tumors of the pineal region | 258 | 52 | 0.05 | (0.04-0.06) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.05 | (0.04-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.07) |
Embryonal tumors | 915 | 183 | 0.17 | (0.16-0.18) | 0.24 | (0.21-0.27) | 0.19 | (0.17-0.22) | 0.18 | (0.15-0.20) | 0.14 | (0.12-0.16) | 0.12 | (0.10-0.14) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 0.91 | (0.88-0.94) | 0.36 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.54-1.69) |
Nerve sheath tumors | 4,545 | 909 | 0.91 | (0.88-0.93) | 0.35 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.53-1.69) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 1.98 | (1.95-2.02) | 0.45 | (0.41-0.49) | 0.76 | (0.71-0.81) | 1.43 | (1.36-1.50) | 2.65 | (2.55-2.76) | 4.25 | (4.12-4.38) |
Meningioma | 8,440 | 1,688 | 1.74 | (1.70-1.77) | 0.30 | (0.27-0.34) | 0.57 | (0.53-0.62) | 1.20 | (1.14-1.27) | 2.34 | (2.24-2.43) | 3.90 | (3.78-4.03) |
Mesenchymal tumors | 336 | 67 | 0.07 | (0.06-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.11) | 0.10 | (0.08-0.12) |
Primary melanocytic lesions | 22 | – | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 0.18 | (0.17-0.19) | 0.10 | (0.08-0.12) | 0.14 | (0.12-0.16) | 0.18 | (0.15-0.21) | 0.22 | (0.20-0.26) | 0.24 | (0.21-0.27) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 0.12 | (0.11-0.13) | 0.04 | (0.03-0.05) | 0.07 | (0.06-0.09) | 0.10 | (0.08-0.12) | 0.16 | (0.14-0.19) | 0.24 | (0.21-0.27) |
Lymphoma | 576 | 115 | 0.12 | (0.11-0.13) | 0.02 | (0.02-0.04) | 0.07 | (0.05-0.08) | 0.09 | (0.07-0.11) | 0.15 | (0.13-0.18) | 0.23 | (0.20-0.26) |
Other hematopoietic neoplasms | 43 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Tumors of Sellar Region | 16,559 | 3,312 | 3.23 | (3.18-3.28) | 1.79 | (1.71-1.87) | 2.44 | (2.35-2.54) | 3.36 | (3.25-3.47) | 4.00 | (3.88-4.13) | 4.43 | (4.30-4.56) |
Tumors of the pituitary | 15,892 | 3,178 | 3.10 | (3.05-3.15) | 1.66 | (1.58-1.73) | 2.32 | (2.24-2.42) | 3.25 | (3.14-3.36) | 3.87 | (3.75-3.99) | 4.27 | (4.15-4.40) |
Craniopharyngioma | 667 | 133 | 0.13 | (0.12-0.14) | 0.13 | (0.11-0.15) | 0.12 | (0.10-0.14) | 0.11 | (0.09-0.13) | 0.13 | (0.11-0.16) | 0.15 | (0.13-0.18) |
Unclassified Tumors | 3,217 | 643 | 0.63 | (0.60-0.65) | 0.46 | (0.42-0.50) | 0.46 | (0.42-0.50) | 0.63 | (0.58-0.68) | 0.72 | (0.67-0.77) | 0.83 | (0.77-0.89) |
Hemangioma | 1,538 | 308 | 0.30 | (0.29-0.32) | 0.20 | (0.17-0.23) | 0.23 | (0.20-0.26) | 0.31 | (0.27-0.34) | 0.34 | (0.31-0.38) | 0.41 | (0.37-0.46) |
Neoplasm, unspecified | 1,667 | 333 | 0.32 | (0.31-0.34) | 0.26 | (0.23-0.29) | 0.23 | (0.20-0.26) | 0.32 | (0.29-0.36) | 0.37 | (0.33-0.41) | 0.42 | (0.38-0.46) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 10.43 | (10.34-10.52) | 6.19 | (6.04-6.34) | 7.12 | (6.97-7.28) | 9.93 | (9.73-10.12) | 12.65 | (12.43-12.88) | 15.54 | (15.3-15.79) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
- Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 3.44 | (3.39-3.49) | 2.83 | (2.73-2.93) | 2.75 | (2.65-2.85) | 3.49 | (3.38-3.61) | 3.91 | (3.79-4.04) | 4.14 | (4.01-4.26) |
Pilocytic astrocytoma | 1,519 | 304 | 0.28 | (0.27-0.30) | 0.60 | (0.55-0.65) | 0.31 | (0.28-0.35) | 0.21 | (0.18-0.24) | 0.18 | (0.16-0.21) | 0.13 | (0.11-0.15) |
Diffuse astrocytoma | 2,413 | 483 | 0.47 | (0.45-0.49) | 0.27 | (0.24-0.31) | 0.35 | (0.32-0.39) | 0.52 | (0.47-0.56) | 0.61 | (0.56-0.66) | 0.58 | (0.53-0.63) |
Anaplastic astrocytoma | 1,398 | 280 | 0.27 | (0.26-0.29) | 0.10 | (0.08-0.12) | 0.19 | (0.16-0.21) | 0.33 | (0.29-0.36) | 0.36 | (0.32-0.40) | 0.39 | (0.35-0.43) |
Unique astrocytoma variants | 381 | 76 | 0.07 | (0.06-0.08) | 0.11 | (0.09-0.13) | 0.10 | (0.09-0.13) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.06) | 0.04 | (0.02-0.05) |
Glioblastoma | 2,393 | 479 | 0.48 | (0.46-0.50) | 0.19 | (0.17-0.22) | 0.28 | (0.25-0.31) | 0.43 | (0.39-0.47) | 0.56 | (0.51-0.61) | 0.88 | (0.82-0.94) |
Oligodendroglioma | 1,488 | 298 | 0.29 | (0.28-0.31) | 0.09 | (0.07-0.11) | 0.16 | (0.14-0.19) | 0.32 | (0.28-0.35) | 0.43 | (0.39-0.47) | 0.45 | (0.41-0.49) |
Anaplastic oligodendroglioma | 420 | 84 | 0.08 | (0.08-0.09) | 0.02 | (0.01-0.02) | 0.04 | (0.03-0.05) | 0.09 | (0.07-0.11) | 0.12 | (0.10-0.14) | 0.15 | (0.13-0.17) |
Oligoastrocytic tumors | 1,333 | 267 | 0.26 | (0.25-0.28) | 0.06 | (0.05-0.08) | 0.16 | (0.13-0.18) | 0.36 | (0.32-0.39) | 0.38 | (0.34-0.42) | 0.35 | (0.31-0.39) |
Ependymal tumors | 1,888 | 378 | 0.37 | (0.35-0.38) | 0.25 | (0.22-0.28) | 0.28 | (0.25-0.32) | 0.38 | (0.34-0.42) | 0.45 | (0.41-0.50) | 0.46 | (0.42-0.51) |
Glioma malignant, NOS | 1,384 | 277 | 0.26 | (0.25-0.28) | 0.32 | (0.29-0.36) | 0.24 | (0.21-0.27) | 0.25 | (0.22-0.28) | 0.26 | (0.23-0.30) | 0.25 | (0.22-0.29) |
Choroid plexus tumors | 183 | 37 | 0.03 | (0.03-0.04) | 0.05 | (0.04-0.06) | 0.02 | (0.01-0.03) | 0.04 | (0.03-0.05) | 0.04 | (0.03-0.05) | 0.03 | (0.02-0.05) |
Other neuroepithelial tumors | 30 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 0.33 | (0.32-0.35) | 0.48 | (0.44-0.53) | 0.37 | (0.33-0.41) | 0.30 | (0.27-0.34) | 0.28 | (0.25-0.32) | 0.25 | (0.22-0.28) |
Tumors of the pineal region | 258 | 52 | 0.05 | (0.04-0.06) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.05 | (0.04-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.07) |
Embryonal tumors | 915 | 183 | 0.17 | (0.16-0.18) | 0.24 | (0.21-0.27) | 0.19 | (0.17-0.22) | 0.18 | (0.15-0.20) | 0.14 | (0.12-0.16) | 0.12 | (0.10-0.14) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 0.91 | (0.88-0.94) | 0.36 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.54-1.69) |
Nerve sheath tumors | 4,545 | 909 | 0.91 | (0.88-0.93) | 0.35 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.53-1.69) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 1.98 | (1.95-2.02) | 0.45 | (0.41-0.49) | 0.76 | (0.71-0.81) | 1.43 | (1.36-1.50) | 2.65 | (2.55-2.76) | 4.25 | (4.12-4.38) |
Meningioma | 8,440 | 1,688 | 1.74 | (1.70-1.77) | 0.30 | (0.27-0.34) | 0.57 | (0.53-0.62) | 1.20 | (1.14-1.27) | 2.34 | (2.24-2.43) | 3.90 | (3.78-4.03) |
Mesenchymal tumors | 336 | 67 | 0.07 | (0.06-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.11) | 0.10 | (0.08-0.12) |
Primary melanocytic lesions | 22 | – | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 0.18 | (0.17-0.19) | 0.10 | (0.08-0.12) | 0.14 | (0.12-0.16) | 0.18 | (0.15-0.21) | 0.22 | (0.20-0.26) | 0.24 | (0.21-0.27) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 0.12 | (0.11-0.13) | 0.04 | (0.03-0.05) | 0.07 | (0.06-0.09) | 0.10 | (0.08-0.12) | 0.16 | (0.14-0.19) | 0.24 | (0.21-0.27) |
Lymphoma | 576 | 115 | 0.12 | (0.11-0.13) | 0.02 | (0.02-0.04) | 0.07 | (0.05-0.08) | 0.09 | (0.07-0.11) | 0.15 | (0.13-0.18) | 0.23 | (0.20-0.26) |
Other hematopoietic neoplasms | 43 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Tumors of Sellar Region | 16,559 | 3,312 | 3.23 | (3.18-3.28) | 1.79 | (1.71-1.87) | 2.44 | (2.35-2.54) | 3.36 | (3.25-3.47) | 4.00 | (3.88-4.13) | 4.43 | (4.30-4.56) |
Tumors of the pituitary | 15,892 | 3,178 | 3.10 | (3.05-3.15) | 1.66 | (1.58-1.73) | 2.32 | (2.24-2.42) | 3.25 | (3.14-3.36) | 3.87 | (3.75-3.99) | 4.27 | (4.15-4.40) |
Craniopharyngioma | 667 | 133 | 0.13 | (0.12-0.14) | 0.13 | (0.11-0.15) | 0.12 | (0.10-0.14) | 0.11 | (0.09-0.13) | 0.13 | (0.11-0.16) | 0.15 | (0.13-0.18) |
Unclassified Tumors | 3,217 | 643 | 0.63 | (0.60-0.65) | 0.46 | (0.42-0.50) | 0.46 | (0.42-0.50) | 0.63 | (0.58-0.68) | 0.72 | (0.67-0.77) | 0.83 | (0.77-0.89) |
Hemangioma | 1,538 | 308 | 0.30 | (0.29-0.32) | 0.20 | (0.17-0.23) | 0.23 | (0.20-0.26) | 0.31 | (0.27-0.34) | 0.34 | (0.31-0.38) | 0.41 | (0.37-0.46) |
Neoplasm, unspecified | 1,667 | 333 | 0.32 | (0.31-0.34) | 0.26 | (0.23-0.29) | 0.23 | (0.20-0.26) | 0.32 | (0.29-0.36) | 0.37 | (0.33-0.41) | 0.42 | (0.38-0.46) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 10.43 | (10.34-10.52) | 6.19 | (6.04-6.34) | 7.12 | (6.97-7.28) | 9.93 | (9.73-10.12) | 12.65 | (12.43-12.88) | 15.54 | (15.3-15.79) |
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 3.44 | (3.39-3.49) | 2.83 | (2.73-2.93) | 2.75 | (2.65-2.85) | 3.49 | (3.38-3.61) | 3.91 | (3.79-4.04) | 4.14 | (4.01-4.26) |
Pilocytic astrocytoma | 1,519 | 304 | 0.28 | (0.27-0.30) | 0.60 | (0.55-0.65) | 0.31 | (0.28-0.35) | 0.21 | (0.18-0.24) | 0.18 | (0.16-0.21) | 0.13 | (0.11-0.15) |
Diffuse astrocytoma | 2,413 | 483 | 0.47 | (0.45-0.49) | 0.27 | (0.24-0.31) | 0.35 | (0.32-0.39) | 0.52 | (0.47-0.56) | 0.61 | (0.56-0.66) | 0.58 | (0.53-0.63) |
Anaplastic astrocytoma | 1,398 | 280 | 0.27 | (0.26-0.29) | 0.10 | (0.08-0.12) | 0.19 | (0.16-0.21) | 0.33 | (0.29-0.36) | 0.36 | (0.32-0.40) | 0.39 | (0.35-0.43) |
Unique astrocytoma variants | 381 | 76 | 0.07 | (0.06-0.08) | 0.11 | (0.09-0.13) | 0.10 | (0.09-0.13) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.06) | 0.04 | (0.02-0.05) |
Glioblastoma | 2,393 | 479 | 0.48 | (0.46-0.50) | 0.19 | (0.17-0.22) | 0.28 | (0.25-0.31) | 0.43 | (0.39-0.47) | 0.56 | (0.51-0.61) | 0.88 | (0.82-0.94) |
Oligodendroglioma | 1,488 | 298 | 0.29 | (0.28-0.31) | 0.09 | (0.07-0.11) | 0.16 | (0.14-0.19) | 0.32 | (0.28-0.35) | 0.43 | (0.39-0.47) | 0.45 | (0.41-0.49) |
Anaplastic oligodendroglioma | 420 | 84 | 0.08 | (0.08-0.09) | 0.02 | (0.01-0.02) | 0.04 | (0.03-0.05) | 0.09 | (0.07-0.11) | 0.12 | (0.10-0.14) | 0.15 | (0.13-0.17) |
Oligoastrocytic tumors | 1,333 | 267 | 0.26 | (0.25-0.28) | 0.06 | (0.05-0.08) | 0.16 | (0.13-0.18) | 0.36 | (0.32-0.39) | 0.38 | (0.34-0.42) | 0.35 | (0.31-0.39) |
Ependymal tumors | 1,888 | 378 | 0.37 | (0.35-0.38) | 0.25 | (0.22-0.28) | 0.28 | (0.25-0.32) | 0.38 | (0.34-0.42) | 0.45 | (0.41-0.50) | 0.46 | (0.42-0.51) |
Glioma malignant, NOS | 1,384 | 277 | 0.26 | (0.25-0.28) | 0.32 | (0.29-0.36) | 0.24 | (0.21-0.27) | 0.25 | (0.22-0.28) | 0.26 | (0.23-0.30) | 0.25 | (0.22-0.29) |
Choroid plexus tumors | 183 | 37 | 0.03 | (0.03-0.04) | 0.05 | (0.04-0.06) | 0.02 | (0.01-0.03) | 0.04 | (0.03-0.05) | 0.04 | (0.03-0.05) | 0.03 | (0.02-0.05) |
Other neuroepithelial tumors | 30 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 0.33 | (0.32-0.35) | 0.48 | (0.44-0.53) | 0.37 | (0.33-0.41) | 0.30 | (0.27-0.34) | 0.28 | (0.25-0.32) | 0.25 | (0.22-0.28) |
Tumors of the pineal region | 258 | 52 | 0.05 | (0.04-0.06) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.05 | (0.04-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.07) |
Embryonal tumors | 915 | 183 | 0.17 | (0.16-0.18) | 0.24 | (0.21-0.27) | 0.19 | (0.17-0.22) | 0.18 | (0.15-0.20) | 0.14 | (0.12-0.16) | 0.12 | (0.10-0.14) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 0.91 | (0.88-0.94) | 0.36 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.54-1.69) |
Nerve sheath tumors | 4,545 | 909 | 0.91 | (0.88-0.93) | 0.35 | (0.32-0.39) | 0.50 | (0.46-0.54) | 0.83 | (0.77-0.88) | 1.14 | (1.08-1.21) | 1.61 | (1.53-1.69) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 1.98 | (1.95-2.02) | 0.45 | (0.41-0.49) | 0.76 | (0.71-0.81) | 1.43 | (1.36-1.50) | 2.65 | (2.55-2.76) | 4.25 | (4.12-4.38) |
Meningioma | 8,440 | 1,688 | 1.74 | (1.70-1.77) | 0.30 | (0.27-0.34) | 0.57 | (0.53-0.62) | 1.20 | (1.14-1.27) | 2.34 | (2.24-2.43) | 3.90 | (3.78-4.03) |
Mesenchymal tumors | 336 | 67 | 0.07 | (0.06-0.07) | 0.05 | (0.03-0.06) | 0.05 | (0.04-0.06) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.11) | 0.10 | (0.08-0.12) |
Primary melanocytic lesions | 22 | – | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 0.18 | (0.17-0.19) | 0.10 | (0.08-0.12) | 0.14 | (0.12-0.16) | 0.18 | (0.15-0.21) | 0.22 | (0.20-0.26) | 0.24 | (0.21-0.27) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 0.12 | (0.11-0.13) | 0.04 | (0.03-0.05) | 0.07 | (0.06-0.09) | 0.10 | (0.08-0.12) | 0.16 | (0.14-0.19) | 0.24 | (0.21-0.27) |
Lymphoma | 576 | 115 | 0.12 | (0.11-0.13) | 0.02 | (0.02-0.04) | 0.07 | (0.05-0.08) | 0.09 | (0.07-0.11) | 0.15 | (0.13-0.18) | 0.23 | (0.20-0.26) |
Other hematopoietic neoplasms | 43 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 0.12 | (0.11-0.13) | 0.27 | (0.24-0.31) | 0.14 | (0.12-0.17) | 0.09 | (0.07-0.11) | 0.06 | (0.05-0.08) | 0.05 | (0.04-0.07) |
Tumors of Sellar Region | 16,559 | 3,312 | 3.23 | (3.18-3.28) | 1.79 | (1.71-1.87) | 2.44 | (2.35-2.54) | 3.36 | (3.25-3.47) | 4.00 | (3.88-4.13) | 4.43 | (4.30-4.56) |
Tumors of the pituitary | 15,892 | 3,178 | 3.10 | (3.05-3.15) | 1.66 | (1.58-1.73) | 2.32 | (2.24-2.42) | 3.25 | (3.14-3.36) | 3.87 | (3.75-3.99) | 4.27 | (4.15-4.40) |
Craniopharyngioma | 667 | 133 | 0.13 | (0.12-0.14) | 0.13 | (0.11-0.15) | 0.12 | (0.10-0.14) | 0.11 | (0.09-0.13) | 0.13 | (0.11-0.16) | 0.15 | (0.13-0.18) |
Unclassified Tumors | 3,217 | 643 | 0.63 | (0.60-0.65) | 0.46 | (0.42-0.50) | 0.46 | (0.42-0.50) | 0.63 | (0.58-0.68) | 0.72 | (0.67-0.77) | 0.83 | (0.77-0.89) |
Hemangioma | 1,538 | 308 | 0.30 | (0.29-0.32) | 0.20 | (0.17-0.23) | 0.23 | (0.20-0.26) | 0.31 | (0.27-0.34) | 0.34 | (0.31-0.38) | 0.41 | (0.37-0.46) |
Neoplasm, unspecified | 1,667 | 333 | 0.32 | (0.31-0.34) | 0.26 | (0.23-0.29) | 0.23 | (0.20-0.26) | 0.32 | (0.29-0.36) | 0.37 | (0.33-0.41) | 0.42 | (0.38-0.46) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 10.43 | (10.34-10.52) | 6.19 | (6.04-6.34) | 7.12 | (6.97-7.28) | 9.93 | (9.73-10.12) | 12.65 | (12.43-12.88) | 15.54 | (15.3-15.79) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
- Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Incidence by Region of the US
Incidence of primary brain and CNS tumors in adolescents and young adults (age 15-39 years) by region of the US is shown in Figure 4a. There are many factors that may affect cancer incidence between different geographic regions including cancer registration practices, and diagnostic practices in addition to true incidence differences. In particular, many central cancer registries vary in their collection of tumors diagnosed only radiographically where persons do not receive surgery, which may have a particularly significant effect on reporting incidence of non-malignant tumors. Incidence of malignant primary brain and CNS tumors in adolescents and young adults (age 15-39 years) by region of the US is shown in Figure 4b.
Incidence is lowest in New England (9.42 per 100,000 population) and Pacific (9.47 per 100,000 population) regions.
Incidence is highest in Middle Atlantic (11.66 per 100,000 population) and Mountain (11.14 per 100,000 population) regions.
Incidence is lowest in Pacific (2.98 per 100,000 population) and South Atlantic (3.19 per 100,000 population).
Incidence is highest in West North Central (3.54 per 100,000 population) and Middle Atlantic (3.50 per 100,000 population) regions.
Incidence of non-malignant primary brain and CNS tumors in adolescents and young adults (age 15-39 years) by region of the US is shown in Figure 4c.
Incidence is lowest in New England (6.14 per 100,000 population) and Pacific (6.49 per 100,000 population) regions.
Incidence is highest in Mountain (7.74 per 100,000 population) and West South Central regions (7.70 per 100,000 population).
Distribution and Incidence by Site and Age Group
Distribution of all primary brain tumors (Table 2a) in adolescents and young adults (age 15-39 years) by site and age groups are shown in Figures 5 and 6
In all AYA age groups, the largest proportion of tumors occurs in the pituitary gland and craniopharyngeal duct (31.8%).
In persons age 25-39 years, tumors of the meninges are the second most common site of tumor occurrence and seem to increase with age (12.3% in age 25-29 years, 18.6% in age 30-34 years, and 25.2% in age 35-39 years).
Distribution of malignant primary brain tumors (Table 2b) in adolescents and young adults (age 15-39 years) by site and age groups are shown in Figure 7.8
Overall, the largest proportion of malignant tumors in those age 15-39 years occur in the frontal lobe (28.8%), followed by other brain (15.4%). Together, 50.2% of all malignant tumors occur in the frontal, temporal, parietal, and occipital lobes of the brain.
In those age 15-19 years, tumors most commonly occur in the cerebellum (17.0%), followed by other brain (15.1%, see Table 1 for more details on what is included in the category other brain). In this group brain stem tumors make up 10.4% of tumors.
Tumors of the frontal lobe are the most common in persons age 20-39 years.
Distribution of non-malignant primary brain tumors (Table 2c) by site and age groups in adolescents and young adults (age 15-39 years) are shown in Figures 9 and 10.
Overall, the largest proportion of non-malignant tumors occurs in the pituitary gland and craniopharyngeal duct (46.1%).
The incidence of tumors in the pituitary gland and craniopharyngeal duct decrease with age whereas incidence of those found in the meninges increase with age.
Distribution and Incidence by Histology and Age Group
Distribution of all primary brain tumors by histology and age groups in adolescents and young adults (age 15-39 years) are shown in Figures 11 and 12.
The most common histologic category among all persons age 15-39 years are tumors of the pituitary (29.9%). These are also the most common tumor within each five-year age group.
In those age 15-29 years, the second most common histology is astrocytomas (20.5% in those age 15-19 years, 17.2% in those age 20-24 years, and 15.5% in those age 25-29 years). The percentage of tumors represented by astrocytomas decreases steadily with increasing age.
In persons age 30-39 years, meningiomas are the second most common histology (18.4% in those age 30-34 years, and 25.1% in those age 35-39 years). The percentage of meningioma increases steadily with increasing age.
Distribution of malignant primary brain tumors by histology and age group in adolescents and young adults (age 15-39 years) are shown in Figures 13 and 14.
The most common malignant histology in all persons age 15-39 years is astrocytoma, including pilocytic astrocytoma (47.6%), and this is also the most common malignant histology in all age groups.
The second most common malignant histology in persons age 20-39 years is oligodendroglioma (12.3% in those age 25-29 years, 14.7% in those age 30-34 years, 14.5% in those age 35-39 years). Germ cell tumors are the second most common malignant histology in those age 15-19 years (9.6%)
Distribution of non-malignant primary brain tumors by histology and age groups in adolescents and young adults (age 15-39 years) are shown in Figures 15 and 16.
The most common histology in all AYA age groups is tumors of the pituitary (43.7% of tumors in those age 15-39 years).
In persons age 15-19 years, neuronal and mixed neuronal-glial tumors are the second most common histology, representing 12.5% of all non-malignant tumors.
In those age 20-39 years, meningiomas are the second most common histology.
Distribution and Incidence of Gliomas by Site, Histologic Group and Age Group
Distribution of all gliomas by site and age group in adolescents and young adults (age 15-39 years) are shown in Figures 17 and 18.
The frontal lobe is the most common site for gliomas in all age groups, and the majority of all gliomas occur in the frontal, occipital, parietal, and temporal lobes of the brain.
In the AYA population, those age 15-19 years have the highest proportion of brain stem gliomas, where these tumors represent 11.9% of all tumors. The proportion of gliomas occurring in the brain stem decreases with increasing age in AYA age groups.
Distribution of all gliomas by histology and age group in adolescents and young adults (age 15-39 years) are shown in Figures 19 and 20.
Diffuse astrocytomas (16.1%) and glioblastoma (16.0%) are the most common glioma histologies in those age 15-39 years.
In persons age 15-19 years, the most common glioma histology is pilocytic astrocytoma, which represents 27.9% of all gliomas in AYA, but decreases in all subsequent AYA age groups.
In those age 35-39 years glioblastoma is the most common glioma histology, where it represents 23.6% of all gliomas. The proportion of glioblastoma among all gliomas increases with age in the AYA population.
Incidence by Gender and Age Groups
Average annual incidence rates overall and in adolescents and young adult age groups for males are shown in Table 4, and for females in Table 5.
Overall, the incidence of primary brain and CNS tumors in females (12.24 per 100,000 population) is higher than those in males (8.64 per 100,000 population) in AYA.
Incidence rates in persons age 15-19 years are only slightly higher in females (6.83 per 100,000 population) as compared to males (5.58 per 100,000 population), but the difference by gender increases with increasing age.
Histology . | 15-39 (Male) . | 15-19 (Male) . | 20-24 (Male) . | 25-29 (Male) . | 30-34 (Male) . | 35-39 (Male) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 9,850 | 1,970 | 3.78 | (3.71-3.86) | 3.01 | (2.87-3.16) | 2.94 | (2.80-3.09) | 3.76 | (3.60-3.93) | 4.35 | (4.17-4.54) | 4.73 | (4.54-4.93) |
Pilocytic astrocytoma | 792 | 158 | 0.29 | (0.27-0.31) | 0.61 | (0.55-0.68) | 0.33 | (0.29-0.38) | 0.20 | (0.17-0.24) | 0.18 | (0.14-0.22) | 0.13 | (0.10-0.17) |
Diffuse astrocytoma | 1,373 | 275 | 0.53 | (0.50-0.56) | 0.27 | (0.23-0.32) | 0.41 | (0.36-0.47) | 0.58 | (0.52-0.65) | 0.70 | (0.63-0.78) | 0.67 | (0.60-0.74) |
Anaplastic astrocytoma | 813 | 163 | 0.32 | (0.29-0.34) | 0.11 | (0.08-0.14) | 0.21 | (0.18-0.26) | 0.35 | (0.30-0.41) | 0.46 | (0.40-0.52) | 0.44 | (0.38-0.50) |
Unique astrocytoma variants | 200 | 40 | 0.07 | (0.06-0.08) | 0.12 | (0.10-0.16) | 0.09 | (0.07-0.12) | 0.07 | (0.05-0.10) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) |
Glioblastoma | 1,458 | 292 | 0.58 | (0.55-0.61) | 0.22 | (0.18-0.26) | 0.31 | (0.27-0.36) | 0.52 | (0.46-0.59) | 0.70 | (0.63-0.77) | 1.08 | (0.99-1.17) |
Oligodendroglioma | 859 | 172 | 0.34 | (0.31-0.36) | 0.10 | (0.08-0.13) | 0.16 | (0.13-0.20) | 0.38 | (0.33-0.44) | 0.51 | (0.44-0.57) | 0.52 | (0.45-0.58) |
Anaplastic oligodendroglioma | 248 | 50 | 0.10 | (0.09-0.11) | – | – | 0.06 | (0.04-0.08) | 0.11 | (0.08-0.14) | 0.13 | (0.10-0.17) | 0.17 | (0.14-0.21) |
Oligoastrocytic tumors | 732 | 146 | 0.28 | (0.26-0.31) | 0.05 | (0.04-0.08) | 0.15 | (0.12-0.19) | 0.40 | (0.35-0.46) | 0.44 | (0.38-0.50) | 0.38 | (0.33-0.44) |
Ependymal tumors | 1,025 | 205 | 0.40 | (0.37-0.42) | 0.27 | (0.23-0.32) | 0.31 | (0.27-0.36) | 0.38 | (0.33-0.44) | 0.46 | (0.40-0.52) | 0.54 | (0.48-0.61) |
Glioma malignant, NOS | 717 | 143 | 0.27 | (0.25-0.29) | 0.33 | (0.29-0.39) | 0.25 | (0.21-0.29) | 0.23 | (0.19-0.27) | 0.27 | (0.23-0.32) | 0.28 | (0.23-0.33) |
Choroid plexus tumors | 87 | 17 | 0.03 | (0.03-0.04) | 0.05 | (0.03-0.07) | – | – | 0.04 | (0.02-0.06) | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 898 | 180 | 0.33 | (0.31-0.36) | 0.52 | (0.46-0.58) | 0.39 | (0.34-0.45) | 0.26 | (0.22-0.31) | 0.24 | (0.20-0.29) | 0.27 | (0.23-0.32) |
Tumors of the pineal region | 98 | 20 | 0.04 | (0.03-0.05) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.03 | (0.02-0.05) | 0.04 | (0.03-0.07) |
Embryonal tumors | 543 | 109 | 0.20 | (0.18-0.22) | 0.31 | (0.26-0.36) | 0.20 | (0.17-0.25) | 0.19 | (0.16-0.23) | 0.16 | (0.13-0.20) | 0.15 | (0.12-0.19) |
Tumors of Cranial and Spinal Nerves | 2,167 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.61 | (1.50-1.72) |
Nerve sheath tumors | 2,165 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.60 | (1.49-1.72) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 3,089 | 618 | 1.23 | (1.19-1.28) | 0.44 | (0.38-0.50) | 0.66 | (0.59-0.73) | 0.98 | (0.90-1.07) | 1.66 | (1.55-1.78) | 2.26 | (2.13-2.40) |
Meningioma | 2,429 | 486 | 0.98 | (0.94-1.02) | 0.27 | (0.23-0.32) | 0.48 | (0.42-0.54) | 0.76 | (0.69-0.84) | 1.33 | (1.23-1.44) | 1.89 | (1.77-2.01) |
Mesenchymal tumors | 160 | 32 | 0.06 | (0.05-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) | 0.05 | (0.03-0.07) | 0.08 | (0.06-0.11) | 0.10 | (0.07-0.13) |
Primary melanocytic lesions | 16 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 484 | 97 | 0.19 | (0.17-0.21) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.17 | (0.14-0.21) | 0.24 | (0.20-0.28) | 0.27 | (0.22-0.32) |
Lymphomas and Hematopoietic Neoplasms | 392 | 78 | 0.16 | (0.14-0.17) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.12) | 0.14 | (0.11-0.17) | 0.19 | (0.16-0.24) | 0.29 | (0.25-0.35) |
Lymphoma | 368 | 74 | 0.15 | (0.13-0.16) | – | – | 0.09 | (0.06-0.11) | 0.13 | (0.10-0.17) | 0.19 | (0.15-0.23) | 0.28 | (0.24-0.33) |
Other hematopoietic neoplasms | 24 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Germ cell tumors, cysts and heterotopias | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Tumors of Sellar Region | 4,721 | 944 | 1.86 | (1.81-1.92) | 0.87 | (0.80-0.95) | 1.07 | (0.99-1.16) | 1.74 | (1.62-1.85) | 2.39 | (2.25-2.53) | 3.07 | (2.92-3.23) |
Tumors of the pituitary | 4,398 | 880 | 1.74 | (1.69-1.79) | 0.76 | (0.69-0.84) | 0.95 | (0.87-1.03) | 1.64 | (1.53-1.75) | 2.25 | (2.12-2.38) | 2.93 | (2.78-3.08) |
Craniopharyngioma | 323 | 65 | 0.12 | (0.11-0.14) | 0.11 | (0.09-0.14) | 0.12 | (0.10-0.16) | 0.10 | (0.07-0.13) | 0.14 | (0.11-0.17) | 0.14 | (0.11-0.18) |
Unclassified Tumors | 1,425 | 285 | 0.55 | (0.52-0.58) | 0.43 | (0.37-0.48) | 0.43 | (0.38-0.49) | 0.51 | (0.45-0.58) | 0.65 | (0.58-0.73) | 0.71 | (0.63-0.78) |
Hemangioma | 644 | 129 | 0.25 | (0.23-0.27) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.25) | 0.24 | (0.20-0.28) | 0.29 | (0.24-0.34) | 0.32 | (0.27-0.37) |
Neoplasm, unspecified | 776 | 155 | 0.30 | (0.28-0.32) | 0.24 | (0.20-0.29) | 0.22 | (0.18-0.26) | 0.27 | (0.23-0.32) | 0.36 | (0.31-0.42) | 0.39 | (0.34-0.45) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 22,168 | 4,434 | 8.64 | (8.52-8.75) | 5.58 | (5.39-5.78) | 5.88 | (5.68-6.08) | 8.01 | (7.77-8.26) | 10.39 | (10.1-10.67) | 12.73 | (12.42-13.05) |
Histology . | 15-39 (Male) . | 15-19 (Male) . | 20-24 (Male) . | 25-29 (Male) . | 30-34 (Male) . | 35-39 (Male) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 9,850 | 1,970 | 3.78 | (3.71-3.86) | 3.01 | (2.87-3.16) | 2.94 | (2.80-3.09) | 3.76 | (3.60-3.93) | 4.35 | (4.17-4.54) | 4.73 | (4.54-4.93) |
Pilocytic astrocytoma | 792 | 158 | 0.29 | (0.27-0.31) | 0.61 | (0.55-0.68) | 0.33 | (0.29-0.38) | 0.20 | (0.17-0.24) | 0.18 | (0.14-0.22) | 0.13 | (0.10-0.17) |
Diffuse astrocytoma | 1,373 | 275 | 0.53 | (0.50-0.56) | 0.27 | (0.23-0.32) | 0.41 | (0.36-0.47) | 0.58 | (0.52-0.65) | 0.70 | (0.63-0.78) | 0.67 | (0.60-0.74) |
Anaplastic astrocytoma | 813 | 163 | 0.32 | (0.29-0.34) | 0.11 | (0.08-0.14) | 0.21 | (0.18-0.26) | 0.35 | (0.30-0.41) | 0.46 | (0.40-0.52) | 0.44 | (0.38-0.50) |
Unique astrocytoma variants | 200 | 40 | 0.07 | (0.06-0.08) | 0.12 | (0.10-0.16) | 0.09 | (0.07-0.12) | 0.07 | (0.05-0.10) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) |
Glioblastoma | 1,458 | 292 | 0.58 | (0.55-0.61) | 0.22 | (0.18-0.26) | 0.31 | (0.27-0.36) | 0.52 | (0.46-0.59) | 0.70 | (0.63-0.77) | 1.08 | (0.99-1.17) |
Oligodendroglioma | 859 | 172 | 0.34 | (0.31-0.36) | 0.10 | (0.08-0.13) | 0.16 | (0.13-0.20) | 0.38 | (0.33-0.44) | 0.51 | (0.44-0.57) | 0.52 | (0.45-0.58) |
Anaplastic oligodendroglioma | 248 | 50 | 0.10 | (0.09-0.11) | – | – | 0.06 | (0.04-0.08) | 0.11 | (0.08-0.14) | 0.13 | (0.10-0.17) | 0.17 | (0.14-0.21) |
Oligoastrocytic tumors | 732 | 146 | 0.28 | (0.26-0.31) | 0.05 | (0.04-0.08) | 0.15 | (0.12-0.19) | 0.40 | (0.35-0.46) | 0.44 | (0.38-0.50) | 0.38 | (0.33-0.44) |
Ependymal tumors | 1,025 | 205 | 0.40 | (0.37-0.42) | 0.27 | (0.23-0.32) | 0.31 | (0.27-0.36) | 0.38 | (0.33-0.44) | 0.46 | (0.40-0.52) | 0.54 | (0.48-0.61) |
Glioma malignant, NOS | 717 | 143 | 0.27 | (0.25-0.29) | 0.33 | (0.29-0.39) | 0.25 | (0.21-0.29) | 0.23 | (0.19-0.27) | 0.27 | (0.23-0.32) | 0.28 | (0.23-0.33) |
Choroid plexus tumors | 87 | 17 | 0.03 | (0.03-0.04) | 0.05 | (0.03-0.07) | – | – | 0.04 | (0.02-0.06) | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 898 | 180 | 0.33 | (0.31-0.36) | 0.52 | (0.46-0.58) | 0.39 | (0.34-0.45) | 0.26 | (0.22-0.31) | 0.24 | (0.20-0.29) | 0.27 | (0.23-0.32) |
Tumors of the pineal region | 98 | 20 | 0.04 | (0.03-0.05) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.03 | (0.02-0.05) | 0.04 | (0.03-0.07) |
Embryonal tumors | 543 | 109 | 0.20 | (0.18-0.22) | 0.31 | (0.26-0.36) | 0.20 | (0.17-0.25) | 0.19 | (0.16-0.23) | 0.16 | (0.13-0.20) | 0.15 | (0.12-0.19) |
Tumors of Cranial and Spinal Nerves | 2,167 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.61 | (1.50-1.72) |
Nerve sheath tumors | 2,165 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.60 | (1.49-1.72) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 3,089 | 618 | 1.23 | (1.19-1.28) | 0.44 | (0.38-0.50) | 0.66 | (0.59-0.73) | 0.98 | (0.90-1.07) | 1.66 | (1.55-1.78) | 2.26 | (2.13-2.40) |
Meningioma | 2,429 | 486 | 0.98 | (0.94-1.02) | 0.27 | (0.23-0.32) | 0.48 | (0.42-0.54) | 0.76 | (0.69-0.84) | 1.33 | (1.23-1.44) | 1.89 | (1.77-2.01) |
Mesenchymal tumors | 160 | 32 | 0.06 | (0.05-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) | 0.05 | (0.03-0.07) | 0.08 | (0.06-0.11) | 0.10 | (0.07-0.13) |
Primary melanocytic lesions | 16 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 484 | 97 | 0.19 | (0.17-0.21) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.17 | (0.14-0.21) | 0.24 | (0.20-0.28) | 0.27 | (0.22-0.32) |
Lymphomas and Hematopoietic Neoplasms | 392 | 78 | 0.16 | (0.14-0.17) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.12) | 0.14 | (0.11-0.17) | 0.19 | (0.16-0.24) | 0.29 | (0.25-0.35) |
Lymphoma | 368 | 74 | 0.15 | (0.13-0.16) | – | – | 0.09 | (0.06-0.11) | 0.13 | (0.10-0.17) | 0.19 | (0.15-0.23) | 0.28 | (0.24-0.33) |
Other hematopoietic neoplasms | 24 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Germ cell tumors, cysts and heterotopias | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Tumors of Sellar Region | 4,721 | 944 | 1.86 | (1.81-1.92) | 0.87 | (0.80-0.95) | 1.07 | (0.99-1.16) | 1.74 | (1.62-1.85) | 2.39 | (2.25-2.53) | 3.07 | (2.92-3.23) |
Tumors of the pituitary | 4,398 | 880 | 1.74 | (1.69-1.79) | 0.76 | (0.69-0.84) | 0.95 | (0.87-1.03) | 1.64 | (1.53-1.75) | 2.25 | (2.12-2.38) | 2.93 | (2.78-3.08) |
Craniopharyngioma | 323 | 65 | 0.12 | (0.11-0.14) | 0.11 | (0.09-0.14) | 0.12 | (0.10-0.16) | 0.10 | (0.07-0.13) | 0.14 | (0.11-0.17) | 0.14 | (0.11-0.18) |
Unclassified Tumors | 1,425 | 285 | 0.55 | (0.52-0.58) | 0.43 | (0.37-0.48) | 0.43 | (0.38-0.49) | 0.51 | (0.45-0.58) | 0.65 | (0.58-0.73) | 0.71 | (0.63-0.78) |
Hemangioma | 644 | 129 | 0.25 | (0.23-0.27) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.25) | 0.24 | (0.20-0.28) | 0.29 | (0.24-0.34) | 0.32 | (0.27-0.37) |
Neoplasm, unspecified | 776 | 155 | 0.30 | (0.28-0.32) | 0.24 | (0.20-0.29) | 0.22 | (0.18-0.26) | 0.27 | (0.23-0.32) | 0.36 | (0.31-0.42) | 0.39 | (0.34-0.45) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 22,168 | 4,434 | 8.64 | (8.52-8.75) | 5.58 | (5.39-5.78) | 5.88 | (5.68-6.08) | 8.01 | (7.77-8.26) | 10.39 | (10.1-10.67) | 12.73 | (12.42-13.05) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | 15-39 (Male) . | 15-19 (Male) . | 20-24 (Male) . | 25-29 (Male) . | 30-34 (Male) . | 35-39 (Male) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 9,850 | 1,970 | 3.78 | (3.71-3.86) | 3.01 | (2.87-3.16) | 2.94 | (2.80-3.09) | 3.76 | (3.60-3.93) | 4.35 | (4.17-4.54) | 4.73 | (4.54-4.93) |
Pilocytic astrocytoma | 792 | 158 | 0.29 | (0.27-0.31) | 0.61 | (0.55-0.68) | 0.33 | (0.29-0.38) | 0.20 | (0.17-0.24) | 0.18 | (0.14-0.22) | 0.13 | (0.10-0.17) |
Diffuse astrocytoma | 1,373 | 275 | 0.53 | (0.50-0.56) | 0.27 | (0.23-0.32) | 0.41 | (0.36-0.47) | 0.58 | (0.52-0.65) | 0.70 | (0.63-0.78) | 0.67 | (0.60-0.74) |
Anaplastic astrocytoma | 813 | 163 | 0.32 | (0.29-0.34) | 0.11 | (0.08-0.14) | 0.21 | (0.18-0.26) | 0.35 | (0.30-0.41) | 0.46 | (0.40-0.52) | 0.44 | (0.38-0.50) |
Unique astrocytoma variants | 200 | 40 | 0.07 | (0.06-0.08) | 0.12 | (0.10-0.16) | 0.09 | (0.07-0.12) | 0.07 | (0.05-0.10) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) |
Glioblastoma | 1,458 | 292 | 0.58 | (0.55-0.61) | 0.22 | (0.18-0.26) | 0.31 | (0.27-0.36) | 0.52 | (0.46-0.59) | 0.70 | (0.63-0.77) | 1.08 | (0.99-1.17) |
Oligodendroglioma | 859 | 172 | 0.34 | (0.31-0.36) | 0.10 | (0.08-0.13) | 0.16 | (0.13-0.20) | 0.38 | (0.33-0.44) | 0.51 | (0.44-0.57) | 0.52 | (0.45-0.58) |
Anaplastic oligodendroglioma | 248 | 50 | 0.10 | (0.09-0.11) | – | – | 0.06 | (0.04-0.08) | 0.11 | (0.08-0.14) | 0.13 | (0.10-0.17) | 0.17 | (0.14-0.21) |
Oligoastrocytic tumors | 732 | 146 | 0.28 | (0.26-0.31) | 0.05 | (0.04-0.08) | 0.15 | (0.12-0.19) | 0.40 | (0.35-0.46) | 0.44 | (0.38-0.50) | 0.38 | (0.33-0.44) |
Ependymal tumors | 1,025 | 205 | 0.40 | (0.37-0.42) | 0.27 | (0.23-0.32) | 0.31 | (0.27-0.36) | 0.38 | (0.33-0.44) | 0.46 | (0.40-0.52) | 0.54 | (0.48-0.61) |
Glioma malignant, NOS | 717 | 143 | 0.27 | (0.25-0.29) | 0.33 | (0.29-0.39) | 0.25 | (0.21-0.29) | 0.23 | (0.19-0.27) | 0.27 | (0.23-0.32) | 0.28 | (0.23-0.33) |
Choroid plexus tumors | 87 | 17 | 0.03 | (0.03-0.04) | 0.05 | (0.03-0.07) | – | – | 0.04 | (0.02-0.06) | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 898 | 180 | 0.33 | (0.31-0.36) | 0.52 | (0.46-0.58) | 0.39 | (0.34-0.45) | 0.26 | (0.22-0.31) | 0.24 | (0.20-0.29) | 0.27 | (0.23-0.32) |
Tumors of the pineal region | 98 | 20 | 0.04 | (0.03-0.05) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.03 | (0.02-0.05) | 0.04 | (0.03-0.07) |
Embryonal tumors | 543 | 109 | 0.20 | (0.18-0.22) | 0.31 | (0.26-0.36) | 0.20 | (0.17-0.25) | 0.19 | (0.16-0.23) | 0.16 | (0.13-0.20) | 0.15 | (0.12-0.19) |
Tumors of Cranial and Spinal Nerves | 2,167 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.61 | (1.50-1.72) |
Nerve sheath tumors | 2,165 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.60 | (1.49-1.72) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 3,089 | 618 | 1.23 | (1.19-1.28) | 0.44 | (0.38-0.50) | 0.66 | (0.59-0.73) | 0.98 | (0.90-1.07) | 1.66 | (1.55-1.78) | 2.26 | (2.13-2.40) |
Meningioma | 2,429 | 486 | 0.98 | (0.94-1.02) | 0.27 | (0.23-0.32) | 0.48 | (0.42-0.54) | 0.76 | (0.69-0.84) | 1.33 | (1.23-1.44) | 1.89 | (1.77-2.01) |
Mesenchymal tumors | 160 | 32 | 0.06 | (0.05-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) | 0.05 | (0.03-0.07) | 0.08 | (0.06-0.11) | 0.10 | (0.07-0.13) |
Primary melanocytic lesions | 16 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 484 | 97 | 0.19 | (0.17-0.21) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.17 | (0.14-0.21) | 0.24 | (0.20-0.28) | 0.27 | (0.22-0.32) |
Lymphomas and Hematopoietic Neoplasms | 392 | 78 | 0.16 | (0.14-0.17) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.12) | 0.14 | (0.11-0.17) | 0.19 | (0.16-0.24) | 0.29 | (0.25-0.35) |
Lymphoma | 368 | 74 | 0.15 | (0.13-0.16) | – | – | 0.09 | (0.06-0.11) | 0.13 | (0.10-0.17) | 0.19 | (0.15-0.23) | 0.28 | (0.24-0.33) |
Other hematopoietic neoplasms | 24 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Germ cell tumors, cysts and heterotopias | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Tumors of Sellar Region | 4,721 | 944 | 1.86 | (1.81-1.92) | 0.87 | (0.80-0.95) | 1.07 | (0.99-1.16) | 1.74 | (1.62-1.85) | 2.39 | (2.25-2.53) | 3.07 | (2.92-3.23) |
Tumors of the pituitary | 4,398 | 880 | 1.74 | (1.69-1.79) | 0.76 | (0.69-0.84) | 0.95 | (0.87-1.03) | 1.64 | (1.53-1.75) | 2.25 | (2.12-2.38) | 2.93 | (2.78-3.08) |
Craniopharyngioma | 323 | 65 | 0.12 | (0.11-0.14) | 0.11 | (0.09-0.14) | 0.12 | (0.10-0.16) | 0.10 | (0.07-0.13) | 0.14 | (0.11-0.17) | 0.14 | (0.11-0.18) |
Unclassified Tumors | 1,425 | 285 | 0.55 | (0.52-0.58) | 0.43 | (0.37-0.48) | 0.43 | (0.38-0.49) | 0.51 | (0.45-0.58) | 0.65 | (0.58-0.73) | 0.71 | (0.63-0.78) |
Hemangioma | 644 | 129 | 0.25 | (0.23-0.27) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.25) | 0.24 | (0.20-0.28) | 0.29 | (0.24-0.34) | 0.32 | (0.27-0.37) |
Neoplasm, unspecified | 776 | 155 | 0.30 | (0.28-0.32) | 0.24 | (0.20-0.29) | 0.22 | (0.18-0.26) | 0.27 | (0.23-0.32) | 0.36 | (0.31-0.42) | 0.39 | (0.34-0.45) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 22,168 | 4,434 | 8.64 | (8.52-8.75) | 5.58 | (5.39-5.78) | 5.88 | (5.68-6.08) | 8.01 | (7.77-8.26) | 10.39 | (10.1-10.67) | 12.73 | (12.42-13.05) |
Histology . | 15-39 (Male) . | 15-19 (Male) . | 20-24 (Male) . | 25-29 (Male) . | 30-34 (Male) . | 35-39 (Male) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 9,850 | 1,970 | 3.78 | (3.71-3.86) | 3.01 | (2.87-3.16) | 2.94 | (2.80-3.09) | 3.76 | (3.60-3.93) | 4.35 | (4.17-4.54) | 4.73 | (4.54-4.93) |
Pilocytic astrocytoma | 792 | 158 | 0.29 | (0.27-0.31) | 0.61 | (0.55-0.68) | 0.33 | (0.29-0.38) | 0.20 | (0.17-0.24) | 0.18 | (0.14-0.22) | 0.13 | (0.10-0.17) |
Diffuse astrocytoma | 1,373 | 275 | 0.53 | (0.50-0.56) | 0.27 | (0.23-0.32) | 0.41 | (0.36-0.47) | 0.58 | (0.52-0.65) | 0.70 | (0.63-0.78) | 0.67 | (0.60-0.74) |
Anaplastic astrocytoma | 813 | 163 | 0.32 | (0.29-0.34) | 0.11 | (0.08-0.14) | 0.21 | (0.18-0.26) | 0.35 | (0.30-0.41) | 0.46 | (0.40-0.52) | 0.44 | (0.38-0.50) |
Unique astrocytoma variants | 200 | 40 | 0.07 | (0.06-0.08) | 0.12 | (0.10-0.16) | 0.09 | (0.07-0.12) | 0.07 | (0.05-0.10) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) |
Glioblastoma | 1,458 | 292 | 0.58 | (0.55-0.61) | 0.22 | (0.18-0.26) | 0.31 | (0.27-0.36) | 0.52 | (0.46-0.59) | 0.70 | (0.63-0.77) | 1.08 | (0.99-1.17) |
Oligodendroglioma | 859 | 172 | 0.34 | (0.31-0.36) | 0.10 | (0.08-0.13) | 0.16 | (0.13-0.20) | 0.38 | (0.33-0.44) | 0.51 | (0.44-0.57) | 0.52 | (0.45-0.58) |
Anaplastic oligodendroglioma | 248 | 50 | 0.10 | (0.09-0.11) | – | – | 0.06 | (0.04-0.08) | 0.11 | (0.08-0.14) | 0.13 | (0.10-0.17) | 0.17 | (0.14-0.21) |
Oligoastrocytic tumors | 732 | 146 | 0.28 | (0.26-0.31) | 0.05 | (0.04-0.08) | 0.15 | (0.12-0.19) | 0.40 | (0.35-0.46) | 0.44 | (0.38-0.50) | 0.38 | (0.33-0.44) |
Ependymal tumors | 1,025 | 205 | 0.40 | (0.37-0.42) | 0.27 | (0.23-0.32) | 0.31 | (0.27-0.36) | 0.38 | (0.33-0.44) | 0.46 | (0.40-0.52) | 0.54 | (0.48-0.61) |
Glioma malignant, NOS | 717 | 143 | 0.27 | (0.25-0.29) | 0.33 | (0.29-0.39) | 0.25 | (0.21-0.29) | 0.23 | (0.19-0.27) | 0.27 | (0.23-0.32) | 0.28 | (0.23-0.33) |
Choroid plexus tumors | 87 | 17 | 0.03 | (0.03-0.04) | 0.05 | (0.03-0.07) | – | – | 0.04 | (0.02-0.06) | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 898 | 180 | 0.33 | (0.31-0.36) | 0.52 | (0.46-0.58) | 0.39 | (0.34-0.45) | 0.26 | (0.22-0.31) | 0.24 | (0.20-0.29) | 0.27 | (0.23-0.32) |
Tumors of the pineal region | 98 | 20 | 0.04 | (0.03-0.05) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) | 0.03 | (0.02-0.05) | 0.04 | (0.03-0.07) |
Embryonal tumors | 543 | 109 | 0.20 | (0.18-0.22) | 0.31 | (0.26-0.36) | 0.20 | (0.17-0.25) | 0.19 | (0.16-0.23) | 0.16 | (0.13-0.20) | 0.15 | (0.12-0.19) |
Tumors of Cranial and Spinal Nerves | 2,167 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.61 | (1.50-1.72) |
Nerve sheath tumors | 2,165 | 433 | 0.86 | (0.83-0.90) | 0.33 | (0.28-0.38) | 0.46 | (0.41-0.52) | 0.75 | (0.68-0.83) | 1.05 | (0.97-1.15) | 1.60 | (1.49-1.72) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 3,089 | 618 | 1.23 | (1.19-1.28) | 0.44 | (0.38-0.50) | 0.66 | (0.59-0.73) | 0.98 | (0.90-1.07) | 1.66 | (1.55-1.78) | 2.26 | (2.13-2.40) |
Meningioma | 2,429 | 486 | 0.98 | (0.94-1.02) | 0.27 | (0.23-0.32) | 0.48 | (0.42-0.54) | 0.76 | (0.69-0.84) | 1.33 | (1.23-1.44) | 1.89 | (1.77-2.01) |
Mesenchymal tumors | 160 | 32 | 0.06 | (0.05-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.03-0.06) | 0.05 | (0.03-0.07) | 0.08 | (0.06-0.11) | 0.10 | (0.07-0.13) |
Primary melanocytic lesions | 16 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 484 | 97 | 0.19 | (0.17-0.21) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.17 | (0.14-0.21) | 0.24 | (0.20-0.28) | 0.27 | (0.22-0.32) |
Lymphomas and Hematopoietic Neoplasms | 392 | 78 | 0.16 | (0.14-0.17) | 0.04 | (0.03-0.06) | 0.09 | (0.07-0.12) | 0.14 | (0.11-0.17) | 0.19 | (0.16-0.24) | 0.29 | (0.25-0.35) |
Lymphoma | 368 | 74 | 0.15 | (0.13-0.16) | – | – | 0.09 | (0.06-0.11) | 0.13 | (0.10-0.17) | 0.19 | (0.15-0.23) | 0.28 | (0.24-0.33) |
Other hematopoietic neoplasms | 24 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Germ cell tumors, cysts and heterotopias | 524 | 105 | 0.19 | (0.17-0.21) | 0.46 | (0.41-0.52) | 0.22 | (0.19-0.27) | 0.13 | (0.10-0.16) | 0.09 | (0.06-0.12) | 0.06 | (0.04-0.09) |
Tumors of Sellar Region | 4,721 | 944 | 1.86 | (1.81-1.92) | 0.87 | (0.80-0.95) | 1.07 | (0.99-1.16) | 1.74 | (1.62-1.85) | 2.39 | (2.25-2.53) | 3.07 | (2.92-3.23) |
Tumors of the pituitary | 4,398 | 880 | 1.74 | (1.69-1.79) | 0.76 | (0.69-0.84) | 0.95 | (0.87-1.03) | 1.64 | (1.53-1.75) | 2.25 | (2.12-2.38) | 2.93 | (2.78-3.08) |
Craniopharyngioma | 323 | 65 | 0.12 | (0.11-0.14) | 0.11 | (0.09-0.14) | 0.12 | (0.10-0.16) | 0.10 | (0.07-0.13) | 0.14 | (0.11-0.17) | 0.14 | (0.11-0.18) |
Unclassified Tumors | 1,425 | 285 | 0.55 | (0.52-0.58) | 0.43 | (0.37-0.48) | 0.43 | (0.38-0.49) | 0.51 | (0.45-0.58) | 0.65 | (0.58-0.73) | 0.71 | (0.63-0.78) |
Hemangioma | 644 | 129 | 0.25 | (0.23-0.27) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.25) | 0.24 | (0.20-0.28) | 0.29 | (0.24-0.34) | 0.32 | (0.27-0.37) |
Neoplasm, unspecified | 776 | 155 | 0.30 | (0.28-0.32) | 0.24 | (0.20-0.29) | 0.22 | (0.18-0.26) | 0.27 | (0.23-0.32) | 0.36 | (0.31-0.42) | 0.39 | (0.34-0.45) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 22,168 | 4,434 | 8.64 | (8.52-8.75) | 5.58 | (5.39-5.78) | 5.88 | (5.68-6.08) | 8.01 | (7.77-8.26) | 10.39 | (10.1-10.67) | 12.73 | (12.42-13.05) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | 15-39 (Female) . | 15-19 (Female) . | 20-24 (Female) . | 25-29 (Female) . | 30-34 (Female) . | 35-39 (Female) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 7,926 | 1,585 | 3.09 | (3.02-3.16) | 2.63 | (2.49-2.77) | 2.54 | (2.40-2.68) | 3.22 | (3.07-3.38) | 3.48 | (3.31-3.64) | 3.55 | (3.38-3.72) |
Pilocytic astrocytoma | 727 | 145 | 0.28 | (0.26-0.30) | 0.58 | (0.52-0.65) | 0.29 | (0.25-0.34) | 0.22 | (0.18-0.26) | 0.18 | (0.15-0.23) | 0.12 | (0.09-0.16) |
Diffuse astrocytoma | 1,040 | 208 | 0.41 | (0.38-0.43) | 0.28 | (0.23-0.33) | 0.29 | (0.25-0.34) | 0.45 | (0.39-0.51) | 0.51 | (0.45-0.58) | 0.50 | (0.44-0.56) |
Anaplastic astrocytoma | 585 | 117 | 0.23 | (0.21-0.25) | 0.09 | (0.06-0.12) | 0.16 | (0.12-0.19) | 0.30 | (0.26-0.35) | 0.26 | (0.22-0.31) | 0.33 | (0.29-0.39) |
Unique astrocytoma variants | 181 | 36 | 0.07 | (0.06-0.08) | 0.10 | (0.07-0.13) | 0.12 | (0.09-0.15) | 0.05 | (0.03-0.07) | 0.06 | (0.04-0.08) | – | – |
Glioblastoma | 935 | 187 | 0.38 | (0.35-0.40) | 0.16 | (0.13-0.20) | 0.24 | (0.20-0.29) | 0.33 | (0.28-0.38) | 0.42 | (0.36-0.48) | 0.69 | (0.62-0.76) |
Oligodendroglioma | 629 | 126 | 0.25 | (0.23-0.27) | 0.08 | (0.06-0.11) | 0.16 | (0.13-0.20) | 0.25 | (0.21-0.30) | 0.36 | (0.31-0.41) | 0.39 | (0.33-0.44) |
Anaplastic oligodendroglioma | 172 | 34 | 0.07 | (0.06-0.08) | – | – | – | – | 0.06 | (0.04-0.09) | 0.11 | (0.08-0.14) | 0.12 | (0.10-0.16) |
Oligoastrocytic tumors | 601 | 120 | 0.24 | (0.22-0.26) | 0.07 | (0.05-0.09) | 0.16 | (0.13-0.19) | 0.31 | (0.27-0.37) | 0.32 | (0.28-0.38) | 0.32 | (0.27-0.37) |
Ependymal tumors | 863 | 173 | 0.34 | (0.31-0.36) | 0.22 | (0.19-0.27) | 0.25 | (0.21-0.29) | 0.37 | (0.32-0.42) | 0.45 | (0.39-0.51) | 0.39 | (0.34-0.45) |
Glioma malignant, NOS | 667 | 133 | 0.26 | (0.24-0.28) | 0.31 | (0.26-0.36) | 0.23 | (0.19-0.28) | 0.27 | (0.23-0.32) | 0.25 | (0.21-0.30) | 0.23 | (0.19-0.28) |
Choroid plexus tumors | 96 | 19 | 0.04 | (0.03-0.05) | 0.05 | (0.03-0.07) | – | – | 0.03 | (0.02-0.05) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) |
Other neuroepithelial tumors | 23 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 875 | 175 | 0.33 | (0.31-0.36) | 0.45 | (0.39-0.51) | 0.34 | (0.30-0.40) | 0.34 | (0.29-0.40) | 0.32 | (0.27-0.37) | 0.23 | (0.19-0.27) |
Tumors of the pineal region | 160 | 32 | 0.06 | (0.05-0.07) | 0.06 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.09) |
Embryonal tumors | 372 | 74 | 0.14 | (0.13-0.16) | 0.17 | (0.14-0.21) | 0.18 | (0.15-0.22) | 0.16 | (0.13-0.20) | 0.12 | (0.09-0.15) | 0.09 | (0.06-0.12) |
Tumors of Cranial and Spinal Nerves | 2,382 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Nerve sheath tumors | 2,380 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 6,618 | 1,324 | 2.74 | (2.67-2.80) | 0.47 | (0.41-0.53) | 0.86 | (0.79-0.95) | 1.88 | (1.76-2.00) | 3.65 | (3.49-3.82) | 6.22 | (6.01-6.45) |
Meningioma | 6,011 | 1,202 | 2.50 | (2.43-2.56) | 0.33 | (0.28-0.38) | 0.67 | (0.60-0.74) | 1.66 | (1.55-1.77) | 3.35 | (3.19-3.51) | 5.91 | (5.70-6.12) |
Mesenchymal tumors | 176 | 35 | 0.07 | (0.06-0.08) | 0.05 | (0.04-0.08) | 0.05 | (0.04-0.08) | 0.04 | (0.02-0.06) | 0.09 | (0.07-0.12) | 0.10 | (0.08-0.14) |
Primary melanocytic lesions | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 425 | 85 | 0.17 | (0.15-0.18) | 0.08 | (0.06-0.11) | 0.14 | (0.11-0.18) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.26) | 0.21 | (0.17-0.25) |
Lymphomas and Hematopoietic Neoplasms | 227 | 45 | 0.09 | (0.08-0.11) | 0.03 | (0.02-0.05) | 0.05 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.13 | (0.10-0.16) | 0.18 | (0.14-0.22) |
Lymphoma | 208 | 42 | 0.08 | (0.07-0.10) | – | – | 0.05 | (0.03-0.07) | 0.05 | (0.03-0.07) | 0.12 | (0.09-0.16) | 0.17 | (0.14-0.21) |
Other hematopoietic neoplasms | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Germ cell tumors, cysts and heterotopias | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Tumors of Sellar Region | 11,838 | 2,368 | 4.62 | (4.53-4.70) | 2.75 | (2.61-2.89) | 3.88 | (3.71-4.05) | 5.01 | (4.82-5.21) | 5.62 | (5.42-5.84) | 5.77 | (5.56-5.98) |
Tumors of the pituitary | 11,494 | 2,299 | 4.48 | (4.40-4.57) | 2.60 | (2.46-2.74) | 3.76 | (3.60-3.93) | 4.89 | (4.70-5.08) | 5.50 | (5.29-5.71) | 5.61 | (5.40-5.82) |
Craniopharyngioma | 344 | 69 | 0.13 | (0.12-0.15) | 0.15 | (0.12-0.19) | 0.11 | (0.09-0.15) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.16 | (0.13-0.20) |
Unclassified Tumors | 1,792 | 358 | 0.70 | (0.67-0.74) | 0.50 | (0.44-0.56) | 0.50 | (0.44-0.56) | 0.76 | (0.68-0.83) | 0.78 | (0.71-0.86) | 0.95 | (0.87-1.04) |
Hemangioma | 894 | 179 | 0.35 | (0.33-0.38) | 0.21 | (0.17-0.25) | 0.25 | (0.21-0.30) | 0.37 | (0.32-0.43) | 0.40 | (0.34-0.46) | 0.51 | (0.45-0.58) |
Neoplasm, unspecified | 891 | 178 | 0.35 | (0.32-0.37) | 0.28 | (0.24-0.33) | 0.24 | (0.20-0.29) | 0.38 | (0.33-0.44) | 0.38 | (0.33-0.44) | 0.44 | (0.39-0.51) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 30,915 | 6,183 | 12.24 | (12.10-12.38) | 6.83 | (6.61-7.06) | 8.42 | (8.18-8.67) | 11.87 | (11.57-12.17) | 14.93 | (14.6-15.28) | 18.33 | (17.96-18.71) |
Histology . | 15-39 (Female) . | 15-19 (Female) . | 20-24 (Female) . | 25-29 (Female) . | 30-34 (Female) . | 35-39 (Female) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 7,926 | 1,585 | 3.09 | (3.02-3.16) | 2.63 | (2.49-2.77) | 2.54 | (2.40-2.68) | 3.22 | (3.07-3.38) | 3.48 | (3.31-3.64) | 3.55 | (3.38-3.72) |
Pilocytic astrocytoma | 727 | 145 | 0.28 | (0.26-0.30) | 0.58 | (0.52-0.65) | 0.29 | (0.25-0.34) | 0.22 | (0.18-0.26) | 0.18 | (0.15-0.23) | 0.12 | (0.09-0.16) |
Diffuse astrocytoma | 1,040 | 208 | 0.41 | (0.38-0.43) | 0.28 | (0.23-0.33) | 0.29 | (0.25-0.34) | 0.45 | (0.39-0.51) | 0.51 | (0.45-0.58) | 0.50 | (0.44-0.56) |
Anaplastic astrocytoma | 585 | 117 | 0.23 | (0.21-0.25) | 0.09 | (0.06-0.12) | 0.16 | (0.12-0.19) | 0.30 | (0.26-0.35) | 0.26 | (0.22-0.31) | 0.33 | (0.29-0.39) |
Unique astrocytoma variants | 181 | 36 | 0.07 | (0.06-0.08) | 0.10 | (0.07-0.13) | 0.12 | (0.09-0.15) | 0.05 | (0.03-0.07) | 0.06 | (0.04-0.08) | – | – |
Glioblastoma | 935 | 187 | 0.38 | (0.35-0.40) | 0.16 | (0.13-0.20) | 0.24 | (0.20-0.29) | 0.33 | (0.28-0.38) | 0.42 | (0.36-0.48) | 0.69 | (0.62-0.76) |
Oligodendroglioma | 629 | 126 | 0.25 | (0.23-0.27) | 0.08 | (0.06-0.11) | 0.16 | (0.13-0.20) | 0.25 | (0.21-0.30) | 0.36 | (0.31-0.41) | 0.39 | (0.33-0.44) |
Anaplastic oligodendroglioma | 172 | 34 | 0.07 | (0.06-0.08) | – | – | – | – | 0.06 | (0.04-0.09) | 0.11 | (0.08-0.14) | 0.12 | (0.10-0.16) |
Oligoastrocytic tumors | 601 | 120 | 0.24 | (0.22-0.26) | 0.07 | (0.05-0.09) | 0.16 | (0.13-0.19) | 0.31 | (0.27-0.37) | 0.32 | (0.28-0.38) | 0.32 | (0.27-0.37) |
Ependymal tumors | 863 | 173 | 0.34 | (0.31-0.36) | 0.22 | (0.19-0.27) | 0.25 | (0.21-0.29) | 0.37 | (0.32-0.42) | 0.45 | (0.39-0.51) | 0.39 | (0.34-0.45) |
Glioma malignant, NOS | 667 | 133 | 0.26 | (0.24-0.28) | 0.31 | (0.26-0.36) | 0.23 | (0.19-0.28) | 0.27 | (0.23-0.32) | 0.25 | (0.21-0.30) | 0.23 | (0.19-0.28) |
Choroid plexus tumors | 96 | 19 | 0.04 | (0.03-0.05) | 0.05 | (0.03-0.07) | – | – | 0.03 | (0.02-0.05) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) |
Other neuroepithelial tumors | 23 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 875 | 175 | 0.33 | (0.31-0.36) | 0.45 | (0.39-0.51) | 0.34 | (0.30-0.40) | 0.34 | (0.29-0.40) | 0.32 | (0.27-0.37) | 0.23 | (0.19-0.27) |
Tumors of the pineal region | 160 | 32 | 0.06 | (0.05-0.07) | 0.06 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.09) |
Embryonal tumors | 372 | 74 | 0.14 | (0.13-0.16) | 0.17 | (0.14-0.21) | 0.18 | (0.15-0.22) | 0.16 | (0.13-0.20) | 0.12 | (0.09-0.15) | 0.09 | (0.06-0.12) |
Tumors of Cranial and Spinal Nerves | 2,382 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Nerve sheath tumors | 2,380 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 6,618 | 1,324 | 2.74 | (2.67-2.80) | 0.47 | (0.41-0.53) | 0.86 | (0.79-0.95) | 1.88 | (1.76-2.00) | 3.65 | (3.49-3.82) | 6.22 | (6.01-6.45) |
Meningioma | 6,011 | 1,202 | 2.50 | (2.43-2.56) | 0.33 | (0.28-0.38) | 0.67 | (0.60-0.74) | 1.66 | (1.55-1.77) | 3.35 | (3.19-3.51) | 5.91 | (5.70-6.12) |
Mesenchymal tumors | 176 | 35 | 0.07 | (0.06-0.08) | 0.05 | (0.04-0.08) | 0.05 | (0.04-0.08) | 0.04 | (0.02-0.06) | 0.09 | (0.07-0.12) | 0.10 | (0.08-0.14) |
Primary melanocytic lesions | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 425 | 85 | 0.17 | (0.15-0.18) | 0.08 | (0.06-0.11) | 0.14 | (0.11-0.18) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.26) | 0.21 | (0.17-0.25) |
Lymphomas and Hematopoietic Neoplasms | 227 | 45 | 0.09 | (0.08-0.11) | 0.03 | (0.02-0.05) | 0.05 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.13 | (0.10-0.16) | 0.18 | (0.14-0.22) |
Lymphoma | 208 | 42 | 0.08 | (0.07-0.10) | – | – | 0.05 | (0.03-0.07) | 0.05 | (0.03-0.07) | 0.12 | (0.09-0.16) | 0.17 | (0.14-0.21) |
Other hematopoietic neoplasms | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Germ cell tumors, cysts and heterotopias | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Tumors of Sellar Region | 11,838 | 2,368 | 4.62 | (4.53-4.70) | 2.75 | (2.61-2.89) | 3.88 | (3.71-4.05) | 5.01 | (4.82-5.21) | 5.62 | (5.42-5.84) | 5.77 | (5.56-5.98) |
Tumors of the pituitary | 11,494 | 2,299 | 4.48 | (4.40-4.57) | 2.60 | (2.46-2.74) | 3.76 | (3.60-3.93) | 4.89 | (4.70-5.08) | 5.50 | (5.29-5.71) | 5.61 | (5.40-5.82) |
Craniopharyngioma | 344 | 69 | 0.13 | (0.12-0.15) | 0.15 | (0.12-0.19) | 0.11 | (0.09-0.15) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.16 | (0.13-0.20) |
Unclassified Tumors | 1,792 | 358 | 0.70 | (0.67-0.74) | 0.50 | (0.44-0.56) | 0.50 | (0.44-0.56) | 0.76 | (0.68-0.83) | 0.78 | (0.71-0.86) | 0.95 | (0.87-1.04) |
Hemangioma | 894 | 179 | 0.35 | (0.33-0.38) | 0.21 | (0.17-0.25) | 0.25 | (0.21-0.30) | 0.37 | (0.32-0.43) | 0.40 | (0.34-0.46) | 0.51 | (0.45-0.58) |
Neoplasm, unspecified | 891 | 178 | 0.35 | (0.32-0.37) | 0.28 | (0.24-0.33) | 0.24 | (0.20-0.29) | 0.38 | (0.33-0.44) | 0.38 | (0.33-0.44) | 0.44 | (0.39-0.51) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 30,915 | 6,183 | 12.24 | (12.10-12.38) | 6.83 | (6.61-7.06) | 8.42 | (8.18-8.67) | 11.87 | (11.57-12.17) | 14.93 | (14.6-15.28) | 18.33 | (17.96-18.71) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | 15-39 (Female) . | 15-19 (Female) . | 20-24 (Female) . | 25-29 (Female) . | 30-34 (Female) . | 35-39 (Female) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 7,926 | 1,585 | 3.09 | (3.02-3.16) | 2.63 | (2.49-2.77) | 2.54 | (2.40-2.68) | 3.22 | (3.07-3.38) | 3.48 | (3.31-3.64) | 3.55 | (3.38-3.72) |
Pilocytic astrocytoma | 727 | 145 | 0.28 | (0.26-0.30) | 0.58 | (0.52-0.65) | 0.29 | (0.25-0.34) | 0.22 | (0.18-0.26) | 0.18 | (0.15-0.23) | 0.12 | (0.09-0.16) |
Diffuse astrocytoma | 1,040 | 208 | 0.41 | (0.38-0.43) | 0.28 | (0.23-0.33) | 0.29 | (0.25-0.34) | 0.45 | (0.39-0.51) | 0.51 | (0.45-0.58) | 0.50 | (0.44-0.56) |
Anaplastic astrocytoma | 585 | 117 | 0.23 | (0.21-0.25) | 0.09 | (0.06-0.12) | 0.16 | (0.12-0.19) | 0.30 | (0.26-0.35) | 0.26 | (0.22-0.31) | 0.33 | (0.29-0.39) |
Unique astrocytoma variants | 181 | 36 | 0.07 | (0.06-0.08) | 0.10 | (0.07-0.13) | 0.12 | (0.09-0.15) | 0.05 | (0.03-0.07) | 0.06 | (0.04-0.08) | – | – |
Glioblastoma | 935 | 187 | 0.38 | (0.35-0.40) | 0.16 | (0.13-0.20) | 0.24 | (0.20-0.29) | 0.33 | (0.28-0.38) | 0.42 | (0.36-0.48) | 0.69 | (0.62-0.76) |
Oligodendroglioma | 629 | 126 | 0.25 | (0.23-0.27) | 0.08 | (0.06-0.11) | 0.16 | (0.13-0.20) | 0.25 | (0.21-0.30) | 0.36 | (0.31-0.41) | 0.39 | (0.33-0.44) |
Anaplastic oligodendroglioma | 172 | 34 | 0.07 | (0.06-0.08) | – | – | – | – | 0.06 | (0.04-0.09) | 0.11 | (0.08-0.14) | 0.12 | (0.10-0.16) |
Oligoastrocytic tumors | 601 | 120 | 0.24 | (0.22-0.26) | 0.07 | (0.05-0.09) | 0.16 | (0.13-0.19) | 0.31 | (0.27-0.37) | 0.32 | (0.28-0.38) | 0.32 | (0.27-0.37) |
Ependymal tumors | 863 | 173 | 0.34 | (0.31-0.36) | 0.22 | (0.19-0.27) | 0.25 | (0.21-0.29) | 0.37 | (0.32-0.42) | 0.45 | (0.39-0.51) | 0.39 | (0.34-0.45) |
Glioma malignant, NOS | 667 | 133 | 0.26 | (0.24-0.28) | 0.31 | (0.26-0.36) | 0.23 | (0.19-0.28) | 0.27 | (0.23-0.32) | 0.25 | (0.21-0.30) | 0.23 | (0.19-0.28) |
Choroid plexus tumors | 96 | 19 | 0.04 | (0.03-0.05) | 0.05 | (0.03-0.07) | – | – | 0.03 | (0.02-0.05) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) |
Other neuroepithelial tumors | 23 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 875 | 175 | 0.33 | (0.31-0.36) | 0.45 | (0.39-0.51) | 0.34 | (0.30-0.40) | 0.34 | (0.29-0.40) | 0.32 | (0.27-0.37) | 0.23 | (0.19-0.27) |
Tumors of the pineal region | 160 | 32 | 0.06 | (0.05-0.07) | 0.06 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.09) |
Embryonal tumors | 372 | 74 | 0.14 | (0.13-0.16) | 0.17 | (0.14-0.21) | 0.18 | (0.15-0.22) | 0.16 | (0.13-0.20) | 0.12 | (0.09-0.15) | 0.09 | (0.06-0.12) |
Tumors of Cranial and Spinal Nerves | 2,382 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Nerve sheath tumors | 2,380 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 6,618 | 1,324 | 2.74 | (2.67-2.80) | 0.47 | (0.41-0.53) | 0.86 | (0.79-0.95) | 1.88 | (1.76-2.00) | 3.65 | (3.49-3.82) | 6.22 | (6.01-6.45) |
Meningioma | 6,011 | 1,202 | 2.50 | (2.43-2.56) | 0.33 | (0.28-0.38) | 0.67 | (0.60-0.74) | 1.66 | (1.55-1.77) | 3.35 | (3.19-3.51) | 5.91 | (5.70-6.12) |
Mesenchymal tumors | 176 | 35 | 0.07 | (0.06-0.08) | 0.05 | (0.04-0.08) | 0.05 | (0.04-0.08) | 0.04 | (0.02-0.06) | 0.09 | (0.07-0.12) | 0.10 | (0.08-0.14) |
Primary melanocytic lesions | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 425 | 85 | 0.17 | (0.15-0.18) | 0.08 | (0.06-0.11) | 0.14 | (0.11-0.18) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.26) | 0.21 | (0.17-0.25) |
Lymphomas and Hematopoietic Neoplasms | 227 | 45 | 0.09 | (0.08-0.11) | 0.03 | (0.02-0.05) | 0.05 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.13 | (0.10-0.16) | 0.18 | (0.14-0.22) |
Lymphoma | 208 | 42 | 0.08 | (0.07-0.10) | – | – | 0.05 | (0.03-0.07) | 0.05 | (0.03-0.07) | 0.12 | (0.09-0.16) | 0.17 | (0.14-0.21) |
Other hematopoietic neoplasms | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Germ cell tumors, cysts and heterotopias | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Tumors of Sellar Region | 11,838 | 2,368 | 4.62 | (4.53-4.70) | 2.75 | (2.61-2.89) | 3.88 | (3.71-4.05) | 5.01 | (4.82-5.21) | 5.62 | (5.42-5.84) | 5.77 | (5.56-5.98) |
Tumors of the pituitary | 11,494 | 2,299 | 4.48 | (4.40-4.57) | 2.60 | (2.46-2.74) | 3.76 | (3.60-3.93) | 4.89 | (4.70-5.08) | 5.50 | (5.29-5.71) | 5.61 | (5.40-5.82) |
Craniopharyngioma | 344 | 69 | 0.13 | (0.12-0.15) | 0.15 | (0.12-0.19) | 0.11 | (0.09-0.15) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.16 | (0.13-0.20) |
Unclassified Tumors | 1,792 | 358 | 0.70 | (0.67-0.74) | 0.50 | (0.44-0.56) | 0.50 | (0.44-0.56) | 0.76 | (0.68-0.83) | 0.78 | (0.71-0.86) | 0.95 | (0.87-1.04) |
Hemangioma | 894 | 179 | 0.35 | (0.33-0.38) | 0.21 | (0.17-0.25) | 0.25 | (0.21-0.30) | 0.37 | (0.32-0.43) | 0.40 | (0.34-0.46) | 0.51 | (0.45-0.58) |
Neoplasm, unspecified | 891 | 178 | 0.35 | (0.32-0.37) | 0.28 | (0.24-0.33) | 0.24 | (0.20-0.29) | 0.38 | (0.33-0.44) | 0.38 | (0.33-0.44) | 0.44 | (0.39-0.51) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 30,915 | 6,183 | 12.24 | (12.10-12.38) | 6.83 | (6.61-7.06) | 8.42 | (8.18-8.67) | 11.87 | (11.57-12.17) | 14.93 | (14.6-15.28) | 18.33 | (17.96-18.71) |
Histology . | 15-39 (Female) . | 15-19 (Female) . | 20-24 (Female) . | 25-29 (Female) . | 30-34 (Female) . | 35-39 (Female) . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 7,926 | 1,585 | 3.09 | (3.02-3.16) | 2.63 | (2.49-2.77) | 2.54 | (2.40-2.68) | 3.22 | (3.07-3.38) | 3.48 | (3.31-3.64) | 3.55 | (3.38-3.72) |
Pilocytic astrocytoma | 727 | 145 | 0.28 | (0.26-0.30) | 0.58 | (0.52-0.65) | 0.29 | (0.25-0.34) | 0.22 | (0.18-0.26) | 0.18 | (0.15-0.23) | 0.12 | (0.09-0.16) |
Diffuse astrocytoma | 1,040 | 208 | 0.41 | (0.38-0.43) | 0.28 | (0.23-0.33) | 0.29 | (0.25-0.34) | 0.45 | (0.39-0.51) | 0.51 | (0.45-0.58) | 0.50 | (0.44-0.56) |
Anaplastic astrocytoma | 585 | 117 | 0.23 | (0.21-0.25) | 0.09 | (0.06-0.12) | 0.16 | (0.12-0.19) | 0.30 | (0.26-0.35) | 0.26 | (0.22-0.31) | 0.33 | (0.29-0.39) |
Unique astrocytoma variants | 181 | 36 | 0.07 | (0.06-0.08) | 0.10 | (0.07-0.13) | 0.12 | (0.09-0.15) | 0.05 | (0.03-0.07) | 0.06 | (0.04-0.08) | – | – |
Glioblastoma | 935 | 187 | 0.38 | (0.35-0.40) | 0.16 | (0.13-0.20) | 0.24 | (0.20-0.29) | 0.33 | (0.28-0.38) | 0.42 | (0.36-0.48) | 0.69 | (0.62-0.76) |
Oligodendroglioma | 629 | 126 | 0.25 | (0.23-0.27) | 0.08 | (0.06-0.11) | 0.16 | (0.13-0.20) | 0.25 | (0.21-0.30) | 0.36 | (0.31-0.41) | 0.39 | (0.33-0.44) |
Anaplastic oligodendroglioma | 172 | 34 | 0.07 | (0.06-0.08) | – | – | – | – | 0.06 | (0.04-0.09) | 0.11 | (0.08-0.14) | 0.12 | (0.10-0.16) |
Oligoastrocytic tumors | 601 | 120 | 0.24 | (0.22-0.26) | 0.07 | (0.05-0.09) | 0.16 | (0.13-0.19) | 0.31 | (0.27-0.37) | 0.32 | (0.28-0.38) | 0.32 | (0.27-0.37) |
Ependymal tumors | 863 | 173 | 0.34 | (0.31-0.36) | 0.22 | (0.19-0.27) | 0.25 | (0.21-0.29) | 0.37 | (0.32-0.42) | 0.45 | (0.39-0.51) | 0.39 | (0.34-0.45) |
Glioma malignant, NOS | 667 | 133 | 0.26 | (0.24-0.28) | 0.31 | (0.26-0.36) | 0.23 | (0.19-0.28) | 0.27 | (0.23-0.32) | 0.25 | (0.21-0.30) | 0.23 | (0.19-0.28) |
Choroid plexus tumors | 96 | 19 | 0.04 | (0.03-0.05) | 0.05 | (0.03-0.07) | – | – | 0.03 | (0.02-0.05) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) |
Other neuroepithelial tumors | 23 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 875 | 175 | 0.33 | (0.31-0.36) | 0.45 | (0.39-0.51) | 0.34 | (0.30-0.40) | 0.34 | (0.29-0.40) | 0.32 | (0.27-0.37) | 0.23 | (0.19-0.27) |
Tumors of the pineal region | 160 | 32 | 0.06 | (0.05-0.07) | 0.06 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.07 | (0.05-0.09) |
Embryonal tumors | 372 | 74 | 0.14 | (0.13-0.16) | 0.17 | (0.14-0.21) | 0.18 | (0.15-0.22) | 0.16 | (0.13-0.20) | 0.12 | (0.09-0.15) | 0.09 | (0.06-0.12) |
Tumors of Cranial and Spinal Nerves | 2,382 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Nerve sheath tumors | 2,380 | 476 | 0.95 | (0.92-0.99) | 0.38 | (0.33-0.44) | 0.53 | (0.47-0.60) | 0.90 | (0.82-0.99) | 1.23 | (1.14-1.34) | 1.62 | (1.51-1.74) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 6,618 | 1,324 | 2.74 | (2.67-2.80) | 0.47 | (0.41-0.53) | 0.86 | (0.79-0.95) | 1.88 | (1.76-2.00) | 3.65 | (3.49-3.82) | 6.22 | (6.01-6.45) |
Meningioma | 6,011 | 1,202 | 2.50 | (2.43-2.56) | 0.33 | (0.28-0.38) | 0.67 | (0.60-0.74) | 1.66 | (1.55-1.77) | 3.35 | (3.19-3.51) | 5.91 | (5.70-6.12) |
Mesenchymal tumors | 176 | 35 | 0.07 | (0.06-0.08) | 0.05 | (0.04-0.08) | 0.05 | (0.04-0.08) | 0.04 | (0.02-0.06) | 0.09 | (0.07-0.12) | 0.10 | (0.08-0.14) |
Primary melanocytic lesions | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 425 | 85 | 0.17 | (0.15-0.18) | 0.08 | (0.06-0.11) | 0.14 | (0.11-0.18) | 0.18 | (0.15-0.22) | 0.21 | (0.17-0.26) | 0.21 | (0.17-0.25) |
Lymphomas and Hematopoietic Neoplasms | 227 | 45 | 0.09 | (0.08-0.11) | 0.03 | (0.02-0.05) | 0.05 | (0.04-0.08) | 0.06 | (0.04-0.08) | 0.13 | (0.10-0.16) | 0.18 | (0.14-0.22) |
Lymphoma | 208 | 42 | 0.08 | (0.07-0.10) | – | – | 0.05 | (0.03-0.07) | 0.05 | (0.03-0.07) | 0.12 | (0.09-0.16) | 0.17 | (0.14-0.21) |
Other hematopoietic neoplasms | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Germ cell tumors, cysts and heterotopias | 132 | 26 | 0.05 | (0.04-0.06) | 0.07 | (0.05-0.10) | 0.06 | (0.04-0.08) | 0.05 | (0.03-0.07) | 0.04 | (0.02-0.06) | 0.04 | (0.02-0.06) |
Tumors of Sellar Region | 11,838 | 2,368 | 4.62 | (4.53-4.70) | 2.75 | (2.61-2.89) | 3.88 | (3.71-4.05) | 5.01 | (4.82-5.21) | 5.62 | (5.42-5.84) | 5.77 | (5.56-5.98) |
Tumors of the pituitary | 11,494 | 2,299 | 4.48 | (4.40-4.57) | 2.60 | (2.46-2.74) | 3.76 | (3.60-3.93) | 4.89 | (4.70-5.08) | 5.50 | (5.29-5.71) | 5.61 | (5.40-5.82) |
Craniopharyngioma | 344 | 69 | 0.13 | (0.12-0.15) | 0.15 | (0.12-0.19) | 0.11 | (0.09-0.15) | 0.12 | (0.09-0.15) | 0.13 | (0.10-0.16) | 0.16 | (0.13-0.20) |
Unclassified Tumors | 1,792 | 358 | 0.70 | (0.67-0.74) | 0.50 | (0.44-0.56) | 0.50 | (0.44-0.56) | 0.76 | (0.68-0.83) | 0.78 | (0.71-0.86) | 0.95 | (0.87-1.04) |
Hemangioma | 894 | 179 | 0.35 | (0.33-0.38) | 0.21 | (0.17-0.25) | 0.25 | (0.21-0.30) | 0.37 | (0.32-0.43) | 0.40 | (0.34-0.46) | 0.51 | (0.45-0.58) |
Neoplasm, unspecified | 891 | 178 | 0.35 | (0.32-0.37) | 0.28 | (0.24-0.33) | 0.24 | (0.20-0.29) | 0.38 | (0.33-0.44) | 0.38 | (0.33-0.44) | 0.44 | (0.39-0.51) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 30,915 | 6,183 | 12.24 | (12.10-12.38) | 6.83 | (6.61-7.06) | 8.42 | (8.18-8.67) | 11.87 | (11.57-12.17) | 14.93 | (14.6-15.28) | 18.33 | (17.96-18.71) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Incidence rate ratios (IRR) by gender (male:female) for selected histologies in adolescents and young adults (age 15-39 years) are shown in Figure 21.
There are significant differences in incidence of multiple tumor types by gender in AYA.
Males are diagnosed with germ cells tumors nearly four times as often as females (IRR: males:females = 3.8), and with lymphoma nearly two times as often (IRR: males:females = 1.7).
Females are diagnosed with meningioma and tumors of the pituitary approximately 2.5 times as often as males (IRR: males:females = 0.4).
Incidence by Race and Ethnicity
Average annual incidence rates by race for adolescents and young adults (age 15-39 years) are shown in Table 6.
Overall, AYA incidence is highest in Whites (10.68 per 100,000 population), followed by Blacks (9.42 per 100,000 population), and API (9.37 per 100,000 population). AIAN have the lowest incidence of all racial groups, with average annual age-adjusted incidence of 6.99 per 100,000.
Incidence of tumors of neuroepithelial tissue is higher in whites than in any other racial group in AYA.
Incidence of tumors of the meninges, tumors of the sellar region, and lymphomas and hematopoietic neoplasms are higher in Blacks in the AYA population.
Incidence of tumors of the cranial and spinal nerves and germ cell tumors in AYA have the highest incidence in API.
Histology . | White . | Black . | AIAN . | API . | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 14,928 | 2,986 | 3.75 | (3.69-3.81) | 1,635 | 327 | 2.11 | (2.00-2.21) | 161 | 32 | 1.93 | (1.64-2.26) | 878 | 176 | 2.58 | (2.41-2.76) |
Pilocytic astrocytoma | 1,257 | 251 | 0.31 | (0.29-0.32) | 172 | 34 | 0.20 | (0.17-0.24) | – | – | – | – | 65 | – | 0.20 | (0.16-0.26) |
Diffuse astrocytoma | 2,050 | 410 | 0.52 | (0.49-0.54) | 217 | 43 | 0.29 | (0.25-0.33) | 27 | – | 0.32 | (0.21-0.47) | 96 | 19 | 0.28 | (0.22-0.34) |
Anaplastic astrocytoma | 1,208 | 242 | 0.31 | (0.29-0.32) | 94 | 19 | 0.13 | (0.10-0.15) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Unique astrocytoma variants | 288 | 58 | 0.07 | (0.06-0.08) | 58 | – | 0.07 | (0.05-0.09) | – | – | – | – | 23 | – | 0.07 | (0.04-0.10) |
Glioblastoma | 1,948 | 390 | 0.51 | (0.48-0.53) | 260 | 52 | 0.36 | (0.31-0.40) | – | – | – | – | 149 | 30 | 0.43 | (0.37-0.51) |
Oligodendroglioma | 1,330 | 266 | 0.34 | (0.32-0.36) | 70 | – | 0.10 | (0.07-0.12) | – | – | – | – | 66 | – | 0.19 | (0.15-0.24) |
Anaplastic oligodendroglioma | 378 | 76 | 0.10 | (0.09-0.11) | 16 | – | 0.02 | (0.01-0.04) | – | – | – | – | 18 | – | 0.05 | (0.03-0.08) |
Oligoastrocytic tumors | 1,165 | 233 | 0.29 | (0.28-0.31) | 77 | – | 0.11 | (0.08-0.13) | – | – | – | – | 61 | – | 0.17 | (0.13-0.22) |
Ependymal tumors | 1,585 | 317 | 0.40 | (0.38-0.42) | 157 | 31 | 0.21 | (0.18-0.24) | 17 | – | 0.20 | (0.12-0.33) | 115 | 23 | 0.33 | (0.27-0.40) |
Glioma malignant, NOS | 1,124 | 225 | 0.28 | (0.26-0.30) | 163 | 33 | 0.20 | (0.17-0.24) | – | – | – | – | 68 | – | 0.20 | (0.16-0.26) |
Choroid plexus tumors | 153 | 31 | 0.04 | (0.03-0.04) | 18 | – | 0.02 | (0.01-0.04) | – | – | – | – | – | – | – | – |
Other neuroepithelial tumors | 26 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,447 | 289 | 0.36 | (0.34-0.37) | 190 | 38 | 0.23 | (0.20-0.27) | – | – | – | – | 102 | 20 | 0.31 | (0.25-0.38) |
Tumors of the pineal region | 205 | 41 | 0.05 | (0.04-0.06) | 41 | – | 0.05 | (0.04-0.07) | – | – | – | – | – | – | – | – |
Embryonal tumors | 764 | 153 | 0.19 | (0.17-0.20) | 100 | 20 | 0.12 | (0.10-0.15) | – | – | – | – | 35 | – | 0.11 | (0.07-0.15) |
Tumors of Cranial and Spinal Nerves | 3,752 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 345 | 69 | 1.01 | (0.90-1.12) |
Nerve sheath tumors | 3,749 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 344 | 69 | 1.01 | (0.90-1.12) |
Other tumors of cranial and spinal nerves | – | – | 0.00 | (0.00-0.00) | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 7,467 | 1,493 | 1.98 | (1.93-2.02) | 1,540 | 308 | 2.20 | (2.09-2.32) | 89 | 18 | 1.19 | (0.95-1.47) | 538 | 108 | 1.59 | (1.46-1.73) |
Meningioma | 6,469 | 1,294 | 1.73 | (1.68-1.77) | 1,385 | 277 | 1.99 | (1.89-2.10) | 76 | – | 1.03 | (0.81-1.29) | 447 | 89 | 1.33 | (1.20-1.45) |
Mesenchymal tumors | 262 | 52 | 0.07 | (0.06-0.08) | 41 | – | 0.06 | (0.04-0.08) | – | – | – | – | 26 | – | 0.08 | (0.05-0.11) |
Primary melanocytic lesions | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 717 | 143 | 0.18 | (0.17-0.20) | 113 | 23 | 0.15 | (0.12-0.18) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Lymphomas and Hematopoietic Neoplasms | 395 | 79 | 0.10 | (0.09-0.11) | 176 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 32 | – | 0.09 | (0.06-0.13) |
Lymphoma | 357 | 71 | 0.09 | (0.08-0.10) | 174 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 31 | – | 0.09 | (0.06-0.13) |
Other hematopoietic neoplasms | 38 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Germ cell tumors, cysts and heterotopias | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Tumors of Sellar Region | 12,266 | 2,453 | 3.10 | (3.04-3.15) | 2,785 | 557 | 3.79 | (3.64-3.93) | 210 | 42 | 2.57 | (2.23-2.95) | 1,148 | 230 | 3.33 | (3.14-3.53) |
Tumors of the pituitary | 11,777 | 2,355 | 2.97 | (2.92-3.03) | 2,662 | 532 | 3.62 | (3.48-3.76) | 207 | 41 | 2.53 | (2.19-2.91) | 1,099 | 220 | 3.19 | (3.00-3.38) |
Craniopharyngioma | 489 | 98 | 0.12 | (0.11-0.13) | 123 | 25 | 0.16 | (0.14-0.20) | – | – | – | – | 49 | – | 0.15 | (0.11-0.19) |
Unclassified Tumors | 2,589 | 518 | 0.65 | (0.63-0.68) | 374 | 75 | 0.50 | (0.45-0.56) | 36 | – | 0.45 | (0.31-0.62) | 195 | 39 | 0.57 | (0.49-0.65) |
Hemangioma | 1,297 | 259 | 0.33 | (0.31-0.35) | 127 | 25 | 0.17 | (0.14-0.20) | 18 | – | 0.23 | (0.14-0.37) | 88 | 18 | 0.25 | (0.20-0.31) |
Neoplasm, unspecified | 1,282 | 256 | 0.32 | (0.30-0.34) | 247 | 49 | 0.33 | (0.29-0.38) | 18 | – | 0.21 | (0.13-0.34) | 105 | 21 | 0.30 | (0.25-0.37) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALd | 41,905 | 8,381 | 10.68 | (10.58-10.78) | 6,936 | 1,387 | 9.42 | (9.19-9.64) | 560 | 112 | 6.99 | (6.42-7.61) | 3,197 | 639 | 9.37 | (9.04-9.70) |
Histology . | White . | Black . | AIAN . | API . | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 14,928 | 2,986 | 3.75 | (3.69-3.81) | 1,635 | 327 | 2.11 | (2.00-2.21) | 161 | 32 | 1.93 | (1.64-2.26) | 878 | 176 | 2.58 | (2.41-2.76) |
Pilocytic astrocytoma | 1,257 | 251 | 0.31 | (0.29-0.32) | 172 | 34 | 0.20 | (0.17-0.24) | – | – | – | – | 65 | – | 0.20 | (0.16-0.26) |
Diffuse astrocytoma | 2,050 | 410 | 0.52 | (0.49-0.54) | 217 | 43 | 0.29 | (0.25-0.33) | 27 | – | 0.32 | (0.21-0.47) | 96 | 19 | 0.28 | (0.22-0.34) |
Anaplastic astrocytoma | 1,208 | 242 | 0.31 | (0.29-0.32) | 94 | 19 | 0.13 | (0.10-0.15) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Unique astrocytoma variants | 288 | 58 | 0.07 | (0.06-0.08) | 58 | – | 0.07 | (0.05-0.09) | – | – | – | – | 23 | – | 0.07 | (0.04-0.10) |
Glioblastoma | 1,948 | 390 | 0.51 | (0.48-0.53) | 260 | 52 | 0.36 | (0.31-0.40) | – | – | – | – | 149 | 30 | 0.43 | (0.37-0.51) |
Oligodendroglioma | 1,330 | 266 | 0.34 | (0.32-0.36) | 70 | – | 0.10 | (0.07-0.12) | – | – | – | – | 66 | – | 0.19 | (0.15-0.24) |
Anaplastic oligodendroglioma | 378 | 76 | 0.10 | (0.09-0.11) | 16 | – | 0.02 | (0.01-0.04) | – | – | – | – | 18 | – | 0.05 | (0.03-0.08) |
Oligoastrocytic tumors | 1,165 | 233 | 0.29 | (0.28-0.31) | 77 | – | 0.11 | (0.08-0.13) | – | – | – | – | 61 | – | 0.17 | (0.13-0.22) |
Ependymal tumors | 1,585 | 317 | 0.40 | (0.38-0.42) | 157 | 31 | 0.21 | (0.18-0.24) | 17 | – | 0.20 | (0.12-0.33) | 115 | 23 | 0.33 | (0.27-0.40) |
Glioma malignant, NOS | 1,124 | 225 | 0.28 | (0.26-0.30) | 163 | 33 | 0.20 | (0.17-0.24) | – | – | – | – | 68 | – | 0.20 | (0.16-0.26) |
Choroid plexus tumors | 153 | 31 | 0.04 | (0.03-0.04) | 18 | – | 0.02 | (0.01-0.04) | – | – | – | – | – | – | – | – |
Other neuroepithelial tumors | 26 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,447 | 289 | 0.36 | (0.34-0.37) | 190 | 38 | 0.23 | (0.20-0.27) | – | – | – | – | 102 | 20 | 0.31 | (0.25-0.38) |
Tumors of the pineal region | 205 | 41 | 0.05 | (0.04-0.06) | 41 | – | 0.05 | (0.04-0.07) | – | – | – | – | – | – | – | – |
Embryonal tumors | 764 | 153 | 0.19 | (0.17-0.20) | 100 | 20 | 0.12 | (0.10-0.15) | – | – | – | – | 35 | – | 0.11 | (0.07-0.15) |
Tumors of Cranial and Spinal Nerves | 3,752 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 345 | 69 | 1.01 | (0.90-1.12) |
Nerve sheath tumors | 3,749 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 344 | 69 | 1.01 | (0.90-1.12) |
Other tumors of cranial and spinal nerves | – | – | 0.00 | (0.00-0.00) | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 7,467 | 1,493 | 1.98 | (1.93-2.02) | 1,540 | 308 | 2.20 | (2.09-2.32) | 89 | 18 | 1.19 | (0.95-1.47) | 538 | 108 | 1.59 | (1.46-1.73) |
Meningioma | 6,469 | 1,294 | 1.73 | (1.68-1.77) | 1,385 | 277 | 1.99 | (1.89-2.10) | 76 | – | 1.03 | (0.81-1.29) | 447 | 89 | 1.33 | (1.20-1.45) |
Mesenchymal tumors | 262 | 52 | 0.07 | (0.06-0.08) | 41 | – | 0.06 | (0.04-0.08) | – | – | – | – | 26 | – | 0.08 | (0.05-0.11) |
Primary melanocytic lesions | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 717 | 143 | 0.18 | (0.17-0.20) | 113 | 23 | 0.15 | (0.12-0.18) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Lymphomas and Hematopoietic Neoplasms | 395 | 79 | 0.10 | (0.09-0.11) | 176 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 32 | – | 0.09 | (0.06-0.13) |
Lymphoma | 357 | 71 | 0.09 | (0.08-0.10) | 174 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 31 | – | 0.09 | (0.06-0.13) |
Other hematopoietic neoplasms | 38 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Germ cell tumors, cysts and heterotopias | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Tumors of Sellar Region | 12,266 | 2,453 | 3.10 | (3.04-3.15) | 2,785 | 557 | 3.79 | (3.64-3.93) | 210 | 42 | 2.57 | (2.23-2.95) | 1,148 | 230 | 3.33 | (3.14-3.53) |
Tumors of the pituitary | 11,777 | 2,355 | 2.97 | (2.92-3.03) | 2,662 | 532 | 3.62 | (3.48-3.76) | 207 | 41 | 2.53 | (2.19-2.91) | 1,099 | 220 | 3.19 | (3.00-3.38) |
Craniopharyngioma | 489 | 98 | 0.12 | (0.11-0.13) | 123 | 25 | 0.16 | (0.14-0.20) | – | – | – | – | 49 | – | 0.15 | (0.11-0.19) |
Unclassified Tumors | 2,589 | 518 | 0.65 | (0.63-0.68) | 374 | 75 | 0.50 | (0.45-0.56) | 36 | – | 0.45 | (0.31-0.62) | 195 | 39 | 0.57 | (0.49-0.65) |
Hemangioma | 1,297 | 259 | 0.33 | (0.31-0.35) | 127 | 25 | 0.17 | (0.14-0.20) | 18 | – | 0.23 | (0.14-0.37) | 88 | 18 | 0.25 | (0.20-0.31) |
Neoplasm, unspecified | 1,282 | 256 | 0.32 | (0.30-0.34) | 247 | 49 | 0.33 | (0.29-0.38) | 18 | – | 0.21 | (0.13-0.34) | 105 | 21 | 0.30 | (0.25-0.37) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALd | 41,905 | 8,381 | 10.68 | (10.58-10.78) | 6,936 | 1,387 | 9.42 | (9.19-9.64) | 560 | 112 | 6.99 | (6.42-7.61) | 3,197 | 639 | 9.37 | (9.04-9.70) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cIndividuals with unknown race were excluded (N = 1,967).
cRefers to all brain tumors including histologies not presented in this table.
– Counts and rates are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified; AIAN, American Indian/Alaskan Native; API, Asian/Pacific Islander.
Histology . | White . | Black . | AIAN . | API . | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 14,928 | 2,986 | 3.75 | (3.69-3.81) | 1,635 | 327 | 2.11 | (2.00-2.21) | 161 | 32 | 1.93 | (1.64-2.26) | 878 | 176 | 2.58 | (2.41-2.76) |
Pilocytic astrocytoma | 1,257 | 251 | 0.31 | (0.29-0.32) | 172 | 34 | 0.20 | (0.17-0.24) | – | – | – | – | 65 | – | 0.20 | (0.16-0.26) |
Diffuse astrocytoma | 2,050 | 410 | 0.52 | (0.49-0.54) | 217 | 43 | 0.29 | (0.25-0.33) | 27 | – | 0.32 | (0.21-0.47) | 96 | 19 | 0.28 | (0.22-0.34) |
Anaplastic astrocytoma | 1,208 | 242 | 0.31 | (0.29-0.32) | 94 | 19 | 0.13 | (0.10-0.15) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Unique astrocytoma variants | 288 | 58 | 0.07 | (0.06-0.08) | 58 | – | 0.07 | (0.05-0.09) | – | – | – | – | 23 | – | 0.07 | (0.04-0.10) |
Glioblastoma | 1,948 | 390 | 0.51 | (0.48-0.53) | 260 | 52 | 0.36 | (0.31-0.40) | – | – | – | – | 149 | 30 | 0.43 | (0.37-0.51) |
Oligodendroglioma | 1,330 | 266 | 0.34 | (0.32-0.36) | 70 | – | 0.10 | (0.07-0.12) | – | – | – | – | 66 | – | 0.19 | (0.15-0.24) |
Anaplastic oligodendroglioma | 378 | 76 | 0.10 | (0.09-0.11) | 16 | – | 0.02 | (0.01-0.04) | – | – | – | – | 18 | – | 0.05 | (0.03-0.08) |
Oligoastrocytic tumors | 1,165 | 233 | 0.29 | (0.28-0.31) | 77 | – | 0.11 | (0.08-0.13) | – | – | – | – | 61 | – | 0.17 | (0.13-0.22) |
Ependymal tumors | 1,585 | 317 | 0.40 | (0.38-0.42) | 157 | 31 | 0.21 | (0.18-0.24) | 17 | – | 0.20 | (0.12-0.33) | 115 | 23 | 0.33 | (0.27-0.40) |
Glioma malignant, NOS | 1,124 | 225 | 0.28 | (0.26-0.30) | 163 | 33 | 0.20 | (0.17-0.24) | – | – | – | – | 68 | – | 0.20 | (0.16-0.26) |
Choroid plexus tumors | 153 | 31 | 0.04 | (0.03-0.04) | 18 | – | 0.02 | (0.01-0.04) | – | – | – | – | – | – | – | – |
Other neuroepithelial tumors | 26 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,447 | 289 | 0.36 | (0.34-0.37) | 190 | 38 | 0.23 | (0.20-0.27) | – | – | – | – | 102 | 20 | 0.31 | (0.25-0.38) |
Tumors of the pineal region | 205 | 41 | 0.05 | (0.04-0.06) | 41 | – | 0.05 | (0.04-0.07) | – | – | – | – | – | – | – | – |
Embryonal tumors | 764 | 153 | 0.19 | (0.17-0.20) | 100 | 20 | 0.12 | (0.10-0.15) | – | – | – | – | 35 | – | 0.11 | (0.07-0.15) |
Tumors of Cranial and Spinal Nerves | 3,752 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 345 | 69 | 1.01 | (0.90-1.12) |
Nerve sheath tumors | 3,749 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 344 | 69 | 1.01 | (0.90-1.12) |
Other tumors of cranial and spinal nerves | – | – | 0.00 | (0.00-0.00) | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 7,467 | 1,493 | 1.98 | (1.93-2.02) | 1,540 | 308 | 2.20 | (2.09-2.32) | 89 | 18 | 1.19 | (0.95-1.47) | 538 | 108 | 1.59 | (1.46-1.73) |
Meningioma | 6,469 | 1,294 | 1.73 | (1.68-1.77) | 1,385 | 277 | 1.99 | (1.89-2.10) | 76 | – | 1.03 | (0.81-1.29) | 447 | 89 | 1.33 | (1.20-1.45) |
Mesenchymal tumors | 262 | 52 | 0.07 | (0.06-0.08) | 41 | – | 0.06 | (0.04-0.08) | – | – | – | – | 26 | – | 0.08 | (0.05-0.11) |
Primary melanocytic lesions | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 717 | 143 | 0.18 | (0.17-0.20) | 113 | 23 | 0.15 | (0.12-0.18) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Lymphomas and Hematopoietic Neoplasms | 395 | 79 | 0.10 | (0.09-0.11) | 176 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 32 | – | 0.09 | (0.06-0.13) |
Lymphoma | 357 | 71 | 0.09 | (0.08-0.10) | 174 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 31 | – | 0.09 | (0.06-0.13) |
Other hematopoietic neoplasms | 38 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Germ cell tumors, cysts and heterotopias | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Tumors of Sellar Region | 12,266 | 2,453 | 3.10 | (3.04-3.15) | 2,785 | 557 | 3.79 | (3.64-3.93) | 210 | 42 | 2.57 | (2.23-2.95) | 1,148 | 230 | 3.33 | (3.14-3.53) |
Tumors of the pituitary | 11,777 | 2,355 | 2.97 | (2.92-3.03) | 2,662 | 532 | 3.62 | (3.48-3.76) | 207 | 41 | 2.53 | (2.19-2.91) | 1,099 | 220 | 3.19 | (3.00-3.38) |
Craniopharyngioma | 489 | 98 | 0.12 | (0.11-0.13) | 123 | 25 | 0.16 | (0.14-0.20) | – | – | – | – | 49 | – | 0.15 | (0.11-0.19) |
Unclassified Tumors | 2,589 | 518 | 0.65 | (0.63-0.68) | 374 | 75 | 0.50 | (0.45-0.56) | 36 | – | 0.45 | (0.31-0.62) | 195 | 39 | 0.57 | (0.49-0.65) |
Hemangioma | 1,297 | 259 | 0.33 | (0.31-0.35) | 127 | 25 | 0.17 | (0.14-0.20) | 18 | – | 0.23 | (0.14-0.37) | 88 | 18 | 0.25 | (0.20-0.31) |
Neoplasm, unspecified | 1,282 | 256 | 0.32 | (0.30-0.34) | 247 | 49 | 0.33 | (0.29-0.38) | 18 | – | 0.21 | (0.13-0.34) | 105 | 21 | 0.30 | (0.25-0.37) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALd | 41,905 | 8,381 | 10.68 | (10.58-10.78) | 6,936 | 1,387 | 9.42 | (9.19-9.64) | 560 | 112 | 6.99 | (6.42-7.61) | 3,197 | 639 | 9.37 | (9.04-9.70) |
Histology . | White . | Black . | AIAN . | API . | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 14,928 | 2,986 | 3.75 | (3.69-3.81) | 1,635 | 327 | 2.11 | (2.00-2.21) | 161 | 32 | 1.93 | (1.64-2.26) | 878 | 176 | 2.58 | (2.41-2.76) |
Pilocytic astrocytoma | 1,257 | 251 | 0.31 | (0.29-0.32) | 172 | 34 | 0.20 | (0.17-0.24) | – | – | – | – | 65 | – | 0.20 | (0.16-0.26) |
Diffuse astrocytoma | 2,050 | 410 | 0.52 | (0.49-0.54) | 217 | 43 | 0.29 | (0.25-0.33) | 27 | – | 0.32 | (0.21-0.47) | 96 | 19 | 0.28 | (0.22-0.34) |
Anaplastic astrocytoma | 1,208 | 242 | 0.31 | (0.29-0.32) | 94 | 19 | 0.13 | (0.10-0.15) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Unique astrocytoma variants | 288 | 58 | 0.07 | (0.06-0.08) | 58 | – | 0.07 | (0.05-0.09) | – | – | – | – | 23 | – | 0.07 | (0.04-0.10) |
Glioblastoma | 1,948 | 390 | 0.51 | (0.48-0.53) | 260 | 52 | 0.36 | (0.31-0.40) | – | – | – | – | 149 | 30 | 0.43 | (0.37-0.51) |
Oligodendroglioma | 1,330 | 266 | 0.34 | (0.32-0.36) | 70 | – | 0.10 | (0.07-0.12) | – | – | – | – | 66 | – | 0.19 | (0.15-0.24) |
Anaplastic oligodendroglioma | 378 | 76 | 0.10 | (0.09-0.11) | 16 | – | 0.02 | (0.01-0.04) | – | – | – | – | 18 | – | 0.05 | (0.03-0.08) |
Oligoastrocytic tumors | 1,165 | 233 | 0.29 | (0.28-0.31) | 77 | – | 0.11 | (0.08-0.13) | – | – | – | – | 61 | – | 0.17 | (0.13-0.22) |
Ependymal tumors | 1,585 | 317 | 0.40 | (0.38-0.42) | 157 | 31 | 0.21 | (0.18-0.24) | 17 | – | 0.20 | (0.12-0.33) | 115 | 23 | 0.33 | (0.27-0.40) |
Glioma malignant, NOS | 1,124 | 225 | 0.28 | (0.26-0.30) | 163 | 33 | 0.20 | (0.17-0.24) | – | – | – | – | 68 | – | 0.20 | (0.16-0.26) |
Choroid plexus tumors | 153 | 31 | 0.04 | (0.03-0.04) | 18 | – | 0.02 | (0.01-0.04) | – | – | – | – | – | – | – | – |
Other neuroepithelial tumors | 26 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,447 | 289 | 0.36 | (0.34-0.37) | 190 | 38 | 0.23 | (0.20-0.27) | – | – | – | – | 102 | 20 | 0.31 | (0.25-0.38) |
Tumors of the pineal region | 205 | 41 | 0.05 | (0.04-0.06) | 41 | – | 0.05 | (0.04-0.07) | – | – | – | – | – | – | – | – |
Embryonal tumors | 764 | 153 | 0.19 | (0.17-0.20) | 100 | 20 | 0.12 | (0.10-0.15) | – | – | – | – | 35 | – | 0.11 | (0.07-0.15) |
Tumors of Cranial and Spinal Nerves | 3,752 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 345 | 69 | 1.01 | (0.90-1.12) |
Nerve sheath tumors | 3,749 | 750 | 0.97 | (0.94-1.00) | 344 | 69 | 0.47 | (0.42-0.53) | 50 | – | 0.67 | (0.50-0.89) | 344 | 69 | 1.01 | (0.90-1.12) |
Other tumors of cranial and spinal nerves | – | – | 0.00 | (0.00-0.00) | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 7,467 | 1,493 | 1.98 | (1.93-2.02) | 1,540 | 308 | 2.20 | (2.09-2.32) | 89 | 18 | 1.19 | (0.95-1.47) | 538 | 108 | 1.59 | (1.46-1.73) |
Meningioma | 6,469 | 1,294 | 1.73 | (1.68-1.77) | 1,385 | 277 | 1.99 | (1.89-2.10) | 76 | – | 1.03 | (0.81-1.29) | 447 | 89 | 1.33 | (1.20-1.45) |
Mesenchymal tumors | 262 | 52 | 0.07 | (0.06-0.08) | 41 | – | 0.06 | (0.04-0.08) | – | – | – | – | 26 | – | 0.08 | (0.05-0.11) |
Primary melanocytic lesions | 19 | – | 0.01 | (0.00-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 717 | 143 | 0.18 | (0.17-0.20) | 113 | 23 | 0.15 | (0.12-0.18) | – | – | – | – | 64 | – | 0.19 | (0.14-0.24) |
Lymphomas and Hematopoietic Neoplasms | 395 | 79 | 0.10 | (0.09-0.11) | 176 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 32 | – | 0.09 | (0.06-0.13) |
Lymphoma | 357 | 71 | 0.09 | (0.08-0.10) | 174 | 35 | 0.25 | (0.21-0.29) | – | – | – | – | 31 | – | 0.09 | (0.06-0.13) |
Other hematopoietic neoplasms | 38 | – | 0.01 | (0.01-0.01) | – | – | – | – | – | – | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Germ cell tumors, cysts and heterotopias | 508 | 102 | 0.12 | (0.11-0.13) | 82 | 16 | 0.10 | (0.08-0.12) | – | – | – | – | 61 | – | 0.19 | (0.15-0.25) |
Tumors of Sellar Region | 12,266 | 2,453 | 3.10 | (3.04-3.15) | 2,785 | 557 | 3.79 | (3.64-3.93) | 210 | 42 | 2.57 | (2.23-2.95) | 1,148 | 230 | 3.33 | (3.14-3.53) |
Tumors of the pituitary | 11,777 | 2,355 | 2.97 | (2.92-3.03) | 2,662 | 532 | 3.62 | (3.48-3.76) | 207 | 41 | 2.53 | (2.19-2.91) | 1,099 | 220 | 3.19 | (3.00-3.38) |
Craniopharyngioma | 489 | 98 | 0.12 | (0.11-0.13) | 123 | 25 | 0.16 | (0.14-0.20) | – | – | – | – | 49 | – | 0.15 | (0.11-0.19) |
Unclassified Tumors | 2,589 | 518 | 0.65 | (0.63-0.68) | 374 | 75 | 0.50 | (0.45-0.56) | 36 | – | 0.45 | (0.31-0.62) | 195 | 39 | 0.57 | (0.49-0.65) |
Hemangioma | 1,297 | 259 | 0.33 | (0.31-0.35) | 127 | 25 | 0.17 | (0.14-0.20) | 18 | – | 0.23 | (0.14-0.37) | 88 | 18 | 0.25 | (0.20-0.31) |
Neoplasm, unspecified | 1,282 | 256 | 0.32 | (0.30-0.34) | 247 | 49 | 0.33 | (0.29-0.38) | 18 | – | 0.21 | (0.13-0.34) | 105 | 21 | 0.30 | (0.25-0.37) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALd | 41,905 | 8,381 | 10.68 | (10.58-10.78) | 6,936 | 1,387 | 9.42 | (9.19-9.64) | 560 | 112 | 6.99 | (6.42-7.61) | 3,197 | 639 | 9.37 | (9.04-9.70) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cIndividuals with unknown race were excluded (N = 1,967).
cRefers to all brain tumors including histologies not presented in this table.
– Counts and rates are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified; AIAN, American Indian/Alaskan Native; API, Asian/Pacific Islander.
Incidence rate ratios (IRR) by race (White:Black) in adolescents and young adults (age 15-39 years) for selected histologies are shown in Figure 22.23
There are statistically significant differences in incidence by race in AYA for several histologies.
Gliomas occur significantly more often in Whites than Blacks in adolescents and young adults.
Oligodendroglioma are diagnosed approximately four times as often in Whites than in Blacks (IRR: Whites:Blacks = 3.7) in adolescents and young adults.
Non-malignant meningiomas (IRR: Whites:Blacks = 0.9) and tumors of the pituitary (IRR: Whites:Blacks = 0.8) are slightly more common in Blacks, while lymphoma occurs approximately 2.5 times as frequently in Blacks (IRR: Whites:Blacks = 0.4).
Average annual incidence rates by Hispanic ethnicity in adolescents and young adults (age 15-39 years) AYA are shown in Table 7.
The overall average annual age-adjusted incidence in non-Hispanics (10.86 per 100,000 population) is higher than that of Hispanics (8.70 per 100,000 population).
Incidence of lymphomas and other hematopoietic neoplasms, as well as tumors of the sellar region are slightly more common among Hispanics.
Histology . | Hispanic . | Non-Hispanic . | ||||||
---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 2,473 | 495 | 2.39 | (2.30-2.49) | 15,301 | 3,060 | 3.70 | (3.64-3.76) |
Pilocytic astrocytoma | 199 | 40 | 0.18 | (0.16-0.21) | 1,320 | 264 | 0.31 | (0.29-0.33) |
Diffuse astrocytoma | 296 | 59 | 0.29 | (0.26-0.33) | 2,117 | 423 | 0.51 | (0.49-0.53) |
Anaplastic astrocytoma | 182 | 36 | 0.18 | (0.15-0.20) | 1,216 | 243 | 0.30 | (0.28-0.31) |
Unique astrocytoma variants | 57 | – | 0.05 | (0.04-0.07) | 324 | 65 | 0.08 | (0.07-0.08) |
Glioblastoma | 380 | 76 | 0.38 | (0.35-0.43) | 2,013 | 403 | 0.50 | (0.48-0.53) |
Oligodendroglioma | 171 | 34 | 0.17 | (0.15-0.20) | 1,316 | 263 | 0.32 | (0.31-0.34) |
Anaplastic oligodendroglioma | 60 | 12 | 0.06 | (0.05-0.08) | 360 | 72 | 0.09 | (0.08-0.10) |
Oligoastrocytic tumors | 146 | 29 | 0.14 | (0.12-0.17) | 1,187 | 237 | 0.29 | (0.27-0.31) |
Ependymal tumors | 286 | 57 | 0.28 | (0.24-0.31) | 1,602 | 320 | 0.39 | (0.37-0.41) |
Glioma malignant, NOS | 169 | 34 | 0.16 | (0.14-0.19) | 1,214 | 243 | 0.29 | (0.27-0.31) |
Choroid plexus tumors | 34 | – | 0.03 | (0.02-0.05) | 149 | 30 | 0.04 | (0.03-0.04) |
Other neuroepithelial tumors | – | – | – | – | 24 | – | 0.01 | (0.00-0.01) |
Neuronal and mixed neuronal-glial tumors | 235 | 47 | 0.22 | (0.19-0.25) | 1,538 | 308 | 0.36 | (0.35-0.38) |
Tumors of the pineal region | 34 | – | 0.03 | (0.02-0.04) | 224 | 45 | 0.05 | (0.05-0.06) |
Embryonal tumors | 218 | 44 | 0.20 | (0.18-0.23) | 697 | 139 | 0.16 | (0.15-0.18) |
Tumors of Cranial and Spinal Nerves | 602 | 120 | 0.60 | (0.56-0.66) | 3,947 | 789 | 0.98 | (0.95-1.02) |
Nerve sheath tumors | 601 | 120 | 0.60 | (0.56-0.65) | 3,944 | 789 | 0.98 | (0.95-1.01) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | 0.00 | (0.00-0.00) |
Tumors of Meninges | 1,510 | 302 | 1.55 | (1.48-1.63) | 8,197 | 1,639 | 2.09 | (2.05-2.14) |
Meningioma | 1,302 | 260 | 1.35 | (1.28-1.43) | 7,138 | 1,428 | 1.83 | (1.79-1.88) |
Mesenchymal tumors | 43 | – | 0.04 | (0.03-0.06) | 293 | 59 | 0.07 | (0.06-0.08) |
Primary melanocytic lesions | – | – | 0.00 | (0.00-0.01) | 19 | – | 0.00 | (0.00-0.01) |
Other neoplasms related to the meninges | 162 | 32 | 0.16 | (0.13-0.18) | 747 | 149 | 0.18 | (0.17-0.20) |
Lymphomas and Hematopoietic Neoplasms | 150 | 30 | 0.15 | (0.13-0.18) | 469 | 94 | 0.12 | (0.11-0.13) |
Lymphoma | 140 | 28 | 0.14 | (0.12-0.17) | 436 | 87 | 0.11 | (0.10-0.12) |
Other hemopoietic neoplasms | – | – | – | – | 33 | – | 0.01 | (0.01-0.01) |
Germ Cell Tumors and Cysts | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Germ cell tumors, cysts and heterotopias | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Tumors of Sellar Region | 3,418 | 684 | 3.32 | (3.21-3.43) | 13,141 | 2,628 | 3.20 | (3.15-3.26) |
Tumors of the pituitary | 3,263 | 653 | 3.17 | (3.06-3.28) | 12,629 | 2,526 | 3.08 | (3.03-3.13) |
Craniopharyngioma | 155 | 31 | 0.15 | (0.12-0.17) | 512 | 102 | 0.12 | (0.11-0.14) |
Unclassified Tumors | 584 | 117 | 0.57 | (0.52-0.62) | 2,633 | 527 | 0.64 | (0.62-0.67) |
Hemangioma | 234 | 47 | 0.23 | (0.20-0.26) | 1,304 | 261 | 0.32 | (0.30-0.34) |
Neoplasm, unspecified | 347 | 69 | 0.34 | (0.30-0.38) | 1,320 | 264 | 0.32 | (0.30-0.34) |
All other | – | – | – | – | – | – | – | – |
TOTALd | 8,857 | 1,771 | 8.70 | (8.52-8.89) | 44,224 | 8,845 | 10.86 | (10.76-10.96) |
Histology . | Hispanic . | Non-Hispanic . | ||||||
---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 2,473 | 495 | 2.39 | (2.30-2.49) | 15,301 | 3,060 | 3.70 | (3.64-3.76) |
Pilocytic astrocytoma | 199 | 40 | 0.18 | (0.16-0.21) | 1,320 | 264 | 0.31 | (0.29-0.33) |
Diffuse astrocytoma | 296 | 59 | 0.29 | (0.26-0.33) | 2,117 | 423 | 0.51 | (0.49-0.53) |
Anaplastic astrocytoma | 182 | 36 | 0.18 | (0.15-0.20) | 1,216 | 243 | 0.30 | (0.28-0.31) |
Unique astrocytoma variants | 57 | – | 0.05 | (0.04-0.07) | 324 | 65 | 0.08 | (0.07-0.08) |
Glioblastoma | 380 | 76 | 0.38 | (0.35-0.43) | 2,013 | 403 | 0.50 | (0.48-0.53) |
Oligodendroglioma | 171 | 34 | 0.17 | (0.15-0.20) | 1,316 | 263 | 0.32 | (0.31-0.34) |
Anaplastic oligodendroglioma | 60 | 12 | 0.06 | (0.05-0.08) | 360 | 72 | 0.09 | (0.08-0.10) |
Oligoastrocytic tumors | 146 | 29 | 0.14 | (0.12-0.17) | 1,187 | 237 | 0.29 | (0.27-0.31) |
Ependymal tumors | 286 | 57 | 0.28 | (0.24-0.31) | 1,602 | 320 | 0.39 | (0.37-0.41) |
Glioma malignant, NOS | 169 | 34 | 0.16 | (0.14-0.19) | 1,214 | 243 | 0.29 | (0.27-0.31) |
Choroid plexus tumors | 34 | – | 0.03 | (0.02-0.05) | 149 | 30 | 0.04 | (0.03-0.04) |
Other neuroepithelial tumors | – | – | – | – | 24 | – | 0.01 | (0.00-0.01) |
Neuronal and mixed neuronal-glial tumors | 235 | 47 | 0.22 | (0.19-0.25) | 1,538 | 308 | 0.36 | (0.35-0.38) |
Tumors of the pineal region | 34 | – | 0.03 | (0.02-0.04) | 224 | 45 | 0.05 | (0.05-0.06) |
Embryonal tumors | 218 | 44 | 0.20 | (0.18-0.23) | 697 | 139 | 0.16 | (0.15-0.18) |
Tumors of Cranial and Spinal Nerves | 602 | 120 | 0.60 | (0.56-0.66) | 3,947 | 789 | 0.98 | (0.95-1.02) |
Nerve sheath tumors | 601 | 120 | 0.60 | (0.56-0.65) | 3,944 | 789 | 0.98 | (0.95-1.01) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | 0.00 | (0.00-0.00) |
Tumors of Meninges | 1,510 | 302 | 1.55 | (1.48-1.63) | 8,197 | 1,639 | 2.09 | (2.05-2.14) |
Meningioma | 1,302 | 260 | 1.35 | (1.28-1.43) | 7,138 | 1,428 | 1.83 | (1.79-1.88) |
Mesenchymal tumors | 43 | – | 0.04 | (0.03-0.06) | 293 | 59 | 0.07 | (0.06-0.08) |
Primary melanocytic lesions | – | – | 0.00 | (0.00-0.01) | 19 | – | 0.00 | (0.00-0.01) |
Other neoplasms related to the meninges | 162 | 32 | 0.16 | (0.13-0.18) | 747 | 149 | 0.18 | (0.17-0.20) |
Lymphomas and Hematopoietic Neoplasms | 150 | 30 | 0.15 | (0.13-0.18) | 469 | 94 | 0.12 | (0.11-0.13) |
Lymphoma | 140 | 28 | 0.14 | (0.12-0.17) | 436 | 87 | 0.11 | (0.10-0.12) |
Other hemopoietic neoplasms | – | – | – | – | 33 | – | 0.01 | (0.01-0.01) |
Germ Cell Tumors and Cysts | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Germ cell tumors, cysts and heterotopias | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Tumors of Sellar Region | 3,418 | 684 | 3.32 | (3.21-3.43) | 13,141 | 2,628 | 3.20 | (3.15-3.26) |
Tumors of the pituitary | 3,263 | 653 | 3.17 | (3.06-3.28) | 12,629 | 2,526 | 3.08 | (3.03-3.13) |
Craniopharyngioma | 155 | 31 | 0.15 | (0.12-0.17) | 512 | 102 | 0.12 | (0.11-0.14) |
Unclassified Tumors | 584 | 117 | 0.57 | (0.52-0.62) | 2,633 | 527 | 0.64 | (0.62-0.67) |
Hemangioma | 234 | 47 | 0.23 | (0.20-0.26) | 1,304 | 261 | 0.32 | (0.30-0.34) |
Neoplasm, unspecified | 347 | 69 | 0.34 | (0.30-0.38) | 1,320 | 264 | 0.32 | (0.30-0.34) |
All other | – | – | – | – | – | – | – | – |
TOTALd | 8,857 | 1,771 | 8.70 | (8.52-8.89) | 44,224 | 8,845 | 10.86 | (10.76-10.96) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cHispanic ethnicity is not mutually exclusive of race; Classified using the North American Association of Central Cancer Registries Hispanic Identification Algorithm, version 2 (NHIA v2).
dRefers to all brain tumors including histologies not presented in this table.
– Counts and rates are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | Hispanic . | Non-Hispanic . | ||||||
---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 2,473 | 495 | 2.39 | (2.30-2.49) | 15,301 | 3,060 | 3.70 | (3.64-3.76) |
Pilocytic astrocytoma | 199 | 40 | 0.18 | (0.16-0.21) | 1,320 | 264 | 0.31 | (0.29-0.33) |
Diffuse astrocytoma | 296 | 59 | 0.29 | (0.26-0.33) | 2,117 | 423 | 0.51 | (0.49-0.53) |
Anaplastic astrocytoma | 182 | 36 | 0.18 | (0.15-0.20) | 1,216 | 243 | 0.30 | (0.28-0.31) |
Unique astrocytoma variants | 57 | – | 0.05 | (0.04-0.07) | 324 | 65 | 0.08 | (0.07-0.08) |
Glioblastoma | 380 | 76 | 0.38 | (0.35-0.43) | 2,013 | 403 | 0.50 | (0.48-0.53) |
Oligodendroglioma | 171 | 34 | 0.17 | (0.15-0.20) | 1,316 | 263 | 0.32 | (0.31-0.34) |
Anaplastic oligodendroglioma | 60 | 12 | 0.06 | (0.05-0.08) | 360 | 72 | 0.09 | (0.08-0.10) |
Oligoastrocytic tumors | 146 | 29 | 0.14 | (0.12-0.17) | 1,187 | 237 | 0.29 | (0.27-0.31) |
Ependymal tumors | 286 | 57 | 0.28 | (0.24-0.31) | 1,602 | 320 | 0.39 | (0.37-0.41) |
Glioma malignant, NOS | 169 | 34 | 0.16 | (0.14-0.19) | 1,214 | 243 | 0.29 | (0.27-0.31) |
Choroid plexus tumors | 34 | – | 0.03 | (0.02-0.05) | 149 | 30 | 0.04 | (0.03-0.04) |
Other neuroepithelial tumors | – | – | – | – | 24 | – | 0.01 | (0.00-0.01) |
Neuronal and mixed neuronal-glial tumors | 235 | 47 | 0.22 | (0.19-0.25) | 1,538 | 308 | 0.36 | (0.35-0.38) |
Tumors of the pineal region | 34 | – | 0.03 | (0.02-0.04) | 224 | 45 | 0.05 | (0.05-0.06) |
Embryonal tumors | 218 | 44 | 0.20 | (0.18-0.23) | 697 | 139 | 0.16 | (0.15-0.18) |
Tumors of Cranial and Spinal Nerves | 602 | 120 | 0.60 | (0.56-0.66) | 3,947 | 789 | 0.98 | (0.95-1.02) |
Nerve sheath tumors | 601 | 120 | 0.60 | (0.56-0.65) | 3,944 | 789 | 0.98 | (0.95-1.01) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | 0.00 | (0.00-0.00) |
Tumors of Meninges | 1,510 | 302 | 1.55 | (1.48-1.63) | 8,197 | 1,639 | 2.09 | (2.05-2.14) |
Meningioma | 1,302 | 260 | 1.35 | (1.28-1.43) | 7,138 | 1,428 | 1.83 | (1.79-1.88) |
Mesenchymal tumors | 43 | – | 0.04 | (0.03-0.06) | 293 | 59 | 0.07 | (0.06-0.08) |
Primary melanocytic lesions | – | – | 0.00 | (0.00-0.01) | 19 | – | 0.00 | (0.00-0.01) |
Other neoplasms related to the meninges | 162 | 32 | 0.16 | (0.13-0.18) | 747 | 149 | 0.18 | (0.17-0.20) |
Lymphomas and Hematopoietic Neoplasms | 150 | 30 | 0.15 | (0.13-0.18) | 469 | 94 | 0.12 | (0.11-0.13) |
Lymphoma | 140 | 28 | 0.14 | (0.12-0.17) | 436 | 87 | 0.11 | (0.10-0.12) |
Other hemopoietic neoplasms | – | – | – | – | 33 | – | 0.01 | (0.01-0.01) |
Germ Cell Tumors and Cysts | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Germ cell tumors, cysts and heterotopias | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Tumors of Sellar Region | 3,418 | 684 | 3.32 | (3.21-3.43) | 13,141 | 2,628 | 3.20 | (3.15-3.26) |
Tumors of the pituitary | 3,263 | 653 | 3.17 | (3.06-3.28) | 12,629 | 2,526 | 3.08 | (3.03-3.13) |
Craniopharyngioma | 155 | 31 | 0.15 | (0.12-0.17) | 512 | 102 | 0.12 | (0.11-0.14) |
Unclassified Tumors | 584 | 117 | 0.57 | (0.52-0.62) | 2,633 | 527 | 0.64 | (0.62-0.67) |
Hemangioma | 234 | 47 | 0.23 | (0.20-0.26) | 1,304 | 261 | 0.32 | (0.30-0.34) |
Neoplasm, unspecified | 347 | 69 | 0.34 | (0.30-0.38) | 1,320 | 264 | 0.32 | (0.30-0.34) |
All other | – | – | – | – | – | – | – | – |
TOTALd | 8,857 | 1,771 | 8.70 | (8.52-8.89) | 44,224 | 8,845 | 10.86 | (10.76-10.96) |
Histology . | Hispanic . | Non-Hispanic . | ||||||
---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
Tumors of Neuroepithelial Tissue | 2,473 | 495 | 2.39 | (2.30-2.49) | 15,301 | 3,060 | 3.70 | (3.64-3.76) |
Pilocytic astrocytoma | 199 | 40 | 0.18 | (0.16-0.21) | 1,320 | 264 | 0.31 | (0.29-0.33) |
Diffuse astrocytoma | 296 | 59 | 0.29 | (0.26-0.33) | 2,117 | 423 | 0.51 | (0.49-0.53) |
Anaplastic astrocytoma | 182 | 36 | 0.18 | (0.15-0.20) | 1,216 | 243 | 0.30 | (0.28-0.31) |
Unique astrocytoma variants | 57 | – | 0.05 | (0.04-0.07) | 324 | 65 | 0.08 | (0.07-0.08) |
Glioblastoma | 380 | 76 | 0.38 | (0.35-0.43) | 2,013 | 403 | 0.50 | (0.48-0.53) |
Oligodendroglioma | 171 | 34 | 0.17 | (0.15-0.20) | 1,316 | 263 | 0.32 | (0.31-0.34) |
Anaplastic oligodendroglioma | 60 | 12 | 0.06 | (0.05-0.08) | 360 | 72 | 0.09 | (0.08-0.10) |
Oligoastrocytic tumors | 146 | 29 | 0.14 | (0.12-0.17) | 1,187 | 237 | 0.29 | (0.27-0.31) |
Ependymal tumors | 286 | 57 | 0.28 | (0.24-0.31) | 1,602 | 320 | 0.39 | (0.37-0.41) |
Glioma malignant, NOS | 169 | 34 | 0.16 | (0.14-0.19) | 1,214 | 243 | 0.29 | (0.27-0.31) |
Choroid plexus tumors | 34 | – | 0.03 | (0.02-0.05) | 149 | 30 | 0.04 | (0.03-0.04) |
Other neuroepithelial tumors | – | – | – | – | 24 | – | 0.01 | (0.00-0.01) |
Neuronal and mixed neuronal-glial tumors | 235 | 47 | 0.22 | (0.19-0.25) | 1,538 | 308 | 0.36 | (0.35-0.38) |
Tumors of the pineal region | 34 | – | 0.03 | (0.02-0.04) | 224 | 45 | 0.05 | (0.05-0.06) |
Embryonal tumors | 218 | 44 | 0.20 | (0.18-0.23) | 697 | 139 | 0.16 | (0.15-0.18) |
Tumors of Cranial and Spinal Nerves | 602 | 120 | 0.60 | (0.56-0.66) | 3,947 | 789 | 0.98 | (0.95-1.02) |
Nerve sheath tumors | 601 | 120 | 0.60 | (0.56-0.65) | 3,944 | 789 | 0.98 | (0.95-1.01) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | 0.00 | (0.00-0.00) |
Tumors of Meninges | 1,510 | 302 | 1.55 | (1.48-1.63) | 8,197 | 1,639 | 2.09 | (2.05-2.14) |
Meningioma | 1,302 | 260 | 1.35 | (1.28-1.43) | 7,138 | 1,428 | 1.83 | (1.79-1.88) |
Mesenchymal tumors | 43 | – | 0.04 | (0.03-0.06) | 293 | 59 | 0.07 | (0.06-0.08) |
Primary melanocytic lesions | – | – | 0.00 | (0.00-0.01) | 19 | – | 0.00 | (0.00-0.01) |
Other neoplasms related to the meninges | 162 | 32 | 0.16 | (0.13-0.18) | 747 | 149 | 0.18 | (0.17-0.20) |
Lymphomas and Hematopoietic Neoplasms | 150 | 30 | 0.15 | (0.13-0.18) | 469 | 94 | 0.12 | (0.11-0.13) |
Lymphoma | 140 | 28 | 0.14 | (0.12-0.17) | 436 | 87 | 0.11 | (0.10-0.12) |
Other hemopoietic neoplasms | – | – | – | – | 33 | – | 0.01 | (0.01-0.01) |
Germ Cell Tumors and Cysts | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Germ cell tumors, cysts and heterotopias | 120 | 24 | 0.11 | (0.09-0.13) | 536 | 107 | 0.12 | (0.11-0.14) |
Tumors of Sellar Region | 3,418 | 684 | 3.32 | (3.21-3.43) | 13,141 | 2,628 | 3.20 | (3.15-3.26) |
Tumors of the pituitary | 3,263 | 653 | 3.17 | (3.06-3.28) | 12,629 | 2,526 | 3.08 | (3.03-3.13) |
Craniopharyngioma | 155 | 31 | 0.15 | (0.12-0.17) | 512 | 102 | 0.12 | (0.11-0.14) |
Unclassified Tumors | 584 | 117 | 0.57 | (0.52-0.62) | 2,633 | 527 | 0.64 | (0.62-0.67) |
Hemangioma | 234 | 47 | 0.23 | (0.20-0.26) | 1,304 | 261 | 0.32 | (0.30-0.34) |
Neoplasm, unspecified | 347 | 69 | 0.34 | (0.30-0.38) | 1,320 | 264 | 0.32 | (0.30-0.34) |
All other | – | – | – | – | – | – | – | – |
TOTALd | 8,857 | 1,771 | 8.70 | (8.52-8.89) | 44,224 | 8,845 | 10.86 | (10.76-10.96) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cHispanic ethnicity is not mutually exclusive of race; Classified using the North American Association of Central Cancer Registries Hispanic Identification Algorithm, version 2 (NHIA v2).
dRefers to all brain tumors including histologies not presented in this table.
– Counts and rates are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts and rates for totals.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Incidence by Histologic Group and Behavior
Average annual age-adjusted incidence rates by histologic type and behavior in adolescents and young adults (age 15-39 years) are shown in Table 8. Incidence of non-malignant tumors (7.21 per 100,000 population) is higher than malignant tumors (3.26 per 100,000 population) in ages 15-39 years.
Histology . | Total . | Malignant . | Non-Malignant . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | % of All Tumors . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 33.5% | 3.44 | (3.39-3.49) | 14,894 | 2,979 | 2.90 | (2.85-2.95) | 2,307 | 461 | 0.55 | (0.53-0.57) |
Pilocytic astrocytoma | 1,519 | 304 | 2.9% | 0.28 | (0.27-0.30) | 1,519 | 304 | 0.28 | (0.27-0.30) | – | – | – | – |
Diffuse astrocytoma | 2,413 | 483 | 4.5% | 0.47 | (0.45-0.49) | 2,413 | 483 | 0.47 | (0.45-0.49) | – | – | – | – |
Anaplastic astrocytoma | 1,398 | 280 | 2.6% | 0.27 | (0.26-0.29) | 1,398 | 280 | 0.27 | (0.26-0.29) | – | – | – | – |
Unique astrocytoma variants | 381 | 76 | 0.7% | 0.07 | (0.06-0.08) | 251 | 50 | 0.05 | (0.04-0.05) | 107 | 21 | 0.02 | (0.02-0.03) |
Glioblastoma | 2,393 | 479 | 4.5% | 0.48 | (0.46-0.50) | 2,393 | 479 | 0.48 | (0.46-0.50) | – | – | – | – |
Oligodendroglioma | 1,488 | 298 | 2.8% | 0.29 | (0.28-0.31) | 1,488 | 298 | 0.29 | (0.28-0.31) | – | – | – | – |
Anaplastic oligodendroglioma | 420 | 84 | 0.8% | 0.08 | (0.08-0.09) | 420 | 84 | 0.08 | (0.08-0.09) | – | – | – | – |
Oligoastrocytic tumors | 1,333 | 267 | 2.5% | 0.26 | (0.25-0.28) | 1,333 | 267 | 0.26 | (0.25-0.28) | – | – | – | – |
Ependymal tumors | 1,888 | 378 | 3.6% | 0.37 | (0.35-0.38) | 1,079 | 216 | 0.21 | (0.20-0.22) | 641 | 128 | 0.16 | (0.14-0.17) |
Glioma malignant, NOS | 1,384 | 277 | 2.6% | 0.26 | (0.25-0.28) | 1,384 | 277 | 0.27 | (0.25-0.28) | – | – | – | – |
Choroid plexus tumors | 183 | 37 | 0.3% | 0.03 | (0.03-0.04) | – | – | – | – | 136 | 27 | 0.03 | (0.03-0.04) |
Other neuroepithelial tumors | 30 | – | 0.1% | 0.01 | (0.00-0.01) | 20 | – | 0.00 | (0.00-0.01) | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 3.3% | 0.33 | (0.32-0.35) | 182 | 36 | 0.04 | (0.03-0.04) | 1,282 | 256 | 0.30 | (0.29-0.32) |
Tumors of the pineal region | 258 | 52 | 0.5% | 0.05 | (0.04-0.06) | 121 | 24 | 0.02 | (0.02-0.03) | 109 | 22 | 0.03 | (0.02-0.03) |
Embryonal tumors | 915 | 183 | 1.7% | 0.17 | (0.16-0.18) | 881 | 176 | 0.17 | (0.15-0.18) | 24 | – | 0.01 | (0.00-0.01) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 8.6% | 0.91 | (0.88-0.94) | 53 | -- | 0.01 | (0.01-0.01) | 3,592 | 718 | 0.90 | (0.87-0.93) |
Nerve sheath tumors | 4,545 | 909 | 8.6% | 0.91 | (0.88-0.93) | 53 | – | 0.01 | (0.01-0.01) | 3,589 | 718 | 0.90 | (0.87-0.93) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 18.3% | 1.98 | (1.95-2.02) | 304 | 61 | 0.06 | (0.05-0.07) | 7,558 | 1,512 | 1.94 | (1.89-1.98) |
Meningioma | 8,440 | 1,688 | 15.9% | 1.74 | (1.70-1.77) | 124 | 25 | 0.03 | (0.02-0.03) | 6,704 | 1,341 | 1.73 | (1.69-1.77) |
Mesenchymal tumors | 336 | 67 | 0.6% | 0.07 | (0.06-0.07) | 99 | 20 | 0.02 | (0.02-0.02) | 187 | 37 | 0.05 | (0.04-0.05) |
Primary melanocytic lesions | 22 | – | 0.0% | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 1.7% | 0.18 | (0.17-0.19) | 68 | 14 | 0.01 | (0.01-0.02) | 659 | 132 | 0.16 | (0.15-0.17) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 1.2% | 0.12 | (0.11-0.13) | 611 | 122 | 0.12 | (0.11-0.13) | -- | -- | -- | -- |
Lymphoma | 576 | 115 | 1.1% | 0.12 | (0.11-0.13) | 576 | 115 | 0.12 | (0.11-0.13) | – | – | – | – |
Other hematopoietic neoplasms | 43 | – | 0.1% | 0.01 | (0.01-0.01) | 35 | – | 0.01 | (0.00-0.01) | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Tumors of Sellar Region | 16,559 | 3,312 | 31.2% | 3.23 | (3.18-3.28) | 19 | -- | 0.00 | (0.00-0.01) | 13,234 | 2,647 | 3.24 | (3.18-3.29) |
Tumors of the pituitary | 15,892 | 3,178 | 29.9% | 3.10 | (3.05-3.15) | 18 | – | 0.00 | (0.00-0.01) | 12,689 | 2,538 | 3.10 | (3.05-3.16) |
Craniopharyngioma | 667 | 133 | 1.3% | 0.13 | (0.12-0.14) | – | – | – | – | 545 | 109 | 0.13 | (0.12-0.14) |
Unclassified Tumors | 3,217 | 643 | 6.1% | 0.63 | (0.60-0.65) | 344 | 69 | 0.07 | (0.06-0.08) | 2,282 | 456 | 0.56 | (0.53-0.58) |
Hemangioma | 1,538 | 308 | 2.9% | 0.30 | (0.29-0.32) | – | – | – | – | 1,188 | 238 | 0.29 | (0.27-0.31) |
Neoplasm, unspecified | 1,667 | 333 | 3.1% | 0.32 | (0.31-0.34) | 329 | 66 | 0.06 | (0.06-0.07) | 1,089 | 218 | 0.26 | (0.25-0.28) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 100.0% | 10.43 | (10.34-10.52) | 16,742 | 3,348 | 3.26 | (3.21-3.31) | 29,095 | 5,819 | 7.21 | (7.13-7.29) |
Histology . | Total . | Malignant . | Non-Malignant . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | % of All Tumors . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 33.5% | 3.44 | (3.39-3.49) | 14,894 | 2,979 | 2.90 | (2.85-2.95) | 2,307 | 461 | 0.55 | (0.53-0.57) |
Pilocytic astrocytoma | 1,519 | 304 | 2.9% | 0.28 | (0.27-0.30) | 1,519 | 304 | 0.28 | (0.27-0.30) | – | – | – | – |
Diffuse astrocytoma | 2,413 | 483 | 4.5% | 0.47 | (0.45-0.49) | 2,413 | 483 | 0.47 | (0.45-0.49) | – | – | – | – |
Anaplastic astrocytoma | 1,398 | 280 | 2.6% | 0.27 | (0.26-0.29) | 1,398 | 280 | 0.27 | (0.26-0.29) | – | – | – | – |
Unique astrocytoma variants | 381 | 76 | 0.7% | 0.07 | (0.06-0.08) | 251 | 50 | 0.05 | (0.04-0.05) | 107 | 21 | 0.02 | (0.02-0.03) |
Glioblastoma | 2,393 | 479 | 4.5% | 0.48 | (0.46-0.50) | 2,393 | 479 | 0.48 | (0.46-0.50) | – | – | – | – |
Oligodendroglioma | 1,488 | 298 | 2.8% | 0.29 | (0.28-0.31) | 1,488 | 298 | 0.29 | (0.28-0.31) | – | – | – | – |
Anaplastic oligodendroglioma | 420 | 84 | 0.8% | 0.08 | (0.08-0.09) | 420 | 84 | 0.08 | (0.08-0.09) | – | – | – | – |
Oligoastrocytic tumors | 1,333 | 267 | 2.5% | 0.26 | (0.25-0.28) | 1,333 | 267 | 0.26 | (0.25-0.28) | – | – | – | – |
Ependymal tumors | 1,888 | 378 | 3.6% | 0.37 | (0.35-0.38) | 1,079 | 216 | 0.21 | (0.20-0.22) | 641 | 128 | 0.16 | (0.14-0.17) |
Glioma malignant, NOS | 1,384 | 277 | 2.6% | 0.26 | (0.25-0.28) | 1,384 | 277 | 0.27 | (0.25-0.28) | – | – | – | – |
Choroid plexus tumors | 183 | 37 | 0.3% | 0.03 | (0.03-0.04) | – | – | – | – | 136 | 27 | 0.03 | (0.03-0.04) |
Other neuroepithelial tumors | 30 | – | 0.1% | 0.01 | (0.00-0.01) | 20 | – | 0.00 | (0.00-0.01) | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 3.3% | 0.33 | (0.32-0.35) | 182 | 36 | 0.04 | (0.03-0.04) | 1,282 | 256 | 0.30 | (0.29-0.32) |
Tumors of the pineal region | 258 | 52 | 0.5% | 0.05 | (0.04-0.06) | 121 | 24 | 0.02 | (0.02-0.03) | 109 | 22 | 0.03 | (0.02-0.03) |
Embryonal tumors | 915 | 183 | 1.7% | 0.17 | (0.16-0.18) | 881 | 176 | 0.17 | (0.15-0.18) | 24 | – | 0.01 | (0.00-0.01) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 8.6% | 0.91 | (0.88-0.94) | 53 | -- | 0.01 | (0.01-0.01) | 3,592 | 718 | 0.90 | (0.87-0.93) |
Nerve sheath tumors | 4,545 | 909 | 8.6% | 0.91 | (0.88-0.93) | 53 | – | 0.01 | (0.01-0.01) | 3,589 | 718 | 0.90 | (0.87-0.93) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 18.3% | 1.98 | (1.95-2.02) | 304 | 61 | 0.06 | (0.05-0.07) | 7,558 | 1,512 | 1.94 | (1.89-1.98) |
Meningioma | 8,440 | 1,688 | 15.9% | 1.74 | (1.70-1.77) | 124 | 25 | 0.03 | (0.02-0.03) | 6,704 | 1,341 | 1.73 | (1.69-1.77) |
Mesenchymal tumors | 336 | 67 | 0.6% | 0.07 | (0.06-0.07) | 99 | 20 | 0.02 | (0.02-0.02) | 187 | 37 | 0.05 | (0.04-0.05) |
Primary melanocytic lesions | 22 | – | 0.0% | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 1.7% | 0.18 | (0.17-0.19) | 68 | 14 | 0.01 | (0.01-0.02) | 659 | 132 | 0.16 | (0.15-0.17) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 1.2% | 0.12 | (0.11-0.13) | 611 | 122 | 0.12 | (0.11-0.13) | -- | -- | -- | -- |
Lymphoma | 576 | 115 | 1.1% | 0.12 | (0.11-0.13) | 576 | 115 | 0.12 | (0.11-0.13) | – | – | – | – |
Other hematopoietic neoplasms | 43 | – | 0.1% | 0.01 | (0.01-0.01) | 35 | – | 0.01 | (0.00-0.01) | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Tumors of Sellar Region | 16,559 | 3,312 | 31.2% | 3.23 | (3.18-3.28) | 19 | -- | 0.00 | (0.00-0.01) | 13,234 | 2,647 | 3.24 | (3.18-3.29) |
Tumors of the pituitary | 15,892 | 3,178 | 29.9% | 3.10 | (3.05-3.15) | 18 | – | 0.00 | (0.00-0.01) | 12,689 | 2,538 | 3.10 | (3.05-3.16) |
Craniopharyngioma | 667 | 133 | 1.3% | 0.13 | (0.12-0.14) | – | – | – | – | 545 | 109 | 0.13 | (0.12-0.14) |
Unclassified Tumors | 3,217 | 643 | 6.1% | 0.63 | (0.60-0.65) | 344 | 69 | 0.07 | (0.06-0.08) | 2,282 | 456 | 0.56 | (0.53-0.58) |
Hemangioma | 1,538 | 308 | 2.9% | 0.30 | (0.29-0.32) | – | – | – | – | 1,188 | 238 | 0.29 | (0.27-0.31) |
Neoplasm, unspecified | 1,667 | 333 | 3.1% | 0.32 | (0.31-0.34) | 329 | 66 | 0.06 | (0.06-0.07) | 1,089 | 218 | 0.26 | (0.25-0.28) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 100.0% | 10.43 | (10.34-10.52) | 16,742 | 3,348 | 3.26 | (3.21-3.31) | 29,095 | 5,819 | 7.21 | (7.13-7.29) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts for totals.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | Total . | Malignant . | Non-Malignant . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | % of All Tumors . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 33.5% | 3.44 | (3.39-3.49) | 14,894 | 2,979 | 2.90 | (2.85-2.95) | 2,307 | 461 | 0.55 | (0.53-0.57) |
Pilocytic astrocytoma | 1,519 | 304 | 2.9% | 0.28 | (0.27-0.30) | 1,519 | 304 | 0.28 | (0.27-0.30) | – | – | – | – |
Diffuse astrocytoma | 2,413 | 483 | 4.5% | 0.47 | (0.45-0.49) | 2,413 | 483 | 0.47 | (0.45-0.49) | – | – | – | – |
Anaplastic astrocytoma | 1,398 | 280 | 2.6% | 0.27 | (0.26-0.29) | 1,398 | 280 | 0.27 | (0.26-0.29) | – | – | – | – |
Unique astrocytoma variants | 381 | 76 | 0.7% | 0.07 | (0.06-0.08) | 251 | 50 | 0.05 | (0.04-0.05) | 107 | 21 | 0.02 | (0.02-0.03) |
Glioblastoma | 2,393 | 479 | 4.5% | 0.48 | (0.46-0.50) | 2,393 | 479 | 0.48 | (0.46-0.50) | – | – | – | – |
Oligodendroglioma | 1,488 | 298 | 2.8% | 0.29 | (0.28-0.31) | 1,488 | 298 | 0.29 | (0.28-0.31) | – | – | – | – |
Anaplastic oligodendroglioma | 420 | 84 | 0.8% | 0.08 | (0.08-0.09) | 420 | 84 | 0.08 | (0.08-0.09) | – | – | – | – |
Oligoastrocytic tumors | 1,333 | 267 | 2.5% | 0.26 | (0.25-0.28) | 1,333 | 267 | 0.26 | (0.25-0.28) | – | – | – | – |
Ependymal tumors | 1,888 | 378 | 3.6% | 0.37 | (0.35-0.38) | 1,079 | 216 | 0.21 | (0.20-0.22) | 641 | 128 | 0.16 | (0.14-0.17) |
Glioma malignant, NOS | 1,384 | 277 | 2.6% | 0.26 | (0.25-0.28) | 1,384 | 277 | 0.27 | (0.25-0.28) | – | – | – | – |
Choroid plexus tumors | 183 | 37 | 0.3% | 0.03 | (0.03-0.04) | – | – | – | – | 136 | 27 | 0.03 | (0.03-0.04) |
Other neuroepithelial tumors | 30 | – | 0.1% | 0.01 | (0.00-0.01) | 20 | – | 0.00 | (0.00-0.01) | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 3.3% | 0.33 | (0.32-0.35) | 182 | 36 | 0.04 | (0.03-0.04) | 1,282 | 256 | 0.30 | (0.29-0.32) |
Tumors of the pineal region | 258 | 52 | 0.5% | 0.05 | (0.04-0.06) | 121 | 24 | 0.02 | (0.02-0.03) | 109 | 22 | 0.03 | (0.02-0.03) |
Embryonal tumors | 915 | 183 | 1.7% | 0.17 | (0.16-0.18) | 881 | 176 | 0.17 | (0.15-0.18) | 24 | – | 0.01 | (0.00-0.01) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 8.6% | 0.91 | (0.88-0.94) | 53 | -- | 0.01 | (0.01-0.01) | 3,592 | 718 | 0.90 | (0.87-0.93) |
Nerve sheath tumors | 4,545 | 909 | 8.6% | 0.91 | (0.88-0.93) | 53 | – | 0.01 | (0.01-0.01) | 3,589 | 718 | 0.90 | (0.87-0.93) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 18.3% | 1.98 | (1.95-2.02) | 304 | 61 | 0.06 | (0.05-0.07) | 7,558 | 1,512 | 1.94 | (1.89-1.98) |
Meningioma | 8,440 | 1,688 | 15.9% | 1.74 | (1.70-1.77) | 124 | 25 | 0.03 | (0.02-0.03) | 6,704 | 1,341 | 1.73 | (1.69-1.77) |
Mesenchymal tumors | 336 | 67 | 0.6% | 0.07 | (0.06-0.07) | 99 | 20 | 0.02 | (0.02-0.02) | 187 | 37 | 0.05 | (0.04-0.05) |
Primary melanocytic lesions | 22 | – | 0.0% | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 1.7% | 0.18 | (0.17-0.19) | 68 | 14 | 0.01 | (0.01-0.02) | 659 | 132 | 0.16 | (0.15-0.17) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 1.2% | 0.12 | (0.11-0.13) | 611 | 122 | 0.12 | (0.11-0.13) | -- | -- | -- | -- |
Lymphoma | 576 | 115 | 1.1% | 0.12 | (0.11-0.13) | 576 | 115 | 0.12 | (0.11-0.13) | – | – | – | – |
Other hematopoietic neoplasms | 43 | – | 0.1% | 0.01 | (0.01-0.01) | 35 | – | 0.01 | (0.00-0.01) | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Tumors of Sellar Region | 16,559 | 3,312 | 31.2% | 3.23 | (3.18-3.28) | 19 | -- | 0.00 | (0.00-0.01) | 13,234 | 2,647 | 3.24 | (3.18-3.29) |
Tumors of the pituitary | 15,892 | 3,178 | 29.9% | 3.10 | (3.05-3.15) | 18 | – | 0.00 | (0.00-0.01) | 12,689 | 2,538 | 3.10 | (3.05-3.16) |
Craniopharyngioma | 667 | 133 | 1.3% | 0.13 | (0.12-0.14) | – | – | – | – | 545 | 109 | 0.13 | (0.12-0.14) |
Unclassified Tumors | 3,217 | 643 | 6.1% | 0.63 | (0.60-0.65) | 344 | 69 | 0.07 | (0.06-0.08) | 2,282 | 456 | 0.56 | (0.53-0.58) |
Hemangioma | 1,538 | 308 | 2.9% | 0.30 | (0.29-0.32) | – | – | – | – | 1,188 | 238 | 0.29 | (0.27-0.31) |
Neoplasm, unspecified | 1,667 | 333 | 3.1% | 0.32 | (0.31-0.34) | 329 | 66 | 0.06 | (0.06-0.07) | 1,089 | 218 | 0.26 | (0.25-0.28) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 100.0% | 10.43 | (10.34-10.52) | 16,742 | 3,348 | 3.26 | (3.21-3.31) | 29,095 | 5,819 | 7.21 | (7.13-7.29) |
Histology . | Total . | Malignant . | Non-Malignant . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual average . | % of All Tumors . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . | 5-year total . | Annual average . | Rate . | (95% CI) . |
Tumors of Neuroepithelial Tissue | 17,776 | 3,555 | 33.5% | 3.44 | (3.39-3.49) | 14,894 | 2,979 | 2.90 | (2.85-2.95) | 2,307 | 461 | 0.55 | (0.53-0.57) |
Pilocytic astrocytoma | 1,519 | 304 | 2.9% | 0.28 | (0.27-0.30) | 1,519 | 304 | 0.28 | (0.27-0.30) | – | – | – | – |
Diffuse astrocytoma | 2,413 | 483 | 4.5% | 0.47 | (0.45-0.49) | 2,413 | 483 | 0.47 | (0.45-0.49) | – | – | – | – |
Anaplastic astrocytoma | 1,398 | 280 | 2.6% | 0.27 | (0.26-0.29) | 1,398 | 280 | 0.27 | (0.26-0.29) | – | – | – | – |
Unique astrocytoma variants | 381 | 76 | 0.7% | 0.07 | (0.06-0.08) | 251 | 50 | 0.05 | (0.04-0.05) | 107 | 21 | 0.02 | (0.02-0.03) |
Glioblastoma | 2,393 | 479 | 4.5% | 0.48 | (0.46-0.50) | 2,393 | 479 | 0.48 | (0.46-0.50) | – | – | – | – |
Oligodendroglioma | 1,488 | 298 | 2.8% | 0.29 | (0.28-0.31) | 1,488 | 298 | 0.29 | (0.28-0.31) | – | – | – | – |
Anaplastic oligodendroglioma | 420 | 84 | 0.8% | 0.08 | (0.08-0.09) | 420 | 84 | 0.08 | (0.08-0.09) | – | – | – | – |
Oligoastrocytic tumors | 1,333 | 267 | 2.5% | 0.26 | (0.25-0.28) | 1,333 | 267 | 0.26 | (0.25-0.28) | – | – | – | – |
Ependymal tumors | 1,888 | 378 | 3.6% | 0.37 | (0.35-0.38) | 1,079 | 216 | 0.21 | (0.20-0.22) | 641 | 128 | 0.16 | (0.14-0.17) |
Glioma malignant, NOS | 1,384 | 277 | 2.6% | 0.26 | (0.25-0.28) | 1,384 | 277 | 0.27 | (0.25-0.28) | – | – | – | – |
Choroid plexus tumors | 183 | 37 | 0.3% | 0.03 | (0.03-0.04) | – | – | – | – | 136 | 27 | 0.03 | (0.03-0.04) |
Other neuroepithelial tumors | 30 | – | 0.1% | 0.01 | (0.00-0.01) | 20 | – | 0.00 | (0.00-0.01) | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 1,773 | 355 | 3.3% | 0.33 | (0.32-0.35) | 182 | 36 | 0.04 | (0.03-0.04) | 1,282 | 256 | 0.30 | (0.29-0.32) |
Tumors of the pineal region | 258 | 52 | 0.5% | 0.05 | (0.04-0.06) | 121 | 24 | 0.02 | (0.02-0.03) | 109 | 22 | 0.03 | (0.02-0.03) |
Embryonal tumors | 915 | 183 | 1.7% | 0.17 | (0.16-0.18) | 881 | 176 | 0.17 | (0.15-0.18) | 24 | – | 0.01 | (0.00-0.01) |
Tumors of Cranial and Spinal Nerves | 4,549 | 910 | 8.6% | 0.91 | (0.88-0.94) | 53 | -- | 0.01 | (0.01-0.01) | 3,592 | 718 | 0.90 | (0.87-0.93) |
Nerve sheath tumors | 4,545 | 909 | 8.6% | 0.91 | (0.88-0.93) | 53 | – | 0.01 | (0.01-0.01) | 3,589 | 718 | 0.90 | (0.87-0.93) |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – | – | – | – | – | – | – | – |
Tumors of Meninges | 9,707 | 1,941 | 18.3% | 1.98 | (1.95-2.02) | 304 | 61 | 0.06 | (0.05-0.07) | 7,558 | 1,512 | 1.94 | (1.89-1.98) |
Meningioma | 8,440 | 1,688 | 15.9% | 1.74 | (1.70-1.77) | 124 | 25 | 0.03 | (0.02-0.03) | 6,704 | 1,341 | 1.73 | (1.69-1.77) |
Mesenchymal tumors | 336 | 67 | 0.6% | 0.07 | (0.06-0.07) | 99 | 20 | 0.02 | (0.02-0.02) | 187 | 37 | 0.05 | (0.04-0.05) |
Primary melanocytic lesions | 22 | – | 0.0% | 0.00 | (0.00-0.01) | – | – | – | – | – | – | – | – |
Other neoplasms related to the meninges | 909 | 182 | 1.7% | 0.18 | (0.17-0.19) | 68 | 14 | 0.01 | (0.01-0.02) | 659 | 132 | 0.16 | (0.15-0.17) |
Lymphomas and Hematopoietic Neoplasms | 619 | 124 | 1.2% | 0.12 | (0.11-0.13) | 611 | 122 | 0.12 | (0.11-0.13) | -- | -- | -- | -- |
Lymphoma | 576 | 115 | 1.1% | 0.12 | (0.11-0.13) | 576 | 115 | 0.12 | (0.11-0.13) | – | – | – | – |
Other hematopoietic neoplasms | 43 | – | 0.1% | 0.01 | (0.01-0.01) | 35 | – | 0.01 | (0.00-0.01) | – | – | – | – |
Germ Cell Tumors and Cysts | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Germ cell tumors, cysts and heterotopias | 656 | 131 | 1.2% | 0.12 | (0.11-0.13) | 517 | 103 | 0.10 | (0.09-0.10) | 115 | 23 | 0.03 | (0.02-0.03) |
Tumors of Sellar Region | 16,559 | 3,312 | 31.2% | 3.23 | (3.18-3.28) | 19 | -- | 0.00 | (0.00-0.01) | 13,234 | 2,647 | 3.24 | (3.18-3.29) |
Tumors of the pituitary | 15,892 | 3,178 | 29.9% | 3.10 | (3.05-3.15) | 18 | – | 0.00 | (0.00-0.01) | 12,689 | 2,538 | 3.10 | (3.05-3.16) |
Craniopharyngioma | 667 | 133 | 1.3% | 0.13 | (0.12-0.14) | – | – | – | – | 545 | 109 | 0.13 | (0.12-0.14) |
Unclassified Tumors | 3,217 | 643 | 6.1% | 0.63 | (0.60-0.65) | 344 | 69 | 0.07 | (0.06-0.08) | 2,282 | 456 | 0.56 | (0.53-0.58) |
Hemangioma | 1,538 | 308 | 2.9% | 0.30 | (0.29-0.32) | – | – | – | – | 1,188 | 238 | 0.29 | (0.27-0.31) |
Neoplasm, unspecified | 1,667 | 333 | 3.1% | 0.32 | (0.31-0.34) | 329 | 66 | 0.06 | (0.06-0.07) | 1,089 | 218 | 0.26 | (0.25-0.28) |
All other | – | – | – | – | – | – | – | – | – | – | – | – | – |
TOTALc | 53,083 | 10,617 | 100.0% | 10.43 | (10.34-10.52) | 16,742 | 3,348 | 3.26 | (3.21-3.31) | 29,095 | 5,819 | 7.21 | (7.13-7.29) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. The suppressed cases are included in the counts for totals.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Number of Estimated New Cases for 2015 and 2016
Estimated number of new brain and CNS cases in adolescents and young adults (age 15-39 years for 2015 and 2016 by histologic type and behavior are shown in Table 9).
It is estimated that there will be 2,200 cases of meningioma and 4,730 cases of tumors of the pituitary diagnosed in 2015 in AYA. Estimated cases for 2016 are 2,290 and 5,050, respectively.
An estimated 3,870 tumors of neuroepithelial tissue will be diagnosed in 2015, and 3,930 in 2016 in AYA.
Histology . | 2015 Estimated New Cases . | 2016 Estimated New Cases . | ||||
---|---|---|---|---|---|---|
. | All . | Malignant . | Non-Malignant . | All . | Malignant . | Non-Malignant . |
Tumors of Neuroepithelial Tissue | 3,870 | 3,150 | 730 | 3,930 | 3,180 | 760 |
Pilocytic astrocytoma | 290 | 290 | – | 290 | 290 | – |
Diffuse astrocytoma | 500 | 500 | – | 500 | 500 | – |
Anaplastic astrocytoma | 260 | 260 | – | 260 | 260 | – |
Unique astrocytoma variants | 110 | 70 | – | 110 | 70 | – |
Glioblastoma | 450 | 450 | – | 450 | 450 | – |
Oligodendroglioma | 260 | 260 | – | 260 | 260 | – |
Anaplastic oligodendroglioma | 70 | 70 | – | 70 | 70 | – |
Oligoastrocytic tumors | 360 | 360 | – | 380 | 380 | – |
Ependymal tumors | 450 | 270 | 170 | 460 | 280 | 170 |
Glioma malignant, NOS | 360 | 360 | – | 380 | 380 | – |
Choroid plexus tumors | – | – | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 430 | – | 420 | 450 | – | 440 |
Tumors of the pineal region | 90 | – | 50 | 90 | – | 60 |
Embryonal tumors | 200 | 190 | – | 200 | 190 | – |
Tumors of Cranial and Spinal Nerves | 960 | – | 950 | 970 | – | 960 |
Nerve sheath tumors | 960 | – | 950 | 960 | – | 960 |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – |
Tumors of Meninges | 2,490 | 60 | 2,430 | 2,600 | 60 | 2,540 |
Meningioma | 2,200 | – | 2,170 | 2,290 | – | 2,270 |
Mesenchymal tumors | 90 | – | 70 | 90 | – | 70 |
Primary melanocytic lesions | – | – | – | – | – | – |
Other neoplasms related to the meninges | 200 | – | 190 | 200 | – | 190 |
Lymphomas and Hematopoietic Neoplasms | 110 | 100 | – | 110 | 100 | – |
Lymphoma | 90 | 90 | – | 80 | 80 | – |
Other hematopoietic neoplasms | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 120 | 110 | -- | 120 | 110 | -- |
Germ cell tumors, cysts and heterotopias | 140 | 120 | – | 140 | 130 | – |
Tumors of Sellar Region | 4,860 | – | 4,850 | 5,180 | – | 5,180 |
Tumors of the pituitary | 4,730 | – | 4,720 | 5,050 | – | 5,050 |
Craniopharyngioma | 130 | – | 130 | 130 | – | 130 |
Unclassified Tumors | 1,150 | – | 1,100 | 1,300 | – | 1,260 |
Hemangioma | 790 | – | 790 | 940 | – | 940 |
Neoplasm, unspecified | 350 | – | 310 | 360 | – | 320 |
All other | – | – | – | – | – | – |
TOTAL‡ | 13,750 | 3,510 | 10,240 | 13,770 | 3,530 | 10,240 |
Histology . | 2015 Estimated New Cases . | 2016 Estimated New Cases . | ||||
---|---|---|---|---|---|---|
. | All . | Malignant . | Non-Malignant . | All . | Malignant . | Non-Malignant . |
Tumors of Neuroepithelial Tissue | 3,870 | 3,150 | 730 | 3,930 | 3,180 | 760 |
Pilocytic astrocytoma | 290 | 290 | – | 290 | 290 | – |
Diffuse astrocytoma | 500 | 500 | – | 500 | 500 | – |
Anaplastic astrocytoma | 260 | 260 | – | 260 | 260 | – |
Unique astrocytoma variants | 110 | 70 | – | 110 | 70 | – |
Glioblastoma | 450 | 450 | – | 450 | 450 | – |
Oligodendroglioma | 260 | 260 | – | 260 | 260 | – |
Anaplastic oligodendroglioma | 70 | 70 | – | 70 | 70 | – |
Oligoastrocytic tumors | 360 | 360 | – | 380 | 380 | – |
Ependymal tumors | 450 | 270 | 170 | 460 | 280 | 170 |
Glioma malignant, NOS | 360 | 360 | – | 380 | 380 | – |
Choroid plexus tumors | – | – | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 430 | – | 420 | 450 | – | 440 |
Tumors of the pineal region | 90 | – | 50 | 90 | – | 60 |
Embryonal tumors | 200 | 190 | – | 200 | 190 | – |
Tumors of Cranial and Spinal Nerves | 960 | – | 950 | 970 | – | 960 |
Nerve sheath tumors | 960 | – | 950 | 960 | – | 960 |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – |
Tumors of Meninges | 2,490 | 60 | 2,430 | 2,600 | 60 | 2,540 |
Meningioma | 2,200 | – | 2,170 | 2,290 | – | 2,270 |
Mesenchymal tumors | 90 | – | 70 | 90 | – | 70 |
Primary melanocytic lesions | – | – | – | – | – | – |
Other neoplasms related to the meninges | 200 | – | 190 | 200 | – | 190 |
Lymphomas and Hematopoietic Neoplasms | 110 | 100 | – | 110 | 100 | – |
Lymphoma | 90 | 90 | – | 80 | 80 | – |
Other hematopoietic neoplasms | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 120 | 110 | -- | 120 | 110 | -- |
Germ cell tumors, cysts and heterotopias | 140 | 120 | – | 140 | 130 | – |
Tumors of Sellar Region | 4,860 | – | 4,850 | 5,180 | – | 5,180 |
Tumors of the pituitary | 4,730 | – | 4,720 | 5,050 | – | 5,050 |
Craniopharyngioma | 130 | – | 130 | 130 | – | 130 |
Unclassified Tumors | 1,150 | – | 1,100 | 1,300 | – | 1,260 |
Hemangioma | 790 | – | 790 | 940 | – | 940 |
Neoplasm, unspecified | 350 | – | 310 | 360 | – | 320 |
All other | – | – | – | – | – | – |
TOTAL‡ | 13,750 | 3,510 | 10,240 | 13,770 | 3,530 | 10,240 |
aSource: Estimation based on CBTRUS 2000-2010 data for malignant tumors, and CBTRUS 2006-2010 data for non-malignant tumors.
bRounded to the nearest 10. Numbers may not add up due to rounding.
–Estimated number is less than 50 and may affect totals.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | 2015 Estimated New Cases . | 2016 Estimated New Cases . | ||||
---|---|---|---|---|---|---|
. | All . | Malignant . | Non-Malignant . | All . | Malignant . | Non-Malignant . |
Tumors of Neuroepithelial Tissue | 3,870 | 3,150 | 730 | 3,930 | 3,180 | 760 |
Pilocytic astrocytoma | 290 | 290 | – | 290 | 290 | – |
Diffuse astrocytoma | 500 | 500 | – | 500 | 500 | – |
Anaplastic astrocytoma | 260 | 260 | – | 260 | 260 | – |
Unique astrocytoma variants | 110 | 70 | – | 110 | 70 | – |
Glioblastoma | 450 | 450 | – | 450 | 450 | – |
Oligodendroglioma | 260 | 260 | – | 260 | 260 | – |
Anaplastic oligodendroglioma | 70 | 70 | – | 70 | 70 | – |
Oligoastrocytic tumors | 360 | 360 | – | 380 | 380 | – |
Ependymal tumors | 450 | 270 | 170 | 460 | 280 | 170 |
Glioma malignant, NOS | 360 | 360 | – | 380 | 380 | – |
Choroid plexus tumors | – | – | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 430 | – | 420 | 450 | – | 440 |
Tumors of the pineal region | 90 | – | 50 | 90 | – | 60 |
Embryonal tumors | 200 | 190 | – | 200 | 190 | – |
Tumors of Cranial and Spinal Nerves | 960 | – | 950 | 970 | – | 960 |
Nerve sheath tumors | 960 | – | 950 | 960 | – | 960 |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – |
Tumors of Meninges | 2,490 | 60 | 2,430 | 2,600 | 60 | 2,540 |
Meningioma | 2,200 | – | 2,170 | 2,290 | – | 2,270 |
Mesenchymal tumors | 90 | – | 70 | 90 | – | 70 |
Primary melanocytic lesions | – | – | – | – | – | – |
Other neoplasms related to the meninges | 200 | – | 190 | 200 | – | 190 |
Lymphomas and Hematopoietic Neoplasms | 110 | 100 | – | 110 | 100 | – |
Lymphoma | 90 | 90 | – | 80 | 80 | – |
Other hematopoietic neoplasms | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 120 | 110 | -- | 120 | 110 | -- |
Germ cell tumors, cysts and heterotopias | 140 | 120 | – | 140 | 130 | – |
Tumors of Sellar Region | 4,860 | – | 4,850 | 5,180 | – | 5,180 |
Tumors of the pituitary | 4,730 | – | 4,720 | 5,050 | – | 5,050 |
Craniopharyngioma | 130 | – | 130 | 130 | – | 130 |
Unclassified Tumors | 1,150 | – | 1,100 | 1,300 | – | 1,260 |
Hemangioma | 790 | – | 790 | 940 | – | 940 |
Neoplasm, unspecified | 350 | – | 310 | 360 | – | 320 |
All other | – | – | – | – | – | – |
TOTAL‡ | 13,750 | 3,510 | 10,240 | 13,770 | 3,530 | 10,240 |
Histology . | 2015 Estimated New Cases . | 2016 Estimated New Cases . | ||||
---|---|---|---|---|---|---|
. | All . | Malignant . | Non-Malignant . | All . | Malignant . | Non-Malignant . |
Tumors of Neuroepithelial Tissue | 3,870 | 3,150 | 730 | 3,930 | 3,180 | 760 |
Pilocytic astrocytoma | 290 | 290 | – | 290 | 290 | – |
Diffuse astrocytoma | 500 | 500 | – | 500 | 500 | – |
Anaplastic astrocytoma | 260 | 260 | – | 260 | 260 | – |
Unique astrocytoma variants | 110 | 70 | – | 110 | 70 | – |
Glioblastoma | 450 | 450 | – | 450 | 450 | – |
Oligodendroglioma | 260 | 260 | – | 260 | 260 | – |
Anaplastic oligodendroglioma | 70 | 70 | – | 70 | 70 | – |
Oligoastrocytic tumors | 360 | 360 | – | 380 | 380 | – |
Ependymal tumors | 450 | 270 | 170 | 460 | 280 | 170 |
Glioma malignant, NOS | 360 | 360 | – | 380 | 380 | – |
Choroid plexus tumors | – | – | – | – | – | – |
Other neuroepithelial tumors | – | – | – | – | – | – |
Neuronal and mixed neuronal-glial tumors | 430 | – | 420 | 450 | – | 440 |
Tumors of the pineal region | 90 | – | 50 | 90 | – | 60 |
Embryonal tumors | 200 | 190 | – | 200 | 190 | – |
Tumors of Cranial and Spinal Nerves | 960 | – | 950 | 970 | – | 960 |
Nerve sheath tumors | 960 | – | 950 | 960 | – | 960 |
Other tumors of cranial and spinal nerves | – | – | – | – | – | – |
Tumors of Meninges | 2,490 | 60 | 2,430 | 2,600 | 60 | 2,540 |
Meningioma | 2,200 | – | 2,170 | 2,290 | – | 2,270 |
Mesenchymal tumors | 90 | – | 70 | 90 | – | 70 |
Primary melanocytic lesions | – | – | – | – | – | – |
Other neoplasms related to the meninges | 200 | – | 190 | 200 | – | 190 |
Lymphomas and Hematopoietic Neoplasms | 110 | 100 | – | 110 | 100 | – |
Lymphoma | 90 | 90 | – | 80 | 80 | – |
Other hematopoietic neoplasms | – | – | – | – | – | – |
Germ Cell Tumors and Cysts | 120 | 110 | -- | 120 | 110 | -- |
Germ cell tumors, cysts and heterotopias | 140 | 120 | – | 140 | 130 | – |
Tumors of Sellar Region | 4,860 | – | 4,850 | 5,180 | – | 5,180 |
Tumors of the pituitary | 4,730 | – | 4,720 | 5,050 | – | 5,050 |
Craniopharyngioma | 130 | – | 130 | 130 | – | 130 |
Unclassified Tumors | 1,150 | – | 1,100 | 1,300 | – | 1,260 |
Hemangioma | 790 | – | 790 | 940 | – | 940 |
Neoplasm, unspecified | 350 | – | 310 | 360 | – | 320 |
All other | – | – | – | – | – | – |
TOTAL‡ | 13,750 | 3,510 | 10,240 | 13,770 | 3,530 | 10,240 |
aSource: Estimation based on CBTRUS 2000-2010 data for malignant tumors, and CBTRUS 2006-2010 data for non-malignant tumors.
bRounded to the nearest 10. Numbers may not add up due to rounding.
–Estimated number is less than 50 and may affect totals.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Mortality Rates by Age Groups, Sex, Race, Ethnicity and Region of the US
Mortality rates due to primary malignant brain and CNS tumors in adolescents and young adults (age 15-39 years) by age at death, sex, race and ethnicity are shown in Table 10.
Overall, average annual age-adjusted mortality for AYA is 1.09 per 100,000 population. It is 0.49 per 100,000 population in those age 15-19 years, and 1.62 per 100,000 population in those age 35-39 years.
Mortality is higher in males than females (1.34 per 100,000 population in males, and 0.84 per 100,000 population in females). This gap in mortality rate increases with increasing age.
Mortality is highest in Whites as compared to other race groups. There is no substantial racial difference in mortality in those age 15-19 years, but this difference increases with increasing age.
Mortality is higher in non-Hispanics as compared to Hispanics (1.18 per 100,000 population in non-Hispanics and 0.70 per 100,000 population in Hispanics).
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Sex | ||||||||||||||
Male | 1,331 | 266 | 1.34 | (1.27-1.41) | 0.56 | (0.50-0.63) | 0.65 | (0.58-0.72) | 0.96 | (0.88-1.05) | 1.40 | (1.29-1.50) | 2.03 | (1.90-2.16) |
Female | 840 | 168 | 0.84 | (0.79-0.90) | 0.42 | (0.37-0.48) | 0.48 | (0.42-0.54) | 0.58 | (0.51-0.64) | 0.83 | (0.75-0.91) | 1.22 | (1.13-1.32) |
Race | ||||||||||||||
White | 1,826 | 365 | 1.19 | (1.14-1.25) | 0.50 | (0.45-0.55) | 0.61 | (0.55-0.66) | 0.85 | (0.79-0.92) | 1.26 | (1.18-1.34) | 1.81 | (1.72-1.91) |
Black | 228 | 46 | 0.75 | (0.65-0.85) | 0.51 | (0.41-0.62) | 0.50 | (0.40-0.62) | 0.52 | (0.42-0.65) | 0.62 | (0.50-0.77) | 0.96 | (0.80-1.14) |
AIAN | 16 | – | 0.56 | (0.32-0.91) | – | – | – | – | – | – | – | – | – | – |
API | 101 | 20 | 0.76 | (0.62-0.92) | 0.48 | (0.32-0.70) | 0.30 | (0.18-0.46) | 0.41 | (0.28-0.59) | 0.64 | (0.47-0.85) | 1.00 | (0.79-1.26) |
Ethnicity | ||||||||||||||
Hispanic | 277 | 55 | 0.70 | (0.62-0.79) | 0.41 | (0.33-0.50) | 0.40 | (0.32-0.49) | 0.42 | (0.34-0.52) | 0.70 | (0.59-0.83) | 0.96 | (0.83-1.11) |
Non-Hispanic | 1,892 | 378 | 1.18 | (1.13-1.24) | 0.51 | (0.47-0.56) | 0.60 | (0.55-0.66) | 0.86 | (0.80-0.92) | 1.22 | (1.14-1.30) | 1.78 | (1.69-1.87) |
TOTALc | 2,171 | 434 | 1.09 | (1.04-1.14) | 0.49 | (0.45-0.54) | 0.56 | (0.52-0.61) | 0.77 | (0.72-0.83) | 1.11 | (1.05-1.18) | 1.62 | (1.55-1.70) |
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Sex | ||||||||||||||
Male | 1,331 | 266 | 1.34 | (1.27-1.41) | 0.56 | (0.50-0.63) | 0.65 | (0.58-0.72) | 0.96 | (0.88-1.05) | 1.40 | (1.29-1.50) | 2.03 | (1.90-2.16) |
Female | 840 | 168 | 0.84 | (0.79-0.90) | 0.42 | (0.37-0.48) | 0.48 | (0.42-0.54) | 0.58 | (0.51-0.64) | 0.83 | (0.75-0.91) | 1.22 | (1.13-1.32) |
Race | ||||||||||||||
White | 1,826 | 365 | 1.19 | (1.14-1.25) | 0.50 | (0.45-0.55) | 0.61 | (0.55-0.66) | 0.85 | (0.79-0.92) | 1.26 | (1.18-1.34) | 1.81 | (1.72-1.91) |
Black | 228 | 46 | 0.75 | (0.65-0.85) | 0.51 | (0.41-0.62) | 0.50 | (0.40-0.62) | 0.52 | (0.42-0.65) | 0.62 | (0.50-0.77) | 0.96 | (0.80-1.14) |
AIAN | 16 | – | 0.56 | (0.32-0.91) | – | – | – | – | – | – | – | – | – | – |
API | 101 | 20 | 0.76 | (0.62-0.92) | 0.48 | (0.32-0.70) | 0.30 | (0.18-0.46) | 0.41 | (0.28-0.59) | 0.64 | (0.47-0.85) | 1.00 | (0.79-1.26) |
Ethnicity | ||||||||||||||
Hispanic | 277 | 55 | 0.70 | (0.62-0.79) | 0.41 | (0.33-0.50) | 0.40 | (0.32-0.49) | 0.42 | (0.34-0.52) | 0.70 | (0.59-0.83) | 0.96 | (0.83-1.11) |
Non-Hispanic | 1,892 | 378 | 1.18 | (1.13-1.24) | 0.51 | (0.47-0.56) | 0.60 | (0.55-0.66) | 0.86 | (0.80-0.92) | 1.22 | (1.14-1.30) | 1.78 | (1.69-1.87) |
TOTALc | 2,171 | 434 | 1.09 | (1.04-1.14) | 0.49 | (0.45-0.54) | 0.56 | (0.52-0.61) | 0.77 | (0.72-0.83) | 1.11 | (1.05-1.18) | 1.62 | (1.55-1.70) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Sex | ||||||||||||||
Male | 1,331 | 266 | 1.34 | (1.27-1.41) | 0.56 | (0.50-0.63) | 0.65 | (0.58-0.72) | 0.96 | (0.88-1.05) | 1.40 | (1.29-1.50) | 2.03 | (1.90-2.16) |
Female | 840 | 168 | 0.84 | (0.79-0.90) | 0.42 | (0.37-0.48) | 0.48 | (0.42-0.54) | 0.58 | (0.51-0.64) | 0.83 | (0.75-0.91) | 1.22 | (1.13-1.32) |
Race | ||||||||||||||
White | 1,826 | 365 | 1.19 | (1.14-1.25) | 0.50 | (0.45-0.55) | 0.61 | (0.55-0.66) | 0.85 | (0.79-0.92) | 1.26 | (1.18-1.34) | 1.81 | (1.72-1.91) |
Black | 228 | 46 | 0.75 | (0.65-0.85) | 0.51 | (0.41-0.62) | 0.50 | (0.40-0.62) | 0.52 | (0.42-0.65) | 0.62 | (0.50-0.77) | 0.96 | (0.80-1.14) |
AIAN | 16 | – | 0.56 | (0.32-0.91) | – | – | – | – | – | – | – | – | – | – |
API | 101 | 20 | 0.76 | (0.62-0.92) | 0.48 | (0.32-0.70) | 0.30 | (0.18-0.46) | 0.41 | (0.28-0.59) | 0.64 | (0.47-0.85) | 1.00 | (0.79-1.26) |
Ethnicity | ||||||||||||||
Hispanic | 277 | 55 | 0.70 | (0.62-0.79) | 0.41 | (0.33-0.50) | 0.40 | (0.32-0.49) | 0.42 | (0.34-0.52) | 0.70 | (0.59-0.83) | 0.96 | (0.83-1.11) |
Non-Hispanic | 1,892 | 378 | 1.18 | (1.13-1.24) | 0.51 | (0.47-0.56) | 0.60 | (0.55-0.66) | 0.86 | (0.80-0.92) | 1.22 | (1.14-1.30) | 1.78 | (1.69-1.87) |
TOTALc | 2,171 | 434 | 1.09 | (1.04-1.14) | 0.49 | (0.45-0.54) | 0.56 | (0.52-0.61) | 0.77 | (0.72-0.83) | 1.11 | (1.05-1.18) | 1.62 | (1.55-1.70) |
Histology . | 15-39 . | 15-19 . | 20-24 . | 25-29 . | 30-34 . | 35-39 . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 5-year total . | Annual Average . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . | Rate . | 95% CI . |
Sex | ||||||||||||||
Male | 1,331 | 266 | 1.34 | (1.27-1.41) | 0.56 | (0.50-0.63) | 0.65 | (0.58-0.72) | 0.96 | (0.88-1.05) | 1.40 | (1.29-1.50) | 2.03 | (1.90-2.16) |
Female | 840 | 168 | 0.84 | (0.79-0.90) | 0.42 | (0.37-0.48) | 0.48 | (0.42-0.54) | 0.58 | (0.51-0.64) | 0.83 | (0.75-0.91) | 1.22 | (1.13-1.32) |
Race | ||||||||||||||
White | 1,826 | 365 | 1.19 | (1.14-1.25) | 0.50 | (0.45-0.55) | 0.61 | (0.55-0.66) | 0.85 | (0.79-0.92) | 1.26 | (1.18-1.34) | 1.81 | (1.72-1.91) |
Black | 228 | 46 | 0.75 | (0.65-0.85) | 0.51 | (0.41-0.62) | 0.50 | (0.40-0.62) | 0.52 | (0.42-0.65) | 0.62 | (0.50-0.77) | 0.96 | (0.80-1.14) |
AIAN | 16 | – | 0.56 | (0.32-0.91) | – | – | – | – | – | – | – | – | – | – |
API | 101 | 20 | 0.76 | (0.62-0.92) | 0.48 | (0.32-0.70) | 0.30 | (0.18-0.46) | 0.41 | (0.28-0.59) | 0.64 | (0.47-0.85) | 1.00 | (0.79-1.26) |
Ethnicity | ||||||||||||||
Hispanic | 277 | 55 | 0.70 | (0.62-0.79) | 0.41 | (0.33-0.50) | 0.40 | (0.32-0.49) | 0.42 | (0.34-0.52) | 0.70 | (0.59-0.83) | 0.96 | (0.83-1.11) |
Non-Hispanic | 1,892 | 378 | 1.18 | (1.13-1.24) | 0.51 | (0.47-0.56) | 0.60 | (0.55-0.66) | 0.86 | (0.80-0.92) | 1.22 | (1.14-1.30) | 1.78 | (1.69-1.87) |
TOTALc | 2,171 | 434 | 1.09 | (1.04-1.14) | 0.49 | (0.45-0.54) | 0.56 | (0.52-0.61) | 0.77 | (0.72-0.83) | 1.11 | (1.05-1.18) | 1.62 | (1.55-1.70) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age-adjusted to the 2000 US standard population.
cRefers to all brain tumors including histologies not presented in this table.
– Counts are not presented when fewer than 16 cases were reported for the specific histology category. Suppressed cases are included in the total count.
Abbreviations: NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval; NOS, not otherwise specified.
Mortality rates in AYA due to primary malignant brain and CNS tumors in adolescents and young adults (age 15-39 years) by region of the US are shown in Figure 15.
Mortality is highest in the West North Central (1.32 per 100,000 population) and East South Central (1.25 per 100,000 population).
Mortality is lowest in the New England (0.90 per 100,000 population), Middle Atlantic, and South Atlantic (both 0.99 per 100,000 population) regions. Though mortality and incidence are inherently linked statistics, higher incidence (as in the case of the Middle Atlantic region) does not necessarily lead to higher mortality within the same age group. Age ranges for mortality figures reflect age at death, as compared to incidence rates that reflect age at diagnosis. Time period between diagnosis and death can vary substantially by tumor type, and by individual.
Incidence by Site and Gender
Average annual age-adjusted incidence rates in AYA by site and gender are shown in Table 11.
The site with the highest incidence is the pituitary and craniopharyngeal duct (3.30 per 100,000 population) which is more common in females than males followed by the frontal, temporal, parietal, and occipital lobes of the brain (2.08 per 100,000 population) which is more common in males.
The frontal, temporal, parietal, and occipital lobes are the site with the highest incidence in males (2.31 per 100,000 population).
In females, pituitary and craniopharyngeal duct (4.72 per 100,000 population) and the cerebral and spinal meninges (2.51 per 100,000 population) are the sites with the highest incidence.
ICD-O-3 Code . | Site . | Total . | Male . | Female . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
C71.0 | Cerebrum | 1,126 | 225 | 0.22 | (0.20-0.23) | 626 | 125 | 0.24 | (0.22-0.26) | 500 | 100 | 0.20 | (0.18-0.21) |
C71.1-C71.4 | Frontal, temporal, parietal, and occipital lobes of the brain | 10,646 | 2,129 | 2.08 | (2.04-2.12) | 5,945 | 1,189 | 2.31 | (2.25-2.37) | 4,701 | 940 | 1.85 | (1.80-1.91) |
C71.1 - Frontal lobe | 5,624 | 1,125 | 1.10 | (1.08-1.13) | 3,128 | 626 | 1.22 | (1.18-1.26) | 2,496 | 499 | 0.99 | (0.95-1.03) | |
C71.2 - Temporal lobe | 3,094 | 619 | 0.60 | (0.58-0.62) | 1,739 | 348 | 0.67 | (0.64-0.71) | 1,355 | 271 | 0.53 | (0.50-0.56) | |
C71.3 - Parietal lobe | 1,535 | 307 | 0.30 | (0.29-0.32) | 856 | 171 | 0.33 | (0.31-0.36) | 679 | 136 | 0.27 | (0.25-0.29) | |
C71.4 - Occipital lobe | 393 | 79 | 0.08 | (0.07-0.08) | 222 | 44 | 0.08 | (0.07-0.10) | 171 | 34 | 0.07 | (0.06-0.08) | |
C71.5 | Ventricle | 1,173 | 235 | 0.22 | (0.21-0.24) | 596 | 119 | 0.22 | (0.21-0.24) | 577 | 115 | 0.22 | (0.21-0.24) |
C71.6 | Cerebellum | 2,352 | 470 | 0.45 | (0.43-0.47) | 1,270 | 254 | 0.48 | (0.46-0.51) | 1,082 | 216 | 0.42 | (0.39-0.45) |
C71.7 | Brain stem | 1,359 | 272 | 0.26 | (0.25-0.27) | 702 | 140 | 0.27 | (0.25-0.29) | 657 | 131 | 0.25 | (0.24-0.27) |
C71.8-C71.9 | Other brain | 3,762 | 752 | 0.73 | (0.71-0.76) | 2,032 | 406 | 0.79 | (0.75-0.82) | 1,730 | 346 | 0.68 | (0.65-0.71) |
C72.0-C72.1 | Spinal cord and cauda equina | 2,710 | 542 | 0.53 | (0.51-0.55) | 1,488 | 298 | 0.58 | (0.55-0.61) | 1,222 | 244 | 0.48 | (0.45-0.51) |
C72.2-C72.5 | Cranial nerves | 3,419 | 684 | 0.69 | (0.66-0.71) | 1,567 | 313 | 0.63 | (0.6-0.66) | 1,852 | 370 | 0.75 | (0.71-0.78) |
C72.8-C72.9 | Other nervous system | 375 | 75 | 0.07 | (0.07-0.08) | 174 | 35 | 0.07 | (0.06-0.08) | 201 | 40 | 0.08 | (0.07-0.09) |
C70.0-C70.9 | Meninges (cerebral & spinal) | 8,527 | 1,705 | 1.76 | (1.72-1.80) | 2,505 | 501 | 1.01 | (0.97-1.05) | 6,022 | 1,204 | 2.51 | (2.45-2.58) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 16,867 | 3,373 | 3.30 | (3.25-3.35) | 4,807 | 961 | 1.90 | (1.85-1.96) | 12,060 | 2,412 | 4.72 | (4.63-4.80) |
C75.3 | Pineal | 672 | 134 | 0.13 | (0.12-0.14) | 408 | 82 | 0.15 | (0.14-0.17) | 264 | 53 | 0.10 | (0.09-0.12) |
C30.0c | Olfactory tumors of the nasal cavity | 95 | 19 | 0.02 | (0.02-0.02) | 48 | – | 0.02 | (0.01-0.03) | 47 | – | 0.02 | (0.01-0.02) |
TOTAL | 53,083 | 10,617 | 10.47 | (10.38-10.56) | 22,168 | 4,434 | 8.67 | (8.55-8.78) | 30,915 | 6,183 | 12.28 | (12.15-12.42) |
ICD-O-3 Code . | Site . | Total . | Male . | Female . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
C71.0 | Cerebrum | 1,126 | 225 | 0.22 | (0.20-0.23) | 626 | 125 | 0.24 | (0.22-0.26) | 500 | 100 | 0.20 | (0.18-0.21) |
C71.1-C71.4 | Frontal, temporal, parietal, and occipital lobes of the brain | 10,646 | 2,129 | 2.08 | (2.04-2.12) | 5,945 | 1,189 | 2.31 | (2.25-2.37) | 4,701 | 940 | 1.85 | (1.80-1.91) |
C71.1 - Frontal lobe | 5,624 | 1,125 | 1.10 | (1.08-1.13) | 3,128 | 626 | 1.22 | (1.18-1.26) | 2,496 | 499 | 0.99 | (0.95-1.03) | |
C71.2 - Temporal lobe | 3,094 | 619 | 0.60 | (0.58-0.62) | 1,739 | 348 | 0.67 | (0.64-0.71) | 1,355 | 271 | 0.53 | (0.50-0.56) | |
C71.3 - Parietal lobe | 1,535 | 307 | 0.30 | (0.29-0.32) | 856 | 171 | 0.33 | (0.31-0.36) | 679 | 136 | 0.27 | (0.25-0.29) | |
C71.4 - Occipital lobe | 393 | 79 | 0.08 | (0.07-0.08) | 222 | 44 | 0.08 | (0.07-0.10) | 171 | 34 | 0.07 | (0.06-0.08) | |
C71.5 | Ventricle | 1,173 | 235 | 0.22 | (0.21-0.24) | 596 | 119 | 0.22 | (0.21-0.24) | 577 | 115 | 0.22 | (0.21-0.24) |
C71.6 | Cerebellum | 2,352 | 470 | 0.45 | (0.43-0.47) | 1,270 | 254 | 0.48 | (0.46-0.51) | 1,082 | 216 | 0.42 | (0.39-0.45) |
C71.7 | Brain stem | 1,359 | 272 | 0.26 | (0.25-0.27) | 702 | 140 | 0.27 | (0.25-0.29) | 657 | 131 | 0.25 | (0.24-0.27) |
C71.8-C71.9 | Other brain | 3,762 | 752 | 0.73 | (0.71-0.76) | 2,032 | 406 | 0.79 | (0.75-0.82) | 1,730 | 346 | 0.68 | (0.65-0.71) |
C72.0-C72.1 | Spinal cord and cauda equina | 2,710 | 542 | 0.53 | (0.51-0.55) | 1,488 | 298 | 0.58 | (0.55-0.61) | 1,222 | 244 | 0.48 | (0.45-0.51) |
C72.2-C72.5 | Cranial nerves | 3,419 | 684 | 0.69 | (0.66-0.71) | 1,567 | 313 | 0.63 | (0.6-0.66) | 1,852 | 370 | 0.75 | (0.71-0.78) |
C72.8-C72.9 | Other nervous system | 375 | 75 | 0.07 | (0.07-0.08) | 174 | 35 | 0.07 | (0.06-0.08) | 201 | 40 | 0.08 | (0.07-0.09) |
C70.0-C70.9 | Meninges (cerebral & spinal) | 8,527 | 1,705 | 1.76 | (1.72-1.80) | 2,505 | 501 | 1.01 | (0.97-1.05) | 6,022 | 1,204 | 2.51 | (2.45-2.58) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 16,867 | 3,373 | 3.30 | (3.25-3.35) | 4,807 | 961 | 1.90 | (1.85-1.96) | 12,060 | 2,412 | 4.72 | (4.63-4.80) |
C75.3 | Pineal | 672 | 134 | 0.13 | (0.12-0.14) | 408 | 82 | 0.15 | (0.14-0.17) | 264 | 53 | 0.10 | (0.09-0.12) |
C30.0c | Olfactory tumors of the nasal cavity | 95 | 19 | 0.02 | (0.02-0.02) | 48 | – | 0.02 | (0.01-0.03) | 47 | – | 0.02 | (0.01-0.02) |
TOTAL | 53,083 | 10,617 | 10.47 | (10.38-10.56) | 22,168 | 4,434 | 8.67 | (8.55-8.78) | 30,915 | 6,183 | 12.28 | (12.15-12.42) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age adjusted to the 2000 US standard population.
cThe sites referred to in this table are loosely based on the categories and site codes defined in the SEER site/histology validation list.
dICD-O-3 histology codes 9522-9523 only.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval.
ICD-O-3 Code . | Site . | Total . | Male . | Female . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
C71.0 | Cerebrum | 1,126 | 225 | 0.22 | (0.20-0.23) | 626 | 125 | 0.24 | (0.22-0.26) | 500 | 100 | 0.20 | (0.18-0.21) |
C71.1-C71.4 | Frontal, temporal, parietal, and occipital lobes of the brain | 10,646 | 2,129 | 2.08 | (2.04-2.12) | 5,945 | 1,189 | 2.31 | (2.25-2.37) | 4,701 | 940 | 1.85 | (1.80-1.91) |
C71.1 - Frontal lobe | 5,624 | 1,125 | 1.10 | (1.08-1.13) | 3,128 | 626 | 1.22 | (1.18-1.26) | 2,496 | 499 | 0.99 | (0.95-1.03) | |
C71.2 - Temporal lobe | 3,094 | 619 | 0.60 | (0.58-0.62) | 1,739 | 348 | 0.67 | (0.64-0.71) | 1,355 | 271 | 0.53 | (0.50-0.56) | |
C71.3 - Parietal lobe | 1,535 | 307 | 0.30 | (0.29-0.32) | 856 | 171 | 0.33 | (0.31-0.36) | 679 | 136 | 0.27 | (0.25-0.29) | |
C71.4 - Occipital lobe | 393 | 79 | 0.08 | (0.07-0.08) | 222 | 44 | 0.08 | (0.07-0.10) | 171 | 34 | 0.07 | (0.06-0.08) | |
C71.5 | Ventricle | 1,173 | 235 | 0.22 | (0.21-0.24) | 596 | 119 | 0.22 | (0.21-0.24) | 577 | 115 | 0.22 | (0.21-0.24) |
C71.6 | Cerebellum | 2,352 | 470 | 0.45 | (0.43-0.47) | 1,270 | 254 | 0.48 | (0.46-0.51) | 1,082 | 216 | 0.42 | (0.39-0.45) |
C71.7 | Brain stem | 1,359 | 272 | 0.26 | (0.25-0.27) | 702 | 140 | 0.27 | (0.25-0.29) | 657 | 131 | 0.25 | (0.24-0.27) |
C71.8-C71.9 | Other brain | 3,762 | 752 | 0.73 | (0.71-0.76) | 2,032 | 406 | 0.79 | (0.75-0.82) | 1,730 | 346 | 0.68 | (0.65-0.71) |
C72.0-C72.1 | Spinal cord and cauda equina | 2,710 | 542 | 0.53 | (0.51-0.55) | 1,488 | 298 | 0.58 | (0.55-0.61) | 1,222 | 244 | 0.48 | (0.45-0.51) |
C72.2-C72.5 | Cranial nerves | 3,419 | 684 | 0.69 | (0.66-0.71) | 1,567 | 313 | 0.63 | (0.6-0.66) | 1,852 | 370 | 0.75 | (0.71-0.78) |
C72.8-C72.9 | Other nervous system | 375 | 75 | 0.07 | (0.07-0.08) | 174 | 35 | 0.07 | (0.06-0.08) | 201 | 40 | 0.08 | (0.07-0.09) |
C70.0-C70.9 | Meninges (cerebral & spinal) | 8,527 | 1,705 | 1.76 | (1.72-1.80) | 2,505 | 501 | 1.01 | (0.97-1.05) | 6,022 | 1,204 | 2.51 | (2.45-2.58) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 16,867 | 3,373 | 3.30 | (3.25-3.35) | 4,807 | 961 | 1.90 | (1.85-1.96) | 12,060 | 2,412 | 4.72 | (4.63-4.80) |
C75.3 | Pineal | 672 | 134 | 0.13 | (0.12-0.14) | 408 | 82 | 0.15 | (0.14-0.17) | 264 | 53 | 0.10 | (0.09-0.12) |
C30.0c | Olfactory tumors of the nasal cavity | 95 | 19 | 0.02 | (0.02-0.02) | 48 | – | 0.02 | (0.01-0.03) | 47 | – | 0.02 | (0.01-0.02) |
TOTAL | 53,083 | 10,617 | 10.47 | (10.38-10.56) | 22,168 | 4,434 | 8.67 | (8.55-8.78) | 30,915 | 6,183 | 12.28 | (12.15-12.42) |
ICD-O-3 Code . | Site . | Total . | Male . | Female . | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . | 5-year total . | Annual average . | Rate . | 95% CI . |
C71.0 | Cerebrum | 1,126 | 225 | 0.22 | (0.20-0.23) | 626 | 125 | 0.24 | (0.22-0.26) | 500 | 100 | 0.20 | (0.18-0.21) |
C71.1-C71.4 | Frontal, temporal, parietal, and occipital lobes of the brain | 10,646 | 2,129 | 2.08 | (2.04-2.12) | 5,945 | 1,189 | 2.31 | (2.25-2.37) | 4,701 | 940 | 1.85 | (1.80-1.91) |
C71.1 - Frontal lobe | 5,624 | 1,125 | 1.10 | (1.08-1.13) | 3,128 | 626 | 1.22 | (1.18-1.26) | 2,496 | 499 | 0.99 | (0.95-1.03) | |
C71.2 - Temporal lobe | 3,094 | 619 | 0.60 | (0.58-0.62) | 1,739 | 348 | 0.67 | (0.64-0.71) | 1,355 | 271 | 0.53 | (0.50-0.56) | |
C71.3 - Parietal lobe | 1,535 | 307 | 0.30 | (0.29-0.32) | 856 | 171 | 0.33 | (0.31-0.36) | 679 | 136 | 0.27 | (0.25-0.29) | |
C71.4 - Occipital lobe | 393 | 79 | 0.08 | (0.07-0.08) | 222 | 44 | 0.08 | (0.07-0.10) | 171 | 34 | 0.07 | (0.06-0.08) | |
C71.5 | Ventricle | 1,173 | 235 | 0.22 | (0.21-0.24) | 596 | 119 | 0.22 | (0.21-0.24) | 577 | 115 | 0.22 | (0.21-0.24) |
C71.6 | Cerebellum | 2,352 | 470 | 0.45 | (0.43-0.47) | 1,270 | 254 | 0.48 | (0.46-0.51) | 1,082 | 216 | 0.42 | (0.39-0.45) |
C71.7 | Brain stem | 1,359 | 272 | 0.26 | (0.25-0.27) | 702 | 140 | 0.27 | (0.25-0.29) | 657 | 131 | 0.25 | (0.24-0.27) |
C71.8-C71.9 | Other brain | 3,762 | 752 | 0.73 | (0.71-0.76) | 2,032 | 406 | 0.79 | (0.75-0.82) | 1,730 | 346 | 0.68 | (0.65-0.71) |
C72.0-C72.1 | Spinal cord and cauda equina | 2,710 | 542 | 0.53 | (0.51-0.55) | 1,488 | 298 | 0.58 | (0.55-0.61) | 1,222 | 244 | 0.48 | (0.45-0.51) |
C72.2-C72.5 | Cranial nerves | 3,419 | 684 | 0.69 | (0.66-0.71) | 1,567 | 313 | 0.63 | (0.6-0.66) | 1,852 | 370 | 0.75 | (0.71-0.78) |
C72.8-C72.9 | Other nervous system | 375 | 75 | 0.07 | (0.07-0.08) | 174 | 35 | 0.07 | (0.06-0.08) | 201 | 40 | 0.08 | (0.07-0.09) |
C70.0-C70.9 | Meninges (cerebral & spinal) | 8,527 | 1,705 | 1.76 | (1.72-1.80) | 2,505 | 501 | 1.01 | (0.97-1.05) | 6,022 | 1,204 | 2.51 | (2.45-2.58) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 16,867 | 3,373 | 3.30 | (3.25-3.35) | 4,807 | 961 | 1.90 | (1.85-1.96) | 12,060 | 2,412 | 4.72 | (4.63-4.80) |
C75.3 | Pineal | 672 | 134 | 0.13 | (0.12-0.14) | 408 | 82 | 0.15 | (0.14-0.17) | 264 | 53 | 0.10 | (0.09-0.12) |
C30.0c | Olfactory tumors of the nasal cavity | 95 | 19 | 0.02 | (0.02-0.02) | 48 | – | 0.02 | (0.01-0.03) | 47 | – | 0.02 | (0.01-0.02) |
TOTAL | 53,083 | 10,617 | 10.47 | (10.38-10.56) | 22,168 | 4,434 | 8.67 | (8.55-8.78) | 30,915 | 6,183 | 12.28 | (12.15-12.42) |
aAnnual average cases are calculated by dividing the five-year total by five.
bRates are per 100,000 and are age adjusted to the 2000 US standard population.
cThe sites referred to in this table are loosely based on the categories and site codes defined in the SEER site/histology validation list.
dICD-O-3 histology codes 9522-9523 only.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology and End Results program; CI, confidence interval.
Relative Survival by Site and Year of Diagnosis
Relative survival rates for malignant tumors by site in AYA are presented in Table 12.
Five-year relative survival is highest for tumors in the pituitary and craniopharyngeal duct (87.6%), and the cranial nerves (87.6%).
Five-year relative survival is lowest for tumors in the Other nervous system (ICD-O-3 site codes C72.0-C72.9), (41.0%) and the cerebrum (ID-O-3 site code C71.0) (41.3%).
ICD-O-3 CODE . | SITEb . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.1 | Frontal lobe of the brain | 3,809 | 92.2 | (91.2-93.0) | 84.2 | (82.9-85.4) | 68.6 | (66.9-70.2) | 52.2 | (50.0-54.3) |
C71.2 | Temporal lobe of the brain | 1,751 | 92.9 | (91.5-94.0) | 82.3 | (80.4-84.1) | 67.5 | (64.9-69.9) | 52.4 | (49.3-55.5) |
C71.3 | Parietal lobe of the brain | 999 | 87.1 | (84.9-89.1) | 76.7 | (73.9-79.3) | 60.1 | (56.6-63.3) | 46.2 | (42.2-50.0) |
C71.4 | Occipital lobe of the brain | 225 | 84.9 | (79.4-89.1) | 74.6 | (68.1-80.0) | 62.1 | (54.8-68.5) | 57.4 | (49.3-64.8) |
C71.0 | Cerebrum | 722 | 74.1 | (70.6-77.2) | 58.5 | (54.6-62.1) | 41.3 | (37.3-45.3) | 33.9 | (29.6-38.3) |
C71.5 | Ventricle | 371 | 87.7 | (83.9-90.8) | 83.5 | (79.2-87.1) | 77.8 | (72.8-82.0) | 74.8 | (69.2-79.5) |
C71.6 | Cerebellum | 1,138 | 91.0 | (89.2-92.6) | 87.5 | (85.3-89.3) | 79.0 | (76.2-81.5) | 73.3 | (70.0-76.2) |
C71.7 | Brain stem | 831 | 83.1 | (80.3-85.5) | 70.9 | (67.5-74.0) | 59.6 | (55.9-63.2) | 52.1 | (47.8-56.2) |
C71.8-C71.9 | Other brain | 2,174 | 77.0 | (75.2-78.8) | 66.3 | (64.2-68.3) | 52.3 | (50.0-54.6) | 41.3 | (38.8-43.8) |
C72.0-C72.1 | Spinal cord and cauda equina | 754 | 92.1 | (89.8-93.8) | 86.4 | (83.6-88.8) | 80.5 | (77.2-83.4) | 76.9 | (72.9-80.4) |
C72.2-C72.5 | Cranial nerves | 103 | 93.1 | (85.9-96.7) | 92.1 | (84.6-96.0) | 87.4 | (78.5-92.8) | 85.8 | (75.6-91.9) |
C72.8-C72.9 | Other nervous system | 133 | 58.2 | (49.2-66.2) | 44.7 | (35.8-53.2) | 41.0 | (32.1-49.7) | 35.5 | (26.2-44.9) |
C70.0-C70.9 | Meninges (cerebral and spinal) | 158 | 92.3 | (86.7-95.6) | 88.9 | (82.6-93.0) | 83.1 | (75.6-88.4) | 80.5 | (72.5-86.3) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 81 | 96.3 | (88.7-98.8) | 96.3 | (88.7-98.8) | 87.6 | (77.0-93.5) | 83.2 | (70.2-90.9) |
C75.3 | Pineal | 367 | 90.1 | (86.5-92.8) | 85.0 | (80.7-88.4) | 78.5 | (73.5-82.8) | 74.4 | (68.4-79.5) |
C30.0d | Olfactory tumors of the nasal cavity | 85 | 95.3 | (87.7-98.3) | 92.9 | (84.6-96.8) | 85.7 | (75.1-92.0) | 70.5 | (52.6-82.7) |
All Codes | All Sites | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
ICD-O-3 CODE . | SITEb . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.1 | Frontal lobe of the brain | 3,809 | 92.2 | (91.2-93.0) | 84.2 | (82.9-85.4) | 68.6 | (66.9-70.2) | 52.2 | (50.0-54.3) |
C71.2 | Temporal lobe of the brain | 1,751 | 92.9 | (91.5-94.0) | 82.3 | (80.4-84.1) | 67.5 | (64.9-69.9) | 52.4 | (49.3-55.5) |
C71.3 | Parietal lobe of the brain | 999 | 87.1 | (84.9-89.1) | 76.7 | (73.9-79.3) | 60.1 | (56.6-63.3) | 46.2 | (42.2-50.0) |
C71.4 | Occipital lobe of the brain | 225 | 84.9 | (79.4-89.1) | 74.6 | (68.1-80.0) | 62.1 | (54.8-68.5) | 57.4 | (49.3-64.8) |
C71.0 | Cerebrum | 722 | 74.1 | (70.6-77.2) | 58.5 | (54.6-62.1) | 41.3 | (37.3-45.3) | 33.9 | (29.6-38.3) |
C71.5 | Ventricle | 371 | 87.7 | (83.9-90.8) | 83.5 | (79.2-87.1) | 77.8 | (72.8-82.0) | 74.8 | (69.2-79.5) |
C71.6 | Cerebellum | 1,138 | 91.0 | (89.2-92.6) | 87.5 | (85.3-89.3) | 79.0 | (76.2-81.5) | 73.3 | (70.0-76.2) |
C71.7 | Brain stem | 831 | 83.1 | (80.3-85.5) | 70.9 | (67.5-74.0) | 59.6 | (55.9-63.2) | 52.1 | (47.8-56.2) |
C71.8-C71.9 | Other brain | 2,174 | 77.0 | (75.2-78.8) | 66.3 | (64.2-68.3) | 52.3 | (50.0-54.6) | 41.3 | (38.8-43.8) |
C72.0-C72.1 | Spinal cord and cauda equina | 754 | 92.1 | (89.8-93.8) | 86.4 | (83.6-88.8) | 80.5 | (77.2-83.4) | 76.9 | (72.9-80.4) |
C72.2-C72.5 | Cranial nerves | 103 | 93.1 | (85.9-96.7) | 92.1 | (84.6-96.0) | 87.4 | (78.5-92.8) | 85.8 | (75.6-91.9) |
C72.8-C72.9 | Other nervous system | 133 | 58.2 | (49.2-66.2) | 44.7 | (35.8-53.2) | 41.0 | (32.1-49.7) | 35.5 | (26.2-44.9) |
C70.0-C70.9 | Meninges (cerebral and spinal) | 158 | 92.3 | (86.7-95.6) | 88.9 | (82.6-93.0) | 83.1 | (75.6-88.4) | 80.5 | (72.5-86.3) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 81 | 96.3 | (88.7-98.8) | 96.3 | (88.7-98.8) | 87.6 | (77.0-93.5) | 83.2 | (70.2-90.9) |
C75.3 | Pineal | 367 | 90.1 | (86.5-92.8) | 85.0 | (80.7-88.4) | 78.5 | (73.5-82.8) | 74.4 | (68.4-79.5) |
C30.0d | Olfactory tumors of the nasal cavity | 85 | 95.3 | (87.7-98.3) | 92.9 | (84.6-96.8) | 85.7 | (75.1-92.0) | 70.5 | (52.6-82.7) |
All Codes | All Sites | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bThe sites referred to in this table are loosely based on the categories and site codes defined in the SEER Site/Histology Validation List.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dICD-O-3 histology codes 9522-9523 only.
Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973-2011 varying) - Linked To County Attributes - Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval.
ICD-O-3 CODE . | SITEb . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.1 | Frontal lobe of the brain | 3,809 | 92.2 | (91.2-93.0) | 84.2 | (82.9-85.4) | 68.6 | (66.9-70.2) | 52.2 | (50.0-54.3) |
C71.2 | Temporal lobe of the brain | 1,751 | 92.9 | (91.5-94.0) | 82.3 | (80.4-84.1) | 67.5 | (64.9-69.9) | 52.4 | (49.3-55.5) |
C71.3 | Parietal lobe of the brain | 999 | 87.1 | (84.9-89.1) | 76.7 | (73.9-79.3) | 60.1 | (56.6-63.3) | 46.2 | (42.2-50.0) |
C71.4 | Occipital lobe of the brain | 225 | 84.9 | (79.4-89.1) | 74.6 | (68.1-80.0) | 62.1 | (54.8-68.5) | 57.4 | (49.3-64.8) |
C71.0 | Cerebrum | 722 | 74.1 | (70.6-77.2) | 58.5 | (54.6-62.1) | 41.3 | (37.3-45.3) | 33.9 | (29.6-38.3) |
C71.5 | Ventricle | 371 | 87.7 | (83.9-90.8) | 83.5 | (79.2-87.1) | 77.8 | (72.8-82.0) | 74.8 | (69.2-79.5) |
C71.6 | Cerebellum | 1,138 | 91.0 | (89.2-92.6) | 87.5 | (85.3-89.3) | 79.0 | (76.2-81.5) | 73.3 | (70.0-76.2) |
C71.7 | Brain stem | 831 | 83.1 | (80.3-85.5) | 70.9 | (67.5-74.0) | 59.6 | (55.9-63.2) | 52.1 | (47.8-56.2) |
C71.8-C71.9 | Other brain | 2,174 | 77.0 | (75.2-78.8) | 66.3 | (64.2-68.3) | 52.3 | (50.0-54.6) | 41.3 | (38.8-43.8) |
C72.0-C72.1 | Spinal cord and cauda equina | 754 | 92.1 | (89.8-93.8) | 86.4 | (83.6-88.8) | 80.5 | (77.2-83.4) | 76.9 | (72.9-80.4) |
C72.2-C72.5 | Cranial nerves | 103 | 93.1 | (85.9-96.7) | 92.1 | (84.6-96.0) | 87.4 | (78.5-92.8) | 85.8 | (75.6-91.9) |
C72.8-C72.9 | Other nervous system | 133 | 58.2 | (49.2-66.2) | 44.7 | (35.8-53.2) | 41.0 | (32.1-49.7) | 35.5 | (26.2-44.9) |
C70.0-C70.9 | Meninges (cerebral and spinal) | 158 | 92.3 | (86.7-95.6) | 88.9 | (82.6-93.0) | 83.1 | (75.6-88.4) | 80.5 | (72.5-86.3) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 81 | 96.3 | (88.7-98.8) | 96.3 | (88.7-98.8) | 87.6 | (77.0-93.5) | 83.2 | (70.2-90.9) |
C75.3 | Pineal | 367 | 90.1 | (86.5-92.8) | 85.0 | (80.7-88.4) | 78.5 | (73.5-82.8) | 74.4 | (68.4-79.5) |
C30.0d | Olfactory tumors of the nasal cavity | 85 | 95.3 | (87.7-98.3) | 92.9 | (84.6-96.8) | 85.7 | (75.1-92.0) | 70.5 | (52.6-82.7) |
All Codes | All Sites | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
ICD-O-3 CODE . | SITEb . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.1 | Frontal lobe of the brain | 3,809 | 92.2 | (91.2-93.0) | 84.2 | (82.9-85.4) | 68.6 | (66.9-70.2) | 52.2 | (50.0-54.3) |
C71.2 | Temporal lobe of the brain | 1,751 | 92.9 | (91.5-94.0) | 82.3 | (80.4-84.1) | 67.5 | (64.9-69.9) | 52.4 | (49.3-55.5) |
C71.3 | Parietal lobe of the brain | 999 | 87.1 | (84.9-89.1) | 76.7 | (73.9-79.3) | 60.1 | (56.6-63.3) | 46.2 | (42.2-50.0) |
C71.4 | Occipital lobe of the brain | 225 | 84.9 | (79.4-89.1) | 74.6 | (68.1-80.0) | 62.1 | (54.8-68.5) | 57.4 | (49.3-64.8) |
C71.0 | Cerebrum | 722 | 74.1 | (70.6-77.2) | 58.5 | (54.6-62.1) | 41.3 | (37.3-45.3) | 33.9 | (29.6-38.3) |
C71.5 | Ventricle | 371 | 87.7 | (83.9-90.8) | 83.5 | (79.2-87.1) | 77.8 | (72.8-82.0) | 74.8 | (69.2-79.5) |
C71.6 | Cerebellum | 1,138 | 91.0 | (89.2-92.6) | 87.5 | (85.3-89.3) | 79.0 | (76.2-81.5) | 73.3 | (70.0-76.2) |
C71.7 | Brain stem | 831 | 83.1 | (80.3-85.5) | 70.9 | (67.5-74.0) | 59.6 | (55.9-63.2) | 52.1 | (47.8-56.2) |
C71.8-C71.9 | Other brain | 2,174 | 77.0 | (75.2-78.8) | 66.3 | (64.2-68.3) | 52.3 | (50.0-54.6) | 41.3 | (38.8-43.8) |
C72.0-C72.1 | Spinal cord and cauda equina | 754 | 92.1 | (89.8-93.8) | 86.4 | (83.6-88.8) | 80.5 | (77.2-83.4) | 76.9 | (72.9-80.4) |
C72.2-C72.5 | Cranial nerves | 103 | 93.1 | (85.9-96.7) | 92.1 | (84.6-96.0) | 87.4 | (78.5-92.8) | 85.8 | (75.6-91.9) |
C72.8-C72.9 | Other nervous system | 133 | 58.2 | (49.2-66.2) | 44.7 | (35.8-53.2) | 41.0 | (32.1-49.7) | 35.5 | (26.2-44.9) |
C70.0-C70.9 | Meninges (cerebral and spinal) | 158 | 92.3 | (86.7-95.6) | 88.9 | (82.6-93.0) | 83.1 | (75.6-88.4) | 80.5 | (72.5-86.3) |
C75.1-C75.2 | Pituitary and craniopharyngeal duct | 81 | 96.3 | (88.7-98.8) | 96.3 | (88.7-98.8) | 87.6 | (77.0-93.5) | 83.2 | (70.2-90.9) |
C75.3 | Pineal | 367 | 90.1 | (86.5-92.8) | 85.0 | (80.7-88.4) | 78.5 | (73.5-82.8) | 74.4 | (68.4-79.5) |
C30.0d | Olfactory tumors of the nasal cavity | 85 | 95.3 | (87.7-98.3) | 92.9 | (84.6-96.8) | 85.7 | (75.1-92.0) | 70.5 | (52.6-82.7) |
All Codes | All Sites | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bThe sites referred to in this table are loosely based on the categories and site codes defined in the SEER Site/Histology Validation List.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dICD-O-3 histology codes 9522-9523 only.
Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973-2011 varying) - Linked To County Attributes - Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval.
Relative survival rates for malignant tumors by site and 5-year groups in AYA are shown in Table 13. Relative survival rates have improved significantly over time for all sites.
Ten-year relative survival for tumors diagnosed supratentorially (frontal, temporal, occipital, or parietal lobes of the brain or the cerebrum) have increased from 25.5% in 1973-1977, to 52.0% in 2003-2007 in adolescents and young adults (age 15-39 years).
Ten-year relative survival for tumors diagnosed in the brain stem have increased from 29.9% in 1978-1982 to 48.8% in 2003-2007 in AYA.
ICD-O-3 Code . | Siteb . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|---|
. | . | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.0-C71.4 | Supratentorial | 1973-1977 | 412 | 78.3 | (73.9-81.9) | 37.4 | (32.7-42.1) | 25.5 | (21.3-29.8) |
1978-1982 | 612 | 83.1 | (79.9-85.9) | 46.7 | (42.6-50.6) | 31.9 | (28.2-35.7) | ||
1983-1987 | 801 | 85.4 | (82.7-87.7) | 54.1 | (50.6-57.5) | 38.8 | (35.3-42.2) | ||
1988-1992 | 979 | 80.2 | (77.5-82.5) | 51.7 | (48.5-54.8) | 42.1 | (38.9-45.2) | ||
1993-1997 | 1,292 | 77.4 | (75.0-79.6) | 55.8 | (53.0-58.5) | 43.0 | (40.3-45.8) | ||
1998-2002 | 1,925 | 88.1 | (86.6-89.5) | 61.9 | (59.7-64.1) | 47.7 | (45.4-50.0) | ||
2003-2007 | 2,397 | 91.0 | (89.8-92.1) | 65.2 | (63.2-67.1) | 52.0 | (49.2-54.8) | ||
2008-2012 | 2,429 | 93.5 | (92.3-94.4) | 71.2 | (67.8-74.3) | – | – | ||
C71.5 | Ventricle, NOS | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | ||
1983-1987 | 53 | 81.2 | (67.8-89.5) | 66.5 | (52.0-77.6) | 64.8 | (50.2-76.1) | ||
1988-1992 | 63 | 85.7 | (74.2-92.3) | 76.4 | (63.6-85.2) | 71.9 | (58.7-81.6) | ||
1993-1997 | 62 | 79.1 | (66.7-87.3) | 64.9 | (51.5-75.4) | 63.3 | (50.0-74.0) | ||
1998-2002 | 89 | 82.9 | (73.2-89.4) | 72.6 | (61.8-80.8) | 71.6 | (60.7-80.0) | ||
2003-2007 | 124 | 92.0 | (85.5-95.6) | 80.7 | (72.4-86.7) | – | – | ||
2008-2012 | 126 | 87.8 | (80.2-92.6) | 75.2 | (52.7-88.1) | – | – | ||
C71.6 | Cerebellum, NOS | 1973-1977 | 90 | 86.8 | (77.8-92.3) | 57.0 | (46.1-66.6) | 50.5 | (39.7-60.4) |
1978-1982 | 123 | 86.3 | (78.8-91.3) | 67.0 | (57.9-74.7) | 60.9 | (51.5-69.0) | ||
1983-1987 | 113 | 89.5 | (82.1-93.9) | 75.8 | (66.6-82.7) | 66.5 | (56.8-74.6) | ||
1988-1992 | 153 | 81.8 | (74.7-87.1) | 66.4 | (58.2-73.4) | 60.6 | (52.2-67.9) | ||
1993-1997 | 168 | 85.2 | (78.9-89.8) | 71.3 | (63.7-77.6) | 62.6 | (54.7-69.5) | ||
1998-2002 | 292 | 90.8 | (86.8-93.6) | 78.5 | (73.2-82.9) | 75.2 | (69.7-79.9) | ||
2003-2007 | 373 | 92.2 | (89.0-94.6) | 81.7 | (77.3-85.4) | – | – | ||
2008-2012 | 375 | 92.1 | (88.6-94.6) | – | – | – | – | ||
C71.7 | Brain stem | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 62 | 61.4 | (48.1-72.2) | 43.9 | (31.3-55.7) | 29.9 | (17.2-43.8) | ||
1983-1987 | 75 | 73.4 | (61.8-82.0) | 60.3 | (48.2-70.4) | 32.8 | (21.4-44.6) | ||
1988-1992 | 101 | 70.2 | (60.2-78.2) | 53.5 | (43.2-62.7) | 51.2 | (39.2-62.0) | ||
1993-1997 | 120 | 81.7 | (73.5-87.6) | 59.7 | (50.2-68.0) | 45.8 | (35.7-55.3) | ||
1998-2002 | 191 | 83.2 | (77.1-87.9) | 57.9 | (50.5-64.7) | 53.2 | (43.6-61.9) | ||
2003-2007 | 269 | 82.4 | (77.3-86.5) | 59.3 | (53.1-65.0) | 48.8 | (41.4-55.9) | ||
2008-2012 | 291 | 84.5 | (79.5-88.3) | – | – | – | – | ||
C71.8-C71.9 | Other Brain | 1973-1977 | 213 | 78.0 | (71.8-83.0) | 49.1 | (42.2-55.7) | 40.3 | (33.6-46.9) |
1978-1982 | 215 | 78.3 | (72.1-83.2) | 49.9 | (43.0-56.4) | 32.0 | (25.7-38.4) | ||
1983-1987 | 251 | 77.0 | (71.2-81.7) | 43.1 | (36.9-49.2) | 31.6 | (25.9-37.5) | ||
1988-1992 | 410 | 56.8 | (51.9-61.5) | 35.0 | (30.4-39.7) | 25.5 | (21.3-29.8) | ||
1993-1997 | 560 | 53.5 | (49.3-57.5) | 34.9 | (30.9-38.9) | 25.7 | (22.1-29.4) | ||
1998-2002 | 604 | 78.9 | (75.4-82.0) | 49.8 | (45.7-53.8) | 39.6 | (35.6-43.6) | ||
2003-2007 | 655 | 81.6 | (78.4-84.4) | 59.3 | (55.3-63.0) | – | – | ||
2008-2012 | 592 | 81.4 | (77.9-84.5) | 54.8 | (47.7-61.3) | – | – | ||
C70.0-C70.9, C72.0-C72.9 C75.1-C75.3 C30.0d | Other Nervous System | 1973-1977 | 97 | 84.7 | (75.8-90.5) | 67.4 | (57.0-75.8) | 59.5 | (48.9-68.6) |
1978-1982 | 140 | 87.9 | (81.2-92.4) | 66.0 | (57.3-73.2) | 59.9 | (51.1-67.7) | ||
1983-1987 | 151 | 87.4 | (80.9-91.8) | 68.9 | (60.6-75.7) | 67.9 | (59.5-74.9) | ||
1988-1992 | 192 | 78.2 | (71.6-83.4) | 64.3 | (57.0-70.7) | 59.5 | (52.0-66.2) | ||
1993-1997 | 262 | 79.5 | (74.0-83.9) | 68.3 | (62.2-73.6) | 65.6 | (59.3-71.1) | ||
1998-2002 | 400 | 87.5 | (83.9-90.4) | 74.1 | (69.5-78.2) | 71.0 | (66.1-75.3) | ||
2003-2007 | 503 | 90.1 | (87.1-92.4) | 81.3 | (77.6-84.6) | – | – | ||
2008-2012 | 534 | 92.1 | (89.3-94.2) | 79.9 | (73.6-84.8) | – | – | ||
All Codes | All Sites | 1973-1997 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | ||
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | ||
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | ||
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | ||
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | ||
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | ||
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
ICD-O-3 Code . | Siteb . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|---|
. | . | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.0-C71.4 | Supratentorial | 1973-1977 | 412 | 78.3 | (73.9-81.9) | 37.4 | (32.7-42.1) | 25.5 | (21.3-29.8) |
1978-1982 | 612 | 83.1 | (79.9-85.9) | 46.7 | (42.6-50.6) | 31.9 | (28.2-35.7) | ||
1983-1987 | 801 | 85.4 | (82.7-87.7) | 54.1 | (50.6-57.5) | 38.8 | (35.3-42.2) | ||
1988-1992 | 979 | 80.2 | (77.5-82.5) | 51.7 | (48.5-54.8) | 42.1 | (38.9-45.2) | ||
1993-1997 | 1,292 | 77.4 | (75.0-79.6) | 55.8 | (53.0-58.5) | 43.0 | (40.3-45.8) | ||
1998-2002 | 1,925 | 88.1 | (86.6-89.5) | 61.9 | (59.7-64.1) | 47.7 | (45.4-50.0) | ||
2003-2007 | 2,397 | 91.0 | (89.8-92.1) | 65.2 | (63.2-67.1) | 52.0 | (49.2-54.8) | ||
2008-2012 | 2,429 | 93.5 | (92.3-94.4) | 71.2 | (67.8-74.3) | – | – | ||
C71.5 | Ventricle, NOS | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | ||
1983-1987 | 53 | 81.2 | (67.8-89.5) | 66.5 | (52.0-77.6) | 64.8 | (50.2-76.1) | ||
1988-1992 | 63 | 85.7 | (74.2-92.3) | 76.4 | (63.6-85.2) | 71.9 | (58.7-81.6) | ||
1993-1997 | 62 | 79.1 | (66.7-87.3) | 64.9 | (51.5-75.4) | 63.3 | (50.0-74.0) | ||
1998-2002 | 89 | 82.9 | (73.2-89.4) | 72.6 | (61.8-80.8) | 71.6 | (60.7-80.0) | ||
2003-2007 | 124 | 92.0 | (85.5-95.6) | 80.7 | (72.4-86.7) | – | – | ||
2008-2012 | 126 | 87.8 | (80.2-92.6) | 75.2 | (52.7-88.1) | – | – | ||
C71.6 | Cerebellum, NOS | 1973-1977 | 90 | 86.8 | (77.8-92.3) | 57.0 | (46.1-66.6) | 50.5 | (39.7-60.4) |
1978-1982 | 123 | 86.3 | (78.8-91.3) | 67.0 | (57.9-74.7) | 60.9 | (51.5-69.0) | ||
1983-1987 | 113 | 89.5 | (82.1-93.9) | 75.8 | (66.6-82.7) | 66.5 | (56.8-74.6) | ||
1988-1992 | 153 | 81.8 | (74.7-87.1) | 66.4 | (58.2-73.4) | 60.6 | (52.2-67.9) | ||
1993-1997 | 168 | 85.2 | (78.9-89.8) | 71.3 | (63.7-77.6) | 62.6 | (54.7-69.5) | ||
1998-2002 | 292 | 90.8 | (86.8-93.6) | 78.5 | (73.2-82.9) | 75.2 | (69.7-79.9) | ||
2003-2007 | 373 | 92.2 | (89.0-94.6) | 81.7 | (77.3-85.4) | – | – | ||
2008-2012 | 375 | 92.1 | (88.6-94.6) | – | – | – | – | ||
C71.7 | Brain stem | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 62 | 61.4 | (48.1-72.2) | 43.9 | (31.3-55.7) | 29.9 | (17.2-43.8) | ||
1983-1987 | 75 | 73.4 | (61.8-82.0) | 60.3 | (48.2-70.4) | 32.8 | (21.4-44.6) | ||
1988-1992 | 101 | 70.2 | (60.2-78.2) | 53.5 | (43.2-62.7) | 51.2 | (39.2-62.0) | ||
1993-1997 | 120 | 81.7 | (73.5-87.6) | 59.7 | (50.2-68.0) | 45.8 | (35.7-55.3) | ||
1998-2002 | 191 | 83.2 | (77.1-87.9) | 57.9 | (50.5-64.7) | 53.2 | (43.6-61.9) | ||
2003-2007 | 269 | 82.4 | (77.3-86.5) | 59.3 | (53.1-65.0) | 48.8 | (41.4-55.9) | ||
2008-2012 | 291 | 84.5 | (79.5-88.3) | – | – | – | – | ||
C71.8-C71.9 | Other Brain | 1973-1977 | 213 | 78.0 | (71.8-83.0) | 49.1 | (42.2-55.7) | 40.3 | (33.6-46.9) |
1978-1982 | 215 | 78.3 | (72.1-83.2) | 49.9 | (43.0-56.4) | 32.0 | (25.7-38.4) | ||
1983-1987 | 251 | 77.0 | (71.2-81.7) | 43.1 | (36.9-49.2) | 31.6 | (25.9-37.5) | ||
1988-1992 | 410 | 56.8 | (51.9-61.5) | 35.0 | (30.4-39.7) | 25.5 | (21.3-29.8) | ||
1993-1997 | 560 | 53.5 | (49.3-57.5) | 34.9 | (30.9-38.9) | 25.7 | (22.1-29.4) | ||
1998-2002 | 604 | 78.9 | (75.4-82.0) | 49.8 | (45.7-53.8) | 39.6 | (35.6-43.6) | ||
2003-2007 | 655 | 81.6 | (78.4-84.4) | 59.3 | (55.3-63.0) | – | – | ||
2008-2012 | 592 | 81.4 | (77.9-84.5) | 54.8 | (47.7-61.3) | – | – | ||
C70.0-C70.9, C72.0-C72.9 C75.1-C75.3 C30.0d | Other Nervous System | 1973-1977 | 97 | 84.7 | (75.8-90.5) | 67.4 | (57.0-75.8) | 59.5 | (48.9-68.6) |
1978-1982 | 140 | 87.9 | (81.2-92.4) | 66.0 | (57.3-73.2) | 59.9 | (51.1-67.7) | ||
1983-1987 | 151 | 87.4 | (80.9-91.8) | 68.9 | (60.6-75.7) | 67.9 | (59.5-74.9) | ||
1988-1992 | 192 | 78.2 | (71.6-83.4) | 64.3 | (57.0-70.7) | 59.5 | (52.0-66.2) | ||
1993-1997 | 262 | 79.5 | (74.0-83.9) | 68.3 | (62.2-73.6) | 65.6 | (59.3-71.1) | ||
1998-2002 | 400 | 87.5 | (83.9-90.4) | 74.1 | (69.5-78.2) | 71.0 | (66.1-75.3) | ||
2003-2007 | 503 | 90.1 | (87.1-92.4) | 81.3 | (77.6-84.6) | – | – | ||
2008-2012 | 534 | 92.1 | (89.3-94.2) | 79.9 | (73.6-84.8) | – | – | ||
All Codes | All Sites | 1973-1997 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | ||
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | ||
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | ||
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | ||
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | ||
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | ||
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bThe sites referred to in this table are loosely based on the categories and site codes defined in the SEER Site/Histology Validation List.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) – Linked To County Attributes – Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2014 submission.
dICD-O-3 histology codes 9522-9523 only.
– Rates are excluded when calculated based on a population of less than 50, when less than 16 remain alive in the survival period, or when not enough follow up time has passed to calculate survival for the listed period.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval.
ICD-O-3 Code . | Siteb . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|---|
. | . | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.0-C71.4 | Supratentorial | 1973-1977 | 412 | 78.3 | (73.9-81.9) | 37.4 | (32.7-42.1) | 25.5 | (21.3-29.8) |
1978-1982 | 612 | 83.1 | (79.9-85.9) | 46.7 | (42.6-50.6) | 31.9 | (28.2-35.7) | ||
1983-1987 | 801 | 85.4 | (82.7-87.7) | 54.1 | (50.6-57.5) | 38.8 | (35.3-42.2) | ||
1988-1992 | 979 | 80.2 | (77.5-82.5) | 51.7 | (48.5-54.8) | 42.1 | (38.9-45.2) | ||
1993-1997 | 1,292 | 77.4 | (75.0-79.6) | 55.8 | (53.0-58.5) | 43.0 | (40.3-45.8) | ||
1998-2002 | 1,925 | 88.1 | (86.6-89.5) | 61.9 | (59.7-64.1) | 47.7 | (45.4-50.0) | ||
2003-2007 | 2,397 | 91.0 | (89.8-92.1) | 65.2 | (63.2-67.1) | 52.0 | (49.2-54.8) | ||
2008-2012 | 2,429 | 93.5 | (92.3-94.4) | 71.2 | (67.8-74.3) | – | – | ||
C71.5 | Ventricle, NOS | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | ||
1983-1987 | 53 | 81.2 | (67.8-89.5) | 66.5 | (52.0-77.6) | 64.8 | (50.2-76.1) | ||
1988-1992 | 63 | 85.7 | (74.2-92.3) | 76.4 | (63.6-85.2) | 71.9 | (58.7-81.6) | ||
1993-1997 | 62 | 79.1 | (66.7-87.3) | 64.9 | (51.5-75.4) | 63.3 | (50.0-74.0) | ||
1998-2002 | 89 | 82.9 | (73.2-89.4) | 72.6 | (61.8-80.8) | 71.6 | (60.7-80.0) | ||
2003-2007 | 124 | 92.0 | (85.5-95.6) | 80.7 | (72.4-86.7) | – | – | ||
2008-2012 | 126 | 87.8 | (80.2-92.6) | 75.2 | (52.7-88.1) | – | – | ||
C71.6 | Cerebellum, NOS | 1973-1977 | 90 | 86.8 | (77.8-92.3) | 57.0 | (46.1-66.6) | 50.5 | (39.7-60.4) |
1978-1982 | 123 | 86.3 | (78.8-91.3) | 67.0 | (57.9-74.7) | 60.9 | (51.5-69.0) | ||
1983-1987 | 113 | 89.5 | (82.1-93.9) | 75.8 | (66.6-82.7) | 66.5 | (56.8-74.6) | ||
1988-1992 | 153 | 81.8 | (74.7-87.1) | 66.4 | (58.2-73.4) | 60.6 | (52.2-67.9) | ||
1993-1997 | 168 | 85.2 | (78.9-89.8) | 71.3 | (63.7-77.6) | 62.6 | (54.7-69.5) | ||
1998-2002 | 292 | 90.8 | (86.8-93.6) | 78.5 | (73.2-82.9) | 75.2 | (69.7-79.9) | ||
2003-2007 | 373 | 92.2 | (89.0-94.6) | 81.7 | (77.3-85.4) | – | – | ||
2008-2012 | 375 | 92.1 | (88.6-94.6) | – | – | – | – | ||
C71.7 | Brain stem | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 62 | 61.4 | (48.1-72.2) | 43.9 | (31.3-55.7) | 29.9 | (17.2-43.8) | ||
1983-1987 | 75 | 73.4 | (61.8-82.0) | 60.3 | (48.2-70.4) | 32.8 | (21.4-44.6) | ||
1988-1992 | 101 | 70.2 | (60.2-78.2) | 53.5 | (43.2-62.7) | 51.2 | (39.2-62.0) | ||
1993-1997 | 120 | 81.7 | (73.5-87.6) | 59.7 | (50.2-68.0) | 45.8 | (35.7-55.3) | ||
1998-2002 | 191 | 83.2 | (77.1-87.9) | 57.9 | (50.5-64.7) | 53.2 | (43.6-61.9) | ||
2003-2007 | 269 | 82.4 | (77.3-86.5) | 59.3 | (53.1-65.0) | 48.8 | (41.4-55.9) | ||
2008-2012 | 291 | 84.5 | (79.5-88.3) | – | – | – | – | ||
C71.8-C71.9 | Other Brain | 1973-1977 | 213 | 78.0 | (71.8-83.0) | 49.1 | (42.2-55.7) | 40.3 | (33.6-46.9) |
1978-1982 | 215 | 78.3 | (72.1-83.2) | 49.9 | (43.0-56.4) | 32.0 | (25.7-38.4) | ||
1983-1987 | 251 | 77.0 | (71.2-81.7) | 43.1 | (36.9-49.2) | 31.6 | (25.9-37.5) | ||
1988-1992 | 410 | 56.8 | (51.9-61.5) | 35.0 | (30.4-39.7) | 25.5 | (21.3-29.8) | ||
1993-1997 | 560 | 53.5 | (49.3-57.5) | 34.9 | (30.9-38.9) | 25.7 | (22.1-29.4) | ||
1998-2002 | 604 | 78.9 | (75.4-82.0) | 49.8 | (45.7-53.8) | 39.6 | (35.6-43.6) | ||
2003-2007 | 655 | 81.6 | (78.4-84.4) | 59.3 | (55.3-63.0) | – | – | ||
2008-2012 | 592 | 81.4 | (77.9-84.5) | 54.8 | (47.7-61.3) | – | – | ||
C70.0-C70.9, C72.0-C72.9 C75.1-C75.3 C30.0d | Other Nervous System | 1973-1977 | 97 | 84.7 | (75.8-90.5) | 67.4 | (57.0-75.8) | 59.5 | (48.9-68.6) |
1978-1982 | 140 | 87.9 | (81.2-92.4) | 66.0 | (57.3-73.2) | 59.9 | (51.1-67.7) | ||
1983-1987 | 151 | 87.4 | (80.9-91.8) | 68.9 | (60.6-75.7) | 67.9 | (59.5-74.9) | ||
1988-1992 | 192 | 78.2 | (71.6-83.4) | 64.3 | (57.0-70.7) | 59.5 | (52.0-66.2) | ||
1993-1997 | 262 | 79.5 | (74.0-83.9) | 68.3 | (62.2-73.6) | 65.6 | (59.3-71.1) | ||
1998-2002 | 400 | 87.5 | (83.9-90.4) | 74.1 | (69.5-78.2) | 71.0 | (66.1-75.3) | ||
2003-2007 | 503 | 90.1 | (87.1-92.4) | 81.3 | (77.6-84.6) | – | – | ||
2008-2012 | 534 | 92.1 | (89.3-94.2) | 79.9 | (73.6-84.8) | – | – | ||
All Codes | All Sites | 1973-1997 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | ||
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | ||
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | ||
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | ||
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | ||
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | ||
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
ICD-O-3 Code . | Siteb . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|---|
. | . | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
C71.0-C71.4 | Supratentorial | 1973-1977 | 412 | 78.3 | (73.9-81.9) | 37.4 | (32.7-42.1) | 25.5 | (21.3-29.8) |
1978-1982 | 612 | 83.1 | (79.9-85.9) | 46.7 | (42.6-50.6) | 31.9 | (28.2-35.7) | ||
1983-1987 | 801 | 85.4 | (82.7-87.7) | 54.1 | (50.6-57.5) | 38.8 | (35.3-42.2) | ||
1988-1992 | 979 | 80.2 | (77.5-82.5) | 51.7 | (48.5-54.8) | 42.1 | (38.9-45.2) | ||
1993-1997 | 1,292 | 77.4 | (75.0-79.6) | 55.8 | (53.0-58.5) | 43.0 | (40.3-45.8) | ||
1998-2002 | 1,925 | 88.1 | (86.6-89.5) | 61.9 | (59.7-64.1) | 47.7 | (45.4-50.0) | ||
2003-2007 | 2,397 | 91.0 | (89.8-92.1) | 65.2 | (63.2-67.1) | 52.0 | (49.2-54.8) | ||
2008-2012 | 2,429 | 93.5 | (92.3-94.4) | 71.2 | (67.8-74.3) | – | – | ||
C71.5 | Ventricle, NOS | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | ||
1983-1987 | 53 | 81.2 | (67.8-89.5) | 66.5 | (52.0-77.6) | 64.8 | (50.2-76.1) | ||
1988-1992 | 63 | 85.7 | (74.2-92.3) | 76.4 | (63.6-85.2) | 71.9 | (58.7-81.6) | ||
1993-1997 | 62 | 79.1 | (66.7-87.3) | 64.9 | (51.5-75.4) | 63.3 | (50.0-74.0) | ||
1998-2002 | 89 | 82.9 | (73.2-89.4) | 72.6 | (61.8-80.8) | 71.6 | (60.7-80.0) | ||
2003-2007 | 124 | 92.0 | (85.5-95.6) | 80.7 | (72.4-86.7) | – | – | ||
2008-2012 | 126 | 87.8 | (80.2-92.6) | 75.2 | (52.7-88.1) | – | – | ||
C71.6 | Cerebellum, NOS | 1973-1977 | 90 | 86.8 | (77.8-92.3) | 57.0 | (46.1-66.6) | 50.5 | (39.7-60.4) |
1978-1982 | 123 | 86.3 | (78.8-91.3) | 67.0 | (57.9-74.7) | 60.9 | (51.5-69.0) | ||
1983-1987 | 113 | 89.5 | (82.1-93.9) | 75.8 | (66.6-82.7) | 66.5 | (56.8-74.6) | ||
1988-1992 | 153 | 81.8 | (74.7-87.1) | 66.4 | (58.2-73.4) | 60.6 | (52.2-67.9) | ||
1993-1997 | 168 | 85.2 | (78.9-89.8) | 71.3 | (63.7-77.6) | 62.6 | (54.7-69.5) | ||
1998-2002 | 292 | 90.8 | (86.8-93.6) | 78.5 | (73.2-82.9) | 75.2 | (69.7-79.9) | ||
2003-2007 | 373 | 92.2 | (89.0-94.6) | 81.7 | (77.3-85.4) | – | – | ||
2008-2012 | 375 | 92.1 | (88.6-94.6) | – | – | – | – | ||
C71.7 | Brain stem | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 62 | 61.4 | (48.1-72.2) | 43.9 | (31.3-55.7) | 29.9 | (17.2-43.8) | ||
1983-1987 | 75 | 73.4 | (61.8-82.0) | 60.3 | (48.2-70.4) | 32.8 | (21.4-44.6) | ||
1988-1992 | 101 | 70.2 | (60.2-78.2) | 53.5 | (43.2-62.7) | 51.2 | (39.2-62.0) | ||
1993-1997 | 120 | 81.7 | (73.5-87.6) | 59.7 | (50.2-68.0) | 45.8 | (35.7-55.3) | ||
1998-2002 | 191 | 83.2 | (77.1-87.9) | 57.9 | (50.5-64.7) | 53.2 | (43.6-61.9) | ||
2003-2007 | 269 | 82.4 | (77.3-86.5) | 59.3 | (53.1-65.0) | 48.8 | (41.4-55.9) | ||
2008-2012 | 291 | 84.5 | (79.5-88.3) | – | – | – | – | ||
C71.8-C71.9 | Other Brain | 1973-1977 | 213 | 78.0 | (71.8-83.0) | 49.1 | (42.2-55.7) | 40.3 | (33.6-46.9) |
1978-1982 | 215 | 78.3 | (72.1-83.2) | 49.9 | (43.0-56.4) | 32.0 | (25.7-38.4) | ||
1983-1987 | 251 | 77.0 | (71.2-81.7) | 43.1 | (36.9-49.2) | 31.6 | (25.9-37.5) | ||
1988-1992 | 410 | 56.8 | (51.9-61.5) | 35.0 | (30.4-39.7) | 25.5 | (21.3-29.8) | ||
1993-1997 | 560 | 53.5 | (49.3-57.5) | 34.9 | (30.9-38.9) | 25.7 | (22.1-29.4) | ||
1998-2002 | 604 | 78.9 | (75.4-82.0) | 49.8 | (45.7-53.8) | 39.6 | (35.6-43.6) | ||
2003-2007 | 655 | 81.6 | (78.4-84.4) | 59.3 | (55.3-63.0) | – | – | ||
2008-2012 | 592 | 81.4 | (77.9-84.5) | 54.8 | (47.7-61.3) | – | – | ||
C70.0-C70.9, C72.0-C72.9 C75.1-C75.3 C30.0d | Other Nervous System | 1973-1977 | 97 | 84.7 | (75.8-90.5) | 67.4 | (57.0-75.8) | 59.5 | (48.9-68.6) |
1978-1982 | 140 | 87.9 | (81.2-92.4) | 66.0 | (57.3-73.2) | 59.9 | (51.1-67.7) | ||
1983-1987 | 151 | 87.4 | (80.9-91.8) | 68.9 | (60.6-75.7) | 67.9 | (59.5-74.9) | ||
1988-1992 | 192 | 78.2 | (71.6-83.4) | 64.3 | (57.0-70.7) | 59.5 | (52.0-66.2) | ||
1993-1997 | 262 | 79.5 | (74.0-83.9) | 68.3 | (62.2-73.6) | 65.6 | (59.3-71.1) | ||
1998-2002 | 400 | 87.5 | (83.9-90.4) | 74.1 | (69.5-78.2) | 71.0 | (66.1-75.3) | ||
2003-2007 | 503 | 90.1 | (87.1-92.4) | 81.3 | (77.6-84.6) | – | – | ||
2008-2012 | 534 | 92.1 | (89.3-94.2) | 79.9 | (73.6-84.8) | – | – | ||
All Codes | All Sites | 1973-1997 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | ||
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | ||
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | ||
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | ||
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | ||
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | ||
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bThe sites referred to in this table are loosely based on the categories and site codes defined in the SEER Site/Histology Validation List.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) – Linked To County Attributes – Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2014 submission.
dICD-O-3 histology codes 9522-9523 only.
– Rates are excluded when calculated based on a population of less than 50, when less than 16 remain alive in the survival period, or when not enough follow up time has passed to calculate survival for the listed period.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval.
Relative Survival by Histologic Group and Year of Diagnosis
Relative survival rates in adolescents and young adults for malignant primary brain and CNS tumors histology are presented in Table 14.
Five-year relative survival in AYA is highest for pilocytic astrocytoma (93.1%) and malignant ependymal tumors (89.8%).
Five-year relative survival is poorest for glioblastoma (22.5%) and lymphoma (31.5%).
Histology . | N . | 1-Year . | 2-Year . | 3-Year . | 4-Year . | 5-Year . | 10-Year . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1,148 | 97.2 | (96.0-98.0) | 95.8 | (94.3-96.8) | 94.8 | (93.2-96.0) | 93.8 | (92.1-95.2) | 93.1 | (91.3-94.6) | 90.4 | (87.9-92.4) |
Diffuse astrocytoma | 2,050 | 93.5 | (92.3-94.5) | 86.7 | (85.0-88.1) | 80.6 | (78.7-82.4) | 74.9 | (72.8-76.9) | 69.5 | (67.2-71.7) | 51.7 | (48.8-54.5) |
Anaplastic astrocytoma | 1,107 | 88.5 | (86.4-90.3) | 74.4 | (71.5-77.0) | 64.1 | (60.9-67.1) | 57.5 | (54.2-60.8) | 51.3 | (47.8-54.7) | 37.6 | (33.7-41.5) |
Glioblastoma | 1,901 | 71.8 | (69.6-73.8) | 44.8 | (42.4-47.1) | 32.1 | (29.8-34.4) | 26.0 | (23.9-28.3) | 22.5 | (20.4-24.7) | 13.7 | (11.7-15.9) |
Oligodendroglioma | 1,476 | 98.4 | (97.6-99.0) | 96.1 | (94.9-97.0) | 93.6 | (92.1-94.8) | 90.8 | (89.1-92.3) | 87.6 | (85.5-89.3) | 71.0 | (67.8-73.9) |
Anaplastic oligodendroglioma | 403 | 93.4 | (90.4-95.5) | 83.6 | (79.3-87.0) | 79.5 | (74.9-83.3) | 73.1 | (68.1-77.5) | 67.2 | (61.8-72.1) | 50.0 | (43.5-56.2) |
Ependymal tumors | 842 | 96.6 | (95.1-97.7) | 94.0 | (92.0-95.5) | 92.5 | (90.3-94.2) | 91.0 | (88.5-92.9) | 89.8 | (87.2-91.9) | 86.2 | (82.8-88.9) |
Oligoastrocytic tumors | 928 | 96.8 | (95.4-97.8) | 90.9 | (88.7-92.7) | 84.6 | (81.9-87.0) | 79.7 | (76.6-82.4) | 74.4 | (71.0-77.5) | 57.1 | (52.5-61.5) |
Glioma malignant, NOS | 872 | 89.2 | (86.9-91.1) | 81.8 | (78.9-84.3) | 76.6 | (73.3-79.4) | 73.1 | (69.6-76.2) | 69.4 | (65.7-72.7) | 56.8 | (52.2-61.1) |
Neuronal and mixed neuronal-glial tumors | 132 | 96.2 | (91.0-98.5) | 91.4 | (84.8-95.2) | 86.0 | (78.2-91.2) | 79.9 | (71.0-86.3) | 78.9 | (69.8-85.5) | 66.6 | (53.2-77.0) |
Embryonal tumors | 773 | 88.6 | (86.1-90.7) | 79.7 | (76.6-82.5) | 71.9 | (68.3-75.1) | 67.3 | (63.5-70.7) | 64.9 | (61.0-68.5) | 55.7 | (51.3-59.9) |
Meningioma | 103 | 98.1 | (92.1-99.6) | 98.1 | (92.1-99.6) | 94.0 | (86.4-97.4) | 91.7 | (83.4-96.0) | 89.4 | (80.4-94.4) | 85.6 | (75.4-91.8) |
Lymphoma | 824 | 42.5 | (39.0-45.9) | 36.5 | (33.2-39.9) | 34.0 | (30.7-37.3) | 32.5 | (29.2-35.8) | 31.5 | (28.2-34.8) | 26.0 | (22.6-29.6) |
TOTAL: All Brain and Other Nervous Systemd | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 72.8 | (72.0-73.6) | 68.8 | (67.9-69.6) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
Histology . | N . | 1-Year . | 2-Year . | 3-Year . | 4-Year . | 5-Year . | 10-Year . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1,148 | 97.2 | (96.0-98.0) | 95.8 | (94.3-96.8) | 94.8 | (93.2-96.0) | 93.8 | (92.1-95.2) | 93.1 | (91.3-94.6) | 90.4 | (87.9-92.4) |
Diffuse astrocytoma | 2,050 | 93.5 | (92.3-94.5) | 86.7 | (85.0-88.1) | 80.6 | (78.7-82.4) | 74.9 | (72.8-76.9) | 69.5 | (67.2-71.7) | 51.7 | (48.8-54.5) |
Anaplastic astrocytoma | 1,107 | 88.5 | (86.4-90.3) | 74.4 | (71.5-77.0) | 64.1 | (60.9-67.1) | 57.5 | (54.2-60.8) | 51.3 | (47.8-54.7) | 37.6 | (33.7-41.5) |
Glioblastoma | 1,901 | 71.8 | (69.6-73.8) | 44.8 | (42.4-47.1) | 32.1 | (29.8-34.4) | 26.0 | (23.9-28.3) | 22.5 | (20.4-24.7) | 13.7 | (11.7-15.9) |
Oligodendroglioma | 1,476 | 98.4 | (97.6-99.0) | 96.1 | (94.9-97.0) | 93.6 | (92.1-94.8) | 90.8 | (89.1-92.3) | 87.6 | (85.5-89.3) | 71.0 | (67.8-73.9) |
Anaplastic oligodendroglioma | 403 | 93.4 | (90.4-95.5) | 83.6 | (79.3-87.0) | 79.5 | (74.9-83.3) | 73.1 | (68.1-77.5) | 67.2 | (61.8-72.1) | 50.0 | (43.5-56.2) |
Ependymal tumors | 842 | 96.6 | (95.1-97.7) | 94.0 | (92.0-95.5) | 92.5 | (90.3-94.2) | 91.0 | (88.5-92.9) | 89.8 | (87.2-91.9) | 86.2 | (82.8-88.9) |
Oligoastrocytic tumors | 928 | 96.8 | (95.4-97.8) | 90.9 | (88.7-92.7) | 84.6 | (81.9-87.0) | 79.7 | (76.6-82.4) | 74.4 | (71.0-77.5) | 57.1 | (52.5-61.5) |
Glioma malignant, NOS | 872 | 89.2 | (86.9-91.1) | 81.8 | (78.9-84.3) | 76.6 | (73.3-79.4) | 73.1 | (69.6-76.2) | 69.4 | (65.7-72.7) | 56.8 | (52.2-61.1) |
Neuronal and mixed neuronal-glial tumors | 132 | 96.2 | (91.0-98.5) | 91.4 | (84.8-95.2) | 86.0 | (78.2-91.2) | 79.9 | (71.0-86.3) | 78.9 | (69.8-85.5) | 66.6 | (53.2-77.0) |
Embryonal tumors | 773 | 88.6 | (86.1-90.7) | 79.7 | (76.6-82.5) | 71.9 | (68.3-75.1) | 67.3 | (63.5-70.7) | 64.9 | (61.0-68.5) | 55.7 | (51.3-59.9) |
Meningioma | 103 | 98.1 | (92.1-99.6) | 98.1 | (92.1-99.6) | 94.0 | (86.4-97.4) | 91.7 | (83.4-96.0) | 89.4 | (80.4-94.4) | 85.6 | (75.4-91.8) |
Lymphoma | 824 | 42.5 | (39.0-45.9) | 36.5 | (33.2-39.9) | 34.0 | (30.7-37.3) | 32.5 | (29.2-35.8) | 31.5 | (28.2-34.8) | 26.0 | (22.6-29.6) |
TOTAL: All Brain and Other Nervous Systemd | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 72.8 | (72.0-73.6) | 68.8 | (67.9-69.6) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dIncludes histologies not listed in this table.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.
Histology . | N . | 1-Year . | 2-Year . | 3-Year . | 4-Year . | 5-Year . | 10-Year . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1,148 | 97.2 | (96.0-98.0) | 95.8 | (94.3-96.8) | 94.8 | (93.2-96.0) | 93.8 | (92.1-95.2) | 93.1 | (91.3-94.6) | 90.4 | (87.9-92.4) |
Diffuse astrocytoma | 2,050 | 93.5 | (92.3-94.5) | 86.7 | (85.0-88.1) | 80.6 | (78.7-82.4) | 74.9 | (72.8-76.9) | 69.5 | (67.2-71.7) | 51.7 | (48.8-54.5) |
Anaplastic astrocytoma | 1,107 | 88.5 | (86.4-90.3) | 74.4 | (71.5-77.0) | 64.1 | (60.9-67.1) | 57.5 | (54.2-60.8) | 51.3 | (47.8-54.7) | 37.6 | (33.7-41.5) |
Glioblastoma | 1,901 | 71.8 | (69.6-73.8) | 44.8 | (42.4-47.1) | 32.1 | (29.8-34.4) | 26.0 | (23.9-28.3) | 22.5 | (20.4-24.7) | 13.7 | (11.7-15.9) |
Oligodendroglioma | 1,476 | 98.4 | (97.6-99.0) | 96.1 | (94.9-97.0) | 93.6 | (92.1-94.8) | 90.8 | (89.1-92.3) | 87.6 | (85.5-89.3) | 71.0 | (67.8-73.9) |
Anaplastic oligodendroglioma | 403 | 93.4 | (90.4-95.5) | 83.6 | (79.3-87.0) | 79.5 | (74.9-83.3) | 73.1 | (68.1-77.5) | 67.2 | (61.8-72.1) | 50.0 | (43.5-56.2) |
Ependymal tumors | 842 | 96.6 | (95.1-97.7) | 94.0 | (92.0-95.5) | 92.5 | (90.3-94.2) | 91.0 | (88.5-92.9) | 89.8 | (87.2-91.9) | 86.2 | (82.8-88.9) |
Oligoastrocytic tumors | 928 | 96.8 | (95.4-97.8) | 90.9 | (88.7-92.7) | 84.6 | (81.9-87.0) | 79.7 | (76.6-82.4) | 74.4 | (71.0-77.5) | 57.1 | (52.5-61.5) |
Glioma malignant, NOS | 872 | 89.2 | (86.9-91.1) | 81.8 | (78.9-84.3) | 76.6 | (73.3-79.4) | 73.1 | (69.6-76.2) | 69.4 | (65.7-72.7) | 56.8 | (52.2-61.1) |
Neuronal and mixed neuronal-glial tumors | 132 | 96.2 | (91.0-98.5) | 91.4 | (84.8-95.2) | 86.0 | (78.2-91.2) | 79.9 | (71.0-86.3) | 78.9 | (69.8-85.5) | 66.6 | (53.2-77.0) |
Embryonal tumors | 773 | 88.6 | (86.1-90.7) | 79.7 | (76.6-82.5) | 71.9 | (68.3-75.1) | 67.3 | (63.5-70.7) | 64.9 | (61.0-68.5) | 55.7 | (51.3-59.9) |
Meningioma | 103 | 98.1 | (92.1-99.6) | 98.1 | (92.1-99.6) | 94.0 | (86.4-97.4) | 91.7 | (83.4-96.0) | 89.4 | (80.4-94.4) | 85.6 | (75.4-91.8) |
Lymphoma | 824 | 42.5 | (39.0-45.9) | 36.5 | (33.2-39.9) | 34.0 | (30.7-37.3) | 32.5 | (29.2-35.8) | 31.5 | (28.2-34.8) | 26.0 | (22.6-29.6) |
TOTAL: All Brain and Other Nervous Systemd | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 72.8 | (72.0-73.6) | 68.8 | (67.9-69.6) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
Histology . | N . | 1-Year . | 2-Year . | 3-Year . | 4-Year . | 5-Year . | 10-Year . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1,148 | 97.2 | (96.0-98.0) | 95.8 | (94.3-96.8) | 94.8 | (93.2-96.0) | 93.8 | (92.1-95.2) | 93.1 | (91.3-94.6) | 90.4 | (87.9-92.4) |
Diffuse astrocytoma | 2,050 | 93.5 | (92.3-94.5) | 86.7 | (85.0-88.1) | 80.6 | (78.7-82.4) | 74.9 | (72.8-76.9) | 69.5 | (67.2-71.7) | 51.7 | (48.8-54.5) |
Anaplastic astrocytoma | 1,107 | 88.5 | (86.4-90.3) | 74.4 | (71.5-77.0) | 64.1 | (60.9-67.1) | 57.5 | (54.2-60.8) | 51.3 | (47.8-54.7) | 37.6 | (33.7-41.5) |
Glioblastoma | 1,901 | 71.8 | (69.6-73.8) | 44.8 | (42.4-47.1) | 32.1 | (29.8-34.4) | 26.0 | (23.9-28.3) | 22.5 | (20.4-24.7) | 13.7 | (11.7-15.9) |
Oligodendroglioma | 1,476 | 98.4 | (97.6-99.0) | 96.1 | (94.9-97.0) | 93.6 | (92.1-94.8) | 90.8 | (89.1-92.3) | 87.6 | (85.5-89.3) | 71.0 | (67.8-73.9) |
Anaplastic oligodendroglioma | 403 | 93.4 | (90.4-95.5) | 83.6 | (79.3-87.0) | 79.5 | (74.9-83.3) | 73.1 | (68.1-77.5) | 67.2 | (61.8-72.1) | 50.0 | (43.5-56.2) |
Ependymal tumors | 842 | 96.6 | (95.1-97.7) | 94.0 | (92.0-95.5) | 92.5 | (90.3-94.2) | 91.0 | (88.5-92.9) | 89.8 | (87.2-91.9) | 86.2 | (82.8-88.9) |
Oligoastrocytic tumors | 928 | 96.8 | (95.4-97.8) | 90.9 | (88.7-92.7) | 84.6 | (81.9-87.0) | 79.7 | (76.6-82.4) | 74.4 | (71.0-77.5) | 57.1 | (52.5-61.5) |
Glioma malignant, NOS | 872 | 89.2 | (86.9-91.1) | 81.8 | (78.9-84.3) | 76.6 | (73.3-79.4) | 73.1 | (69.6-76.2) | 69.4 | (65.7-72.7) | 56.8 | (52.2-61.1) |
Neuronal and mixed neuronal-glial tumors | 132 | 96.2 | (91.0-98.5) | 91.4 | (84.8-95.2) | 86.0 | (78.2-91.2) | 79.9 | (71.0-86.3) | 78.9 | (69.8-85.5) | 66.6 | (53.2-77.0) |
Embryonal tumors | 773 | 88.6 | (86.1-90.7) | 79.7 | (76.6-82.5) | 71.9 | (68.3-75.1) | 67.3 | (63.5-70.7) | 64.9 | (61.0-68.5) | 55.7 | (51.3-59.9) |
Meningioma | 103 | 98.1 | (92.1-99.6) | 98.1 | (92.1-99.6) | 94.0 | (86.4-97.4) | 91.7 | (83.4-96.0) | 89.4 | (80.4-94.4) | 85.6 | (75.4-91.8) |
Lymphoma | 824 | 42.5 | (39.0-45.9) | 36.5 | (33.2-39.9) | 34.0 | (30.7-37.3) | 32.5 | (29.2-35.8) | 31.5 | (28.2-34.8) | 26.0 | (22.6-29.6) |
TOTAL: All Brain and Other Nervous Systemd | 13,701 | 87.3 | (86.7-87.8) | 78.5 | (77.7-79.2) | 72.8 | (72.0-73.6) | 68.8 | (67.9-69.6) | 65.4 | (64.5-66.3) | 54.2 | (53.1-55.2) |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dIncludes histologies not listed in this table.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.
Relative survival rates in adolescents and young adults for malignant brain and CNS tumors by histology and 5-year groups are presented in Table 15.
Overall, ten-year survival after diagnosis with a malignant brain and CNS tumor has risen from 36.3% in 1973-1977 to 57.6% in 2003-2007 in AYA.
For many histologies, relative survival rates in AYA have not seen large improvements over time.
Histology . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 69 | 98.7 | (89.4-99.8) | 93.3 | (83.5-97.3) | 89.4 | (78.5-94.9) | |
1993-1997 | 154 | 96.8 | (92.4-98.7) | 92.5 | (86.8-95.8) | 90.5 | (84.2-94.4) | |
1998-2002 | 275 | 96.4 | (93.4-98.1) | 90.9 | (86.7-93.8) | 87.6 | (82.8-91.2) | |
2003-2007 | 394 | 97.5 | (95.4-98.7) | 93.7 | (90.7-95.8) | – | – | |
2008-2012 | 380 | 97.7 | (95.3-98.9) | – | – | – | – | |
Diffuse astrocytoma | 1973-1977 | 288 | 87.3 | (82.8-90.6) | 57.0 | (51.0-62.5) | 44.6 | (38.7-50.3) |
1978-1982 | 535 | 86.5 | (83.3-89.1) | 53.7 | (49.4-57.9) | 38.8 | (34.6-43.0) | |
1983-1987 | 600 | 89.0 | (86.1-91.2) | 57.4 | (53.3-61.3) | 41.7 | (37.7-45.7) | |
1988-1992 | 475 | 90.0 | (86.9-92.4) | 62.8 | (58.2-67.0) | 49.5 | (44.9-54.0) | |
1993-1997 | 386 | 92.1 | (88.9-94.4) | 67.9 | (63.0-72.4) | 52.0 | (46.8-57.0) | |
1998-2002 | 541 | 92.5 | (89.9-94.4) | 66.2 | (62.0-70.1) | 47.6 | (43.2-51.8) | |
2003-2007 | 658 | 93.5 | (91.3-95.2) | 70.1 | (66.3-73.5) | 53.6 | (47.4-59.4) | |
2008-2012 | 650 | 94.6 | (92.4-96.2) | 74.3 | (66.6-80.4) | – | – | |
Anaplastic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 103 | 85.6 | (77.1-91.1) | 57.7 | (47.5-66.6) | 42.4 | (32.7-51.9) | |
1988-1992 | 195 | 85.2 | (79.3-89.5) | 52.2 | (44.9-59.0) | 37.9 | (31.0-44.8) | |
1993-1997 | 194 | 81.5 | (75.2-86.3) | 46.0 | (38.7-52.9) | 34.2 | (27.4-41.0) | |
1998-2002 | 278 | 86.4 | (81.7-89.9) | 47.4 | (41.4-53.3) | 33.3 | (27.7-39.1) | |
2003-2007 | 333 | 87.3 | (83.2-90.5) | 51.6 | (46.0-56.9) | – | – | |
2008-2012 | 400 | 93.5 | (90.4-95.7) | 60.3 | (48.6-70.2) | – | – | |
Glioblastoma | 1973-1977 | 230 | 60.1 | (53.5-66.1) | 17.5 | (12.9-22.7) | 13.3 | (9.2-18.0) |
1978-1982 | 172 | 62.8 | (55.1-69.5) | 20.3 | (14.6-26.7) | – | – | |
1983-1987 | 194 | 63.5 | (56.3-69.9) | 16.7 | (11.8-22.3) | 11.3 | (7.3-16.4) | |
1988-1992 | 225 | 62.1 | (55.3-68.1) | 13.9 | (9.7-18.9) | 13.0 | (9.0-17.9) | |
1993-1997 | 297 | 56.2 | (50.3-61.7) | 16.1 | (12.1-20.5) | 11.2 | (7.8-15.2) | |
1998-2002 | 505 | 68.0 | (63.7-71.9) | 20.7 | (17.2-24.4) | 12.8 | (10.0-16.0) | |
2003-2007 | 607 | 73.9 | (70.2-77.2) | 24.3 | (20.9-27.9) | – | – | |
2008-2012 | 623 | 76.5 | (72.7-79.8) | 23.0 | (16.5-30.2) | – | – | |
Oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 59 | 86.6 | (74.8-93.1) | 70.1 | (56.4-80.2) | 58.6 | (44.7-70.1) | |
1983-1987 | 89 | 94.5 | (87.0-97.7) | 81.3 | (71.2-88.1) | 63.5 | (52.3-72.8) | |
1988-1992 | 149 | 97.4 | (93.0-99.1) | 82.3 | (75.0-87.7) | 72.7 | (64.5-79.3) | |
1993-1997 | 305 | 97.2 | (94.5-98.6) | 85.7 | (81.1-89.3) | 65.2 | (59.3-70.4) | |
1998-2002 | 448 | 98.3 | (96.5-99.2) | 84.9 | (81.1-88.0) | 69.9 | (65.2-74.0) | |
2003-2007 | 452 | 99.0 | (97.4-99.6) | 88.4 | (84.9-91.2) | – | – | |
2008-2012 | 374 | 98.6 | (96.5-99.5) | – | – | – | – | |
Anaplastic oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | – | – | – | – | – | – | – | |
1993-1997 | – | – | – | – | – | – | – | |
1998-2002 | 128 | 93.9 | (88.0-96.9) | 65.3 | (56.3-72.9) | 47.6 | (38.6-56.1) | |
2003-2007 | 122 | 91.8 | (85.3-95.6) | 66.1 | (56.8-73.9) | – | – | |
2008-2012 | 118 | 95.3 | (88.9-98.1) | 80.6 | (58.9-91.6) | – | – | |
Ependymal tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 54 | 89.0 | (77.0-95.0) | 78.2 | (64.5-87.2) | 64.0 | (49.4-75.4) | |
1983-1987 | 59 | 96.7 | (86.9-99.2) | 95.3 | (84.9-98.6) | 89.5 | (77.3-95.4) | |
1988-1992 | 74 | 93.3 | (84.5-97.2) | 90.9 | (81.2-95.7) | 83.8 | (72.4-90.7) | |
1993-1997 | 117 | 94.1 | (87.9-97.2) | 87.8 | (80.1-92.6) | 82.9 | (74.5-88.7) | |
1998-2002 | 192 | 95.9 | (91.9-98.0) | 90.0 | (84.5-93.6) | 85.5 | (79.2-90.0) | |
2003-2007 | 278 | 96.5 | (93.4-98.1) | 90.5 | (86.2-93.5) | – | – | |
2008-2012 | 299 | 98.2 | (95.6-99.3) | 85.6 | (74.4-92.2) | – | – | |
Oligoastrocytic tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 78 | 97.6 | (89.9-99.4) | 74.8 | (63.4-83.1) | 60.8 | (48.8-70.9) | |
1993-1997 | 118 | 90.8 | (83.9-94.8) | 70.8 | (61.6-78.2) | 56.7 | (47.1-65.2) | |
1998-2002 | 202 | 97.1 | (93.5-98.7) | 69.3 | (62.3-75.3) | 55.1 | (47.7-61.8) | |
2003-2007 | 339 | 97.4 | (95.0-98.7) | 76.9 | (71.9-81.2) | – | – | |
2008-2012 | 319 | 97.3 | (94.4-98.7) | 79.0 | (68.6-86.3) | – | – | |
Embryonal tumors | 1973-1977 | 52 | 84.7 | (71.6-92.1) | 38.7 | (25.6-51.7) | 31.1 | (19.1-43.9) |
1978-1982 | 59 | 90.0 | (78.8-95.4) | 56.3 | (42.7-67.9) | 48.2 | (34.8-60.3) | |
1983-1987 | 59 | 91.6 | (80.9-96.5) | 66.6 | (52.9-77.1) | 51.6 | (38.0-63.6) | |
1988-1992 | 103 | 81.7 | (72.7-87.9) | 57.6 | (47.4-66.5) | 48.9 | (38.7-58.2) | |
1993-1997 | 109 | 89.1 | (81.5-93.7) | 62.6 | (52.6-71.0) | 50.6 | (40.7-59.7) | |
1998-2002 | 220 | 88.6 | (83.6-92.2) | 65.2 | (58.3-71.2) | 59.6 | (52.6-65.9) | |
2003-2007 | 244 | 88.1 | (83.3-91.6) | 65.7 | (59.2-71.4) | – | – | |
2008-2012 | 243 | 89.0 | (84.0-92.5) | – | – | – | – | |
Lymphoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 57 | 38.7 | (26.2-51.0) | 29.7 | (18.4-41.9) | 29.7 | (18.4-41.9) | |
1988-1992 | 281 | 12.1 | (8.6-16.3) | 3.8 | (1.9-6.5) | 2.7 | (1.2-5.2) | |
1993-1997 | 458 | 16.6 | (13.4-20.2) | 8.4 | (6.1-11.2) | 6.0 | (4.0-8.4) | |
1998-2002 | 195 | 37.4 | (30.6-44.2) | 27.4 | (21.3-33.9) | 24.4 | (18.5-30.7) | |
2003-2007 | 195 | 59.6 | (52.3-66.1) | 51.8 | (44.4-58.7) | – | – | |
2008-2012 | 160 | 66.5 | (58.2-73.6) | – | – | – | – | |
TOTAL: All Brain and Other Nervous Systemd | 1973-1977 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | |
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | |
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | |
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | |
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | |
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | |
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
Histology . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 69 | 98.7 | (89.4-99.8) | 93.3 | (83.5-97.3) | 89.4 | (78.5-94.9) | |
1993-1997 | 154 | 96.8 | (92.4-98.7) | 92.5 | (86.8-95.8) | 90.5 | (84.2-94.4) | |
1998-2002 | 275 | 96.4 | (93.4-98.1) | 90.9 | (86.7-93.8) | 87.6 | (82.8-91.2) | |
2003-2007 | 394 | 97.5 | (95.4-98.7) | 93.7 | (90.7-95.8) | – | – | |
2008-2012 | 380 | 97.7 | (95.3-98.9) | – | – | – | – | |
Diffuse astrocytoma | 1973-1977 | 288 | 87.3 | (82.8-90.6) | 57.0 | (51.0-62.5) | 44.6 | (38.7-50.3) |
1978-1982 | 535 | 86.5 | (83.3-89.1) | 53.7 | (49.4-57.9) | 38.8 | (34.6-43.0) | |
1983-1987 | 600 | 89.0 | (86.1-91.2) | 57.4 | (53.3-61.3) | 41.7 | (37.7-45.7) | |
1988-1992 | 475 | 90.0 | (86.9-92.4) | 62.8 | (58.2-67.0) | 49.5 | (44.9-54.0) | |
1993-1997 | 386 | 92.1 | (88.9-94.4) | 67.9 | (63.0-72.4) | 52.0 | (46.8-57.0) | |
1998-2002 | 541 | 92.5 | (89.9-94.4) | 66.2 | (62.0-70.1) | 47.6 | (43.2-51.8) | |
2003-2007 | 658 | 93.5 | (91.3-95.2) | 70.1 | (66.3-73.5) | 53.6 | (47.4-59.4) | |
2008-2012 | 650 | 94.6 | (92.4-96.2) | 74.3 | (66.6-80.4) | – | – | |
Anaplastic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 103 | 85.6 | (77.1-91.1) | 57.7 | (47.5-66.6) | 42.4 | (32.7-51.9) | |
1988-1992 | 195 | 85.2 | (79.3-89.5) | 52.2 | (44.9-59.0) | 37.9 | (31.0-44.8) | |
1993-1997 | 194 | 81.5 | (75.2-86.3) | 46.0 | (38.7-52.9) | 34.2 | (27.4-41.0) | |
1998-2002 | 278 | 86.4 | (81.7-89.9) | 47.4 | (41.4-53.3) | 33.3 | (27.7-39.1) | |
2003-2007 | 333 | 87.3 | (83.2-90.5) | 51.6 | (46.0-56.9) | – | – | |
2008-2012 | 400 | 93.5 | (90.4-95.7) | 60.3 | (48.6-70.2) | – | – | |
Glioblastoma | 1973-1977 | 230 | 60.1 | (53.5-66.1) | 17.5 | (12.9-22.7) | 13.3 | (9.2-18.0) |
1978-1982 | 172 | 62.8 | (55.1-69.5) | 20.3 | (14.6-26.7) | – | – | |
1983-1987 | 194 | 63.5 | (56.3-69.9) | 16.7 | (11.8-22.3) | 11.3 | (7.3-16.4) | |
1988-1992 | 225 | 62.1 | (55.3-68.1) | 13.9 | (9.7-18.9) | 13.0 | (9.0-17.9) | |
1993-1997 | 297 | 56.2 | (50.3-61.7) | 16.1 | (12.1-20.5) | 11.2 | (7.8-15.2) | |
1998-2002 | 505 | 68.0 | (63.7-71.9) | 20.7 | (17.2-24.4) | 12.8 | (10.0-16.0) | |
2003-2007 | 607 | 73.9 | (70.2-77.2) | 24.3 | (20.9-27.9) | – | – | |
2008-2012 | 623 | 76.5 | (72.7-79.8) | 23.0 | (16.5-30.2) | – | – | |
Oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 59 | 86.6 | (74.8-93.1) | 70.1 | (56.4-80.2) | 58.6 | (44.7-70.1) | |
1983-1987 | 89 | 94.5 | (87.0-97.7) | 81.3 | (71.2-88.1) | 63.5 | (52.3-72.8) | |
1988-1992 | 149 | 97.4 | (93.0-99.1) | 82.3 | (75.0-87.7) | 72.7 | (64.5-79.3) | |
1993-1997 | 305 | 97.2 | (94.5-98.6) | 85.7 | (81.1-89.3) | 65.2 | (59.3-70.4) | |
1998-2002 | 448 | 98.3 | (96.5-99.2) | 84.9 | (81.1-88.0) | 69.9 | (65.2-74.0) | |
2003-2007 | 452 | 99.0 | (97.4-99.6) | 88.4 | (84.9-91.2) | – | – | |
2008-2012 | 374 | 98.6 | (96.5-99.5) | – | – | – | – | |
Anaplastic oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | – | – | – | – | – | – | – | |
1993-1997 | – | – | – | – | – | – | – | |
1998-2002 | 128 | 93.9 | (88.0-96.9) | 65.3 | (56.3-72.9) | 47.6 | (38.6-56.1) | |
2003-2007 | 122 | 91.8 | (85.3-95.6) | 66.1 | (56.8-73.9) | – | – | |
2008-2012 | 118 | 95.3 | (88.9-98.1) | 80.6 | (58.9-91.6) | – | – | |
Ependymal tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 54 | 89.0 | (77.0-95.0) | 78.2 | (64.5-87.2) | 64.0 | (49.4-75.4) | |
1983-1987 | 59 | 96.7 | (86.9-99.2) | 95.3 | (84.9-98.6) | 89.5 | (77.3-95.4) | |
1988-1992 | 74 | 93.3 | (84.5-97.2) | 90.9 | (81.2-95.7) | 83.8 | (72.4-90.7) | |
1993-1997 | 117 | 94.1 | (87.9-97.2) | 87.8 | (80.1-92.6) | 82.9 | (74.5-88.7) | |
1998-2002 | 192 | 95.9 | (91.9-98.0) | 90.0 | (84.5-93.6) | 85.5 | (79.2-90.0) | |
2003-2007 | 278 | 96.5 | (93.4-98.1) | 90.5 | (86.2-93.5) | – | – | |
2008-2012 | 299 | 98.2 | (95.6-99.3) | 85.6 | (74.4-92.2) | – | – | |
Oligoastrocytic tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 78 | 97.6 | (89.9-99.4) | 74.8 | (63.4-83.1) | 60.8 | (48.8-70.9) | |
1993-1997 | 118 | 90.8 | (83.9-94.8) | 70.8 | (61.6-78.2) | 56.7 | (47.1-65.2) | |
1998-2002 | 202 | 97.1 | (93.5-98.7) | 69.3 | (62.3-75.3) | 55.1 | (47.7-61.8) | |
2003-2007 | 339 | 97.4 | (95.0-98.7) | 76.9 | (71.9-81.2) | – | – | |
2008-2012 | 319 | 97.3 | (94.4-98.7) | 79.0 | (68.6-86.3) | – | – | |
Embryonal tumors | 1973-1977 | 52 | 84.7 | (71.6-92.1) | 38.7 | (25.6-51.7) | 31.1 | (19.1-43.9) |
1978-1982 | 59 | 90.0 | (78.8-95.4) | 56.3 | (42.7-67.9) | 48.2 | (34.8-60.3) | |
1983-1987 | 59 | 91.6 | (80.9-96.5) | 66.6 | (52.9-77.1) | 51.6 | (38.0-63.6) | |
1988-1992 | 103 | 81.7 | (72.7-87.9) | 57.6 | (47.4-66.5) | 48.9 | (38.7-58.2) | |
1993-1997 | 109 | 89.1 | (81.5-93.7) | 62.6 | (52.6-71.0) | 50.6 | (40.7-59.7) | |
1998-2002 | 220 | 88.6 | (83.6-92.2) | 65.2 | (58.3-71.2) | 59.6 | (52.6-65.9) | |
2003-2007 | 244 | 88.1 | (83.3-91.6) | 65.7 | (59.2-71.4) | – | – | |
2008-2012 | 243 | 89.0 | (84.0-92.5) | – | – | – | – | |
Lymphoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 57 | 38.7 | (26.2-51.0) | 29.7 | (18.4-41.9) | 29.7 | (18.4-41.9) | |
1988-1992 | 281 | 12.1 | (8.6-16.3) | 3.8 | (1.9-6.5) | 2.7 | (1.2-5.2) | |
1993-1997 | 458 | 16.6 | (13.4-20.2) | 8.4 | (6.1-11.2) | 6.0 | (4.0-8.4) | |
1998-2002 | 195 | 37.4 | (30.6-44.2) | 27.4 | (21.3-33.9) | 24.4 | (18.5-30.7) | |
2003-2007 | 195 | 59.6 | (52.3-66.1) | 51.8 | (44.4-58.7) | – | – | |
2008-2012 | 160 | 66.5 | (58.2-73.6) | – | – | – | – | |
TOTAL: All Brain and Other Nervous Systemd | 1973-1977 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | |
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | |
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | |
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | |
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | |
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | |
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dIncludes histologies not listed in this table.
– Rates are excluded when calculated based on a population of less than 50, when less than 16 remain alive in the survival period, or when not enough follow up time has passed to calculate survival for the listed period.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.
Histology . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 69 | 98.7 | (89.4-99.8) | 93.3 | (83.5-97.3) | 89.4 | (78.5-94.9) | |
1993-1997 | 154 | 96.8 | (92.4-98.7) | 92.5 | (86.8-95.8) | 90.5 | (84.2-94.4) | |
1998-2002 | 275 | 96.4 | (93.4-98.1) | 90.9 | (86.7-93.8) | 87.6 | (82.8-91.2) | |
2003-2007 | 394 | 97.5 | (95.4-98.7) | 93.7 | (90.7-95.8) | – | – | |
2008-2012 | 380 | 97.7 | (95.3-98.9) | – | – | – | – | |
Diffuse astrocytoma | 1973-1977 | 288 | 87.3 | (82.8-90.6) | 57.0 | (51.0-62.5) | 44.6 | (38.7-50.3) |
1978-1982 | 535 | 86.5 | (83.3-89.1) | 53.7 | (49.4-57.9) | 38.8 | (34.6-43.0) | |
1983-1987 | 600 | 89.0 | (86.1-91.2) | 57.4 | (53.3-61.3) | 41.7 | (37.7-45.7) | |
1988-1992 | 475 | 90.0 | (86.9-92.4) | 62.8 | (58.2-67.0) | 49.5 | (44.9-54.0) | |
1993-1997 | 386 | 92.1 | (88.9-94.4) | 67.9 | (63.0-72.4) | 52.0 | (46.8-57.0) | |
1998-2002 | 541 | 92.5 | (89.9-94.4) | 66.2 | (62.0-70.1) | 47.6 | (43.2-51.8) | |
2003-2007 | 658 | 93.5 | (91.3-95.2) | 70.1 | (66.3-73.5) | 53.6 | (47.4-59.4) | |
2008-2012 | 650 | 94.6 | (92.4-96.2) | 74.3 | (66.6-80.4) | – | – | |
Anaplastic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 103 | 85.6 | (77.1-91.1) | 57.7 | (47.5-66.6) | 42.4 | (32.7-51.9) | |
1988-1992 | 195 | 85.2 | (79.3-89.5) | 52.2 | (44.9-59.0) | 37.9 | (31.0-44.8) | |
1993-1997 | 194 | 81.5 | (75.2-86.3) | 46.0 | (38.7-52.9) | 34.2 | (27.4-41.0) | |
1998-2002 | 278 | 86.4 | (81.7-89.9) | 47.4 | (41.4-53.3) | 33.3 | (27.7-39.1) | |
2003-2007 | 333 | 87.3 | (83.2-90.5) | 51.6 | (46.0-56.9) | – | – | |
2008-2012 | 400 | 93.5 | (90.4-95.7) | 60.3 | (48.6-70.2) | – | – | |
Glioblastoma | 1973-1977 | 230 | 60.1 | (53.5-66.1) | 17.5 | (12.9-22.7) | 13.3 | (9.2-18.0) |
1978-1982 | 172 | 62.8 | (55.1-69.5) | 20.3 | (14.6-26.7) | – | – | |
1983-1987 | 194 | 63.5 | (56.3-69.9) | 16.7 | (11.8-22.3) | 11.3 | (7.3-16.4) | |
1988-1992 | 225 | 62.1 | (55.3-68.1) | 13.9 | (9.7-18.9) | 13.0 | (9.0-17.9) | |
1993-1997 | 297 | 56.2 | (50.3-61.7) | 16.1 | (12.1-20.5) | 11.2 | (7.8-15.2) | |
1998-2002 | 505 | 68.0 | (63.7-71.9) | 20.7 | (17.2-24.4) | 12.8 | (10.0-16.0) | |
2003-2007 | 607 | 73.9 | (70.2-77.2) | 24.3 | (20.9-27.9) | – | – | |
2008-2012 | 623 | 76.5 | (72.7-79.8) | 23.0 | (16.5-30.2) | – | – | |
Oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 59 | 86.6 | (74.8-93.1) | 70.1 | (56.4-80.2) | 58.6 | (44.7-70.1) | |
1983-1987 | 89 | 94.5 | (87.0-97.7) | 81.3 | (71.2-88.1) | 63.5 | (52.3-72.8) | |
1988-1992 | 149 | 97.4 | (93.0-99.1) | 82.3 | (75.0-87.7) | 72.7 | (64.5-79.3) | |
1993-1997 | 305 | 97.2 | (94.5-98.6) | 85.7 | (81.1-89.3) | 65.2 | (59.3-70.4) | |
1998-2002 | 448 | 98.3 | (96.5-99.2) | 84.9 | (81.1-88.0) | 69.9 | (65.2-74.0) | |
2003-2007 | 452 | 99.0 | (97.4-99.6) | 88.4 | (84.9-91.2) | – | – | |
2008-2012 | 374 | 98.6 | (96.5-99.5) | – | – | – | – | |
Anaplastic oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | – | – | – | – | – | – | – | |
1993-1997 | – | – | – | – | – | – | – | |
1998-2002 | 128 | 93.9 | (88.0-96.9) | 65.3 | (56.3-72.9) | 47.6 | (38.6-56.1) | |
2003-2007 | 122 | 91.8 | (85.3-95.6) | 66.1 | (56.8-73.9) | – | – | |
2008-2012 | 118 | 95.3 | (88.9-98.1) | 80.6 | (58.9-91.6) | – | – | |
Ependymal tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 54 | 89.0 | (77.0-95.0) | 78.2 | (64.5-87.2) | 64.0 | (49.4-75.4) | |
1983-1987 | 59 | 96.7 | (86.9-99.2) | 95.3 | (84.9-98.6) | 89.5 | (77.3-95.4) | |
1988-1992 | 74 | 93.3 | (84.5-97.2) | 90.9 | (81.2-95.7) | 83.8 | (72.4-90.7) | |
1993-1997 | 117 | 94.1 | (87.9-97.2) | 87.8 | (80.1-92.6) | 82.9 | (74.5-88.7) | |
1998-2002 | 192 | 95.9 | (91.9-98.0) | 90.0 | (84.5-93.6) | 85.5 | (79.2-90.0) | |
2003-2007 | 278 | 96.5 | (93.4-98.1) | 90.5 | (86.2-93.5) | – | – | |
2008-2012 | 299 | 98.2 | (95.6-99.3) | 85.6 | (74.4-92.2) | – | – | |
Oligoastrocytic tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 78 | 97.6 | (89.9-99.4) | 74.8 | (63.4-83.1) | 60.8 | (48.8-70.9) | |
1993-1997 | 118 | 90.8 | (83.9-94.8) | 70.8 | (61.6-78.2) | 56.7 | (47.1-65.2) | |
1998-2002 | 202 | 97.1 | (93.5-98.7) | 69.3 | (62.3-75.3) | 55.1 | (47.7-61.8) | |
2003-2007 | 339 | 97.4 | (95.0-98.7) | 76.9 | (71.9-81.2) | – | – | |
2008-2012 | 319 | 97.3 | (94.4-98.7) | 79.0 | (68.6-86.3) | – | – | |
Embryonal tumors | 1973-1977 | 52 | 84.7 | (71.6-92.1) | 38.7 | (25.6-51.7) | 31.1 | (19.1-43.9) |
1978-1982 | 59 | 90.0 | (78.8-95.4) | 56.3 | (42.7-67.9) | 48.2 | (34.8-60.3) | |
1983-1987 | 59 | 91.6 | (80.9-96.5) | 66.6 | (52.9-77.1) | 51.6 | (38.0-63.6) | |
1988-1992 | 103 | 81.7 | (72.7-87.9) | 57.6 | (47.4-66.5) | 48.9 | (38.7-58.2) | |
1993-1997 | 109 | 89.1 | (81.5-93.7) | 62.6 | (52.6-71.0) | 50.6 | (40.7-59.7) | |
1998-2002 | 220 | 88.6 | (83.6-92.2) | 65.2 | (58.3-71.2) | 59.6 | (52.6-65.9) | |
2003-2007 | 244 | 88.1 | (83.3-91.6) | 65.7 | (59.2-71.4) | – | – | |
2008-2012 | 243 | 89.0 | (84.0-92.5) | – | – | – | – | |
Lymphoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 57 | 38.7 | (26.2-51.0) | 29.7 | (18.4-41.9) | 29.7 | (18.4-41.9) | |
1988-1992 | 281 | 12.1 | (8.6-16.3) | 3.8 | (1.9-6.5) | 2.7 | (1.2-5.2) | |
1993-1997 | 458 | 16.6 | (13.4-20.2) | 8.4 | (6.1-11.2) | 6.0 | (4.0-8.4) | |
1998-2002 | 195 | 37.4 | (30.6-44.2) | 27.4 | (21.3-33.9) | 24.4 | (18.5-30.7) | |
2003-2007 | 195 | 59.6 | (52.3-66.1) | 51.8 | (44.4-58.7) | – | – | |
2008-2012 | 160 | 66.5 | (58.2-73.6) | – | – | – | – | |
TOTAL: All Brain and Other Nervous Systemd | 1973-1977 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | |
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | |
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | |
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | |
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | |
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | |
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
Histology . | Years of Diagnosis . | N . | 1-Year . | 5-Year . | 10-Year . | |||
---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 69 | 98.7 | (89.4-99.8) | 93.3 | (83.5-97.3) | 89.4 | (78.5-94.9) | |
1993-1997 | 154 | 96.8 | (92.4-98.7) | 92.5 | (86.8-95.8) | 90.5 | (84.2-94.4) | |
1998-2002 | 275 | 96.4 | (93.4-98.1) | 90.9 | (86.7-93.8) | 87.6 | (82.8-91.2) | |
2003-2007 | 394 | 97.5 | (95.4-98.7) | 93.7 | (90.7-95.8) | – | – | |
2008-2012 | 380 | 97.7 | (95.3-98.9) | – | – | – | – | |
Diffuse astrocytoma | 1973-1977 | 288 | 87.3 | (82.8-90.6) | 57.0 | (51.0-62.5) | 44.6 | (38.7-50.3) |
1978-1982 | 535 | 86.5 | (83.3-89.1) | 53.7 | (49.4-57.9) | 38.8 | (34.6-43.0) | |
1983-1987 | 600 | 89.0 | (86.1-91.2) | 57.4 | (53.3-61.3) | 41.7 | (37.7-45.7) | |
1988-1992 | 475 | 90.0 | (86.9-92.4) | 62.8 | (58.2-67.0) | 49.5 | (44.9-54.0) | |
1993-1997 | 386 | 92.1 | (88.9-94.4) | 67.9 | (63.0-72.4) | 52.0 | (46.8-57.0) | |
1998-2002 | 541 | 92.5 | (89.9-94.4) | 66.2 | (62.0-70.1) | 47.6 | (43.2-51.8) | |
2003-2007 | 658 | 93.5 | (91.3-95.2) | 70.1 | (66.3-73.5) | 53.6 | (47.4-59.4) | |
2008-2012 | 650 | 94.6 | (92.4-96.2) | 74.3 | (66.6-80.4) | – | – | |
Anaplastic astrocytoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 103 | 85.6 | (77.1-91.1) | 57.7 | (47.5-66.6) | 42.4 | (32.7-51.9) | |
1988-1992 | 195 | 85.2 | (79.3-89.5) | 52.2 | (44.9-59.0) | 37.9 | (31.0-44.8) | |
1993-1997 | 194 | 81.5 | (75.2-86.3) | 46.0 | (38.7-52.9) | 34.2 | (27.4-41.0) | |
1998-2002 | 278 | 86.4 | (81.7-89.9) | 47.4 | (41.4-53.3) | 33.3 | (27.7-39.1) | |
2003-2007 | 333 | 87.3 | (83.2-90.5) | 51.6 | (46.0-56.9) | – | – | |
2008-2012 | 400 | 93.5 | (90.4-95.7) | 60.3 | (48.6-70.2) | – | – | |
Glioblastoma | 1973-1977 | 230 | 60.1 | (53.5-66.1) | 17.5 | (12.9-22.7) | 13.3 | (9.2-18.0) |
1978-1982 | 172 | 62.8 | (55.1-69.5) | 20.3 | (14.6-26.7) | – | – | |
1983-1987 | 194 | 63.5 | (56.3-69.9) | 16.7 | (11.8-22.3) | 11.3 | (7.3-16.4) | |
1988-1992 | 225 | 62.1 | (55.3-68.1) | 13.9 | (9.7-18.9) | 13.0 | (9.0-17.9) | |
1993-1997 | 297 | 56.2 | (50.3-61.7) | 16.1 | (12.1-20.5) | 11.2 | (7.8-15.2) | |
1998-2002 | 505 | 68.0 | (63.7-71.9) | 20.7 | (17.2-24.4) | 12.8 | (10.0-16.0) | |
2003-2007 | 607 | 73.9 | (70.2-77.2) | 24.3 | (20.9-27.9) | – | – | |
2008-2012 | 623 | 76.5 | (72.7-79.8) | 23.0 | (16.5-30.2) | – | – | |
Oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 59 | 86.6 | (74.8-93.1) | 70.1 | (56.4-80.2) | 58.6 | (44.7-70.1) | |
1983-1987 | 89 | 94.5 | (87.0-97.7) | 81.3 | (71.2-88.1) | 63.5 | (52.3-72.8) | |
1988-1992 | 149 | 97.4 | (93.0-99.1) | 82.3 | (75.0-87.7) | 72.7 | (64.5-79.3) | |
1993-1997 | 305 | 97.2 | (94.5-98.6) | 85.7 | (81.1-89.3) | 65.2 | (59.3-70.4) | |
1998-2002 | 448 | 98.3 | (96.5-99.2) | 84.9 | (81.1-88.0) | 69.9 | (65.2-74.0) | |
2003-2007 | 452 | 99.0 | (97.4-99.6) | 88.4 | (84.9-91.2) | – | – | |
2008-2012 | 374 | 98.6 | (96.5-99.5) | – | – | – | – | |
Anaplastic oligodendroglioma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | – | – | – | – | – | – | – | |
1993-1997 | – | – | – | – | – | – | – | |
1998-2002 | 128 | 93.9 | (88.0-96.9) | 65.3 | (56.3-72.9) | 47.6 | (38.6-56.1) | |
2003-2007 | 122 | 91.8 | (85.3-95.6) | 66.1 | (56.8-73.9) | – | – | |
2008-2012 | 118 | 95.3 | (88.9-98.1) | 80.6 | (58.9-91.6) | – | – | |
Ependymal tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | 54 | 89.0 | (77.0-95.0) | 78.2 | (64.5-87.2) | 64.0 | (49.4-75.4) | |
1983-1987 | 59 | 96.7 | (86.9-99.2) | 95.3 | (84.9-98.6) | 89.5 | (77.3-95.4) | |
1988-1992 | 74 | 93.3 | (84.5-97.2) | 90.9 | (81.2-95.7) | 83.8 | (72.4-90.7) | |
1993-1997 | 117 | 94.1 | (87.9-97.2) | 87.8 | (80.1-92.6) | 82.9 | (74.5-88.7) | |
1998-2002 | 192 | 95.9 | (91.9-98.0) | 90.0 | (84.5-93.6) | 85.5 | (79.2-90.0) | |
2003-2007 | 278 | 96.5 | (93.4-98.1) | 90.5 | (86.2-93.5) | – | – | |
2008-2012 | 299 | 98.2 | (95.6-99.3) | 85.6 | (74.4-92.2) | – | – | |
Oligoastrocytic tumors | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | – | – | – | – | – | – | – | |
1988-1992 | 78 | 97.6 | (89.9-99.4) | 74.8 | (63.4-83.1) | 60.8 | (48.8-70.9) | |
1993-1997 | 118 | 90.8 | (83.9-94.8) | 70.8 | (61.6-78.2) | 56.7 | (47.1-65.2) | |
1998-2002 | 202 | 97.1 | (93.5-98.7) | 69.3 | (62.3-75.3) | 55.1 | (47.7-61.8) | |
2003-2007 | 339 | 97.4 | (95.0-98.7) | 76.9 | (71.9-81.2) | – | – | |
2008-2012 | 319 | 97.3 | (94.4-98.7) | 79.0 | (68.6-86.3) | – | – | |
Embryonal tumors | 1973-1977 | 52 | 84.7 | (71.6-92.1) | 38.7 | (25.6-51.7) | 31.1 | (19.1-43.9) |
1978-1982 | 59 | 90.0 | (78.8-95.4) | 56.3 | (42.7-67.9) | 48.2 | (34.8-60.3) | |
1983-1987 | 59 | 91.6 | (80.9-96.5) | 66.6 | (52.9-77.1) | 51.6 | (38.0-63.6) | |
1988-1992 | 103 | 81.7 | (72.7-87.9) | 57.6 | (47.4-66.5) | 48.9 | (38.7-58.2) | |
1993-1997 | 109 | 89.1 | (81.5-93.7) | 62.6 | (52.6-71.0) | 50.6 | (40.7-59.7) | |
1998-2002 | 220 | 88.6 | (83.6-92.2) | 65.2 | (58.3-71.2) | 59.6 | (52.6-65.9) | |
2003-2007 | 244 | 88.1 | (83.3-91.6) | 65.7 | (59.2-71.4) | – | – | |
2008-2012 | 243 | 89.0 | (84.0-92.5) | – | – | – | – | |
Lymphoma | 1973-1977 | – | – | – | – | – | – | – |
1978-1982 | – | – | – | – | – | – | – | |
1983-1987 | 57 | 38.7 | (26.2-51.0) | 29.7 | (18.4-41.9) | 29.7 | (18.4-41.9) | |
1988-1992 | 281 | 12.1 | (8.6-16.3) | 3.8 | (1.9-6.5) | 2.7 | (1.2-5.2) | |
1993-1997 | 458 | 16.6 | (13.4-20.2) | 8.4 | (6.1-11.2) | 6.0 | (4.0-8.4) | |
1998-2002 | 195 | 37.4 | (30.6-44.2) | 27.4 | (21.3-33.9) | 24.4 | (18.5-30.7) | |
2003-2007 | 195 | 59.6 | (52.3-66.1) | 51.8 | (44.4-58.7) | – | – | |
2008-2012 | 160 | 66.5 | (58.2-73.6) | – | – | – | – | |
TOTAL: All Brain and Other Nervous Systemd | 1973-1977 | 887 | 78.9 | (76.1-81.5) | 46.3 | (43.0-49.6) | 36.3 | (33.1-39.5) |
1978-1982 | 1,199 | 81.7 | (79.4-83.8) | 52.0 | (49.1-54.8) | 39.1 | (36.3-41.9) | |
1983-1987 | 1,447 | 83.7 | (81.7-85.5) | 56.3 | (53.6-58.8) | 44.4 | (41.8-47.0) | |
1988-1992 | 1,902 | 74.7 | (72.7-76.6) | 51.5 | (49.2-53.7) | 43.0 | (40.7-45.2) | |
1993-1997 | 2,471 | 73.1 | (71.3-74.8) | 54.0 | (51.9-55.9) | 44.0 | (42.0-45.9) | |
1998-2002 | 3,521 | 86.3 | (85.1-87.4) | 62.7 | (61.1-64.3) | 52.0 | (50.3-53.7) | |
2003-2007 | 4,355 | 89.1 | (88.1-90.0) | 67.9 | (66.4-69.3) | 57.6 | (55.7-59.5) | |
2008-2012 | 4,375 | 90.8 | (89.9-91.7) | 70.7 | (68.3-72.9) | – | – |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dIncludes histologies not listed in this table.
– Rates are excluded when calculated based on a population of less than 50, when less than 16 remain alive in the survival period, or when not enough follow up time has passed to calculate survival for the listed period.
Abbreviations: SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.
Relative Survival by Age Group and Histologic Group
Relative survival rates for adolescents and young adults (age 15-39 years) by histology and age group are shown in Table 16.
Overall, persons age 15-19 years have the highest survival after diagnosis with a malignant brain tumor. Ten-year relative survival in this group is 73.5%, as compared to 44.1% in ages 35-39 years.
A similar trend is seen in most histologies in AYA with the exception of anaplastic astrocytoma and glioblastoma in which there are few differences between age groups.
Histology . | Age Group (years) . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 15-19 | 475 | 98.1 | (96.2-99.0) | 97.6 | (95.6-98.7) | 95.5 | (92.8-97.2) | 95.3 | (92.4-97.1) |
20-24 | 261 | 98.1 | (95.3-99.2) | 96.5 | (93.2-98.2) | 93.8 | (89.5-96.4) | 91.0 | (85.2-94.6) | |
25-29 | 165 | 97.6 | (93.5-99.1) | 95.6 | (90.8-98.0) | 89.7 | (83.1-93.8) | 83.6 | (74.9-89.5) | |
30-34 | 138 | 94.7 | (89.1-97.5) | 92.3 | (85.9-95.8) | 90.6 | (83.4-94.7) | 84.8 | (74.8-91.0) | |
35-39 | 109 | 93.5 | (86.7-96.9) | 90.5 | (82.8-94.9) | 89.5 | (81.2-94.3) | 84.5 | (72.9-91.5) | |
Diffuse astrocytoma | 15-19 | 222 | 96.8 | (93.3-98.5) | 88.6 | (83.3-92.3) | 84.0 | (77.7-88.6) | 79.8 | (72.5-85.3) |
20-24 | 342 | 92.7 | (89.3-95.1) | 85.0 | (80.4-88.5) | 69.0 | (63.0-74.2) | 51.0 | (43.8-57.7) | |
25-29 | 421 | 95.6 | (93.1-97.3) | 92.0 | (88.8-94.3) | 73.0 | (67.8-77.5) | 48.6 | (42.0-55.0) | |
30-34 | 515 | 93.9 | (91.4-95.7) | 88.5 | (85.3-91.1) | 68.0 | (63.2-72.3) | 49.6 | (44.0-55.0) | |
35-39 | 550 | 90.6 | (87.8-92.8) | 81.1 | (77.4-84.2) | 63.4 | (58.8-67.7) | 46.0 | (40.4-51.5) | |
Anaplastic astrocytoma | 15-19 | 88 | 79.4 | (69.0-86.7) | 54.6 | (30.5-53.3) | 42.2 | (42.7-65.0) | 32.8 | (20.2-46.1) |
20-24 | 160 | 91.5 | (85.7-95.0) | 75.7 | (50.1-67.2) | 59.2 | (67.8-82.0) | 38.3 | (28.0-48.5) | |
25-29 | 238 | 92.7 | (88.4-95.5) | 81.5 | (47.6-63.3) | 55.9 | (75.3-86.3) | 45.3 | (36.3-53.8) | |
30-34 | 292 | 90.9 | (86.8-93.7) | 75.2 | (42.2-55.7) | 49.2 | (69.5-80.0) | 37.7 | (30.5-44.8) | |
35-39 | 329 | 84.4 | (79.9-88.0) | 73.3 | (42.3-54.6) | 48.6 | (67.9-77.9) | 34.3 | (27.5-41.1) | |
Glioblastoma | 15-19 | 136 | 71.5 | (62.8-78.4) | 41.7 | (6.4-19.5) | 12.0 | (32.7-50.4) | 8.0 | (3.0-16.2) |
20-24 | 198 | 73.2 | (66.2-78.9) | 50.6 | (22.3-36.4) | 29.2 | (43.0-57.6) | 14.8 | (8.5-22.8) | |
25-29 | 339 | 74.1 | (68.9-78.5) | 51.4 | (22.1-32.8) | 27.3 | (45.6-56.9) | 18.1 | (12.9-24.0) | |
30-34 | 455 | 72.8 | (68.3-76.8) | 48.1 | (18.1-27.3) | 22.5 | (43.1-53.0) | 14.4 | (10.3-19.1) | |
35-39 | 773 | 69.9 | (66.4-73.0) | 39.2 | (17.3-23.6) | 20.4 | (35.6-42.8) | 12.2 | (9.4-15.3) | |
Oligodendroglioma | 15-19 | 116 | 98.3 | (93.0-99.6) | 94.6 | (88.2-97.6) | 91.7 | (84.1-95.7) | 87.8 | (78.6-93.2) |
20-24 | 166 | – | – | 97.6 | (93.2-99.1) | 90.5 | (84.1-94.4) | 81.0 | (72.0-87.4) | |
25-29 | 312 | 98.5 | (96.1-99.4) | 95.8 | (92.7-97.6) | 87.5 | (82.7-91.0) | 65.5 | (57.9-72.1) | |
30-34 | 389 | 98.8 | (96.8-99.5) | 95.7 | (92.8-97.4) | 85.0 | (80.3-88.6) | 70.3 | (63.7-75.9) | |
35-39 | 493 | 97.7 | (95.8-98.7) | 96.5 | (94.3-97.9) | 87.5 | (83.9-90.4) | 67.7 | (62.1-72.6) | |
Anaplastic oligodendroglioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 39 | 84.5 | (68.6-92.7) | 62.7 | (45.2-76.1) | 50.7 | (33.4-65.7) | 44.6 | (25.8-61.8) | |
25-29 | 83 | 96.3 | (88.8-98.8) | 84.4 | (74.0-90.9) | 67.6 | (55.1-77.4) | 46.1 | (32.4-58.7) | |
30-34 | 105 | 93.2 | (86.1-96.7) | 83.7 | (74.6-89.7) | 62.7 | (51.0-72.3) | 50.2 | (37.4-61.8) | |
35-39 | 155 | 96.1 | (91.3-98.3) | 91.1 | (84.8-94.8) | 77.8 | (69.1-84.2) | 55.4 | (44.1-65.3) | |
Ependymal tumors | 15-19 | 137 | 96.2 | (91.0-98.4) | 92.8 | (86.5-96.3) | 86.9 | (78.9-92.1) | 77.9 | (67.0-85.7) |
20-24 | 138 | 94.1 | (88.4-97.0) | 92.5 | (86.3-96.0) | 87.3 | (79.3-92.4) | 82.5 | (72.1-89.3) | |
25-29 | 161 | 96.3 | (91.7-98.3) | 92.9 | (87.5-96.1) | 88.5 | (81.8-92.9) | 85.6 | (77.8-90.8) | |
30-34 | 196 | 97.5 | (93.8-99.0) | 95.8 | (91.6-98.0) | 92.0 | (86.4-95.4) | 88.2 | (80.3-93.0) | |
35-39 | 210 | 98.1 | (94.7-99.3) | 94.8 | (90.3-97.3) | 91.9 | (86.4-95.2) | 91.4 | (85.5-95.0) | |
Oligoastrocytic tumors | 15-19 | 54 | 90.6 | (78.8-96.0) | 86.7 | (73.9-93.5) | 84.5 | (70.8-92.1) | 75.9 | (59.5-86.3) |
20-24 | 109 | 98.1 | (92.4-99.6) | 90.8 | (82.9-95.2) | 73.8 | (62.9-82.0) | 62.4 | (48.5-73.6) | |
25-29 | 229 | 96.9 | (93.4-98.5) | 90.9 | (86.0-94.2) | 77.3 | (70.3-82.8) | 61.6 | (52.5-69.5) | |
30-34 | 296 | 96.6 | (93.6-98.2) | 91.6 | (87.5-94.4) | 73.9 | (67.5-79.3) | 52.3 | (43.5-60.4) | |
35-39 | 240 | 98.0 | (94.8-99.2) | 90.9 | (86.1-94.1) | 70.1 | (62.9-76.2) | 51.4 | (42.3-59.8) | |
Glioma malignant, NOS | 15-19 | 172 | 90.3 | (84.7-94.0) | 83.6 | (76.8-88.6) | 75.1 | (67.0-81.4) | 73.8 | (65.3-80.5) |
20-24 | 151 | 90.2 | (83.9-94.1) | 84.6 | (77.2-89.7) | 73.8 | (64.5-81.0) | 65.7 | (53.5-75.4) | |
25-29 | 159 | 88.8 | (82.6-92.9) | 83.7 | (76.6-88.8) | 69.6 | (60.6-76.9) | 51.7 | (39.9-62.2) | |
30-34 | 195 | 87.3 | (81.5-91.3) | 75.7 | (68.7-81.4) | 68.3 | (60.5-74.8) | 48.4 | (38.9-57.3) | |
35-39 | 195 | 89.8 | (84.4-93.4) | 82.6 | (76.1-87.5) | 62.1 | (53.6-69.5) | 50.2 | (40.5-59.1) | |
Neuronal and mixed neuronal-glial tumors | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Embryonal tumors | 15-19 | 205 | 90.5 | (85.5-93.9) | 78.5 | (71.9-83.7) | 62.5 | (54.7-69.3) | 56.7 | (48.2-64.3) |
20-24 | 194 | 90.0 | (84.7-93.5) | 81.5 | (75.0-86.5) | 65.0 | (57.1-71.8) | 54.7 | (45.9-62.6) | |
25-29 | 151 | 88.0 | (81.3-92.4) | 81.7 | (74.0-87.3) | 66.1 | (56.7-73.9) | 59.6 | (49.2-68.5) | |
30-34 | 124 | 90.0 | (83.0-94.2) | 78.3 | (69.5-84.8) | 71.4 | (61.8-79.0) | 58.8 | (47.4-68.5) | |
35-39 | 99 | 81.2 | (71.7-87.7) | 77.8 | (67.9-85.0) | 59.7 | (48.1-69.5) | 48.1 | (35.4-59.7) | |
Meningioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Lymphoma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 66 | 62.7 | (49.3-73.4) | 51.3 | (37.8-63.3) | 43.3 | (30.1-55.9) | 39.6 | (25.6-53.3) | |
25-29 | 151 | 44.2 | (36.1-52.0) | 36.3 | (28.6-44.1) | 31.6 | (24.0-39.4) | 30.4 | (22.9-38.3) | |
30-34 | 247 | 40.1 | (33.9-46.2) | 36.2 | (30.1-42.2) | 31.8 | (25.9-37.8) | 25.0 | (18.9-31.5) | |
35-39 | 329 | 36.1 | (30.9-41.3) | 30.7 | (25.7-35.9) | 25.5 | (20.7-30.6) | 19.3 | (14.5-24.6) | |
TOTAL: All Brain and Other Nervous Systemd | 15-19 | 2,066 | 92.2 | (90.9-93.3) | 85.2 | (83.5-86.7) | 77.4 | (75.4-79.4) | 73.5 | (71.1-75.7) |
20-24 | 2,084 | 90.7 | (89.3-91.9) | 83.1 | (81.3-84.7) | 71.5 | (69.3-73.6) | 61.3 | (58.6-63.9) | |
25-29 | 2,641 | 88.8 | (87.5-90.0) | 80.9 | (79.3-82.4) | 66.8 | (64.8-68.8) | 53.1 | (50.5-55.5) | |
30-34 | 3,180 | 86.5 | (85.2-87.7) | 77.8 | (76.2-79.3) | 62.9 | (61.0-64.7) | 50.5 | (48.2-52.7) | |
35-39 | 3,730 | 82.3 | (81.0-83.5) | 71.2 | (69.6-72.7) | 56.8 | (55.0-58.5) | 44.1 | (42.1-46.1) |
Histology . | Age Group (years) . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 15-19 | 475 | 98.1 | (96.2-99.0) | 97.6 | (95.6-98.7) | 95.5 | (92.8-97.2) | 95.3 | (92.4-97.1) |
20-24 | 261 | 98.1 | (95.3-99.2) | 96.5 | (93.2-98.2) | 93.8 | (89.5-96.4) | 91.0 | (85.2-94.6) | |
25-29 | 165 | 97.6 | (93.5-99.1) | 95.6 | (90.8-98.0) | 89.7 | (83.1-93.8) | 83.6 | (74.9-89.5) | |
30-34 | 138 | 94.7 | (89.1-97.5) | 92.3 | (85.9-95.8) | 90.6 | (83.4-94.7) | 84.8 | (74.8-91.0) | |
35-39 | 109 | 93.5 | (86.7-96.9) | 90.5 | (82.8-94.9) | 89.5 | (81.2-94.3) | 84.5 | (72.9-91.5) | |
Diffuse astrocytoma | 15-19 | 222 | 96.8 | (93.3-98.5) | 88.6 | (83.3-92.3) | 84.0 | (77.7-88.6) | 79.8 | (72.5-85.3) |
20-24 | 342 | 92.7 | (89.3-95.1) | 85.0 | (80.4-88.5) | 69.0 | (63.0-74.2) | 51.0 | (43.8-57.7) | |
25-29 | 421 | 95.6 | (93.1-97.3) | 92.0 | (88.8-94.3) | 73.0 | (67.8-77.5) | 48.6 | (42.0-55.0) | |
30-34 | 515 | 93.9 | (91.4-95.7) | 88.5 | (85.3-91.1) | 68.0 | (63.2-72.3) | 49.6 | (44.0-55.0) | |
35-39 | 550 | 90.6 | (87.8-92.8) | 81.1 | (77.4-84.2) | 63.4 | (58.8-67.7) | 46.0 | (40.4-51.5) | |
Anaplastic astrocytoma | 15-19 | 88 | 79.4 | (69.0-86.7) | 54.6 | (30.5-53.3) | 42.2 | (42.7-65.0) | 32.8 | (20.2-46.1) |
20-24 | 160 | 91.5 | (85.7-95.0) | 75.7 | (50.1-67.2) | 59.2 | (67.8-82.0) | 38.3 | (28.0-48.5) | |
25-29 | 238 | 92.7 | (88.4-95.5) | 81.5 | (47.6-63.3) | 55.9 | (75.3-86.3) | 45.3 | (36.3-53.8) | |
30-34 | 292 | 90.9 | (86.8-93.7) | 75.2 | (42.2-55.7) | 49.2 | (69.5-80.0) | 37.7 | (30.5-44.8) | |
35-39 | 329 | 84.4 | (79.9-88.0) | 73.3 | (42.3-54.6) | 48.6 | (67.9-77.9) | 34.3 | (27.5-41.1) | |
Glioblastoma | 15-19 | 136 | 71.5 | (62.8-78.4) | 41.7 | (6.4-19.5) | 12.0 | (32.7-50.4) | 8.0 | (3.0-16.2) |
20-24 | 198 | 73.2 | (66.2-78.9) | 50.6 | (22.3-36.4) | 29.2 | (43.0-57.6) | 14.8 | (8.5-22.8) | |
25-29 | 339 | 74.1 | (68.9-78.5) | 51.4 | (22.1-32.8) | 27.3 | (45.6-56.9) | 18.1 | (12.9-24.0) | |
30-34 | 455 | 72.8 | (68.3-76.8) | 48.1 | (18.1-27.3) | 22.5 | (43.1-53.0) | 14.4 | (10.3-19.1) | |
35-39 | 773 | 69.9 | (66.4-73.0) | 39.2 | (17.3-23.6) | 20.4 | (35.6-42.8) | 12.2 | (9.4-15.3) | |
Oligodendroglioma | 15-19 | 116 | 98.3 | (93.0-99.6) | 94.6 | (88.2-97.6) | 91.7 | (84.1-95.7) | 87.8 | (78.6-93.2) |
20-24 | 166 | – | – | 97.6 | (93.2-99.1) | 90.5 | (84.1-94.4) | 81.0 | (72.0-87.4) | |
25-29 | 312 | 98.5 | (96.1-99.4) | 95.8 | (92.7-97.6) | 87.5 | (82.7-91.0) | 65.5 | (57.9-72.1) | |
30-34 | 389 | 98.8 | (96.8-99.5) | 95.7 | (92.8-97.4) | 85.0 | (80.3-88.6) | 70.3 | (63.7-75.9) | |
35-39 | 493 | 97.7 | (95.8-98.7) | 96.5 | (94.3-97.9) | 87.5 | (83.9-90.4) | 67.7 | (62.1-72.6) | |
Anaplastic oligodendroglioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 39 | 84.5 | (68.6-92.7) | 62.7 | (45.2-76.1) | 50.7 | (33.4-65.7) | 44.6 | (25.8-61.8) | |
25-29 | 83 | 96.3 | (88.8-98.8) | 84.4 | (74.0-90.9) | 67.6 | (55.1-77.4) | 46.1 | (32.4-58.7) | |
30-34 | 105 | 93.2 | (86.1-96.7) | 83.7 | (74.6-89.7) | 62.7 | (51.0-72.3) | 50.2 | (37.4-61.8) | |
35-39 | 155 | 96.1 | (91.3-98.3) | 91.1 | (84.8-94.8) | 77.8 | (69.1-84.2) | 55.4 | (44.1-65.3) | |
Ependymal tumors | 15-19 | 137 | 96.2 | (91.0-98.4) | 92.8 | (86.5-96.3) | 86.9 | (78.9-92.1) | 77.9 | (67.0-85.7) |
20-24 | 138 | 94.1 | (88.4-97.0) | 92.5 | (86.3-96.0) | 87.3 | (79.3-92.4) | 82.5 | (72.1-89.3) | |
25-29 | 161 | 96.3 | (91.7-98.3) | 92.9 | (87.5-96.1) | 88.5 | (81.8-92.9) | 85.6 | (77.8-90.8) | |
30-34 | 196 | 97.5 | (93.8-99.0) | 95.8 | (91.6-98.0) | 92.0 | (86.4-95.4) | 88.2 | (80.3-93.0) | |
35-39 | 210 | 98.1 | (94.7-99.3) | 94.8 | (90.3-97.3) | 91.9 | (86.4-95.2) | 91.4 | (85.5-95.0) | |
Oligoastrocytic tumors | 15-19 | 54 | 90.6 | (78.8-96.0) | 86.7 | (73.9-93.5) | 84.5 | (70.8-92.1) | 75.9 | (59.5-86.3) |
20-24 | 109 | 98.1 | (92.4-99.6) | 90.8 | (82.9-95.2) | 73.8 | (62.9-82.0) | 62.4 | (48.5-73.6) | |
25-29 | 229 | 96.9 | (93.4-98.5) | 90.9 | (86.0-94.2) | 77.3 | (70.3-82.8) | 61.6 | (52.5-69.5) | |
30-34 | 296 | 96.6 | (93.6-98.2) | 91.6 | (87.5-94.4) | 73.9 | (67.5-79.3) | 52.3 | (43.5-60.4) | |
35-39 | 240 | 98.0 | (94.8-99.2) | 90.9 | (86.1-94.1) | 70.1 | (62.9-76.2) | 51.4 | (42.3-59.8) | |
Glioma malignant, NOS | 15-19 | 172 | 90.3 | (84.7-94.0) | 83.6 | (76.8-88.6) | 75.1 | (67.0-81.4) | 73.8 | (65.3-80.5) |
20-24 | 151 | 90.2 | (83.9-94.1) | 84.6 | (77.2-89.7) | 73.8 | (64.5-81.0) | 65.7 | (53.5-75.4) | |
25-29 | 159 | 88.8 | (82.6-92.9) | 83.7 | (76.6-88.8) | 69.6 | (60.6-76.9) | 51.7 | (39.9-62.2) | |
30-34 | 195 | 87.3 | (81.5-91.3) | 75.7 | (68.7-81.4) | 68.3 | (60.5-74.8) | 48.4 | (38.9-57.3) | |
35-39 | 195 | 89.8 | (84.4-93.4) | 82.6 | (76.1-87.5) | 62.1 | (53.6-69.5) | 50.2 | (40.5-59.1) | |
Neuronal and mixed neuronal-glial tumors | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Embryonal tumors | 15-19 | 205 | 90.5 | (85.5-93.9) | 78.5 | (71.9-83.7) | 62.5 | (54.7-69.3) | 56.7 | (48.2-64.3) |
20-24 | 194 | 90.0 | (84.7-93.5) | 81.5 | (75.0-86.5) | 65.0 | (57.1-71.8) | 54.7 | (45.9-62.6) | |
25-29 | 151 | 88.0 | (81.3-92.4) | 81.7 | (74.0-87.3) | 66.1 | (56.7-73.9) | 59.6 | (49.2-68.5) | |
30-34 | 124 | 90.0 | (83.0-94.2) | 78.3 | (69.5-84.8) | 71.4 | (61.8-79.0) | 58.8 | (47.4-68.5) | |
35-39 | 99 | 81.2 | (71.7-87.7) | 77.8 | (67.9-85.0) | 59.7 | (48.1-69.5) | 48.1 | (35.4-59.7) | |
Meningioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Lymphoma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 66 | 62.7 | (49.3-73.4) | 51.3 | (37.8-63.3) | 43.3 | (30.1-55.9) | 39.6 | (25.6-53.3) | |
25-29 | 151 | 44.2 | (36.1-52.0) | 36.3 | (28.6-44.1) | 31.6 | (24.0-39.4) | 30.4 | (22.9-38.3) | |
30-34 | 247 | 40.1 | (33.9-46.2) | 36.2 | (30.1-42.2) | 31.8 | (25.9-37.8) | 25.0 | (18.9-31.5) | |
35-39 | 329 | 36.1 | (30.9-41.3) | 30.7 | (25.7-35.9) | 25.5 | (20.7-30.6) | 19.3 | (14.5-24.6) | |
TOTAL: All Brain and Other Nervous Systemd | 15-19 | 2,066 | 92.2 | (90.9-93.3) | 85.2 | (83.5-86.7) | 77.4 | (75.4-79.4) | 73.5 | (71.1-75.7) |
20-24 | 2,084 | 90.7 | (89.3-91.9) | 83.1 | (81.3-84.7) | 71.5 | (69.3-73.6) | 61.3 | (58.6-63.9) | |
25-29 | 2,641 | 88.8 | (87.5-90.0) | 80.9 | (79.3-82.4) | 66.8 | (64.8-68.8) | 53.1 | (50.5-55.5) | |
30-34 | 3,180 | 86.5 | (85.2-87.7) | 77.8 | (76.2-79.3) | 62.9 | (61.0-64.7) | 50.5 | (48.2-52.7) | |
35-39 | 3,730 | 82.3 | (81.0-83.5) | 71.2 | (69.6-72.7) | 56.8 | (55.0-58.5) | 44.1 | (42.1-46.1) |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, five, and ten year, respectively. Rates were not presented for categories with 50 or less cases and were suppressed for rates where less than 16 cases were surviving within a category.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dIncludes histologies not listed in this table.
Histology . | Age Group (years) . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 15-19 | 475 | 98.1 | (96.2-99.0) | 97.6 | (95.6-98.7) | 95.5 | (92.8-97.2) | 95.3 | (92.4-97.1) |
20-24 | 261 | 98.1 | (95.3-99.2) | 96.5 | (93.2-98.2) | 93.8 | (89.5-96.4) | 91.0 | (85.2-94.6) | |
25-29 | 165 | 97.6 | (93.5-99.1) | 95.6 | (90.8-98.0) | 89.7 | (83.1-93.8) | 83.6 | (74.9-89.5) | |
30-34 | 138 | 94.7 | (89.1-97.5) | 92.3 | (85.9-95.8) | 90.6 | (83.4-94.7) | 84.8 | (74.8-91.0) | |
35-39 | 109 | 93.5 | (86.7-96.9) | 90.5 | (82.8-94.9) | 89.5 | (81.2-94.3) | 84.5 | (72.9-91.5) | |
Diffuse astrocytoma | 15-19 | 222 | 96.8 | (93.3-98.5) | 88.6 | (83.3-92.3) | 84.0 | (77.7-88.6) | 79.8 | (72.5-85.3) |
20-24 | 342 | 92.7 | (89.3-95.1) | 85.0 | (80.4-88.5) | 69.0 | (63.0-74.2) | 51.0 | (43.8-57.7) | |
25-29 | 421 | 95.6 | (93.1-97.3) | 92.0 | (88.8-94.3) | 73.0 | (67.8-77.5) | 48.6 | (42.0-55.0) | |
30-34 | 515 | 93.9 | (91.4-95.7) | 88.5 | (85.3-91.1) | 68.0 | (63.2-72.3) | 49.6 | (44.0-55.0) | |
35-39 | 550 | 90.6 | (87.8-92.8) | 81.1 | (77.4-84.2) | 63.4 | (58.8-67.7) | 46.0 | (40.4-51.5) | |
Anaplastic astrocytoma | 15-19 | 88 | 79.4 | (69.0-86.7) | 54.6 | (30.5-53.3) | 42.2 | (42.7-65.0) | 32.8 | (20.2-46.1) |
20-24 | 160 | 91.5 | (85.7-95.0) | 75.7 | (50.1-67.2) | 59.2 | (67.8-82.0) | 38.3 | (28.0-48.5) | |
25-29 | 238 | 92.7 | (88.4-95.5) | 81.5 | (47.6-63.3) | 55.9 | (75.3-86.3) | 45.3 | (36.3-53.8) | |
30-34 | 292 | 90.9 | (86.8-93.7) | 75.2 | (42.2-55.7) | 49.2 | (69.5-80.0) | 37.7 | (30.5-44.8) | |
35-39 | 329 | 84.4 | (79.9-88.0) | 73.3 | (42.3-54.6) | 48.6 | (67.9-77.9) | 34.3 | (27.5-41.1) | |
Glioblastoma | 15-19 | 136 | 71.5 | (62.8-78.4) | 41.7 | (6.4-19.5) | 12.0 | (32.7-50.4) | 8.0 | (3.0-16.2) |
20-24 | 198 | 73.2 | (66.2-78.9) | 50.6 | (22.3-36.4) | 29.2 | (43.0-57.6) | 14.8 | (8.5-22.8) | |
25-29 | 339 | 74.1 | (68.9-78.5) | 51.4 | (22.1-32.8) | 27.3 | (45.6-56.9) | 18.1 | (12.9-24.0) | |
30-34 | 455 | 72.8 | (68.3-76.8) | 48.1 | (18.1-27.3) | 22.5 | (43.1-53.0) | 14.4 | (10.3-19.1) | |
35-39 | 773 | 69.9 | (66.4-73.0) | 39.2 | (17.3-23.6) | 20.4 | (35.6-42.8) | 12.2 | (9.4-15.3) | |
Oligodendroglioma | 15-19 | 116 | 98.3 | (93.0-99.6) | 94.6 | (88.2-97.6) | 91.7 | (84.1-95.7) | 87.8 | (78.6-93.2) |
20-24 | 166 | – | – | 97.6 | (93.2-99.1) | 90.5 | (84.1-94.4) | 81.0 | (72.0-87.4) | |
25-29 | 312 | 98.5 | (96.1-99.4) | 95.8 | (92.7-97.6) | 87.5 | (82.7-91.0) | 65.5 | (57.9-72.1) | |
30-34 | 389 | 98.8 | (96.8-99.5) | 95.7 | (92.8-97.4) | 85.0 | (80.3-88.6) | 70.3 | (63.7-75.9) | |
35-39 | 493 | 97.7 | (95.8-98.7) | 96.5 | (94.3-97.9) | 87.5 | (83.9-90.4) | 67.7 | (62.1-72.6) | |
Anaplastic oligodendroglioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 39 | 84.5 | (68.6-92.7) | 62.7 | (45.2-76.1) | 50.7 | (33.4-65.7) | 44.6 | (25.8-61.8) | |
25-29 | 83 | 96.3 | (88.8-98.8) | 84.4 | (74.0-90.9) | 67.6 | (55.1-77.4) | 46.1 | (32.4-58.7) | |
30-34 | 105 | 93.2 | (86.1-96.7) | 83.7 | (74.6-89.7) | 62.7 | (51.0-72.3) | 50.2 | (37.4-61.8) | |
35-39 | 155 | 96.1 | (91.3-98.3) | 91.1 | (84.8-94.8) | 77.8 | (69.1-84.2) | 55.4 | (44.1-65.3) | |
Ependymal tumors | 15-19 | 137 | 96.2 | (91.0-98.4) | 92.8 | (86.5-96.3) | 86.9 | (78.9-92.1) | 77.9 | (67.0-85.7) |
20-24 | 138 | 94.1 | (88.4-97.0) | 92.5 | (86.3-96.0) | 87.3 | (79.3-92.4) | 82.5 | (72.1-89.3) | |
25-29 | 161 | 96.3 | (91.7-98.3) | 92.9 | (87.5-96.1) | 88.5 | (81.8-92.9) | 85.6 | (77.8-90.8) | |
30-34 | 196 | 97.5 | (93.8-99.0) | 95.8 | (91.6-98.0) | 92.0 | (86.4-95.4) | 88.2 | (80.3-93.0) | |
35-39 | 210 | 98.1 | (94.7-99.3) | 94.8 | (90.3-97.3) | 91.9 | (86.4-95.2) | 91.4 | (85.5-95.0) | |
Oligoastrocytic tumors | 15-19 | 54 | 90.6 | (78.8-96.0) | 86.7 | (73.9-93.5) | 84.5 | (70.8-92.1) | 75.9 | (59.5-86.3) |
20-24 | 109 | 98.1 | (92.4-99.6) | 90.8 | (82.9-95.2) | 73.8 | (62.9-82.0) | 62.4 | (48.5-73.6) | |
25-29 | 229 | 96.9 | (93.4-98.5) | 90.9 | (86.0-94.2) | 77.3 | (70.3-82.8) | 61.6 | (52.5-69.5) | |
30-34 | 296 | 96.6 | (93.6-98.2) | 91.6 | (87.5-94.4) | 73.9 | (67.5-79.3) | 52.3 | (43.5-60.4) | |
35-39 | 240 | 98.0 | (94.8-99.2) | 90.9 | (86.1-94.1) | 70.1 | (62.9-76.2) | 51.4 | (42.3-59.8) | |
Glioma malignant, NOS | 15-19 | 172 | 90.3 | (84.7-94.0) | 83.6 | (76.8-88.6) | 75.1 | (67.0-81.4) | 73.8 | (65.3-80.5) |
20-24 | 151 | 90.2 | (83.9-94.1) | 84.6 | (77.2-89.7) | 73.8 | (64.5-81.0) | 65.7 | (53.5-75.4) | |
25-29 | 159 | 88.8 | (82.6-92.9) | 83.7 | (76.6-88.8) | 69.6 | (60.6-76.9) | 51.7 | (39.9-62.2) | |
30-34 | 195 | 87.3 | (81.5-91.3) | 75.7 | (68.7-81.4) | 68.3 | (60.5-74.8) | 48.4 | (38.9-57.3) | |
35-39 | 195 | 89.8 | (84.4-93.4) | 82.6 | (76.1-87.5) | 62.1 | (53.6-69.5) | 50.2 | (40.5-59.1) | |
Neuronal and mixed neuronal-glial tumors | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Embryonal tumors | 15-19 | 205 | 90.5 | (85.5-93.9) | 78.5 | (71.9-83.7) | 62.5 | (54.7-69.3) | 56.7 | (48.2-64.3) |
20-24 | 194 | 90.0 | (84.7-93.5) | 81.5 | (75.0-86.5) | 65.0 | (57.1-71.8) | 54.7 | (45.9-62.6) | |
25-29 | 151 | 88.0 | (81.3-92.4) | 81.7 | (74.0-87.3) | 66.1 | (56.7-73.9) | 59.6 | (49.2-68.5) | |
30-34 | 124 | 90.0 | (83.0-94.2) | 78.3 | (69.5-84.8) | 71.4 | (61.8-79.0) | 58.8 | (47.4-68.5) | |
35-39 | 99 | 81.2 | (71.7-87.7) | 77.8 | (67.9-85.0) | 59.7 | (48.1-69.5) | 48.1 | (35.4-59.7) | |
Meningioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Lymphoma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 66 | 62.7 | (49.3-73.4) | 51.3 | (37.8-63.3) | 43.3 | (30.1-55.9) | 39.6 | (25.6-53.3) | |
25-29 | 151 | 44.2 | (36.1-52.0) | 36.3 | (28.6-44.1) | 31.6 | (24.0-39.4) | 30.4 | (22.9-38.3) | |
30-34 | 247 | 40.1 | (33.9-46.2) | 36.2 | (30.1-42.2) | 31.8 | (25.9-37.8) | 25.0 | (18.9-31.5) | |
35-39 | 329 | 36.1 | (30.9-41.3) | 30.7 | (25.7-35.9) | 25.5 | (20.7-30.6) | 19.3 | (14.5-24.6) | |
TOTAL: All Brain and Other Nervous Systemd | 15-19 | 2,066 | 92.2 | (90.9-93.3) | 85.2 | (83.5-86.7) | 77.4 | (75.4-79.4) | 73.5 | (71.1-75.7) |
20-24 | 2,084 | 90.7 | (89.3-91.9) | 83.1 | (81.3-84.7) | 71.5 | (69.3-73.6) | 61.3 | (58.6-63.9) | |
25-29 | 2,641 | 88.8 | (87.5-90.0) | 80.9 | (79.3-82.4) | 66.8 | (64.8-68.8) | 53.1 | (50.5-55.5) | |
30-34 | 3,180 | 86.5 | (85.2-87.7) | 77.8 | (76.2-79.3) | 62.9 | (61.0-64.7) | 50.5 | (48.2-52.7) | |
35-39 | 3,730 | 82.3 | (81.0-83.5) | 71.2 | (69.6-72.7) | 56.8 | (55.0-58.5) | 44.1 | (42.1-46.1) |
Histology . | Age Group (years) . | N . | 1-Year . | 2-Year . | 5-Year . | 10-Year . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . | % . | 95% CI . |
Pilocytic astrocytoma | 15-19 | 475 | 98.1 | (96.2-99.0) | 97.6 | (95.6-98.7) | 95.5 | (92.8-97.2) | 95.3 | (92.4-97.1) |
20-24 | 261 | 98.1 | (95.3-99.2) | 96.5 | (93.2-98.2) | 93.8 | (89.5-96.4) | 91.0 | (85.2-94.6) | |
25-29 | 165 | 97.6 | (93.5-99.1) | 95.6 | (90.8-98.0) | 89.7 | (83.1-93.8) | 83.6 | (74.9-89.5) | |
30-34 | 138 | 94.7 | (89.1-97.5) | 92.3 | (85.9-95.8) | 90.6 | (83.4-94.7) | 84.8 | (74.8-91.0) | |
35-39 | 109 | 93.5 | (86.7-96.9) | 90.5 | (82.8-94.9) | 89.5 | (81.2-94.3) | 84.5 | (72.9-91.5) | |
Diffuse astrocytoma | 15-19 | 222 | 96.8 | (93.3-98.5) | 88.6 | (83.3-92.3) | 84.0 | (77.7-88.6) | 79.8 | (72.5-85.3) |
20-24 | 342 | 92.7 | (89.3-95.1) | 85.0 | (80.4-88.5) | 69.0 | (63.0-74.2) | 51.0 | (43.8-57.7) | |
25-29 | 421 | 95.6 | (93.1-97.3) | 92.0 | (88.8-94.3) | 73.0 | (67.8-77.5) | 48.6 | (42.0-55.0) | |
30-34 | 515 | 93.9 | (91.4-95.7) | 88.5 | (85.3-91.1) | 68.0 | (63.2-72.3) | 49.6 | (44.0-55.0) | |
35-39 | 550 | 90.6 | (87.8-92.8) | 81.1 | (77.4-84.2) | 63.4 | (58.8-67.7) | 46.0 | (40.4-51.5) | |
Anaplastic astrocytoma | 15-19 | 88 | 79.4 | (69.0-86.7) | 54.6 | (30.5-53.3) | 42.2 | (42.7-65.0) | 32.8 | (20.2-46.1) |
20-24 | 160 | 91.5 | (85.7-95.0) | 75.7 | (50.1-67.2) | 59.2 | (67.8-82.0) | 38.3 | (28.0-48.5) | |
25-29 | 238 | 92.7 | (88.4-95.5) | 81.5 | (47.6-63.3) | 55.9 | (75.3-86.3) | 45.3 | (36.3-53.8) | |
30-34 | 292 | 90.9 | (86.8-93.7) | 75.2 | (42.2-55.7) | 49.2 | (69.5-80.0) | 37.7 | (30.5-44.8) | |
35-39 | 329 | 84.4 | (79.9-88.0) | 73.3 | (42.3-54.6) | 48.6 | (67.9-77.9) | 34.3 | (27.5-41.1) | |
Glioblastoma | 15-19 | 136 | 71.5 | (62.8-78.4) | 41.7 | (6.4-19.5) | 12.0 | (32.7-50.4) | 8.0 | (3.0-16.2) |
20-24 | 198 | 73.2 | (66.2-78.9) | 50.6 | (22.3-36.4) | 29.2 | (43.0-57.6) | 14.8 | (8.5-22.8) | |
25-29 | 339 | 74.1 | (68.9-78.5) | 51.4 | (22.1-32.8) | 27.3 | (45.6-56.9) | 18.1 | (12.9-24.0) | |
30-34 | 455 | 72.8 | (68.3-76.8) | 48.1 | (18.1-27.3) | 22.5 | (43.1-53.0) | 14.4 | (10.3-19.1) | |
35-39 | 773 | 69.9 | (66.4-73.0) | 39.2 | (17.3-23.6) | 20.4 | (35.6-42.8) | 12.2 | (9.4-15.3) | |
Oligodendroglioma | 15-19 | 116 | 98.3 | (93.0-99.6) | 94.6 | (88.2-97.6) | 91.7 | (84.1-95.7) | 87.8 | (78.6-93.2) |
20-24 | 166 | – | – | 97.6 | (93.2-99.1) | 90.5 | (84.1-94.4) | 81.0 | (72.0-87.4) | |
25-29 | 312 | 98.5 | (96.1-99.4) | 95.8 | (92.7-97.6) | 87.5 | (82.7-91.0) | 65.5 | (57.9-72.1) | |
30-34 | 389 | 98.8 | (96.8-99.5) | 95.7 | (92.8-97.4) | 85.0 | (80.3-88.6) | 70.3 | (63.7-75.9) | |
35-39 | 493 | 97.7 | (95.8-98.7) | 96.5 | (94.3-97.9) | 87.5 | (83.9-90.4) | 67.7 | (62.1-72.6) | |
Anaplastic oligodendroglioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 39 | 84.5 | (68.6-92.7) | 62.7 | (45.2-76.1) | 50.7 | (33.4-65.7) | 44.6 | (25.8-61.8) | |
25-29 | 83 | 96.3 | (88.8-98.8) | 84.4 | (74.0-90.9) | 67.6 | (55.1-77.4) | 46.1 | (32.4-58.7) | |
30-34 | 105 | 93.2 | (86.1-96.7) | 83.7 | (74.6-89.7) | 62.7 | (51.0-72.3) | 50.2 | (37.4-61.8) | |
35-39 | 155 | 96.1 | (91.3-98.3) | 91.1 | (84.8-94.8) | 77.8 | (69.1-84.2) | 55.4 | (44.1-65.3) | |
Ependymal tumors | 15-19 | 137 | 96.2 | (91.0-98.4) | 92.8 | (86.5-96.3) | 86.9 | (78.9-92.1) | 77.9 | (67.0-85.7) |
20-24 | 138 | 94.1 | (88.4-97.0) | 92.5 | (86.3-96.0) | 87.3 | (79.3-92.4) | 82.5 | (72.1-89.3) | |
25-29 | 161 | 96.3 | (91.7-98.3) | 92.9 | (87.5-96.1) | 88.5 | (81.8-92.9) | 85.6 | (77.8-90.8) | |
30-34 | 196 | 97.5 | (93.8-99.0) | 95.8 | (91.6-98.0) | 92.0 | (86.4-95.4) | 88.2 | (80.3-93.0) | |
35-39 | 210 | 98.1 | (94.7-99.3) | 94.8 | (90.3-97.3) | 91.9 | (86.4-95.2) | 91.4 | (85.5-95.0) | |
Oligoastrocytic tumors | 15-19 | 54 | 90.6 | (78.8-96.0) | 86.7 | (73.9-93.5) | 84.5 | (70.8-92.1) | 75.9 | (59.5-86.3) |
20-24 | 109 | 98.1 | (92.4-99.6) | 90.8 | (82.9-95.2) | 73.8 | (62.9-82.0) | 62.4 | (48.5-73.6) | |
25-29 | 229 | 96.9 | (93.4-98.5) | 90.9 | (86.0-94.2) | 77.3 | (70.3-82.8) | 61.6 | (52.5-69.5) | |
30-34 | 296 | 96.6 | (93.6-98.2) | 91.6 | (87.5-94.4) | 73.9 | (67.5-79.3) | 52.3 | (43.5-60.4) | |
35-39 | 240 | 98.0 | (94.8-99.2) | 90.9 | (86.1-94.1) | 70.1 | (62.9-76.2) | 51.4 | (42.3-59.8) | |
Glioma malignant, NOS | 15-19 | 172 | 90.3 | (84.7-94.0) | 83.6 | (76.8-88.6) | 75.1 | (67.0-81.4) | 73.8 | (65.3-80.5) |
20-24 | 151 | 90.2 | (83.9-94.1) | 84.6 | (77.2-89.7) | 73.8 | (64.5-81.0) | 65.7 | (53.5-75.4) | |
25-29 | 159 | 88.8 | (82.6-92.9) | 83.7 | (76.6-88.8) | 69.6 | (60.6-76.9) | 51.7 | (39.9-62.2) | |
30-34 | 195 | 87.3 | (81.5-91.3) | 75.7 | (68.7-81.4) | 68.3 | (60.5-74.8) | 48.4 | (38.9-57.3) | |
35-39 | 195 | 89.8 | (84.4-93.4) | 82.6 | (76.1-87.5) | 62.1 | (53.6-69.5) | 50.2 | (40.5-59.1) | |
Neuronal and mixed neuronal-glial tumors | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Embryonal tumors | 15-19 | 205 | 90.5 | (85.5-93.9) | 78.5 | (71.9-83.7) | 62.5 | (54.7-69.3) | 56.7 | (48.2-64.3) |
20-24 | 194 | 90.0 | (84.7-93.5) | 81.5 | (75.0-86.5) | 65.0 | (57.1-71.8) | 54.7 | (45.9-62.6) | |
25-29 | 151 | 88.0 | (81.3-92.4) | 81.7 | (74.0-87.3) | 66.1 | (56.7-73.9) | 59.6 | (49.2-68.5) | |
30-34 | 124 | 90.0 | (83.0-94.2) | 78.3 | (69.5-84.8) | 71.4 | (61.8-79.0) | 58.8 | (47.4-68.5) | |
35-39 | 99 | 81.2 | (71.7-87.7) | 77.8 | (67.9-85.0) | 59.7 | (48.1-69.5) | 48.1 | (35.4-59.7) | |
Meningioma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | – | – | – | – | – | – | – | – | – | |
25-29 | – | – | – | – | – | – | – | – | – | |
30-34 | – | – | – | – | – | – | – | – | – | |
35-39 | – | – | – | – | – | – | – | – | – | |
Lymphoma | 15-19 | – | – | – | – | – | – | – | – | – |
20-24 | 66 | 62.7 | (49.3-73.4) | 51.3 | (37.8-63.3) | 43.3 | (30.1-55.9) | 39.6 | (25.6-53.3) | |
25-29 | 151 | 44.2 | (36.1-52.0) | 36.3 | (28.6-44.1) | 31.6 | (24.0-39.4) | 30.4 | (22.9-38.3) | |
30-34 | 247 | 40.1 | (33.9-46.2) | 36.2 | (30.1-42.2) | 31.8 | (25.9-37.8) | 25.0 | (18.9-31.5) | |
35-39 | 329 | 36.1 | (30.9-41.3) | 30.7 | (25.7-35.9) | 25.5 | (20.7-30.6) | 19.3 | (14.5-24.6) | |
TOTAL: All Brain and Other Nervous Systemd | 15-19 | 2,066 | 92.2 | (90.9-93.3) | 85.2 | (83.5-86.7) | 77.4 | (75.4-79.4) | 73.5 | (71.1-75.7) |
20-24 | 2,084 | 90.7 | (89.3-91.9) | 83.1 | (81.3-84.7) | 71.5 | (69.3-73.6) | 61.3 | (58.6-63.9) | |
25-29 | 2,641 | 88.8 | (87.5-90.0) | 80.9 | (79.3-82.4) | 66.8 | (64.8-68.8) | 53.1 | (50.5-55.5) | |
30-34 | 3,180 | 86.5 | (85.2-87.7) | 77.8 | (76.2-79.3) | 62.9 | (61.0-64.7) | 50.5 | (48.2-52.7) | |
35-39 | 3,730 | 82.3 | (81.0-83.5) | 71.2 | (69.6-72.7) | 56.8 | (55.0-58.5) | 44.1 | (42.1-46.1) |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, five, and ten year, respectively. Rates were not presented for categories with 50 or less cases and were suppressed for rates where less than 16 cases were surviving within a category.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2014 Sub (1973-2012 varying) - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2015, based on the November 2014 submission.
dIncludes histologies not listed in this table.
Relative Survival in Glioma by Age Groups, Sex, Race/Ethnicity and Insurance Status
Relative survival by sex, race/ethnicity, and insurance status in adolescents and young adults (age 15-39 years) is shown in Figures 24A–24D.
Relative survival rates are highest in younger age groups in AYA and decrease with increasing age. This may be accentuated by the increased incidence of pilocytic astrocytomas in younger age groups, although malignant gliomas show a decrease in survival with increased age at diagnosis as well (Table 16).
Females have higher relative survival rates than males in AYA.
White non-Hispanics have the highest survival rates in AYA, although there are not notable differences by race/ethnicity.
Persons with private insurance have the highest rates of relative survival. This is consistent with analyses done on survival in other cancer types,36 and is likely due a combination of factors that may be associated with insurance status including: geographic access to care, type of health care facility utilized, differences in treatment pattern, and many factors of socioeconomic status.
There is little difference between the relative survival rates of persons with no insurance versus persons with Medicaid in AYA. Previous studies have shown that many people enroll in Medicaid after diagnosis with cancer, which may have been delayed due to prior lack of insurance coverage.37,38 This is one potential explanation for the poorer outcomes seen in this group.
Five-Year Conditional Survival after Diagnosis by Selected Histologic Groups
Relative survival provides data on cancer prognosis that is useful at a population level, but these numbers may not be informative for individual patients. In the case of individuals that have already survived a year, or several years after diagnosis with their brain tumor, conditional survival estimates provide information about the likelihood that they will survive into the next period of time. Five-year conditional survival estimates by age group and selected histologies for adolescents and young adults are presented in Figure 25.
Diagnosis at a younger age in AYA generally led to higher survival rates in all histologies.
For a person age 15-19 years at the time of diagnosis with an astrocytoma, 76.5% survived five years. For those that have already survived two years, 91.0% will go on to survive five years.
For a person age 35-39 years at the time of diagnosis with an astrocytoma, 43.3% survived five years from time of diagnosis. For those that have already survived two years, 68.9% will go on to survive five years.
Time Trends in Incidence of Primary Brain and CNS Tumors in Adolescents and Young Adults
Time trends in cancer incidence rates are an important measure of the changing burden of cancer in a population over time. These time trends are provided for adolescents and young adults in Table 17. Collection of data on non-malignant brain and CNS tumors began in 2004, after the passage of the Benign Brain Tumor Act39 in 2002. Previous analyses have suggested that increased incidence in the time period between 2004 and 2006 may be the result of the initiation of this collection rather than a ‘true’ increase in incidence.40
Incidence of anaplastic astrocytoma in AYA has significantly increased from 2006-2012 (Annual Percent Change (APC) = 2.7).
Incidence of oligodendroglioma (APC = −2.9) and anaplastic oligodendroglioma (APC = −4.1) in AYA has significantly decreased from 2004-2012.
Incidence of tumors of the meninges in AYA has significantly increased from 2004-2012 (APC = 2.5), which is largely driven by the increase of meningioma incidence during that time (APC = 2.6).
Incidence of lymphomas and hematopoietic neoplasms has significantly decreased from 2004-2012 (APC = −2.8) in AYA.
Incidence of tumors of the sellar region in AYA has significantly increased from 2004-2008 (APC = 8.5), which is largely driven by the increase of tumors of the pituitary incidence from 2004-2009 (APC = 7.6).
Incidence of unclassified tumors in AYA has significantly increased from 2004-2012 (APC = 5.5), which is largely driven by the increase of hemangioma incidence from 2004-2010 (APC = 18.8).
Histology . | Malignant . | Non-malignant . | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Trend 1 . | Trend 2 . | Trend 3 . | Trend 1 . | Trend 2 . | ||||||||||
. | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . |
Tumors of Neuroepithelial Tissue | 1995-2012 | 0.1 | (−0.1,0.3) | 2004-2012 | 2.2 | (0.3,4.1)* | |||||||||
Pilocytic astrocytoma | 1995-2012 | 1.1 | (0.3,1.8)* | – | – | – | |||||||||
Diffuse astrocytoma | 1995-2002 | −2.5 | (−4.1,-0.9)* | 2002-2012 | −1.1 | (−2.0,-0.2)* | – | – | – | ||||||
Anaplastic astrocytoma | 1995-2000 | 2.0 | (−0.8,4.9) | 2000-2006 | −3.2 | (−6.1,-0.3)* | 2006-2012 | 2.5 | (0.3,4.8)* | – | – | – | |||
Unique astrocytoma variants | 1995-2012 | 4.5 | (2.1,7.0)* | – | – | – | |||||||||
Glioblastoma | 1995-2012 | 0.6 | (0.0,1.2) | – | – | – | |||||||||
Oligodendroglioma | 1995-1997 | 9.2 | (−7.5,29) | 1997-2012 | −3.2 | (−4.0,-2.4)* | – | – | – | ||||||
Anaplastic oligodendroglioma | 1995-1998 | 23.3 | (8.3,40.3)* | 1998-2012 | −4.3 | (−5.3,-3.3)* | – | – | – | ||||||
Oligoastrocytic tumors | 1995-2012 | 4.3 | (3.4,5.3)* | – | – | – | |||||||||
Ependymal tumors | 1995-2002 | −1.5 | (−4.8,1.9) | 2002-2004 | 14.8 | ** | 2004-2012 | −1.6 | (−3.5,0.3) | 2004-2012 | 1.5 | (−2.4,5.6) | |||
Glioma malignant, NOS | 1995-2012 | 3.1 | (2.1,4.1)* | ||||||||||||
Choroid plexus tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | −3.5 | (−7.4,0.6) | |||
Neuronal and mixed neuronal-glial tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | 2.6 | (0.8,4.3)* | |||
Embryonal tumors | 1995-2012 | −0.6 | (−1.3,0.0) | ||||||||||||
Tumors of Cranial and Spinal Nerves | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Nerve sheath tumors | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Tumors of Meninges | 1995-2012 | −1.8 | (−3.6,0.1) | 2004-2006 | 10.4 | (−7.3,31.5) | 2006-2012 | 1.2 | (−1.4,3.8) | ||||||
Meningioma | – | – | – | 2004-2012 | 2.8 | (0.8,4.7)* | |||||||||
Mesenchymal tumors | – | – | – | 2004-2012 | 1.2 | (−5.3,8.1) | |||||||||
Other neoplasms related to the meninges | – | – | – | 2004-2012 | 1.4 | (−0.5,3.4) | |||||||||
Lymphomas and Hematopoietic Neoplasms | 1995-1998 | −32.7 | (−39.6,-25)* | 1998-2012 | -4.4 | (−5.6,-3.1)* | |||||||||
Lymphoma | 1995-1998 | −31.8 | (−40.1,-22.3)* | 1998-2012 | −5.0 | (−6.4,-3.5)* | |||||||||
Germ Cell Tumors and Cysts | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Germ cell tumors, cysts and heterotopias | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Tumors of Sellar Region | – | – | – | 2004-2008 | 8.6 | (5.3,12)* | 2008-2012 | 0.5 | (−2.3,3.5) | ||||||
Tumors of the pituitary | – | – | – | 2004-2009 | 7.6 | (4.9,10.5)* | 2009-2012 | −0.9 | (−6.4,4.8) | ||||||
Craniopharyngioma | – | – | – | 2004-2012 | −1.6 | (−3.6,0.4) | |||||||||
Unclassified Tumors | 1995-2012 | -3.7 | (−4.8,-2.6)* | 2004-2012 | 6.7 | (4.4,8.9)* | |||||||||
Hemangioma | – | – | – | 2004-2010 | 18.5 | (12.3,25.2)* | 2010-2012 | 2.4 | (−20.8,32.2) | ||||||
Neoplasm, unspecified | 1995-2012 | −2.9 | (−3.9,-2.0)* | 2004-2012 | 1.6 | (−0.4,3.7) | |||||||||
TOTALc | 1995-2012 | -0.6 | (−0.8,-0.4)* | 2004-2006 | 11.0 | (−4.3,28.9) | 2006-2012 | 1.9 | (−0.5,4.3) |
Histology . | Malignant . | Non-malignant . | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Trend 1 . | Trend 2 . | Trend 3 . | Trend 1 . | Trend 2 . | ||||||||||
. | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . |
Tumors of Neuroepithelial Tissue | 1995-2012 | 0.1 | (−0.1,0.3) | 2004-2012 | 2.2 | (0.3,4.1)* | |||||||||
Pilocytic astrocytoma | 1995-2012 | 1.1 | (0.3,1.8)* | – | – | – | |||||||||
Diffuse astrocytoma | 1995-2002 | −2.5 | (−4.1,-0.9)* | 2002-2012 | −1.1 | (−2.0,-0.2)* | – | – | – | ||||||
Anaplastic astrocytoma | 1995-2000 | 2.0 | (−0.8,4.9) | 2000-2006 | −3.2 | (−6.1,-0.3)* | 2006-2012 | 2.5 | (0.3,4.8)* | – | – | – | |||
Unique astrocytoma variants | 1995-2012 | 4.5 | (2.1,7.0)* | – | – | – | |||||||||
Glioblastoma | 1995-2012 | 0.6 | (0.0,1.2) | – | – | – | |||||||||
Oligodendroglioma | 1995-1997 | 9.2 | (−7.5,29) | 1997-2012 | −3.2 | (−4.0,-2.4)* | – | – | – | ||||||
Anaplastic oligodendroglioma | 1995-1998 | 23.3 | (8.3,40.3)* | 1998-2012 | −4.3 | (−5.3,-3.3)* | – | – | – | ||||||
Oligoastrocytic tumors | 1995-2012 | 4.3 | (3.4,5.3)* | – | – | – | |||||||||
Ependymal tumors | 1995-2002 | −1.5 | (−4.8,1.9) | 2002-2004 | 14.8 | ** | 2004-2012 | −1.6 | (−3.5,0.3) | 2004-2012 | 1.5 | (−2.4,5.6) | |||
Glioma malignant, NOS | 1995-2012 | 3.1 | (2.1,4.1)* | ||||||||||||
Choroid plexus tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | −3.5 | (−7.4,0.6) | |||
Neuronal and mixed neuronal-glial tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | 2.6 | (0.8,4.3)* | |||
Embryonal tumors | 1995-2012 | −0.6 | (−1.3,0.0) | ||||||||||||
Tumors of Cranial and Spinal Nerves | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Nerve sheath tumors | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Tumors of Meninges | 1995-2012 | −1.8 | (−3.6,0.1) | 2004-2006 | 10.4 | (−7.3,31.5) | 2006-2012 | 1.2 | (−1.4,3.8) | ||||||
Meningioma | – | – | – | 2004-2012 | 2.8 | (0.8,4.7)* | |||||||||
Mesenchymal tumors | – | – | – | 2004-2012 | 1.2 | (−5.3,8.1) | |||||||||
Other neoplasms related to the meninges | – | – | – | 2004-2012 | 1.4 | (−0.5,3.4) | |||||||||
Lymphomas and Hematopoietic Neoplasms | 1995-1998 | −32.7 | (−39.6,-25)* | 1998-2012 | -4.4 | (−5.6,-3.1)* | |||||||||
Lymphoma | 1995-1998 | −31.8 | (−40.1,-22.3)* | 1998-2012 | −5.0 | (−6.4,-3.5)* | |||||||||
Germ Cell Tumors and Cysts | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Germ cell tumors, cysts and heterotopias | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Tumors of Sellar Region | – | – | – | 2004-2008 | 8.6 | (5.3,12)* | 2008-2012 | 0.5 | (−2.3,3.5) | ||||||
Tumors of the pituitary | – | – | – | 2004-2009 | 7.6 | (4.9,10.5)* | 2009-2012 | −0.9 | (−6.4,4.8) | ||||||
Craniopharyngioma | – | – | – | 2004-2012 | −1.6 | (−3.6,0.4) | |||||||||
Unclassified Tumors | 1995-2012 | -3.7 | (−4.8,-2.6)* | 2004-2012 | 6.7 | (4.4,8.9)* | |||||||||
Hemangioma | – | – | – | 2004-2010 | 18.5 | (12.3,25.2)* | 2010-2012 | 2.4 | (−20.8,32.2) | ||||||
Neoplasm, unspecified | 1995-2012 | −2.9 | (−3.9,-2.0)* | 2004-2012 | 1.6 | (−0.4,3.7) | |||||||||
TOTALc | 1995-2012 | -0.6 | (−0.8,-0.4)* | 2004-2006 | 11.0 | (−4.3,28.9) | 2006-2012 | 1.9 | (−0.5,4.3) |
*Statistic is significantly statistic at the p < .05 level.
** Confidence interval unable to be calculated.
– Rates are excluded when annual rate is based on a population of less than 16.
Abbreviation: APC, annual percentage change; NPCR, National Program of Cancer Registries; SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.
Histology . | Malignant . | Non-malignant . | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Trend 1 . | Trend 2 . | Trend 3 . | Trend 1 . | Trend 2 . | ||||||||||
. | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . |
Tumors of Neuroepithelial Tissue | 1995-2012 | 0.1 | (−0.1,0.3) | 2004-2012 | 2.2 | (0.3,4.1)* | |||||||||
Pilocytic astrocytoma | 1995-2012 | 1.1 | (0.3,1.8)* | – | – | – | |||||||||
Diffuse astrocytoma | 1995-2002 | −2.5 | (−4.1,-0.9)* | 2002-2012 | −1.1 | (−2.0,-0.2)* | – | – | – | ||||||
Anaplastic astrocytoma | 1995-2000 | 2.0 | (−0.8,4.9) | 2000-2006 | −3.2 | (−6.1,-0.3)* | 2006-2012 | 2.5 | (0.3,4.8)* | – | – | – | |||
Unique astrocytoma variants | 1995-2012 | 4.5 | (2.1,7.0)* | – | – | – | |||||||||
Glioblastoma | 1995-2012 | 0.6 | (0.0,1.2) | – | – | – | |||||||||
Oligodendroglioma | 1995-1997 | 9.2 | (−7.5,29) | 1997-2012 | −3.2 | (−4.0,-2.4)* | – | – | – | ||||||
Anaplastic oligodendroglioma | 1995-1998 | 23.3 | (8.3,40.3)* | 1998-2012 | −4.3 | (−5.3,-3.3)* | – | – | – | ||||||
Oligoastrocytic tumors | 1995-2012 | 4.3 | (3.4,5.3)* | – | – | – | |||||||||
Ependymal tumors | 1995-2002 | −1.5 | (−4.8,1.9) | 2002-2004 | 14.8 | ** | 2004-2012 | −1.6 | (−3.5,0.3) | 2004-2012 | 1.5 | (−2.4,5.6) | |||
Glioma malignant, NOS | 1995-2012 | 3.1 | (2.1,4.1)* | ||||||||||||
Choroid plexus tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | −3.5 | (−7.4,0.6) | |||
Neuronal and mixed neuronal-glial tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | 2.6 | (0.8,4.3)* | |||
Embryonal tumors | 1995-2012 | −0.6 | (−1.3,0.0) | ||||||||||||
Tumors of Cranial and Spinal Nerves | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Nerve sheath tumors | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Tumors of Meninges | 1995-2012 | −1.8 | (−3.6,0.1) | 2004-2006 | 10.4 | (−7.3,31.5) | 2006-2012 | 1.2 | (−1.4,3.8) | ||||||
Meningioma | – | – | – | 2004-2012 | 2.8 | (0.8,4.7)* | |||||||||
Mesenchymal tumors | – | – | – | 2004-2012 | 1.2 | (−5.3,8.1) | |||||||||
Other neoplasms related to the meninges | – | – | – | 2004-2012 | 1.4 | (−0.5,3.4) | |||||||||
Lymphomas and Hematopoietic Neoplasms | 1995-1998 | −32.7 | (−39.6,-25)* | 1998-2012 | -4.4 | (−5.6,-3.1)* | |||||||||
Lymphoma | 1995-1998 | −31.8 | (−40.1,-22.3)* | 1998-2012 | −5.0 | (−6.4,-3.5)* | |||||||||
Germ Cell Tumors and Cysts | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Germ cell tumors, cysts and heterotopias | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Tumors of Sellar Region | – | – | – | 2004-2008 | 8.6 | (5.3,12)* | 2008-2012 | 0.5 | (−2.3,3.5) | ||||||
Tumors of the pituitary | – | – | – | 2004-2009 | 7.6 | (4.9,10.5)* | 2009-2012 | −0.9 | (−6.4,4.8) | ||||||
Craniopharyngioma | – | – | – | 2004-2012 | −1.6 | (−3.6,0.4) | |||||||||
Unclassified Tumors | 1995-2012 | -3.7 | (−4.8,-2.6)* | 2004-2012 | 6.7 | (4.4,8.9)* | |||||||||
Hemangioma | – | – | – | 2004-2010 | 18.5 | (12.3,25.2)* | 2010-2012 | 2.4 | (−20.8,32.2) | ||||||
Neoplasm, unspecified | 1995-2012 | −2.9 | (−3.9,-2.0)* | 2004-2012 | 1.6 | (−0.4,3.7) | |||||||||
TOTALc | 1995-2012 | -0.6 | (−0.8,-0.4)* | 2004-2006 | 11.0 | (−4.3,28.9) | 2006-2012 | 1.9 | (−0.5,4.3) |
Histology . | Malignant . | Non-malignant . | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Trend 1 . | Trend 2 . | Trend 3 . | Trend 1 . | Trend 2 . | ||||||||||
. | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . | Years . | APC . | 95% CI . |
Tumors of Neuroepithelial Tissue | 1995-2012 | 0.1 | (−0.1,0.3) | 2004-2012 | 2.2 | (0.3,4.1)* | |||||||||
Pilocytic astrocytoma | 1995-2012 | 1.1 | (0.3,1.8)* | – | – | – | |||||||||
Diffuse astrocytoma | 1995-2002 | −2.5 | (−4.1,-0.9)* | 2002-2012 | −1.1 | (−2.0,-0.2)* | – | – | – | ||||||
Anaplastic astrocytoma | 1995-2000 | 2.0 | (−0.8,4.9) | 2000-2006 | −3.2 | (−6.1,-0.3)* | 2006-2012 | 2.5 | (0.3,4.8)* | – | – | – | |||
Unique astrocytoma variants | 1995-2012 | 4.5 | (2.1,7.0)* | – | – | – | |||||||||
Glioblastoma | 1995-2012 | 0.6 | (0.0,1.2) | – | – | – | |||||||||
Oligodendroglioma | 1995-1997 | 9.2 | (−7.5,29) | 1997-2012 | −3.2 | (−4.0,-2.4)* | – | – | – | ||||||
Anaplastic oligodendroglioma | 1995-1998 | 23.3 | (8.3,40.3)* | 1998-2012 | −4.3 | (−5.3,-3.3)* | – | – | – | ||||||
Oligoastrocytic tumors | 1995-2012 | 4.3 | (3.4,5.3)* | – | – | – | |||||||||
Ependymal tumors | 1995-2002 | −1.5 | (−4.8,1.9) | 2002-2004 | 14.8 | ** | 2004-2012 | −1.6 | (−3.5,0.3) | 2004-2012 | 1.5 | (−2.4,5.6) | |||
Glioma malignant, NOS | 1995-2012 | 3.1 | (2.1,4.1)* | ||||||||||||
Choroid plexus tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | −3.5 | (−7.4,0.6) | |||
Neuronal and mixed neuronal-glial tumors | – | – | – | – | – | – | – | – | – | 2004-2012 | 2.6 | (0.8,4.3)* | |||
Embryonal tumors | 1995-2012 | −0.6 | (−1.3,0.0) | ||||||||||||
Tumors of Cranial and Spinal Nerves | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Nerve sheath tumors | – | – | – | 2004-2012 | 0.3 | (−1.5,2.0) | |||||||||
Tumors of Meninges | 1995-2012 | −1.8 | (−3.6,0.1) | 2004-2006 | 10.4 | (−7.3,31.5) | 2006-2012 | 1.2 | (−1.4,3.8) | ||||||
Meningioma | – | – | – | 2004-2012 | 2.8 | (0.8,4.7)* | |||||||||
Mesenchymal tumors | – | – | – | 2004-2012 | 1.2 | (−5.3,8.1) | |||||||||
Other neoplasms related to the meninges | – | – | – | 2004-2012 | 1.4 | (−0.5,3.4) | |||||||||
Lymphomas and Hematopoietic Neoplasms | 1995-1998 | −32.7 | (−39.6,-25)* | 1998-2012 | -4.4 | (−5.6,-3.1)* | |||||||||
Lymphoma | 1995-1998 | −31.8 | (−40.1,-22.3)* | 1998-2012 | −5.0 | (−6.4,-3.5)* | |||||||||
Germ Cell Tumors and Cysts | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Germ cell tumors, cysts and heterotopias | 1995-2012 | 0.6 | (−0.5,1.8) | ||||||||||||
Tumors of Sellar Region | – | – | – | 2004-2008 | 8.6 | (5.3,12)* | 2008-2012 | 0.5 | (−2.3,3.5) | ||||||
Tumors of the pituitary | – | – | – | 2004-2009 | 7.6 | (4.9,10.5)* | 2009-2012 | −0.9 | (−6.4,4.8) | ||||||
Craniopharyngioma | – | – | – | 2004-2012 | −1.6 | (−3.6,0.4) | |||||||||
Unclassified Tumors | 1995-2012 | -3.7 | (−4.8,-2.6)* | 2004-2012 | 6.7 | (4.4,8.9)* | |||||||||
Hemangioma | – | – | – | 2004-2010 | 18.5 | (12.3,25.2)* | 2010-2012 | 2.4 | (−20.8,32.2) | ||||||
Neoplasm, unspecified | 1995-2012 | −2.9 | (−3.9,-2.0)* | 2004-2012 | 1.6 | (−0.4,3.7) | |||||||||
TOTALc | 1995-2012 | -0.6 | (−0.8,-0.4)* | 2004-2006 | 11.0 | (−4.3,28.9) | 2006-2012 | 1.9 | (−0.5,4.3) |
*Statistic is significantly statistic at the p < .05 level.
** Confidence interval unable to be calculated.
– Rates are excluded when annual rate is based on a population of less than 16.
Abbreviation: APC, annual percentage change; NPCR, National Program of Cancer Registries; SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.
Descriptive Summary of Gliomas, Meningioma, and Tumors of the Pituitary in Adolescents and Young Adults.
The data in the American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the US in 2008-2012 are synthesized to describe the most common malignant histology groupings in age 15-39 years: gliomas, meningiomas, and tumors of the pituitary.
Descriptive Summary of Gliomas
The distribution of gliomas in adolescents and young adults by site and histology are shown in Figures 17–20.
Gliomas represent approximately 28% of all tumors and 82% of malignant tumors in persons age 15-39 years.
Overall, gliomas make up the largest percentage of brain and CNS tumors in those age 15-19 years (34.5%) and lowest in those age 35-39 years (24.0%).
Gliomas make up the largest percentage of malignant brain and CNS tumors in those age 35-39 years (83.9%), and lowest in those age 15-19 years (74.4%).
The majority of gliomas in AYA occur in the frontal lobe, temporal lobe, and other brain (see Table 1 for more details on what is included in the category other brain) combined (59.9%).
Diffuse astrocytoma (16.1%) and glioblastoma (16.0%) account for the majority of gliomas in age 15-39 years.
Relative survival rates decrease with increasing age, male sex, having AIAN race/ethnicity, and not having health insurance among age 15-39 years (Figure 24).
Descriptive Summary of Meningioma
Meningioma is the second most frequently reported brain and CNS tumor histology, accounting for 15.9% of tumors overall in adolescents and young adults (age 15-39 years) (Figure 11).
Non-malignant meningiomas with ICD-O-3 behavior codes /0 (benign) or /1 (uncertain) account for 79.4% of meningiomas (Table 8) in AYA.
Meningioma is most common in the 35-39 year age group, accounting for 25.1% of tumors, and least common in the 15-19 year age group, accounting for 4.9% of tumors (Figure 12).
Non-malignant meningioma in AYA is 2.5 times more common in females as compared to males (Figure 21).
Non-malignant meningioma is 1.1 times more common in Blacks as compared to Whites in AYA (Figure 22).
Ten-year relative survival for malignant meningioma in AYA is 85.6% (Table 14).
Descriptive Summary of Tumors of the Pituitary
Tumors of the pituitary are the most frequently reported tumors in adolescents and young adults (age 15-39 years), accounting for 29.9% of tumors overall (Figure 11).
Non-malignant tumors of the pituitary with ICD-O-3 behavior codes /0 (benign) or /1 (uncertain) in AYA account for 79.8% of tumors of the pituitary (Table 8).
Tumors of the pituitary are most common in the age group 25-29 years, accounting for 32.8% of tumors (Figure 12).
Tumors of the pituitary are 2.5 times more common in females as compared to males in AYA (Figure 21).
Tumors of the pituitary in AYA are 1.3 times more common in Blacks as compared to Whites (Figure 22).
Risk Factors for Primary Brain and CNS Tumors
Many environmental and behavioral risk factors have been investigated for brain and CNS tumors. The only well-validated factors are increased risk for these tumors (particularly meningiomas) with exposure to ionizing radiation41 (the type of radiation generated by atomic bombs, therapeutic radiation treatment, CT scans, MRI scans, and X-rays) and decreased risk for these tumors (particularly glioma) in persons with history of allergy or other atopic disease 42 (including eczema, psoriasis, and asthma). Several recent review articles have further elaborated on the current state of risk factor research in primary brain and CNS tumors.43–45
Strengths and Limitations
CBTRUS is the largest population-based registry focused exclusively on primary brain and CNS tumors in the US and covers 99.9% of the US population (for 2011-2012 only, data were available for 50 out of 51 registries). The American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the US in 2008-2012 contains the most up-to-date population-based data on primary AYA brain tumor and CNS tumors available through the surveillance system in the US.
Registration of individual cases is conducted by cancer registrars at the institution where diagnosis occurs and is then transmitted to the central cancer registry, which further transmits this information to NPCR or SEER. Central cancer registries (both NPCR and SEER) only report cases to the CDC and NCI for persons that are residents of that particular state, so duplicate records should not occur for persons that may have traveled across state lines for treatment. As a result, the CBTRUS dataset is a complete recording of all cases for the time period examined (with the exception of cases from one registry from 2011-2012) with no duplicates.
No mechanism currently exists for central pathology review of cases within the US cancer registry system, and histology code assignment at case registration is based on histology information contained in the patient's medical record. As a result, histologies are reflective of the prevailing histologic criteria for a histology at the time of registration. This also means that incomplete, incorrect or alternatively stated diagnoses included in a pathology report or other medical record can result in an incorrect reporting of the details of an individual case. For example, an anaplastic oligodendroglioma recorded in a pathology record as oligodendroglioma WHO grade III may be incorrectly recorded as an oligodendroglioma when the accurate category is an anaplastic oligodendroglioma.
Currently, there is no system for the collection of survival and outcomes data from all geographic regions in the US via the cancer registry system. SEER registries are specifically funded to collect active follow-up on patients, and as a result have highly accurate survival data for patients who are diagnosed within the geographic regions covered by these registries. The SEER 18 population dataset used for the survival analyses is a subset of the larger CBTRUS dataset used to generate incidence (99.9% of the US population)11 and covers approximately 28% of the US population. Survival estimates obtained from the SEER dataset may be less reliable as representations of ‘real’ relative survival rates for the US than if they were based on data from a larger portion of the population.
Concluding Comment
The American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the US in 2008-2012 comprehensively describes the current population-based incidence of primary malignant and non-malignant brain and other CNS tumors in adolescents and young adults age 15-39 years collected and reported by central cancer registries covering approximately 99.9% of the US population.
Despite the significant scientific developments that have occurred in treating cancer in recent years, brain tumors remain a significant source of cancer-related morbidity and mortality in adolescents and young adults. Brain tumor mortality has remained relatively stable, and mortality due to other cancers has not significantly improved. This report aims to provide a level of detail in a comprehensive report that allows for more accurate comparison of the incidence and survival of primary brain and CNS tumors affecting adolescents and young adults, to recognize the impact of these tumors on individuals belonging to this age group and on society overall, and to serve as a useful resource for patients and patient families, surveillance organizations, policy makers, advocates, industry, researchers and clinicians.
Abbreviations
- AIAN
– American Indian/Alaskan Native
- APC
– Annual percentage change
- API
– Asian/Pacific Islander
- AYA
– Adolescents and Young Adults
- CBTRUS
– Central Brain Tumor Registry of the United States
- CDC
– Centers for Disease Control and Prevention
- CSS
– Cancer Surveillance System
- CI
– Confidence interval
- CNS
– Central nervous system
- ICD-O-3
– International Classification of Diseases for Oncology, Third Edition
- ICCC
– International Classification of Childhood Cancer
- NAACCR
– North American Association of Central Cancer Registries
- NCDB
– National Cancer Data Base
- NCHS
– National Center for Health Statistics
- NCI
– National Cancer Institute
- NOS
– Not otherwise specified
- NPCR
– National Program of Cancer Registries
- SEER
– Surveillance, Epidemiology and End Results
- US
– United States
- USCS
– US Cancer Statistics
- WHO
– World Health Organization
References
Male . | |||||
---|---|---|---|---|---|
Age Group . | White . | Black . | AIAN . | API . | Total . |
15-19 | 8,515,937 | 1,888,284 | 197,230 | 591,389 | 11,192,840 |
20-24 | 8,525,811 | 1,713,867 | 190,386 | 670,783 | 11,100,847 |
25-29 | 8,296,572 | 1,465,887 | 173,417 | 700,196 | 10,636,071 |
30-34 | 7,846,363 | 1,345,942 | 157,470 | 679,973 | 10,029,748 |
35-39 | 7,842,959 | 1,300,866 | 145,846 | 685,568 | 9,975,239 |
TOTAL | 41,027,642 | 7,714,846 | 864,349 | 3,327,909 | 52,934,745 |
Female | |||||
Age Group | White | Black | AIAN | API | Total |
15-19 | 8,036,429 | 1,824,444 | 187,411 | 564,881 | 10,613,165 |
20-24 | 8,063,674 | 1,733,094 | 173,432 | 654,697 | 10,624,898 |
25-29 | 7,954,215 | 1,576,831 | 160,632 | 753,699 | 10,445,377 |
30-34 | 7,575,765 | 1,494,150 | 149,669 | 760,239 | 9,979,823 |
35-39 | 7,680,538 | 1,465,788 | 141,416 | 761,376 | 10,049,117 |
TOTAL | 39,310,621 | 8,094,307 | 812,560 | 3,494,892 | 51,712,380 |
Male . | |||||
---|---|---|---|---|---|
Age Group . | White . | Black . | AIAN . | API . | Total . |
15-19 | 8,515,937 | 1,888,284 | 197,230 | 591,389 | 11,192,840 |
20-24 | 8,525,811 | 1,713,867 | 190,386 | 670,783 | 11,100,847 |
25-29 | 8,296,572 | 1,465,887 | 173,417 | 700,196 | 10,636,071 |
30-34 | 7,846,363 | 1,345,942 | 157,470 | 679,973 | 10,029,748 |
35-39 | 7,842,959 | 1,300,866 | 145,846 | 685,568 | 9,975,239 |
TOTAL | 41,027,642 | 7,714,846 | 864,349 | 3,327,909 | 52,934,745 |
Female | |||||
Age Group | White | Black | AIAN | API | Total |
15-19 | 8,036,429 | 1,824,444 | 187,411 | 564,881 | 10,613,165 |
20-24 | 8,063,674 | 1,733,094 | 173,432 | 654,697 | 10,624,898 |
25-29 | 7,954,215 | 1,576,831 | 160,632 | 753,699 | 10,445,377 |
30-34 | 7,575,765 | 1,494,150 | 149,669 | 760,239 | 9,979,823 |
35-39 | 7,680,538 | 1,465,788 | 141,416 | 761,376 | 10,049,117 |
TOTAL | 39,310,621 | 8,094,307 | 812,560 | 3,494,892 | 51,712,380 |
aPopulation data source for 51 population-based geographic regions: Estimates from the United States. Bureau of the Census <http://seer.cancer.gov/popdata/index.html>.
Abbreviations: AIAN, American Indian Alaskan Native; API, Asian Pacific Islander.
bEstimated population for Nevada is for 2008-2010 only.
Male . | |||||
---|---|---|---|---|---|
Age Group . | White . | Black . | AIAN . | API . | Total . |
15-19 | 8,515,937 | 1,888,284 | 197,230 | 591,389 | 11,192,840 |
20-24 | 8,525,811 | 1,713,867 | 190,386 | 670,783 | 11,100,847 |
25-29 | 8,296,572 | 1,465,887 | 173,417 | 700,196 | 10,636,071 |
30-34 | 7,846,363 | 1,345,942 | 157,470 | 679,973 | 10,029,748 |
35-39 | 7,842,959 | 1,300,866 | 145,846 | 685,568 | 9,975,239 |
TOTAL | 41,027,642 | 7,714,846 | 864,349 | 3,327,909 | 52,934,745 |
Female | |||||
Age Group | White | Black | AIAN | API | Total |
15-19 | 8,036,429 | 1,824,444 | 187,411 | 564,881 | 10,613,165 |
20-24 | 8,063,674 | 1,733,094 | 173,432 | 654,697 | 10,624,898 |
25-29 | 7,954,215 | 1,576,831 | 160,632 | 753,699 | 10,445,377 |
30-34 | 7,575,765 | 1,494,150 | 149,669 | 760,239 | 9,979,823 |
35-39 | 7,680,538 | 1,465,788 | 141,416 | 761,376 | 10,049,117 |
TOTAL | 39,310,621 | 8,094,307 | 812,560 | 3,494,892 | 51,712,380 |
Male . | |||||
---|---|---|---|---|---|
Age Group . | White . | Black . | AIAN . | API . | Total . |
15-19 | 8,515,937 | 1,888,284 | 197,230 | 591,389 | 11,192,840 |
20-24 | 8,525,811 | 1,713,867 | 190,386 | 670,783 | 11,100,847 |
25-29 | 8,296,572 | 1,465,887 | 173,417 | 700,196 | 10,636,071 |
30-34 | 7,846,363 | 1,345,942 | 157,470 | 679,973 | 10,029,748 |
35-39 | 7,842,959 | 1,300,866 | 145,846 | 685,568 | 9,975,239 |
TOTAL | 41,027,642 | 7,714,846 | 864,349 | 3,327,909 | 52,934,745 |
Female | |||||
Age Group | White | Black | AIAN | API | Total |
15-19 | 8,036,429 | 1,824,444 | 187,411 | 564,881 | 10,613,165 |
20-24 | 8,063,674 | 1,733,094 | 173,432 | 654,697 | 10,624,898 |
25-29 | 7,954,215 | 1,576,831 | 160,632 | 753,699 | 10,445,377 |
30-34 | 7,575,765 | 1,494,150 | 149,669 | 760,239 | 9,979,823 |
35-39 | 7,680,538 | 1,465,788 | 141,416 | 761,376 | 10,049,117 |
TOTAL | 39,310,621 | 8,094,307 | 812,560 | 3,494,892 | 51,712,380 |
aPopulation data source for 51 population-based geographic regions: Estimates from the United States. Bureau of the Census <http://seer.cancer.gov/popdata/index.html>.
Abbreviations: AIAN, American Indian Alaskan Native; API, Asian Pacific Islander.
bEstimated population for Nevada is for 2008-2010 only.
Male . | |||
---|---|---|---|
Age Group . | Hispanic . | Non-Hispanic . | Total . |
15-19 | 2,307,027 | 8,885,813 | 11,192,840 |
20-24 | 2,295,374 | 8,805,474 | 11,100,847 |
25-29 | 2,270,630 | 8,365,441 | 10,636,071 |
30-34 | 2,143,149 | 7,886,599 | 10,029,748 |
35-39 | 1,964,206 | 8,011,034 | 9,975,239 |
TOTAL | 10,980,386 | 41,954,361 | 52,934,745 |
Female | |||
Age Group | Hispanic | Non-Hispanic | Total |
15-19 | 2,149,441 | 8,463,724 | 10,613,165 |
20-24 | 2,017,353 | 8,607,545 | 10,624,898 |
25-29 | 2,009,218 | 8,436,159 | 10,445,377 |
30-34 | 1,966,944 | 8,012,879 | 9,979,823 |
35-39 | 1,867,593 | 8,181,524 | 10,049,117 |
TOTAL | 10,010,549 | 41,701,831 | 51,712,380 |
Male . | |||
---|---|---|---|
Age Group . | Hispanic . | Non-Hispanic . | Total . |
15-19 | 2,307,027 | 8,885,813 | 11,192,840 |
20-24 | 2,295,374 | 8,805,474 | 11,100,847 |
25-29 | 2,270,630 | 8,365,441 | 10,636,071 |
30-34 | 2,143,149 | 7,886,599 | 10,029,748 |
35-39 | 1,964,206 | 8,011,034 | 9,975,239 |
TOTAL | 10,980,386 | 41,954,361 | 52,934,745 |
Female | |||
Age Group | Hispanic | Non-Hispanic | Total |
15-19 | 2,149,441 | 8,463,724 | 10,613,165 |
20-24 | 2,017,353 | 8,607,545 | 10,624,898 |
25-29 | 2,009,218 | 8,436,159 | 10,445,377 |
30-34 | 1,966,944 | 8,012,879 | 9,979,823 |
35-39 | 1,867,593 | 8,181,524 | 10,049,117 |
TOTAL | 10,010,549 | 41,701,831 | 51,712,380 |
aPopulation data source for 51 population-based geographic regions: Estimates from the U.S. Census Bureau http://seer.cancer.gov/popdata/index.html.
bEstimated population for Nevada is for 2008-2010 only.
Male . | |||
---|---|---|---|
Age Group . | Hispanic . | Non-Hispanic . | Total . |
15-19 | 2,307,027 | 8,885,813 | 11,192,840 |
20-24 | 2,295,374 | 8,805,474 | 11,100,847 |
25-29 | 2,270,630 | 8,365,441 | 10,636,071 |
30-34 | 2,143,149 | 7,886,599 | 10,029,748 |
35-39 | 1,964,206 | 8,011,034 | 9,975,239 |
TOTAL | 10,980,386 | 41,954,361 | 52,934,745 |
Female | |||
Age Group | Hispanic | Non-Hispanic | Total |
15-19 | 2,149,441 | 8,463,724 | 10,613,165 |
20-24 | 2,017,353 | 8,607,545 | 10,624,898 |
25-29 | 2,009,218 | 8,436,159 | 10,445,377 |
30-34 | 1,966,944 | 8,012,879 | 9,979,823 |
35-39 | 1,867,593 | 8,181,524 | 10,049,117 |
TOTAL | 10,010,549 | 41,701,831 | 51,712,380 |
Male . | |||
---|---|---|---|
Age Group . | Hispanic . | Non-Hispanic . | Total . |
15-19 | 2,307,027 | 8,885,813 | 11,192,840 |
20-24 | 2,295,374 | 8,805,474 | 11,100,847 |
25-29 | 2,270,630 | 8,365,441 | 10,636,071 |
30-34 | 2,143,149 | 7,886,599 | 10,029,748 |
35-39 | 1,964,206 | 8,011,034 | 9,975,239 |
TOTAL | 10,980,386 | 41,954,361 | 52,934,745 |
Female | |||
Age Group | Hispanic | Non-Hispanic | Total |
15-19 | 2,149,441 | 8,463,724 | 10,613,165 |
20-24 | 2,017,353 | 8,607,545 | 10,624,898 |
25-29 | 2,009,218 | 8,436,159 | 10,445,377 |
30-34 | 1,966,944 | 8,012,879 | 9,979,823 |
35-39 | 1,867,593 | 8,181,524 | 10,049,117 |
TOTAL | 10,010,549 | 41,701,831 | 51,712,380 |
aPopulation data source for 51 population-based geographic regions: Estimates from the U.S. Census Bureau http://seer.cancer.gov/popdata/index.html.
bEstimated population for Nevada is for 2008-2010 only.